"companyid","keydevid","transcriptid","headline","mostimportantdateutc","keydeveventtypename","companyname","speakertypename","componenttextpreview","word_count","componenttext"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Welcome to Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance for Investor Relations",49,"Welcome to Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance for Investor Relations for Intuitive Surgical, Mr. Calvin Darling. Please go ahead, sir."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance",264,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015; and 10-Q filed on October 21, 2015. These filings can be found through our website or at the SEC's EDGAR Database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with our highlights from our fourth quarter results as described in our press release announced earlier today, followed by a question-and-answer session. 
Gary will present the quarter's business and operational highlights. Marshall will provide a review of our fourth quarter financial results, Patrick will discuss marketing and clinical highlights, and I will provide our financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I will turn it over to Gary."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surg",924,"Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surgery, expand our da Vinci Xi Surgical System product line, increase our organizational capability and performance in international markets and improve contribution margins for our newly launched products. Themes that emerged at the close of 2014 continued into 2015, with strong performance in general surgery and international procedure growth. Full year global procedure growth was approximately 14%, led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States and strength in urology. U.S. general surgery growth was approximately 31% for the year, made up of strong growth in adrenal hernia repair, ventral hernia repair and colorectal surgery. Use of Single-Site in cholecystectomy and hysterectomy declined for the year. Outside of the United States, procedure growth was strong, rising approximately 26% of the procedures in 2014. Patrick will review procedural trends in greater detail later in the call. 
Looking at the trend in capital sales for the year. Capital placements increased in 2015 to 492 from 431 placements in 2014. Customer interest and acceptance of our latest platform, da Vinci Xi, has been positive, with Xi making up the majority of placements for the year. In 2015, we shipped 298 systems in the United States, 90 in Europe, 77 in Asia and 27 in other global markets. Our operations team remained focused on optimizing our manufacturing, design and supply chains for our new products. Partners in the back half of 2015 has been solid, with steady improvements in reducing product costs for new systems and advance instruments. We expect our product cost to continue to improve in 2016 and 2017 as a result of these efforts. 
As we've said before, our offerings make up an ecosystem designed to encompass our customers' needs in building and running outstanding robotic surgery programs. 2015 was a year in which we focused on enabling our ecosystem with new product launches globally. We launched our da Vinci Xi System with a course of instruments, Vessel Sealer and Firefly fluorescence imaging in 2014. We broadened access to Xi system with international regulatory clearances through the year. We also added our 45-millimeter Xi stapler in Q1, as well as some [indiscernible] shears and a second set of instruments in Q2 of 2015. We submitted our 510(k)s for our 30-millimeter stapler for Xi, Single-Site instrument kit for Xi as well as other Xi accessories in the second half of 2015. I'm pleased to report that we obtained FDA clearance for integrated Xi table motion this month. 
In addition the products, our surgeon customers can choose from dozens of training courses provided by academic surgeons as well as courses designed for assistance and other operating room staff. Our customers own over 1,400 surgical simulators and over 600 new consoles system and technology training. In addition, our teams have provided detailed analytic and operational support for customers seeking to optimize and benchmark programs relative to international norms. We believe the combination of these products and services are important to fully enable our customers. 
Looking back at the full year 2015. Our operating performance is summarized as follows: Global procedures grew by approximately 14%. We shipped 492 da Vinci Surgical Systems in the year, up from 431 in 2014. Total revenue was $2.4 billion, up 12% from 2014 and up 15% on a constant-currency basis. The recurring revenue grew to $1.7 billion, up 11% and comprising 70% of total revenue. We generated $946 million in pro forma operating profit, up 16% from last year. Pro forma net income was $731 million, up 20% from 2014, and we repurchased 366,000 shares at an average price of $502 per share during 2015. 
Turning to operating performance for the fourth quarter. Procedures grew approximately 15% over the fourth quarter of last year. We shipped 158 da Vinci Surgical Systems, up from 137 in the fourth quarter of 2014. 
Total pro forma revenue for the quarter was $677 million, up 13% from prior year. Instrument accessory revenue increased to $326 million, up 16%. We generated a pro forma operating profit of $293 million in the quarter, up 28% from the fourth quarter last year, and pro forma net income was $224 million, up 22% from Q4 of 2014. 
As we look to the future, we passionately believe that robotic-assisted surgery is in its infancy in application and technology. As we have improved our cost and supply chains for new products, we anticipate increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. These include product investments in advanced imaging, advanced instrumentation and next-generation robotics. We will also continue to invest in procedure, product and program analytics, international market development and economic and clinical validation. 
Looking to 2016, our priorities are as follows: first, we'll focus on the expanded use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair. Second, we'll work to advance our ecosystem, expand -- including expanding our Xi line and taking our XP product line into initial clinical use. Third, we'll drive our organizational capabilities in markets in Europe and Asia. And finally, we'll continue to assist our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior-year Xi trade-in programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and inve",1404,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior-year Xi trade-in programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and investor impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of pro forma results to our GAAP results on our website so that there's no confusion. 
Pro forma fourth quarter revenue was $677 million, an increase of 13% compared with $601 million for the fourth quarter of 2014 and an increase of 15% compared with last quarter. Pro forma revenue for the fourth quarter of 2014 excludes $4 million of revenue associated with offers made in 2014 to trade out Si products for Xi product. All trade-out offers are either fulfilled or lapsed in 2014. 
Fourth quarter 2015 procedures of approximately 177,000 increased 15% compared with the fourth quarter of 2014 and increased 9% compared to the third quarter of 2015. Procedure growth was primarily driven by general surgery procedures in the U.S. and urology worldwide. 
Revenue highlights are as follows: pro forma instrument accessory revenue increased 16% [ph] compared with last year and increased 9% compared with the third quarter 2015. The increase relative to prior year reflects procedure growth and increased sales of advance instruments, partially offset by the impact of foreign exchange. The increase over the prior quarter reflects procedure growth and sales of advanced instruments, partially offset by customer buying patterns. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,840 per procedure. This metric has now been trending in a tight range between $1,830 and $1,840 per procedure over the past year with recent quarters reflecting higher sales of advanced instruments, offset by the impact of foreign exchange. 
Pro forma system revenue of $231 million increased 9% compared with last year and increased 32% compared with last quarter. The increase relative to the prior year primarily reflects increased unit sales. The increase relative to the third quarter reflects increased unit sales, partially offset by lower ASPs. 158 systems were placed in the fourth quarter compared with 137 systems in the fourth quarter of 2014 and 117 systems last quarter. Approximately 72% of the systems shipped in the quarter were Xis, which is comparable to prior quarter. Globally, our average system price of $1,550,000 is comparable to the fourth quarter of 2014 and slightly less than the $1,600,000 ASP last quarter. Relative to the prior year, increases related to the lower trade-in mix were up -- mostly offset by foreign exchange. The decrease relative to the third quarter reflects geographic mix and a lower proportion of Xi dual consoles. ASPs fluctuate quarter-to-quarter based on geographic and product mix, trade-in volumes and changes in foreign exchange rate. Hospitals financed approximately 17% of the systems placed in the fourth quarter, down from 25% last quarter. We directly financed 20 systems, including placing the most operating leases, 16, since we began our direct leasing program in the second quarter of 2014. As of the end of the fourth quarter, 49 of the 3,597 systems out in the field were under operating leases. We exclude the impact of operating leases from our system ASP calculations. 
Service revenue, $120 million, increased 9% year-over-year and increased 2% compared with the third quarter of 2015. The year-over-year and quarter-over-quarter increases reflect the increase in our installed base for da Vinci system. 
Outside of U.S. results were as follows: fourth quarter pro forma revenue outside of the U.S. of $219 million increased 11% compared with $198 million for the fourth quarter of 2014 and increased 45% compared with $151 million last quarter. The increase compared with the previous year reflects higher system unit sales and higher recurring revenue driven by procedure growth of 27%. 
Outside the U.S., we placed 75 systems in the fourth quarter compared with 66 in the fourth quarter of 2014 and 37 systems last quarter. Current quarter system sales include 13 into China, 11 into Japan, 8 into Italy and 7 into Brazil. System placements outside the U.S. will continue to be lumpy as some of these markets are in the early stages of adoption, some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales into some markets are constrained by government regulation. 
The pro forma gross margin for the fourth quarter of 2015 was 69.6% compared with 67.1% for the fourth quarter of 2014 and 69.3% for the third quarter of 2015. Compared with the fourth quarter of 2014, the higher gross margin reflects lower inventory charges, improved efficiencies, partially offset by foreign exchange and higher mix of our newer products, which carry lower gross margins than our mature products. Gross margin includes the impact of the medical device tax, which has been suspended for the next 2 years. The medical device tax reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products on whether we are required to pay the medical device tax and costs associated with manufacturing efficiencies and product charges. 
In 2014, we recorded pretax charges of approximately $82 million, representing the estimated cost of settling a number of product and legal liability claims under a tolling agreement. During 2015, we refined our estimate of the overall cost for settling claims and recorded additional charges of approximately $14 million in the first half of the year. There were no charges in the second half of 2015. Charges made related to this agreement are excluded from our pro forma results and are included in our GAAP results. As of the end of the fourth quarter, $24 million were made accrued on our balance sheet as a significant portion of the estimated costs have been paid. 
Pro forma operating expenses, which exclude reserves for legal claims, stock compensation expense and amortization of purchased IP, increased 7% compared with the fourth quarter of 2014 and increased 6% compared with last quarter. Year-over-year increase of pro forma operating expenses primarily reflects headcount addition and higher incentive compensation. The increase relative to the third quarter primarily reflects increased incentive compensation. 
Our pro forma effective tax rate for the fourth quarter was 24.9% compared with an effective tax rate of 23.5% for the fourth quarter of 2014 and 18.4% last quarter. The effective tax rate for the third quarter of 2015 included tax benefits of $29 million or $0.77 per share related to a recent favorable tax court ruling involving an independent third party. In late December, Congress renewed the federal research and development credit, resulting in a benefit of $6 million or $0.17 per share. Congress also made the R&D tax credit permanent, so our 2016 rate guidance will reflect this benefit. Our tax rate will fluctuate with changes in the mix of U.S. and OUS income. 
Our fourth quarter 2015 pro forma net income was $224 million or $5.89 per share compared with $184 million or $4.92 per share for the fourth quarter of 2014 and $199 million or $5.24 per share for the third quarter of 2015. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $677 million for the fourth quarter of 2015 compared with $605 million for the fourth quarter 2014 and $590 million for the third quarter of 2015. GAAP net income was $190 million or $4.99 per share for the fourth quarter of 2015 compared with $147 million or $3.94 per share for the fourth quarter of 2014 and $167 million or $4.40 per share for the third quarter of 2015. 
We ended the year with cash and investments of $3.3 billion, up from $3.1 billion as of September 30, 2015. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 167,000 shares for $84 million at an average price of $505 per share. This brings our total stock repurchases for 2015 to approximately $184 million. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S",864,"Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S. procedures growing approximately 11% and international procedures growing approximately 26%. 
In the U.S., fourth quarter procedure growth of approximately 12% was driven by continued strength in general surgery procedures with solid contribution coming from mature procedures despite already high levels of market penetration. We do not expect a strong 2015 growth in established U.S. urology and gynecology procedures to continue in 2016. In U.S. urology, fourth quarter growth in da Vinci prostatectomy and kidney cancer procedures continued in similar rates as early in the year. We continue to believe the U.S. prostatectomy volumes has been tracking to the broader prostate surgery market. 2015 procedure growth in U.S. urology was approximately 12%, led by an approximate 11% growth in da Vinci Prostatectomy. We expect U.S. da Vinci Prostatectomy procedure volumes to return to a level more in line with prostate cancer incidence rates moving forward. 
In U.S. gynecology, fourth quarter procedures grew modestly year-over-year with growth in malignant and complex hysterectomy, partially offset by declines in benign procedures. During 2015, a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists compared to 2014. For the year, growth in U.S. gynecology procedures was approximately 1%. In 2016, sustaining growth in U.S. gynecology may be a challenge as we believe the total market for benign hysterectomies will continue to decline at a low single-digit rate. 
Fourth quarter growth in U.S. general surgery remains strong with robust growth in hernia repair and continued adoption of colorectal procedures being partially offset by continued declines in cholecystectomies. U.S. general surgery procedure growth was approximately 31% for the year with broad-based growth across several procedures, led by hernia repair, which generated the largest number of new general surgery procedures. Growth in colorectal resections was also strong during 2015.  In 2016, there remains a large opportunity in hernia repair and colorectal resections, and driving adoption in these markets remains among our top priorities. 
During the quarter, a group of general surgeons, led by Dr. Vorst from St. Joseph Mercy Health System and Dr. Carbonell from the University of South Carolina School of Medicine published their perspective on advances in ventral and incisional hernia repair in the World Journal of Gastrointestinal Surgery. Within the paper, they have been comparing the robotic to open [indiscernible] technique for more complex hernias, favored the robotic approach with the reduction of blood loss, shorter length of hospital stay, fewer surgical site infections and no difference in operative times or direct costs. The paper states that robotic approach ""permits relatively easy access to the anterior abdominal wall, allowing the surgeon to perform the ideal repair for that patient. It also might allow for standardization of surgical technique in order to develop a reliable approach to hernia repair that can be offered to an increasing number of patients."" 
Regarding our U.S. Single-Site business, cholecystectomy volumes continued to decline during the fourth quarter, but mostly offset by growth in multiport cholecystectomies. In addition, our Single-Site gynecology procedure volumes declined in the fourth quarter. Taken together, Single-Site procedures represented less than 5% of our fourth quarter U.S. procedure volume. 
Looking abroad during the fourth quarter. The approximate 27% international procedure growth was led by the global adoption of da Vinci Prostatectomy with solid contributions from kidney procedures, malignant hysterectomies and colorectal resections. For the full year, procedure growth was approximately 26%. Procedure growth in Europe remained steady throughout 2015. In Asia, procedure growth was led by broad-based adoption in China and South Korea and da Vinci Prostatectomy adoption in Japan. During 2016, we expect several external factors to impact international procedure growth. In Japan, the Surgical Society have submitted full reimbursement of partial nephrectomies to the MHLW. And MHLW's decision, this makes services [indiscernible] to Japanese procedure growth. In China, we placed 32 of the 38 da Vinci systems on the current authorization. And sustaining strong procedure growth throughout 2016, they require additional authorization from the government. 
During the quarter, the global evidence for the cost-effectiveness for the use of da Vinci surgery in gynecologic oncology continue to build. A new study from Copenhagen University Hospital by Dr. Hurley and colleagues modeled the clinical and economic impact of the adoption of da Vinci for malignant hysterectomies, capturing the comprehensive cost of care associated with these interventions. The study compared 158 open hysterectomies to 202 da Vinci hysterectomies and found the da Vinci hysterectomies were 17% less expensive than open hysterectomies based on operating costs and 7% less expensive than open hysterectomies when the da Vinci system cost was included. The study found that cost savings associated with fewer complications and shorter hospitalization more than offset the incremental cost associated with the use of da Vinci technology in the operating room. 
2015 was a robust year for clinical publications featuring da Vinci surgery with over 1,600 papers published during the year, bringing total clinical publications to over 10,000. 
This concludes my remarks. I thank you for your time. I will now turn the call over to Calvin."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our financial outlook for 2016. Starting with procedures. We have described in our announcement last week, 2015 saw da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed world",346,"Thank you, Patrick. I will be providing you with our financial outlook for 2016. 
Starting with procedures. We have described in our announcement last week, 2015 saw da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. During 2016, we anticipate full year procedure growth within the range of 9% to 12%. We expect similar seasonal timing of procedures in 2016 as we've experienced in previous years, with Q1 being the seasonally weakest quarter as patient deductibles are reset. 
With respect to revenue, we expect 2016 capital sale to follow historical seasonal patterns, which we anticipate will become more pronounced with Q1 being sequentially lower than the recently completed Q4. [ph] System placements will likely continue to be lumpy, particularly in markets outside of the U.S. as some of these markets are in early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales in some markets are constrained by government regulation. 
Turning to gross profit. We expect our 2016 grew pro forma gross profit margin to be within the range of between 68% and 69.5% of net revenue. Our actual gross profit margin will vary quarter-to-quarter, depending largely on product and regional mix. 
Turning to operating expenses. As Gary mentioned, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. We expect to grow 2016 operating expenses between 9% and 13% above 2015 levels. We expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income, which is comprised mostly of interest income, to total between $20 million and $25 million in 2016. With regard to income tax, we expect our 2015 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. This forecast does reflect the reinstatement of the R&D tax credit in 2016. 
That concludes our prepared remarks. We will now open the call to your questions."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape in robotics we",106,"I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape in robotics we've heard over the past several months, announcements from a couple of emerging competitors, and there's an expected announcement from another competitor later in 2016. Can you maybe talk about how you envision the competitive landscape unfolding and some of the activities you may be undertaking to prepare Intuitive for moving from a monopoly-type market to the one that has multiple players?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive their outcomes and compared or weighed against the price of those things. We think about it as the eco",261,"Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive their outcomes and compared or weighed against the price of those things. We think about it as the ecosystem. We think the ecosystem is really important. So it's easy to think just about the robotic system because that's the most visible part, but there's the system, the instruments and accessories, advanced instrumentation like stapling, imaging systems, fluorescence imaging, training technologies like simulators and build console, clinical validation, training courses offered by academic surgeons that number in the dozens, that whole set of products and ecosystem we think is important. So as competitors enter, they have to choose. Can they show that value in terms of outcomes and price? And can they offer the set of ecosystem elements that are going to be useful? We've known for years, and have anticipated for years, we didn't wake up yesterday and think, ""Competitors are coming. We better do something."" So we've been thoughtful about what we need to do to create value for our customers. We have a range of products in the system side that hits different price points for different feature content. We have different options available in terms of instrumentation, instrumentation price points. And so we feel we are well positioned. There are some other companies out there that will be capable. We expect the customers will explore what they're offering. We think we're well positioned when that exploration occurs."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's helpful. And then maybe just to go into the financial site for a second. Calvin, just to make sure I understand what you're saying for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit of t",131,"Okay. That's helpful. And then maybe just to go into the financial site for a second. Calvin, just to make sure I understand what you're saying for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit of the medical device tax, you're seeing a deterioration from where you sort of exited the second half of 2015. One of the factors influencing that mass and then on the OpEx side, the 9% to 13%, represents a pretty decent acceleration from what we saw this year. Can you maybe help us some of those investments in the context, where those dollars are going and whether 2016 represents a new normal year of investment spending or there's something particular that you're after this year?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. As Gary said on the call, we're focus on reducing our cost of the new products, and we are managing our fixed co",218,"Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. As Gary said on the call, we're focus on reducing our cost of the new products, and we are managing our fixed cost very carefully. We're pleased with the progress we've been making throughout 2015. Our second half 2015 gross profit benefited from favorable product mix, potentially 0 product charges and other favorable outcomes. In 20 to -- in 2016, we do expect to deliver cost reductions in newer products, including the Xi stapler, Vessel Sealer and Xi endoscopes. At the same time, as compared with second half of 2015, we expect a higher proportion of 2016 sales to be of newer products. We do expect a lower proportion of dual console system sales, probably higher proportion of system sales involving trade-ins and probably some product charges, at some point, will be more in line with historical norms from the past. And FX is not likely to be a strong a headwind as it was in 2015, it doesn't appear as though we'll have some negative impact on revenue and margins. And then lastly, I'd say that from a competitive side, any pressure there, the impacts there are unknown at this stage."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And for the investment side, as I mentioned in the script, we think there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically, and we've been working on that for years and w",166,"And for the investment side, as I mentioned in the script, we think there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically, and we've been working on that for years and will continue to do so. I think there's great potential there. On the instrumentation side, we're expanding our stapling line and our advanced energy lines. The reception has been quite good. Those are not single instruments. They're really families of instruments, and we're filling out those families as we go. We feel good about it and think it's important we'll continue to invest there. And we think opportunities in robotics, in terms of both structure and things like Sp and other things that can change different segments of the market. They can allow us to enter other procedures that we're not currently in today or access other regions of the world that may have different needs. And so we'll continue to invest in those things."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of David Lewis with Morgan Stanley.",15,"And we do have a question from the line of David Lewis with Morgan Stanley."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I want to come back to Marshall here for a second. The spread on margin, Marshall or Calvin, the sort of 68 to 69 50, it's a wider spread. Hope you can give a spread through the last year. So what defines to the upper end and the lower end of those ran",121,"So I want to come back to Marshall here for a second. The spread on margin, Marshall or Calvin, the sort of 68 to 69 50, it's a wider spread. Hope you can give a spread through the last year. So what defines to the upper end and the lower end of those ranges. And I guess, secondarily, when I think about these product manufacturing, improvements you're making, they seem to have a substantial impact on gross margins in the second half of the year. I guess I would presume those advantages or those costs would be a bigger tailwind in '16 over '15. Is that kind of a correct statement? Those are the 2 quick questions. I have a follow-up."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So to characterize the cost reductions, they had some impact in the second half of 2016 -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the cost. I think the bigg",161,"So to characterize the cost reductions, they had some impact in the second half of 2016 -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the cost. I think the bigger improvement during 2015 had to do with the lack of product charges that we mentioned in Q1. And as we move forward, the range is really -- the breadth of the range is really reflective of the items that Calvin gave you, which is expect to see a higher proportion of newer products, the extent of that, we'll see. We expect to see a lower proportion of dual consoles and higher proportion of trade-ins. The mix of systems is always difficult to predict. And frankly, geographic mix also has an implication here. And as I said in my script, there's quite a bit of lumpiness to some of those geographic markets."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then Gary, a quick strategic and margin question for you as well. So the expense that we saw a couple of years ago, you made a decision to sort of reinvest. Is that -- I mean this is a 50% [ph] increase in OpEx spending relative to '15, 400 to 5",114,"Okay. And then Gary, a quick strategic and margin question for you as well. So the expense that we saw a couple of years ago, you made a decision to sort of reinvest. Is that -- I mean this is a 50% [ph] increase in OpEx spending relative to '15, 400 to 500 basis point about. Is it -- do you see this sort of opportunity to reinvest? And is the investment spend heavier on SG&A or R&D? And the follow-up on this is, on Sps, as you mentioned, in light of what's happening with Single-Site procedures, does that change your thinking of the opportunity around Sp? Sorry for the couple of questions there."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. Yes, so in terms of the balance of investment, it's really targeted to a couple of years. R&D is clearly one area that will get investment. And then our support for international markets and more structural, not necessarily just sales approach clini",204,"Sure. Yes, so in terms of the balance of investment, it's really targeted to a couple of years. R&D is clearly one area that will get investment. And then our support for international markets and more structural, not necessarily just sales approach clinical trials and other things. So that's where the balance or the bulk of that increase is going to lay in. And we think we have technologies that are important, and we think we have process that we can bring that's important and that will serve us well in the long term. And I've -- in the future. With regard to the TVs of the Single-Site, we think that Sp really enters and add value in a different place than Single-Site. Single-Site tended to work on a little bit more limited workspace, a little bit more constrained set of procedures. Sp is more broader and more capable. Price points are a little bit different. So we think about Sp when we think transoral, trans-anal, colorectal, places where there's specimen removal. So we look at those things, and we think about it. Sp is less oriented towards cosmetic benefits and more oriented towards being able to reach complex structures where we need to."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Tao Levy with Wedbush.",13,"And we have a question from the line of Tao Levy with Wedbush."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe we could start with U.S. system utilization. When you [indiscernible] you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace where hospitals potentially accelerate the addition of",56,"So maybe we could start with U.S. system utilization. When you [indiscernible] you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace where hospitals potentially accelerate the addition of new systems in order to again meet your procedure growth expectations that you've laid out?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing really important to remember in United -- around the world but in the U.S. as well, is that there's not a single customer profile",201,"Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing really important to remember in United -- around the world but in the U.S. as well, is that there's not a single customer profile that fits them all. So the average does not cover all the endpoints. And so you -- we definitely see some integrated delivery networks who are very interested in optimizing procedures to their system per year, and that's just trying to drive up the better capital utilization, and we will help them do that. We see other health systems that may be in the exact same market who really interested in driving convenience for patients and for their surgeons and are willing to invest in capital once they get to kind of a minimum hurdle rate for procedure to use for utilization. And so we see both predicting which of the strategies is going to dominate into the year is always a little bit hard. And at the end of the day, we really focus the organization on great utilization and great support, whichever strategy our customer wants to take a step."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, right. And as my follow-up. You've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the other companies. So maybe you could highlight a couple of the i",55,"Okay, right. And as my follow-up. You've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the other companies. So maybe you could highlight a couple of the interesting projects within imaging that we should be paying attention to."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think I've -- first statement is, I beg to differ. But I look at imaging platforms that we bought out with Xi, and it's a fundamentally different technology basis. [indiscernible] chip imaging. It gives us room to do different things in visibility",244,"Sure. I think I've -- first statement is, I beg to differ. But I look at imaging platforms that we bought out with Xi, and it's a fundamentally different technology basis. [indiscernible] chip imaging. It gives us room to do different things in visibility and workflow point of view that would very hard to do otherwise. And so we continue down that pathway. So for example, in Xi, you can move a scope arm to time. There's not a dedicated robot to hold one endoscope. So that gives you the idea of [indiscernible] the ability and look around the avenue differently. The other thing is the [indiscernible] the ability gives us the ability to articulate endoscope, which is part of the Sp product line endoscopic articulation. We continue to invest in that sort of technologies and expand our leadership position there because I think that if you can get better image quality and more flexibility and better price points by doing the technology. So that's one set of investments. The other side is that, as we've mentioned with Firefly, the ability to look and see things that you can't see easily with lifeline. So the ability to look and see beneath tissue or highlight tissue structure and a set of technologies there that are useful and we're investing in. But those are longer term. They take a while to develop. And as we get down the pipeline, we'll share with you where we are."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Ben Andrew with William Blair.",14,"And we have a question from the line of Ben Andrew with William Blair."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","On the initial Sp use, Gary, that you talked about it, and you listed a few applications there, should we assume that that is where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is th",62,"On the initial Sp use, Gary, that you talked about it, and you listed a few applications there, should we assume that that is where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is that later this year? Next year that maybe leads to next steps to commercializing the product?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Right. Yes, in terms of the first question, those are the places we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are initial experience. We expect to have our initial experiences. In terms of",87,"Right. Yes, in terms of the first question, those are the places we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are initial experience. We expect to have our initial experiences. In terms of time line, we're not ready yet to tell you when in the year we'll have them. still in conversations with regulatory bodies about the pathway. And so as we get some clarity there, then we'll describe it to you later in the year."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, in that same vein, if you look out 3 or 4 years, can the Sp flat form be a material percentage of the company's volumes? Or is that something that probably remains a niche given the price point and we really should be thinking differently about dist",56,"Okay, in that same vein, if you look out 3 or 4 years, can the Sp flat form be a material percentage of the company's volumes? Or is that something that probably remains a niche given the price point and we really should be thinking differently about distribution in maybe 5% or 10%, if you will?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multiquadr",147,"I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multiquadrant access. So I think it's hard to predict long term. I think, for sure, near term, there are niches that I think matters. Whether those niches grow into bigger opportunities, I think, remains to be seen. Having said that, the history of the Intuitive and the history of technology is that as you bring raw technology into the hands of experts and they start to use it and develop it, leads the way. And I believe that. I think that we'll see things develop as surgeons get used to it. How big that gets? Impossible to predict right now."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, and then lastly for me. The range of procedure guidance is a little wide to start the year, obviously. Can you sort of try to isolate one effect, if we can. China, if we don't see another authorization for system sales, is that a material impact wit",71,"Okay, and then lastly for me. The range of procedure guidance is a little wide to start the year, obviously. Can you sort of try to isolate one effect, if we can. China, if we don't see another authorization for system sales, is that a material impact within the range of a percentage point or 2 in terms of potential swing? Or how should we look, as an example, China, specifically?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to be driving growth in general surgery in our international markets, including China. When you look at the breadth of the range to your question, there's far bigger imp",85,"Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to be driving growth in general surgery in our international markets, including China. When you look at the breadth of the range to your question, there's far bigger impact than just the system authorization in China when it comes to the mature procedures in the U.S. and the rates that grow that you may see that it benefited us in '15 and certainly across a much wider range of markets."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Matt O'Brien with Piper Jaffray.",16,"And we do have a question from the line of Matt O'Brien with Piper Jaffray."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","This is actually JP, in for Matt. Just want to get back to the margin kind of profile next year and ask in a more simpler way. If you exclude the 70 basis points that you gave to the med tax credit, given the guidance you gave for OpEx next year, would we",64,"This is actually JP, in for Matt. Just want to get back to the margin kind of profile next year and ask in a more simpler way. If you exclude the 70 basis points that you gave to the med tax credit, given the guidance you gave for OpEx next year, would we be expecting the adjusted EBIT margins to actually be down year-over-year?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I mean I think there are a lot of layers assumptions that go into model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors certainly underlying the overall assumptions there. I think what we try to do is t",73,"Yes, I mean I think there are a lot of layers assumptions that go into model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors certainly underlying the overall assumptions there. I think what we try to do is to lay out a lot of the factors that would be impacting the gross margin as well as investments we're making on the expense side."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","If I could ask one on the recent clearance of the integrated table motion. How is that still going to be? And how are you guys going to get revenue from that? Is that going to be sales from trumps medical? Can you guys [indiscernible] opening? Or how will",51,"If I could ask one on the recent clearance of the integrated table motion. How is that still going to be? And how are you guys going to get revenue from that? Is that going to be sales from trumps medical? Can you guys [indiscernible] opening? Or how will that work?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Actually, Trump will sell the table in independent transaction to the hospital. What we get out of it is, we sell a software upgrade package for the tables that allows it to be -- to operate in an integrated fashion.",41,"Yes. Actually, Trump will sell the table in independent transaction to the hospital. What we get out of it is, we sell a software upgrade package for the tables that allows it to be -- to operate in an integrated fashion."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think for us the key is working to make the more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms, redock during the procedure, make it more efficient, and therefore, the",64,"Yes, I think for us the key is working to make the more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms, redock during the procedure, make it more efficient, and therefore, the benefit certain groups of procedures and hopefully drive adoption. And I think that's really the key benefit from our perspective."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We do have a question from the line of Bob Hopkins from Bank of America.",15,"We do have a question from the line of Bob Hopkins from Bank of America."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I won't ask about a question about 2016 revenue growth, to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories that you see potential for accelerating",92,"So I won't ask about a question about 2016 revenue growth, to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories that you see potential for accelerating revenue growth or entirely new growth drivers in 2016 versus what you experienced in '15? And obviously we're well aware of the major growth levers are. I'm kind of curious about the things that are potential available to you in '16 that weren't available in '15."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, we look at '16 in a couple of places. I think we have opportunity in OUS markets and other places that are important for us. Now there are some structural things that we have to overcome and invest in, sometimes a reimbursement and sometimes other pa",153,"Yes, we look at '16 in a couple of places. I think we have opportunity in OUS markets and other places that are important for us. Now there are some structural things that we have to overcome and invest in, sometimes a reimbursement and sometimes other parts of market access. And we'll do that. But I think the opportunity there is quite good. I think in terms of other verticals, we are working on a 30-millimeter stapler. The 30-millimeter stapler is really targeted to thoracic procedures. Si system design is -- parts of its design intent was to facilitate thoracic procedures, and we're in early days there. So as time goes on, don't think that's something that's going to leap out of the gate in the early part of the year, but things that we're investing in from a product and support point of view should build momentum over the next multiple quarters."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then Marshall, to follow up on 2 quick things. On the revenue per procedure number, you highlighted that's been very stable within the range. But it feels like the cadence of new products will pick up as they move forward there. Can we expect that lin",112,"And then Marshall, to follow up on 2 quick things. On the revenue per procedure number, you highlighted that's been very stable within the range. But it feels like the cadence of new products will pick up as they move forward there. Can we expect that line item to start moving back up towards the old highs as we go forward here? And then the other quick thing I want ask of you is that I appreciate the comment that 70% of revenues now come from disposables. Can you give us a rough sense as to what the relative profitability of that disposal stream is versus the capital side of the business?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So first, talking about the range of [indiscernible] revenue per procedure. We would hope that we'd be able to add to that number through increases in the advanced instrument -- and simulation including stapling, investment ceiling. As I said, that's been",91,"So first, talking about the range of [indiscernible] revenue per procedure. We would hope that we'd be able to add to that number through increases in the advanced instrument -- and simulation including stapling, investment ceiling. As I said, that's been somewhat muted or offset by the effects of foreign exchange over the last few quarters. But there are other factors that could change that. I don't know what the historical high you were speaking about was, but I do think that there is room for it to grow going forward."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","It was about $2,000, I think.",6,"It was about $2,000, I think."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, that number has in its own stocking orders and timing of other things. So longer term, as you have bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of the pure econo",69,"Yes, that number has in its own stocking orders and timing of other things. So longer term, as you have bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of the pure economics of the exchange. The other question was around recurrent revenue. And the number is not just instruments, it's also service."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","50% is kind of the instruments and accessories of revenue, and the 20% will be the service element to get to the 70% recurring.",24,"50% is kind of the instruments and accessories of revenue, and the 20% will be the service element to get to the 70% recurring."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And the margins instrument and accessories are better than systems? And so as we get a quarter where we have a higher mix of systems and the margins are going to be lower. And that trend is likely to be durable and [indiscernible] and service will be high",49,"And the margins instrument and accessories are better than systems? And so as we get a quarter where we have a higher mix of systems and the margins are going to be lower. And that trend is likely to be durable and [indiscernible] and service will be higher-margin systems."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Brandon Henry with RBC Capital Markets.",16,"And we do have a question from the line of Brandon Henry with RBC Capital Markets."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive has now shown kind of 2-year [ph] strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think the strong performance in 2016?",34,"So Intuitive has now shown kind of 2-year [ph] strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think the strong performance in 2016?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Brandon, thanks for the question. A year ago, you saw turnaround in the volumes of da Vinci prostatectomy in the U.S., kind of the midpoint of the year and the back half of the year started to see some growth. And that's the same throughout 2015. The",144,"Yes, Brandon, thanks for the question. A year ago, you saw turnaround in the volumes of da Vinci prostatectomy in the U.S., kind of the midpoint of the year and the back half of the year started to see some growth. And that's the same throughout 2015. The rate of growth has been certainly above what we believe the incidence rates of prostate cancer to be in the country. There also has been U.S. urology has growth in partial nephrectomy as well has been pretty consistent and sustained, given the profile of what da Vinci technology brings to that procedure for both the clinical outcomes and cost-effectiveness perspective. As we look at 2016, our baseline assumption is that the high levels of growth that we've seen over the last 6 quarters are likely to be returning more towards the incidence rates that we've seen."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then one quick question an SPE. Can you talk about why you decided developed Sp and additionally add-on to the Xi platform and not as its own stand-alone platform? And then maybe could you talk about your expectations for XP instrumentation at l",59,"Okay. And then one quick question an SPE. Can you talk about why you decided developed Sp and additionally add-on to the Xi platform and not as its own stand-alone platform? And then maybe could you talk about your expectations for XP instrumentation at launch, you anticipate having a Vessel Sealer and a stapler to launch along with Sp?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the reason to make it compatible with Xi, it's really straightforward thing, which is a lot of components are shared in terms of certain console and imaging system. We want the customer experience to be seamless for our customers. We think there a",148,"Yes, on the reason to make it compatible with Xi, it's really straightforward thing, which is a lot of components are shared in terms of certain console and imaging system. We want the customer experience to be seamless for our customers. We think there are surgeons who go back and forth between Sps and Xis, what that means is they do want the user experience to be common. We also make it easier for hospital departments to acquire capital if they already have a dual console or an Xi and they wanted to just add Sp power capability that makes that the capital hurdle for them lower. And so it strengthens the Xi ecosystem. And I think that has been well received. So that -- been [indiscernible] Calvin yet to announce what our instruments will be for Sp, when we get to that point, we'll let you now."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Richard Newitter with Leerink Partners.",15,"And we do have a question from the line of Richard Newitter with Leerink Partners."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or essentially a limited launch by the end of this year? Does that mean that that's kind of your official launch in end",53,"Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or essentially a limited launch by the end of this year? Does that mean that that's kind of your official launch in end of 2016?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We expect -- we don't expect material revenues in '16. We are planning on clinical experiences in '16.",18,"We expect -- we don't expect material revenues in '16. We are planning on clinical experiences in '16."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for the device for so",103,"Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for the device for some larger kind of buckets or broader definitions of categories like urological procedures or general abdominal procedures. Can you help us understand if this is something that you've heard the FDA say to you as well? Or is it more new ones that you need to go much more specific by individual procedures?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The issue of kind of broad claim lines [indiscernible] claim line, which is actually was a part of the discussion of the FDA workshop. And I can refer you to those minutes, and you'll see pretty much what the changes been. The issue, I would not view",218,"Yes. The issue of kind of broad claim lines [indiscernible] claim line, which is actually was a part of the discussion of the FDA workshop. And I can refer you to those minutes, and you'll see pretty much what the changes been. The issue, I would not view that as something that's architecture-dependent or only offered to a certain company. That have to do -- as you know, the FDA is going to respond to these kinds of products in like manner as far as I can tell. And that comes down to FDA asked for certain amount of data based on the kinds of things you want to talk your customer about. If you just want to talk about broad things and specific things, then they ask for one set of data. And the more specific you get, the more data they ask for around that set of specifics. So in general, it's a matching of their requirements with claims. And so they're describing to you a strategy around what they think they can do from a requirement point of view. I think the claim level to be fair [indiscernible] and to the extent that customers need a certain amount of information, then it's just going to [indiscernible] be to go create the data and deliver it."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And just lastly, on the beds. Can you help us understand what procedures, if any, or certain sets of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and procedur",66,"Got it. And just lastly, on the beds. Can you help us understand what procedures, if any, or certain sets of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and procedures that otherwise might have been slower to adopt? Are there any specific procedures that they do really open up?"
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The those -- general surgeons would really use bed motion to do 2 things, to either use gravity as a retractor. So it's an extra hand using gravity. And for the anesthesiologist, to manage the patient in terms of positioning with regard to other vita",120,"Yes. The those -- general surgeons would really use bed motion to do 2 things, to either use gravity as a retractor. So it's an extra hand using gravity. And for the anesthesiologist, to manage the patient in terms of positioning with regard to other vital signs and things like that. So in procedures where you're trying to manage bowel, for example, is really to have table motion, and that is clearly something that jumps out. However, once we had -- we've now seen in the market in Europe, and we've had trials in different specialties, I think it's appeal is broad. So we thought about it upfront initially around surgery. I think it's appeal will be better than that."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Rick Weiss with Stifel.",14,"And we do have a question from the line of Rick Weiss with Stifel."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, you'll be our last question.",6,"Rick, you'll be our last question."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I appreciate it, Gary. To start with you, Gary. You said several times in the questions, your prepared remarks and in the Q&A that robotics is going to -- the big picture of the second. For you, are you [indiscernible perhaps this next wave of pipeline pr",105,"I appreciate it, Gary. To start with you, Gary. You said several times in the questions, your prepared remarks and in the Q&A that robotics is going to -- the big picture of the second. For you, are you [indiscernible perhaps this next wave of pipeline products that you talked about and maybe some you haven't talked about are getting you more confident or excited about the potential for another growth acceleration or an inflection point in the adoption of robotic surgery? It's just -- I appreciated the numbers of systems placed to small hospitals and all, but just wondering if there's anything more there."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think a couple of things that excite me and lead me to believe there's a lot of opportunity  a couple. One of them is I think in the architecture that we're in today, our [indiscernible] in the markets for which we have clearances, there's still a lot o",245,"I think a couple of things that excite me and lead me to believe there's a lot of opportunity  a couple. One of them is I think in the architecture that we're in today, our [indiscernible] in the markets for which we have clearances, there's still a lot of procedures that are being done open, have the opportunity to being done basically with the product. And I think that is -- that comes down to execution and delivery of some of the things we have in the pipeline. Having said that, I think that as you just stand back and look out to the next decade, then ask do we think that robotic-assisted surgery can impact more procedures and more types of procedures than they are being impacted today? I think the answer to that is absolutely yes. Some things are things like Sp. Product that looks different. Sp won't be the last set of product that look different. We think there are opportunities for other products and technologies that can really make a difference in surgeons delivering the great care. So we're excited about it and investing in it. And I think asked us about any surgeon, do you think the use of competition analytics in robotics is going to improve your practice over time? Or it will become as important in the answer is pretty uniform that those kinds of technologies should help them if they are well delivered and well executed."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Two last quick ones. I'll ask at the same time. Instrument and accessory is good. I think for the first time in at least 12 [ph] quarters, maybe longer, but certainly since '12 annually, grew -- they grow faster than procedures. I mean is there something",113,"Two last quick ones. I'll ask at the same time. Instrument and accessory is good. I think for the first time in at least 12 [ph] quarters, maybe longer, but certainly since '12 annually, grew -- they grow faster than procedures. I mean is there something that we should read into that with implications for the next couple of years? Or is destock-ing and given the flattish revenues per procedure? And the second one, at the same time, the bed approval, you launched it in Europe in '15 and just maybe the did your early experience there, to drive you with procedures or Xi or capital sales? Any color there would be welcome."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On the revenue for procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 18 40. it did kind of take over to a growth this last quarter",100,"On the revenue for procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 18 40. it did kind of take over to a growth this last quarter as we saw utilization advance instruments kind of more than offset some of the headwinds mostly from exchange. But again, there a lot of those factors could vary in the future in terms of procedure mix, customer efficiency, buying pattern, foreign exchange. So it's really a lot of factors here."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. I think, Rick, that was our last question. As we said previously, we'll focus on finan",186,"On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. I think, Rick, that was our last question. As we said previously, we'll focus on financial metrics such as revenues, and cash flow organizational focus remains an increasing value, enabling surgeons to improve surgical outcomes and reduce surgical trauma. The following comments from Dr. Sullivan, general surgeon from Florida to give you something on the impact of profits have been surgery. ""The advanced technologies and pre-dexterity of da Vinci Xi System how allowed me to perform complex minimally invasive operations with a statistically measurable improvement in outcomes for patients are clearly and beneficially benefiting from less pain, shorter length of hospital day, [indiscernible] and short- and long-term complications."" We've built our company to take surgery [indiscernible] and assure you, that we remain committed to driving a lot of that will make a difference. This concludes today's call. Thank you for your participation, and we look forward to talking to you again in 3 months."
30239,319152206,920058,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And ladies and gentlemen, that does conclude the conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service. You may now disconnect.",28,"And ladies and gentlemen, that does conclude the conference for today. Thank you for your participation and for using the AT&T Executive Teleconference Service. You may now disconnect."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Welcome to the Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance or Investor Relatio",50,"Welcome to the Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance or Investor Relations for Intuitive Surgical, Mr. Calvin Darling. Please go ahead, sir."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance",264,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015, and 10-Q filed on October 21, 2015. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with our highlights from our fourth quarter results as described in our press release announced earlier today, followed by a question-and-answer session. 
Gary will present the quarter's business and operational highlights. Marshall will provide a review of our fourth quarter financial results. Patrick will discuss marketing and clinical highlights, and I will provide our financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I will turn it over to Gary."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surg",932,"Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surgery, expand our da Vinci Xi Surgical System product line, increase our organizational capability and performance in international markets and improve contribution margins for our newly launched products. Themes that emerged at the close of 2014 continued into 2015, with strong performance in general surgery and international procedure growth. 
Full year global procedure growth was approximately 14%, led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States and strength in urology. U.S. general surgery growth was approximately 31% for the year, made up of strong growth in inguinal hernia repair and ventral hernia repair and colorectal surgery. Use of Single-Site in cholecystectomy and hysterectomy declined for the year. Outside of the United States, procedure growth was strong, rising approximately 26% of the procedures in 2014. Patrick will review procedure trends in greater detail later in the call. 
Looking at trends in capital sales for the year. Capital placements increased in 2015 to 492 from 431 placements in 2014. Customer interest and acceptance of our latest platform, da Vinci Xi, has been positive, with Xi making up the majority of placements for the year. In 2015, we shipped 298 systems in the United States, 90 in Europe, 77 in Asia and 27 in other global markets. Our operations teams remained focused on optimizing our manufacturing, design and supply chains for our newer products. Orders in the back half of 2015 has been solid, with steady improvements in reducing product costs for our new systems and advanced instruments. We expect our product cost to continue to improve in 2016 and 2017 as a result of these efforts. 
As we've said before, our offerings make up an ecosystem designed to encompass our customers' needs in building and running outstanding robotic surgery programs. 2015 was a year in which we focused on enabling our ecosystem with new product launches globally. We launched our da Vinci Xi System with a core set of instruments, Vessel Sealer and Firefly Fluorescence Imaging in 2014. We broadened access to our Xi system with international regulatory clearances through the year. We also added our 45-millimeter Xi stapler in Q1 as well as Harmonic Curved Shears and a second set of instruments in Q2 of 2015. We submitted our 510(k)s for our 30-millimeter stapler for Xi, Single-Site instrument kit for Xi as well as other Xi accessories in the second half of 2015. I'm pleased to report that we obtained FDA clearance for Integrated Xi Table Motion this month. In addition to products, our surgeon customers can choose from dozens of training courses provided by academic surgeons as well as courses designed for assistance and other operating room staff. Our customers own over 1,400 surgical simulators and over 600 dual consoles to assist them in technology training. In addition, our teams have provided detailed analytic and operational support for customers seeking to optimize and benchmark their programs relative to international norms. We believe the combination of these products and services are important to fully enable our customers. 
Looking back at the full year of 2015. Our operating performance is summarized as follows: Worldwide procedures grew by approximately 14%. We shipped 492 da Vinci Surgical Systems in the year, up from 431 in 2014. Total revenue was $2.4 billion, up 12% from 2014 and up 15% on a constant-currency basis. The recurring revenue grew to $1.7 billion, up 11% and comprising 70% of total revenue. We generated $946 million in pro forma operating profit, up 16% from last year. Pro forma net income was $731 million, up 20% from 2014, and we repurchased 366,000 shares at an average price of $502 per share during 2015. 
Turning to operating performance for the fourth quarter. Procedures grew approximately 15% over the fourth quarter of last year. We shipped 158 da Vinci Surgical Systems, up from 137 in the fourth quarter of 2014. 
Total pro forma revenue for the quarter was $677 million, up 13% from prior year. Instrument accessory revenue increased to $326 million, up 16%. We generated a pro forma operating profit of $293 million in the quarter, up 28% from the fourth quarter of last year; and pro forma net income was $224 million, up 22% from Q4 of 2014. 
As we look to the future, we passionately believe that robotic-assisted surgery is in its infancy in application and technology. As we have improved our cost and supply chains for new products, we anticipate increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. These include product investments in advanced imaging, advanced instrumentation and next-generation robotics. We will also continue to invest in procedure, product and program analytics, international market development and economic and clinical validation. 
Looking to 2016, our priorities are as follows: First, we'll focus on the expanded use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair. Second, we'll work to advance our ecosystem, expand -- including expanding our Xi line and taking our Sp product line into initial clinical use. Third, we'll drive our organizational capabilities in markets in Europe and Asia. And finally, we'll continue to assist our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior year Xi-traded programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and invest",1405,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior year Xi-traded programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and investor impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of pro forma results to our GAAP results on our website so that there's no confusion. 
Pro forma fourth quarter revenue was $677 million, an increase of 13% compared with $601 million for the fourth quarter of 2014 and an increase of 15% compared with last quarter. Pro forma revenue for the fourth quarter of 2014 excludes $4 million of revenue associated with offers made in 2014 to trade out Si products or Xi product. All trade-out offers were either fulfilled or lapsed in 2014. 
Fourth quarter 2015 procedures of approximately 177,000 increased 15% compared with the fourth quarter of 2014 and increased 9% compared with the third quarter of 2015. Procedure growth was primarily driven by general surgery procedures in the U.S., in urology worldwide. 
Revenue highlights are as follows: Pro forma instrument accessory revenue increased 16% compared with last year and increased 9% compared with the third quarter of 2015. The increase relative to prior year reflects procedure growth and increased sales of advanced instruments, partially offset by the impact of foreign exchange. The increase over the prior quarter reflects procedure growth and sales of advanced instruments, partially offset by customer-buying patterns. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,840 per procedure. This metric has now been trending in a tight range between $1,830 and $1,840 per procedure over the past year with recent quarters reflecting higher sales of advanced instruments, offset by the impact of foreign exchange. 
Pro forma system revenue of $231 million increased 9% compared with last year and increased 32% compared with last quarter. The increase relative to the prior year primarily reflects increased unit sales. The increase relative to the third quarter reflects increased unit sales, partially offset by lower ASPs. 158 systems were placed in the fourth quarter compared with 137 systems in the fourth quarter of 2014 and 117 systems last quarter. Approximately 72% of the systems shipped in the quarter were Xis, which is comparable to prior quarter. 
Globally, our average system price of $1,550,000 was comparable to the fourth quarter of 2014 and slightly less than the $1,600,000 ASP last quarter. Relative to the prior year, increases related to a lower trade-in mix were up -- mostly offset by foreign exchange. The decrease relative to the third quarter reflects geographic mix and a lower proportion of Xi dual consoles. ASPs fluctuate quarter-to-quarter based on geographic and product mix, trade-in volume and changes in foreign exchange rate. Hospitals financed approximately 17% of the systems placed in the fourth quarter, down from 25% last quarter. We directly financed 20 systems, including placing the most operating leases, 16, since we began our direct leasing program in the second quarter of 2014. As of the end of the fourth quarter, 49 of the 3,597 systems out in the field were under operating leases. We exclude the impact of operating leases from our system ASP calculations. 
Service revenue of $120 million increased 9% year-over-year and increased 2% compared with the third quarter of 2015. The year-over-year and quarter-over-quarter increases reflect the increase in our installed base for da Vinci system. 
Outside of U.S. results were as follows: Fourth quarter pro forma revenue outside of the U.S. of $219 million increased 11% compared with $198 million for the fourth quarter of 2014 and increased 45% compared with $151 million last quarter. The increase compared with the previous year reflects higher system unit sales and higher recurring revenue driven by procedure growth of 27%. 
Outside the U.S., we placed 75 systems in the fourth quarter compared with 66 in the fourth quarter of 2014 and 37 systems last quarter. Current quarter system sales include 13 into China, 11 into Japan, 8 into Italy and 7 into Brazil. System placements outside the U.S. will continue to be lumpy as some of these markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns, and sales into some markets are constrained by government regulation. 
The pro forma gross margin for the fourth quarter of 2015 was 69.6% compared with 67.1% for the fourth quarter of 2014 and 69.3% for the third quarter of 2015. Compared with the fourth quarter of 2014, the higher gross margin reflects lower inventory charges, improved efficiencies, partially offset by foreign exchange and a higher mix of our newer products, which carry lower gross margins than our mature products. Gross margin includes the impact of the medical device tax, which has been suspended for the next 2 years. The medical device tax reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products on whether we are required to pay the medical device tax and costs associated with manufacturing efficiencies and product charges. 
In 2014, we recorded pretax charges of approximately $82 million, representing the estimated cost of settling a number of product and legal liability claims under a tolling agreement. During 2015, we refined our estimate of the overall cost for the settling claims and recorded additional charges of approximately $14 million in the first half of the year. There were no charges in the second half of 2015. Charges made related to this agreement are excluded from our pro forma results and are included in our GAAP results. As of the end of the fourth quarter, $24 million remained accrued on our balance sheet as a significant portion of the estimated costs have been paid. 
Pro forma operating expenses, which exclude reserves for legal claims, stock compensation expense and amortization of purchased IP, increased 7% compared with the fourth quarter of 2014 and increased 6% compared with last quarter. Year-over-year increase of pro forma operating expenses primarily reflects headcount addition and higher incentive compensation. The increase relative to the third quarter primarily reflects increased incentive compensation. 
Our pro forma effective tax rate for the fourth quarter was 24.9% compared with an effective tax rate of 23.5% for the fourth quarter of 2014 and 18.4% last quarter. The effective tax rate for the third quarter of 2015 included tax benefits of $29 million or $0.77 per share related to a recent favorable tax court ruling involving an independent third party. In late December, Congress renewed the federal research and development credit, resulting in a benefit of $6 million or $0.17 per share. Congress also made the R&D tax credit permanent, so our 2016 rate guidance will reflect this benefit. Our tax rate will fluctuate with changes in the mix of U.S. and OUS income. 
Our fourth quarter 2015 pro forma net income was $224 million or $5.89 per share compared with $184 million or $4.92 per share for the fourth quarter of 2014 and $199 million or $5.24 per share for the third quarter of 2015. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $677 million for the fourth quarter of 2015 compared with $605 million for the fourth quarter 2014 and $590 million for the third quarter of 2015. GAAP net income was $190 million or $4.99 per share for the fourth quarter of 2015 compared with $147 million or $3.94 per share for the fourth quarter of 2014 and $167 million or $4.40 per share for the third quarter of 2015. 
We ended the year with cash and investments of $3.3 billion, up from $3.1 billion as of September 30, 2015. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 167,000 shares for $84 million at an average price of $505 per share. This brings our total stock repurchases for 2015 to approximately $184 million. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S",870,"Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S. procedures growing approximately 11% and international procedures growing approximately 26%. 
In the U.S., fourth quarter procedure growth of approximately 12% was driven by continued strength in general surgery procedures with solid contribution coming from mature procedures despite already high levels of market penetration. We do not expect a strong 2015 growth in established U.S. urology and gynecology procedures to continue in 2016. In U.S. urology, fourth quarter growth in da Vinci prostatectomy and kidney cancer procedures continued at similar rates as early in the year. We continue to believe that our U.S. prostatectomy volumes had been tracking to the broader prostate surgery market. 2015 procedure growth in U.S. urology was approximately 12%, led by an approximate 11% growth in da Vinci Prostatectomy. We expect U.S. da Vinci Prostatectomy procedure volumes to return to a level more in line with prostate cancer incidence rates moving forward. 
In U.S. gynecology, fourth quarter procedures grew modestly year-over-year with growth in malignant and complex hysterectomy, partially offset by declines in benign procedures. During 2015, a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists compared to 2014. For the year, growth in U.S. gynecology procedures was approximately 1%. In 2016, sustaining growth in U.S. gynecology may be a challenge as we believe the total market for benign hysterectomies will continue to decline at a low single-digit rate. 
Fourth quarter growth in U.S. general surgery remains strong, with robust growth in hernia repair and continued adoption of colorectal procedures being partially offset by continued declines in cholecystectomies. U.S. general surgery procedure growth was approximately 31% for the year with broad-based growth across several procedures, led by hernia repair, which generated the largest number of new general surgery procedures. Growth in colorectal resections was also strong during 2015.  In 2016, there remains a large opportunity in hernia repair and colorectal resections, and driving adoption in these markets remains among our top priorities. 
During the quarter, a group of general surgeons led by Dr. Vorst from St. Joseph Mercy Health System and Dr. Carbonell from the University of South Carolina School of Medicine published their perspective on advances in ventral and incisional hernia repair in the World Journal of Gastrointestinal Surgery. Within the paper, data comparing the robotic to open Rives-Stoppa technique for more complex hernias favored the robotic approach with the reduction of blood loss, shorter length of hospital stay, fewer surgical site infections and no difference in operative times or direct costs. The paper states that robotic approach ""permits relatively easy access to the anterior abdominal wall, allowing the surgeon to perform the ideal repair for that patient. It also might allow for standardization of surgical technique in order to develop a reliable approach to hernia repair that can be offered to an increasing number of patients."" 
Regarding our U.S. Single-Site business, cholecystectomy volumes continued to decline during the fourth quarter but mostly offset by growth in multiport cholecystectomies. In addition, our Single-Site gynecology procedure volumes declined in the fourth quarter. Taken together, Single-Site procedure represented less than 5% of our fourth quarter U.S. procedure volume. 
Looking abroad during the fourth quarter, the approximate 27% international procedure growth was led by the global adoption of da Vinci Prostatectomy with solid contributions from kidney procedures, malignant hysterectomies and colorectal resections. For the full year, procedure growth was approximately 26%. Procedure growth in Europe remained steady throughout 2015. In Asia, procedure growth was led by broad-based adoption in China and South Korea and da Vinci Prostatectomy adoption in Japan. 
During 2016, we expect several external factors to impact international procedure growth. In Japan, the Surgical Society have submitted full reimbursement of partial nephrectomies to the MHLW. And in the MHLW's decision, this may serve as a tail end to Japanese procedure growth. In China, we placed 32 of the 38 da Vinci systems under the current authorization. And sustaining strong procedure growth throughout 2016, they require additional authorizations from the government. 
During the quarter, the global evidence for the cost effectiveness for the use of da Vinci surgery in gynecologic oncology continued to build. A new study from Copenhagen University Hospital by Dr. Hurley [ph] and colleagues modeled the clinical and economic impact of the adoption of da Vinci for malignant hysterectomies, capturing the comprehensive cost of care associated with these interventions. The study compared 158 open hysterectomies to 202 da Vinci hysterectomies and found the da Vinci hysterectomies were 17% less expensive than open hysterectomies based on operating costs and 7% less expensive than open hysterectomies when the da Vinci system cost was included. The study found that cost savings associated with fewer complications and shorter hospitalization more than offset the incremental costs associated with the use of da Vinci technology in the operating room. 
2015 was a robust year for clinical publications featuring da Vinci surgery with over 1,600 papers published during the year, bringing total clinical publications to over 10,000. 
This concludes my remarks. I thank you for your time. I will now turn the call over to Calvin."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our financial outlook for 2016. Starting with procedures. As described in our announcement last week, 2015 da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. Dur",342,"Thank you, Patrick. I will be providing you with our financial outlook for 2016. 
Starting with procedures. As described in our announcement last week, 2015 da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. During 2016, we anticipate full year procedure growth within a range of 9% to 12%. We expect similar seasonal timing of procedures in 2016 as we've experienced in previous years, with Q1 being the seasonally weakest quarter as patient deductibles are reset. 
With respect to revenue, we expect 2016 capital sale to follow historical seasonal patterns, which we anticipate will become more pronounced, with Q1 being sequentially lower than the recently completed Q4. System placements will likely continue to be lumpy, particularly in markets outside of the U.S. as some of these markets are in early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns, and sales into some markets are constrained by government regulations. 
Turning to gross profit. We expect our 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. Our actual gross profit margin will vary quarter-to-quarter, depending largely on product and regional mix. 
Turning to operating expenses. As Gary mentioned, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. We expect to grow 2016 operating expenses between 9% and 13% above 2015 levels. We expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income, which is comprised mostly of interest income, to total between $20 million and $25 million in 2016. 
With regard to income tax, we expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. This forecast does reflect the reinstatement of the R&D tax credit in 2016. 
That concludes our prepared remarks. We will now open the call to your questions."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape. In robotics,",105,"I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape. In robotics, we've heard over the past several months announcements from a couple of emerging competitors, and there's an expected announcement from another competitor later in 2016. Can you maybe talk about how you envision the competitive landscape unfolding and some of the activities you may be undertaking to prepare Intuitive for moving from a monopoly-type market to one that has multiple players?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive great outcomes and compared or weighed against the price of those things. We think about it as an ecos",263,"Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive great outcomes and compared or weighed against the price of those things. We think about it as an ecosystem. We think the ecosystem is really important. So it's easy to think just about the robotic system because that's the most visible part, but there's the system, the instruments and accessories, advanced instrumentation like stapling, imaging systems, fluorescence imaging, training technologies like simulators and dual console, clinical validation, training courses offered by academic surgeons that number in the dozens, that whole set of products and ecosystem we think is important. And so as competitors enter, they have to choose. Can they show that value in terms of outcomes and price? And can they offer the set of ecosystem elements that are going to be useful? We've known for years, and have anticipated for years, we didn't wake up yesterday and think, ""Competitors are coming. We better do something."" And so we've been thoughtful about what we need to do to create value for our customers. We have a range of products in the system side that hits different price points for different feature content. We have different options that are available in terms of instrumentation price points, and so we think we're really well positioned. There are some other companies out there.  They'll be capable. We expect that customers will explore what they're offering. We think we're well positioned when that exploration occurs."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's helpful. And then maybe just to go into the financial side for a second. Calvin, I just to understand what you're saying on the margins for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit",131,"Okay. That's helpful. And then maybe just to go into the financial side for a second. Calvin, I just to understand what you're saying on the margins for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit of the medical device tax, you're seeing a deterioration from where you sort of exited the second half of 2015, one of the factors influencing that math. And then on the OpEx side, the 9% to 13%, represents a pretty decent acceleration from what we saw this year. Can you maybe help put some of those investments into context, where those dollars are going and whether 2016 represents a new normal year of investment spending or there's something particular that you're after this year?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. Like Gary said on the call, we're focused on reducing our cost of the new products and then we've been managing",219,"Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. Like Gary said on the call, we're focused on reducing our cost of the new products and then we've been managing our fixed cost very carefully. We're pleased with the progress we've been making throughout 2015. Our second half 2015 gross profit benefited from favorable product mix, essentially 0 product charges and other favorable outcomes. In 2016, we do expect to deliver continued cost reductions on the newer products, including the Xi stapler, Vessel Sealer and Xi endoscopes. At the same time, as compared with the second half of 2015, we'd expect a higher proportion of 2016 sales to be of the newer products. We'd expect a lower proportion of dual console system sales, probably a higher proportion of system sales involving trade-ins and probably some product charges, at some point, will be more aligned with historical norms from the past. And while FX is not likely to be a strong headwind as it was in 2015, it doesn't appear as though we'll have some negative impact on revenue and margins. And then lastly, I'd say that from a competitive side, any pressure there, the impacts there [ph] are unknown at this stage."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On the investment side, as I mentioned in the script, we think that there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically. And we've been working on that for years, and",168,"On the investment side, as I mentioned in the script, we think that there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically. And we've been working on that for years, and we'll continue to do so. I think there's great potential there. On the instrumentation side, we're expanding our stapling line and our advanced energy lines. The reception has been quite good. Those are not single instruments. They're really families of instruments, and we're filling out those families as we go. We feel good about it and think it's important we'll continue to invest there. And we think that there are opportunities in robotics in terms of both structure, things like Sp and other things that can change different segments of the market. They can allow us to enter other procedures that we're not currently in today or access other regions of the world that may have different needs. And so we'll continue to invest in those things."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of David Lewis with Morgan Stanley.",15,"And we do have a question from the line of David Lewis with Morgan Stanley."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I want to come back to margins here for a second. The spread on margins, Marshall or Calvin, the sort of 68% to 69.50%, it's a wider spread. I don't think you gave us the spreads for the last year. So what defines to the upper end and lower end of thos",120,"So I want to come back to margins here for a second. The spread on margins, Marshall or Calvin, the sort of 68% to 69.50%, it's a wider spread. I don't think you gave us the spreads for the last year. So what defines to the upper end and lower end of those ranges? And I guess, secondarily, when I think about these product manufacturing improvements you're making, which seemed to have a substantial impact on gross margins in the second half of the year, I guess, I would presume those advantages or those costs would be a bigger tailwind in '16 over '15. Is that kind of a correct statement? Those 2 questions, and I have a quick follow-up."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So to characterize the -- those reductions, they had some impact in the second half of 2016. They -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the costs. I thi",169,"So to characterize the -- those reductions, they had some impact in the second half of 2016. They -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the costs. I think the bigger improvement during 2015 had to do with the lack of product charges that we mentioned in Q1. And as we move forward, the range is really -- the breadth of the range is really reflective of the items that Calvin gave you, which is that we expect to see a higher proportion of newer products. To the extent of that, we'll see. We expect to see a lower proportion of dual consoles and a higher proportion of trade-ins. The mix of systems is always difficult to predict. And frankly, geographic mix also has an implication here. And as I said in my script, there's quite a bit of lumpiness to some of the -- those geographic markets."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, Gary, a quick strategic and margin question for you as well. So the expenses we saw a couple of years ago, you made a selective [ph] decision to sort of reinvest. Is that -- I mean, this is a 50% increase in OpEx spending relative to '15,",120,"Okay. And then, Gary, a quick strategic and margin question for you as well. So the expenses we saw a couple of years ago, you made a selective [ph] decision to sort of reinvest. Is that -- I mean, this is a 50% increase in OpEx spending relative to '15, 400 to 500 basis points above. Is it -- do you see this sort of similarly [ph] as sort of the opportunity to reinvest? And is the investment spend heavier on SG&A or R&D? And the follow-up is, as -- on Sp, as you mentioned, in light of what's happening with Single-Site procedures, does that change your thinking of the opportunity around Sp? Sorry for the couple of questions there."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. Yes, in terms of the balance of investment, it really is targeted in a couple of areas. R&D is clearly one area that will get investment and then support for international markets and some of those things are more structural, not necessarily just sa",206,"Sure. Yes, in terms of the balance of investment, it really is targeted in a couple of areas. R&D is clearly one area that will get investment and then support for international markets and some of those things are more structural, not necessarily just sales folks but clinical trials and other things. So that's where the balance or the bulk of that increase is going to lay in. And we think we have technologies that are important, and we think we have process that we can bring that's important and that will serve us well in the long term in the future. With regard to Sp vis--vis Single-Site, we think that Sp really enters and add value in a different place than Single-Site does. Single-Site tended to work on a little bit more limited workspace, a little bit more constrained set of procedures. Sp is both broader and more capable. Price points are a little bit different. So when you think about Sp, when we think transoral, transanal, colorectal, places where there's specimen removal. So we look at those things, and we think about it. Sp is less oriented towards cosmetic benefits and more oriented towards being able to reach complex structures where you need to."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Tao Levy with Wedbush.",13,"And we have a question from the line of Tao Levy with Wedbush."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe we can start with U.S. system utilization. When you did the math, you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace whereby hospitals are -- could potentially accelerate the",61,"So maybe we can start with U.S. system utilization. When you did the math, you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace whereby hospitals are -- could potentially accelerate the addition of new systems in order to, again, meet your procedure growth expectations that you've laid out?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing that's important to remember in the United -- around the world but in the U.S. as well is there's not a single customer profile t",200,"Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing that's important to remember in the United -- around the world but in the U.S. as well is there's not a single customer profile that fits them all, so the average does not cover all the endpoints. And so you -- we definitely see some integrated delivery networks who are very interested in optimizing procedures per system per year and trying to drive that up to get better capital utilization, and we will help them do that. We'd see other health systems that, maybe in the exact same market, who are really interested in driving convenience for patients and for their surgeons and are willing to invest in capital once they get to the kind of a minimum hurdle rate for procedure use or utilization, and so we see both. Predicting which of the strategies is going to dominate into the year is always a little bit hard. And at the end of the day, we really focus the organization on great utilization and great support, whichever strategy our customer wants to take us down."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, right. And just my follow-up, you've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the company. So maybe you could highlight a couple of the interes",54,"Okay, right. And just my follow-up, you've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the company. So maybe you could highlight a couple of the interesting projects within imaging that we should be paying attention to."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think I -- first statement is I beg to differ. But I look at imaging platform that we brought out with Xi, and it's a fundamentally different technology basis. Distal chip imaging, it gives us room to do some things from a usability, reach and wor",255,"Sure. I think I -- first statement is I beg to differ. But I look at imaging platform that we brought out with Xi, and it's a fundamentally different technology basis. Distal chip imaging, it gives us room to do some things from a usability, reach and workflow point of view that were very hard to do otherwise, and so we continue down that pathway. So for example, in Xi, you can move a scope arm to arm. There's not a dedicated robot to hold one endoscope. So that gives you the idea of port hopping, the ability to look around the abdomen differently. The other thing that distal chip imaging gets you is the ability to articulate your endoscope, which is a part of the Sp product line, is endoscopic articulation. We continue to invest in that sort of technologies and extend our leadership position there because I think that both, you can get better image quality and more flexibility and better price points by doing that technology. So that's one set of investments. The other set is as we've mentioned with Firefly, the ability to look and see things that you can't see easily with a white light, so the ability to look and see beneath tissue or to highlight tissue structure. And there are a set of technologies there that are useful and we're investing in, but those are longer term. They take a while to develop, and as we get further down the pipeline, we'll share with you where we are."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Ben Andrew with William Blair.",14,"And we have a question from the line of Ben Andrew with William Blair."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","On the initial Sp use, Gary, that you talked about, and you listed a few applications there, should we assume that, that's where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is that",61,"On the initial Sp use, Gary, that you talked about, and you listed a few applications there, should we assume that, that's where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is that later this year or next year that maybe leads to next steps of commercializing the product?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Right. Yes, in terms of the first question, those are places where we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are our initial experience -- or we expect to have our initial experiences. I",90,"Right. Yes, in terms of the first question, those are places where we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are our initial experience -- or we expect to have our initial experiences. In terms of time lines, I'm not ready yet to tell you when in the year it will happen. We're still in conversations with regulatory bodies about pathway, and so as we get some clarity there, then we'll describe it to you later in the year."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. In that same vein, if you look out 3 or 4 years, can the Sp platform be a material percentage of the company's volumes? Or is this something that probably remains a niche, given the price point and we shouldn't really think differently about kind of",57,"Okay. In that same vein, if you look out 3 or 4 years, can the Sp platform be a material percentage of the company's volumes? Or is this something that probably remains a niche, given the price point and we shouldn't really think differently about kind of the distribution in maybe 5% or 10%, if you will?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multi-quad",150,"I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multi-quadrant access. So I think it's hard to predict long term. I think, for sure, near term, there are niches that I think it matters. Whether those niches grow into bigger opportunities, I think, remains to be seen. Having said that, the history of Intuitive and the history of technology is that as you bring raw technology into the hands of experts and they start to use it and develop it, a way leads the way. And I believe that. I think that we'll see things that develop as surgeons get deep with it. How big that gets? Impossible to predict right now."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then lastly for me, the range of procedure guidance is a little wide to start the year, obviously. And let's just try to isolate one effect, if we can. China, so if we don't see another authorization for system sales, is that a material impact w",73,"Okay. And then lastly for me, the range of procedure guidance is a little wide to start the year, obviously. And let's just try to isolate one effect, if we can. China, so if we don't see another authorization for system sales, is that a material impact within the range? Is that a percentage point or 2 in terms of a potential swing? Or how should we look at, for example, China, specifically?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to continue to be on driving growth in general surgery in our international markets, including China. When you look at the breadth of the range to your question, there's",87,"Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to continue to be on driving growth in general surgery in our international markets, including China. When you look at the breadth of the range to your question, there's far bigger impacts than just the system authorization in China when it comes to mature procedures in the U.S. and the rates of growth that we may see there that benefited us in '15 and, certainly, across a much wider range of markets."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Matt O'Brien with Piper Jaffray.",16,"And we do have a question from the line of Matt O'Brien with Piper Jaffray."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","This is actually JP, in for Matt. I just want to get back to the margin kind of profile for next year and ask in a more simpler way. So if you exclude the 70 basis points that you gained from the med tax credit, given the guidance you gave for OpEx next y",67,"This is actually JP, in for Matt. I just want to get back to the margin kind of profile for next year and ask in a more simpler way. So if you exclude the 70 basis points that you gained from the med tax credit, given the guidance you gave for OpEx next year, would we be expecting the adjusted EBIT margins to actually be down year-over-year?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I mean, I think there are a lot of layered assumptions that go into the model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors, certainly, underlying the overall assumptions there. I think what we tried",75,"Yes. I mean, I think there are a lot of layered assumptions that go into the model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors, certainly, underlying the overall assumptions there. I think what we tried to do is to lay out a lot of the factors that would be impacting the gross margin as well as the investment we're making on the expense side."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And if I could ask one on the recent clearance of the Integrated Table Motion. How is that sale going to be? And how are you guys going to get revenue from that? Is that going to be sales from Trumpf Medical, and you guys got a piece of the revenu",58,"Got it. And if I could ask one on the recent clearance of the Integrated Table Motion. How is that sale going to be? And how are you guys going to get revenue from that? Is that going to be sales from Trumpf Medical, and you guys got a piece of the revenue? Or how will that work?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Actually, Trumpf will sell the table in an independent transaction to the hospital. What we get out of it is we sell a software upgrade package for the tables that allows it to be -- to operate in an integrated fashion.",42,"Yes. Actually, Trumpf will sell the table in an independent transaction to the hospital. What we get out of it is we sell a software upgrade package for the tables that allows it to be -- to operate in an integrated fashion."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think for us the key here is we're working to make the operation more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms and redock during the procedure, make it more effici",67,"Yes. I think for us the key here is we're working to make the operation more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms and redock during the procedure, make it more efficient and, therefore, benefit certain groups of procedures and hopefully drive adoption. And I think that's really the key benefit from our perspective."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We do have a question from the line of Bob Hopkins from Bank of America.",15,"We do have a question from the line of Bob Hopkins from Bank of America."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I wanted to ask a question about 2016 revenue growth to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories where you see the potential for acceleratin",92,"So I wanted to ask a question about 2016 revenue growth to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories where you see the potential for accelerating revenue growth or entirely new growth drivers in 2016 versus what you experienced in '15? And obviously, we're well aware what the major growth drivers are. I'm kind of curious about the things that potentially are available to you in '16 that weren't available in '15."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. As you know, we look at '16 in a couple of places. I think that we have opportunity in OUS markets and various places that are important to us. Now there are some structural things that we have to overcome and invest in, and sometimes a reimbursement",161,"Yes. As you know, we look at '16 in a couple of places. I think that we have opportunity in OUS markets and various places that are important to us. Now there are some structural things that we have to overcome and invest in, and sometimes a reimbursement and sometimes they're other parts of market access. And we'll do that, but I think the opportunity there is quite good. I think in terms of other verticals, we are working on a 30-millimeter stapler. The 30-millimeter stapler is really targeted at thoracic procedures. Xi system design is -- part of its design intent was to facilitate thoracic procedures, and we're in early days there. So as time goes on, I don't think that's something that's going to leap out of the gate in the beginning part of the year, but things that we're investing in from a product and support point of view that should build momentum over the next multiple quarters."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then, Marshall, to follow up on 2 quick things, on the revenue per procedure number, you highlighted that's been very stable within a range. But it feels like the cadence of new products will pick up as we move forward there. Can we expect that line i",113,"And then, Marshall, to follow up on 2 quick things, on the revenue per procedure number, you highlighted that's been very stable within a range. But it feels like the cadence of new products will pick up as we move forward there. Can we expect that line item to start moving back up towards the old highs as we go forward here? And then the other quick thing I wanted to ask of you is that I appreciate the comment that 70% of revenues now come from disposables. Can you give us a rough sense as to what the relative profitability of that disposable stream is versus the capital side of the business?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So first, talking about the range of I&A of revenue per procedure, we would hope that we'd be able to add to that number through increases in the advanced instrument -- instrumentation, including stapling and vessel sealing. As I said, that's been so",96,"Yes. So first, talking about the range of I&A of revenue per procedure, we would hope that we'd be able to add to that number through increases in the advanced instrument -- instrumentation, including stapling and vessel sealing. As I said, that's been somewhat muted or offset by the effects of foreign exchange over the last few quarters. But there's a -- there are other factors that could change that. I don't know what the historical high you were speaking about was, but I do think that there is room for it to grow going forward."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","It was about $2,000, I think.",6,"It was about $2,000, I think."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Remember, that number has in it stocking orders and some timing of other things. So longer term, as you have a bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of th",70,"Yes. Remember, that number has in it stocking orders and some timing of other things. So longer term, as you have a bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of the pure economics of the exchange. The other question was around recurrent revenue. And remember, it's not just instruments. It's also service."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","About 50% is kind of the instruments and accessories of revenue, and 20% would be the service element to get to the 70% of recurring.",25,"About 50% is kind of the instruments and accessories of revenue, and 20% would be the service element to get to the 70% of recurring."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the margins on instruments and accessories are better than systems, and so as we get a quarter where we have a higher mix of systems, then the margins are going to be lower.",34,"And the margins on instruments and accessories are better than systems, and so as we get a quarter where we have a higher mix of systems, then the margins are going to be lower."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And that trend is likely to be durable that I&A and service will be higher-margin systems.",17,"And that trend is likely to be durable that I&A and service will be higher-margin systems."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Brandon Henry with RBC Capital Markets.",16,"And we do have a question from the line of Brandon Henry with RBC Capital Markets."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive has now shown kind of 2 years of strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think this strong performance is in 2016?",36,"So Intuitive has now shown kind of 2 years of strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think this strong performance is in 2016?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Brandon, thanks for the question. A year ago, you saw a turnaround in the volumes of da Vinci Prostatectomy in the U.S., kind of the midpoint of the year and the back half of the year started to see some growth. And that's the same throughout 2015. A",147,"Yes. Brandon, thanks for the question. A year ago, you saw a turnaround in the volumes of da Vinci Prostatectomy in the U.S., kind of the midpoint of the year and the back half of the year started to see some growth. And that's the same throughout 2015. And the rate of growth has been, certainly, above what we believe the incidence rates of prostate cancer to be in the country. And also within U.S. urology is growth in partial nephrectomy as well, which has been pretty consistent and sustained, given the profile of what da Vinci technology brings to that procedure from both a clinical outcomes and cost effectiveness perspective. As we look at 2016, our baseline assumption is that the high levels of growth that we've seen over the last 6 quarters are likely to begin returning more towards the incidence rates of the disease."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then one quick question on Sp. Can you talk about why you decided to develop Sp and essentially add on to the Xi platform and not as its own stand-alone platform? And then maybe also talk about your expectations for Sp instrumentation at launch.",63,"Okay. And then one quick question on Sp. Can you talk about why you decided to develop Sp and essentially add on to the Xi platform and not as its own stand-alone platform? And then maybe also talk about your expectations for Sp instrumentation at launch. Do you anticipate having a Vessel Sealer and a stapler at launch that will work with Sp?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the reason to make it compatible with Xi, I think it's really a straightforward thing, which is a lot of the components are shared in terms of surgeon's console and imaging systems. We want the customer experience to be seamless for our customers.",164,"Yes, on the reason to make it compatible with Xi, I think it's really a straightforward thing, which is a lot of the components are shared in terms of surgeon's console and imaging systems. We want the customer experience to be seamless for our customers. We think there are surgeons who go back and forth between Sps and Xis, and what that means is they do want the user experience to be common. We also make it easier for hospital departments to acquire capital if they already have the dual console or an Xi and they wanted just to add the Sp cart capability that makes the capital hurdle for them lower. And so it strengthens the Xi ecosystem, and I think that is a good idea and it's well received. So that has -- makes sense for us. We haven't yet announced what our instrument kit be -- will be for Sp. And when we get to that point, we'll let you now."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Richard Newitter with Leerink Partners.",15,"And we do have a question from the line of Richard Newitter with Leerink Partners."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or essentially a limited launch by the end of this year? Does that mean that, that's kind of your official launch in the",54,"Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or essentially a limited launch by the end of this year? Does that mean that, that's kind of your official launch in the end of 2016?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We don't expect material revenues in '16. We are planning on clinical experiences in '16.",16,"We don't expect material revenues in '16. We are planning on clinical experiences in '16."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for their device base",103,"Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for their device based on larger kind of buckets or broader definitions of categories like urological procedures or general abdominal procedures. Can you help us understand if this is something that you've heard the FDA say to you as well? Or is it more nuanced and that you need to go much more specific by individual procedures?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So the issue of kind of broad claim language versus narrower claim language is actually -- was part of the discussion at the FDA workshop. And I can refer you there to those minutes, and you'll see pretty much what the exchange has been. The issue, I",228,"Yes. So the issue of kind of broad claim language versus narrower claim language is actually -- was part of the discussion at the FDA workshop. And I can refer you there to those minutes, and you'll see pretty much what the exchange has been. The issue, I would not view that as something that's architecture dependent or only offered to a certain company. That has to do -- and the FDA is going to respond to these kinds of products in like manner as far as I can tell. And so that comes down to FDA asked for a certain amount of data based on the kinds of things you want to talk your customer about. And if you just want to talk about broad things and not specific things, then they ask for one set of data. And the more specific you get, the more data they ask for around that set of specifics. So in general, it's a matching of data requirements with claims. And so they're describing to you a strategy around what they think they can do from a data requirement point of view. I think the playing field will be  level here. And to the extent that customers need a certain amount of information, then it's just going to be for all of us to go create that data and deliver it."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And just lastly, on the beds, can you help us understand what procedures, if any, or certain types of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and the pro",67,"Got it. And just lastly, on the beds, can you help us understand what procedures, if any, or certain types of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and the procedures that otherwise might have been slower to adopt? Are there any specific procedures that they could really open up?"
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I -- those -- general surgeons routinely use bed motion to do 2 things: to use gravity as a retractor, so it's an extra hand using gravity; and for the anesthesiologist to manage the patient in terms of positioning with regard to other vital signs an",121,"Yes, I -- those -- general surgeons routinely use bed motion to do 2 things: to use gravity as a retractor, so it's an extra hand using gravity; and for the anesthesiologist to manage the patient in terms of positioning with regard to other vital signs and things like that. So in procedures where you're trying to manage bowel, for example, it's really helpful to have table motion, and that is clearly something that jumps out. However, once we've had it, we've now been CE marked in Europe and we've had it trialed in different specialties, I think it's appeal is broad. So we thought about it upfront initially around general surgery. I think its appeal will be broader than that."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Rick Wise with Stifel.",14,"And we do have a question from the line of Rick Wise with Stifel."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, you'll be our last questioner.",6,"Rick, you'll be our last questioner."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. I appreciate it, Gary. The -- maybe just to start here, Gary, you said several times in the course of your prepared remarks and in the Q&A that robotics is in its infancy. Just a big picture for a second, for you, are you emphasizing it because perh",115,"Okay. I appreciate it, Gary. The -- maybe just to start here, Gary, you said several times in the course of your prepared remarks and in the Q&A that robotics is in its infancy. Just a big picture for a second, for you, are you emphasizing it because perhaps this next wave of pipeline products that you've talked about and maybe some you haven't talked about are getting you more confident or excited about the potential for another growth reacceleration or an inflection point in the adoption of robotic surgery? It just -- I appreciate that the numbers of systems placed relative to hospitals are small, but just wondered if there was anything more there."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think a couple of things that excite me and lead me to believe there's a lot of opportunity, a couple. One of them is that I think in the architectures we're in today, our [indiscernible] in the markets for which we have clearances, there's still",244,"Sure. I think a couple of things that excite me and lead me to believe there's a lot of opportunity, a couple. One of them is that I think in the architectures we're in today, our [indiscernible] in the markets for which we have clearances, there's still a lot of procedures that are being done open and have opportunity to be done minimally invasively with our products, and I think that is -- comes down to execution and delivery of some of the things we have in the pipeline. Having said that, I think that as you just stand back and look out over the next decade and ask do we think that robotic-assisted surgery can impact more procedures and more types of procedures than are -- they are being impacted today, I think the answer to that is absolutely yes. Some things or things like Sp, products that look different, Sp won't be the last set of products that look different. We think there are opportunities for other products and technologies that can really make difference in surgeons delivering great care. And so we're excited about it and we're investing in it. And I think asked just about any surgeon, do you think the use of computation analytics in robotics is going to improve your practice over time or become less important, and the answer is pretty uniform that those kinds of technologies should help them if they're well delivered and well executed."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. Two last quick ones, I'll ask at the same time. Instrument and accessories growth, I think for the first time in at least 5 quarters, maybe longer, certainly since '12, annually grew -- did grow faster than procedures. I mean, is there something",116,"Got you. Two last quick ones, I'll ask at the same time. Instrument and accessories growth, I think for the first time in at least 5 quarters, maybe longer, certainly since '12, annually grew -- did grow faster than procedures. I mean, is there something that we should read into that with implications for the next couple of years? Or is it just stocking, given the flattish revenues per procedure? And the second one, I'll throw it at the same time. The bed approval, you launched it in Europe in '15. And just maybe, did your early experience there, did it drive utilization or procedures or Xi or capital sales? Any color there would be welcome."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. On the revenue per procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 to 18 40. It did kind of tick over to a growth this last",104,"Yes. On the revenue per procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 to 18 40. It did kind of tick over to a growth this last quarter as we saw utilization of advanced instruments kind of more than offset some of the headwinds mostly from exchange. But again, they're -- a lot of those factors could vary in the future in terms of procedure mix, customer efficiency, buying pattern, foreign exchange. So it's really a lot of factors there."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. Thanks, Rick. That was our last question. As we've said previously, while we focus o",213,"On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. Thanks, Rick. That was our last question. 
As we've said previously, while we focus on financial metrics such as revenues, profits and cash flow during the conference call, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. I hope the following comments from Dr. Solomon [ph], a general surgeon from Florida, gives you some sense of the impact our products have been in surgery. ""The advanced technologies and improved dexterity of the da Vinci Xi System have allowed me to perform complex minimally invasive operations with a statistically measurable improvement in outcomes. My patients are clearly and reproducibly benefiting from less pain, a shorter length of hospital stay, less time off work and lower short- and long-term complications."" We've built our company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving about a few things that clearly make a difference. This concludes today's call. Thank you for your participation, and we look forward to talking to you again in 3 months."
30239,319152206,920126,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And ladies and gentlemen, that does conclude your conference for today. Thank you for your participation and for using the AT&T Executive TeleConference Service. You may now disconnect.",28,"And ladies and gentlemen, that does conclude your conference for today. Thank you for your participation and for using the AT&T Executive TeleConference Service. You may now disconnect."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Welcome to the Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance for Investor Relati",50,"Welcome to the Intuitive Surgical Q4 2015 Earnings Release Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded. And I would now like to turn the conference over to the Senior Director of Finance for Investor Relations for Intuitive Surgical, Mr. Calvin Darling. Please go ahead, sir."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance",264,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Fourth Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 5, 2015, and 10-Q filed on October 21, 2015. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with our highlights from our fourth quarter results as described in our press release announced earlier today, followed by a question-and-answer session. 
Gary will present the quarter's business and operational highlights. Marshall will provide a review of our fourth quarter financial results. Patrick will discuss marketing and clinical highlights, and I will provide our financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I will turn it over to Gary."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surg",932,"Good afternoon, and thank you for joining us on the call today. 2015 was a good year for Intuitive with increased use of our products around the globe and solid operational execution. Our focus in 2015 was to drive adoption of our platform in general surgery, expand our da Vinci Xi Surgical System product line, increase our organizational capability and performance in international markets and improve contribution margins for our newly launched products. Themes that emerged at the close of 2014 continued into 2015, with strong performance in general surgery and international procedure growth. 
Full year global procedure growth was approximately 14%, led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States and strength in urology. U.S. general surgery growth was approximately 31% for the year, made up of strong growth in inguinal hernia repair and ventral hernia repair and colorectal surgery. Use of Single-Site in cholecystectomy and hysterectomy declined for the year. Outside of the United States, procedure growth was strong, rising approximately 26% over the procedures in 2014. Patrick will review procedure trends in greater detail later in the call. 
Looking at trends in capital sales for the year. Capital placements increased in 2015 to 492 from 431 placements in 2014. Customer interest and acceptance of our latest platform, da Vinci Xi, has been positive, with Xi making up the majority of placements for the year. In 2015, we shipped 298 systems in the United States, 90 in Europe, 77 in Asia and 27 in other global markets. Our operations teams remained focused on optimizing our manufacturing, design and supply chains for our newer products. Progress in the back half of 2015 has been solid, with steady improvements in reducing product costs for our new systems and advanced instruments. We expect our product costs to continue to improve in 2016 and 2017 as a result of these efforts. 
As we've said before, our offerings make up an ecosystem designed to encompass our customers' needs in building and running outstanding robotic surgery programs. 2015 was a year in which we focused on enabling our ecosystem with new product launches globally. We launched our da Vinci Xi System with a core set of instruments, Vessel Sealer and Firefly Fluorescence Imaging in 2014. We broadened access to our Xi system with international regulatory clearances through the year. We also added our 45-millimeter Xi stapler in Q1 as well as Harmonic Curved Shears and a second set of instruments in Q2 of 2015. We submitted our 510(k)s for our 30-millimeter stapler for Xi, Single-Site instrument kit for Xi as well as other Xi accessories in the second half of 2015. I'm pleased to report that we obtained FDA clearance for Integrated Xi Table Motion this month. In addition to products, our surgeon customers can choose from dozens of training courses provided by academic surgeons as well as courses designed for assistants and other operating room staff. Our customers own over 1,400 surgical simulators and over 600 dual consoles to assist them in technology training. In addition, our teams have provided detailed analytic and operational support for customers seeking to optimize and benchmark their programs relative to international norms. We believe the combination of these products and services are important to fully enable our customers. 
Looking back at the full year of 2015. Our operating performance is summarized as follows. Worldwide procedures grew by approximately 14%. We shipped 492 da Vinci Surgical Systems in the year, up from 431 in 2014. Total revenue was $2.4 billion, up 12% from 2014 and up 15% on a constant-currency basis. The recurring revenue grew to $1.7 billion, up 11% and comprising 70% of total revenue. We generated $946 million in pro forma operating profit, up 16% from last year. Pro forma net income was $731 million, up 20% from 2014, and we repurchased 366,000 shares at an average price of $502 per share during 2015. 
Turning to operating performance for the fourth quarter. Procedures grew approximately 15% over the fourth quarter of last year. We shipped 158 da Vinci Surgical Systems, up from 137 in the fourth quarter of 2014. 
Total pro forma revenue for the quarter was $677 million, up 13% from prior year. Instrument accessory revenue increased to $326 million, up 16%. We generated a pro forma operating profit of $293 million in the quarter, up 28% from the fourth quarter of last year; and pro forma net income was $224 million, up 22% from Q4 of 2014. 
As we look to the future, we passionately believe that robotic-assisted surgery is in its infancy in application and technology. As we have improved our costs and supply chains for new products, we anticipate increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. These include product investments in advanced imaging, advanced instrumentation and next-generation robotics. We will also continue to invest in procedure, product and program analytics, international market development and economic and clinical validation. 
Looking to 2016, our priorities are as follows. First, we'll focus on the expanded use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair. Second, we'll work to advance our ecosystem, expand -- including expanding our Xi line and taking our Sp product line into initial clinical use. Third, we'll drive our organizational capabilities in markets in Europe and Asia. And finally, we'll continue to assist our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior year Xi-traded programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and invest",1406,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes the impact of our prior year Xi-traded programs, legal settlements and legal claim accruals, stock-based compensation, amortization of purchased IP and investor impairments. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of pro forma results to our GAAP results on our website so that there's no confusion. 
Pro forma fourth quarter revenue was $677 million, an increase of 13% compared with $601 million for the fourth quarter of 2014 and an increase of 15% compared with last quarter. Pro forma revenue for the fourth quarter of 2014 excludes $4 million of revenue associated with offers made in 2014 to trade out Si products or Xi product. All trade-out offers were either fulfilled or lapsed in 2014. 
Fourth quarter 2015 procedures of approximately 177,000 increased 15% compared with the fourth quarter of 2014 and increased 9% compared with the third quarter of 2015. Procedure growth was primarily driven by general surgery procedures in the U.S., and urology worldwide. 
Revenue highlights are as follows. Pro forma instrument and accessory revenue increased 16% compared with last year and increased 9% compared with the third quarter of 2015. The increase relative to prior year reflects procedure growth and increased sales of advanced instruments, partially offset by the impact of foreign exchange. The increase over the prior quarter reflects procedure growth and sales of advanced instruments, partially offset by customer-buying patterns. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,840 per procedure. This metric has now been trending in a tight range between $1,830 and $1,840 per procedure over the past year with recent quarters reflecting higher sales of advanced instruments, offset by the impact of foreign exchange. 
Pro forma system revenue of $231 million increased 9% compared with last year and increased 32% compared with last quarter. The increase relative to the prior year primarily reflects increased unit sales. The increase relative to the third quarter reflects increased unit sales, partially offset by lower ASPs. 158 systems were placed in the fourth quarter compared with 137 systems in the fourth quarter of 2014 and 117 systems last quarter. Approximately 72% of the systems shipped in the quarter were Xis, which is comparable to prior quarter. 
Globally, our average system price of $1,550,000 was comparable to the fourth quarter of 2014 and slightly less than the $1,600,000 ASP last quarter. Relative to the prior year, increases related to a lower trade-in mix were up -- mostly offset by foreign exchange. The decrease relative to the third quarter reflects geographic mix and a lower proportion of Xi dual consoles. ASPs fluctuate quarter-to-quarter based on geographic and product mix, trade-in volume and changes in foreign exchange rates. Hospitals financed approximately 17% of the systems placed in the fourth quarter, down from 25% last quarter. We directly financed 20 systems, including placing the most operating leases, 16, since we began our direct leasing program in the second quarter of 2014. As of the end of the fourth quarter, 49 of the 3,597 systems out in the field were under operating leases. We exclude the impact of operating leases from our system ASP calculations. 
Service revenue of $120 million increased 9% year-over-year and increased 2% compared with the third quarter of 2015. The year-over-year and quarter-over-quarter increases reflect the increase in our installed base of da Vinci systems. 
Outside of U.S. results were as follows. Fourth quarter pro forma revenue outside of the U.S. of $219 million increased 11% compared with $198 million for the fourth quarter of 2014 and increased 45% compared with $151 million last quarter. The increase compared with the previous year reflects higher system unit sales and higher recurring revenue driven by procedure growth of 27%. 
Outside the U.S., we placed 75 systems in the fourth quarter compared with 66 in the fourth quarter of 2014 and 37 systems last quarter. Current quarter system sales include 13 into China, 11 into Japan, 8 into Italy and 7 into Brazil. System placements outside the U.S. will continue to be lumpy as some of these markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns, and sales into some markets are constrained by government regulation. 
The pro forma gross margin for the fourth quarter of 2015 was 69.6% compared with 67.1% for the fourth quarter of 2014 and 69.3% for the third quarter of 2015. Compared with the fourth quarter of 2014, the higher gross margin reflects lower inventory charges, improved efficiencies, partially offset by foreign exchange and a higher mix of our newer products, which carry lower gross margins than our mature products. Gross margin includes the impact of the medical device tax, which has been suspended for the next 2 years. The medical device tax reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products, on whether we are required to pay the medical device tax and costs associated with manufacturing efficiencies and product charges. 
In 2014, we recorded pretax charges of approximately $82 million, representing the estimated cost of settling a number of product and legal liability claims under a tolling agreement. During 2015, we refined our estimate of the overall cost of settling claims and recorded additional charges of approximately $14 million in the first half of the year. There were no charges in the second half of 2015. Charges made related to this agreement are excluded from our pro forma results and are included in our GAAP results. As of the end of the fourth quarter, $24 million remained accrued on our balance sheet as a significant portion of the estimated costs have been paid. 
Pro forma operating expenses, which exclude reserves for legal claims, stock compensation expense and amortization of purchased IP, increased 7% compared with the fourth quarter of 2014 and increased 6% compared with last quarter. The year-over-year increase of pro forma operating expenses primarily reflects headcount additions and higher incentive compensation. The increase relative to the third quarter primarily reflects increased incentive compensation. 
Our pro forma effective tax rate for the fourth quarter was 24.9% compared with an effective tax rate of 23.5% for the fourth quarter of 2014 and 18.4% last quarter. The effective tax rate for the third quarter of 2015 included tax benefits of $29 million or $0.77 per share related to a recent favorable tax court ruling involving an independent third party. In late December, Congress renewed the federal research and development credit, resulting in a benefit of $6 million or $0.17 per share. Congress also made the R&D tax credit permanent, so our 2016 rate guidance will reflect this benefit. Our tax rate will fluctuate with changes in the mix of U.S. and OUS income. 
Our fourth quarter 2015 pro forma net income was $224 million or $5.89 per share compared with $184 million or $4.92 per share for the fourth quarter of 2014 and $199 million or $5.24 per share for the third quarter of 2015. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $677 million for the fourth quarter of 2015 compared with $605 million for the fourth quarter 2014 and $590 million for the third quarter of 2015. GAAP net income was $190 million or $4.99 per share for the fourth quarter of 2015 compared with $147 million or $3.94 per share for the fourth quarter of 2014 and $167 million or $4.40 per share for the third quarter of 2015. 
We ended the year with cash and investments of $3.3 billion, up from $3.1 billion as of September 30, 2015. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises, partially offset by stock buybacks. During the quarter, we repurchased approximately 167,000 shares for $84 million at an average price of $505 per share. This brings our total stock repurchases for 2015 to approximately $184 million. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S",868,"Thanks, Marshall. For the fourth quarter, year-over-year procedures grew approximately 15%, with U.S. procedures growing approximately 12%, international procedures growing approximately 27%. Full year 2015 procedure growth was approximately 14%, with U.S. procedures growing approximately 11% and international procedures growing approximately 26%. 
In the U.S., fourth quarter procedure growth of approximately 12% was driven by continued strength in general surgery procedures with solid contribution coming from mature procedures despite already high levels of market penetration. We do not expect the strong 2015 growth in established U.S. urology and gynecology procedures to continue in 2016. In U.S. urology, fourth quarter growth in da Vinci prostatectomy and kidney cancer procedures continued at similar rates as earlier in the year. We continue to believe that our U.S. prostatectomy volumes has been tracking to the broader prostate surgery market. 2015 procedure growth in U.S. urology was approximately 12%, led by an approximate 11% growth in da Vinci Prostatectomy. We expect U.S. da Vinci Prostatectomy procedure volumes to return to a level more in line with prostate cancer incidence rates moving forward. 
In U.S. gynecology, fourth quarter procedures grew modestly year-over-year with growth in malignant and complex hysterectomy, partially offset by declines in benign procedures. During 2015, a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists compared to 2014. For the year, growth in U.S. gynecology procedures was approximately 1%. In 2016, sustaining growth in U.S. gynecology may be a challenge as we believe the total market for benign hysterectomies will continue to decline at a low single-digit rate. 
Fourth quarter growth in U.S. general surgery remains strong, with robust growth in hernia repair and continued adoption of colorectal procedures being partially offset by continued declines in cholecystectomies. U.S. general surgery procedure growth was approximately 31% for the year with broad-based growth across several procedures, led by hernia repair, which generated the largest number of new general surgery procedures. Growth in colorectal resections was also strong during 2015.  In 2016, there remains a large opportunity in hernia repair and colorectal resections, and driving adoption in these markets remains among our top priorities. 
During the quarter, a group of general surgeons led by Dr. Vorst from St. Joseph Mercy Health System and Dr. Carbonell from the University of South Carolina School of Medicine published their perspective on advances in ventral and incisional hernia repair in the World Journal of Gastrointestinal Surgery. Within the paper, data comparing the robotic to open Rives-Stoppa technique for more complex hernias favored the robotic approach with the reduction of blood loss, shorter length of hospital stay, fewer surgical site infections and no difference in operative times or direct costs. The paper states that robotic approach ""permits relatively easy access to the anterior abdominal wall, allowing the surgeon to perform the ideal repair for that patient. It also might allow for standardization of surgical technique in order to develop a reliable approach to hernia repair that can be offered to an increasing number of patients."" 
Regarding our U.S. Single-Site business, cholecystectomy volumes continued to decline during the fourth quarter though mostly offset by growth in multiport cholecystectomies. In addition, our Single-Site gynecology procedure volumes declined in the fourth quarter. Taken together, Single-Site procedures represented less than 5% of our fourth quarter U.S. procedure volume. 
Looking abroad during the fourth quarter, the approximate 27% international procedure growth was led by the global adoption of da Vinci Prostatectomy with solid contributions from kidney procedures, malignant hysterectomies and colorectal resections. For the full year, procedure growth was approximately 26%. Procedure growth in Europe remained steady throughout 2015. In Asia, procedure growth was led by broad-based adoption in China and South Korea and da Vinci Prostatectomy adoption in Japan. 
During 2016, we expect several external factors to impact international procedure growth. In Japan, the Surgical Society have submitted for reimbursement of partial nephrectomies to the MHLW. Pending the MHLW's decision, this may serve as a tailwind to Japanese procedure growth. In China, we've placed 32 of the 38 da Vinci systems under the current authorization. And sustaining strong procedure growth throughout 2016 may require additional authorizations from the government. 
During the quarter, the global evidence for the cost effectiveness for the use of da Vinci surgery in gynecologic oncology continued to build. A new study from Copenhagen University Hospital by Dr. Hurley [ph] and colleagues modeled the clinical and economic impact of the adoption of da Vinci for malignant hysterectomies, capturing the comprehensive cost of care associated with these interventions. The study compared 158 open hysterectomies to 202 da Vinci hysterectomies and found the da Vinci hysterectomies were 17% less expensive than open hysterectomies based on operating costs and 7% less expensive than open hysterectomies when the da Vinci system cost was included. The study found that cost savings associated with fewer complications and shorter hospitalization more than offset the incremental costs associated with the use of da Vinci technology in the operating room. 
2015 was a robust year for clinical publications featuring da Vinci surgery with over 1,600 papers published during the year, bringing total clinical publications to over 10,000. 
This concludes my remarks. I thank you for your time. I will now turn the call over to Calvin."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our financial outlook for 2016. Starting with procedures. As described in our announcement last week, 2015 da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. Dur",342,"Thank you, Patrick. I will be providing you with our financial outlook for 2016. 
Starting with procedures. As described in our announcement last week, 2015 da Vinci procedures grew approximately 14% to roughly 652,000 procedures performed worldwide. During 2016, we anticipate full year procedure growth within a range of 9% to 12%. We expect similar seasonal timing of procedures in 2016 as we've experienced in previous years, with Q1 being the seasonally weakest quarter as patient deductibles are reset. 
With respect to revenue, we expect 2016 capital sales to follow historical seasonal patterns, which we anticipate will become more pronounced, with Q1 being sequentially lower than the recently completed Q4. System placements will likely continue to be lumpy, particularly in markets outside of the U.S. as some of these markets are in early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns, and sales into some markets are constrained by government regulations. 
Turning to gross profit. We expect our 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. Our actual gross profit margin will vary quarter-to-quarter, depending largely on product and regional mix. 
Turning to operating expenses. As Gary mentioned, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. We expect to grow 2016 operating expenses between 9% and 13% above 2015 levels. We expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income, which is comprised mostly of interest income, to total between $20 million and $25 million in 2016. 
With regard to income tax, we expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. This forecast does reflect the reinstatement of the R&D tax credit in 2016. 
That concludes our prepared remarks. We will now open the call to your questions."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs.",17,"[Operator Instructions] And our first question today comes from the line of David Roman with Goldman Sachs."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape. In robotics,",105,"I wanted to start with one strategic question and one follow-up on the financial guidance that Calvin just provided. Maybe on the strategic side, I was hoping, Gary, you could go into your thoughts as it relates to the competitive landscape. In robotics, we've heard over the past several months announcements from a couple of emerging competitors, and there's an expected announcement from another competitor later in 2016. Can you maybe talk about how you envision the competitive landscape unfolding and some of the activities you may be undertaking to prepare Intuitive for moving from a monopoly-type market to one that has multiple players?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive great outcomes and compared or weighed against the price of those things. We think about it as an ecos",263,"Sure. As we look at it, value and competition, at the end of the day, value is going to be driven by the ability of these products and services to drive great outcomes and compared or weighed against the price of those things. We think about it as an ecosystem. We think the ecosystem is really important. So it's easy to think just about the robotic system because that's the most visible part, but there's the system, the instruments and accessories, advanced instrumentation like stapling, imaging systems, fluorescence imaging, training technologies like simulators and dual console, clinical validation, training courses offered by academic surgeons that number in the dozens, that whole set of products and ecosystem we think is important. And so as competitors enter, they have to choose. Can they show that value in terms of outcomes and price? And can they offer the set of ecosystem elements that are going to be useful? We've known for years, and have anticipated for years, we didn't wake up yesterday and think, ""Competitors are coming. We better do something."" And so we've been thoughtful about what we need to do to create value for our customers. We have a range of products in the system side that hits different price points for different feature content. We have different options that are available in terms of instrumentation price points, and so we think we're really well positioned. There are some other companies out there. They'll be capable. We expect that customers will explore what they're offering. We think we're well positioned when that exploration occurs."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's helpful. And then maybe just to go into the financial side for a second. Calvin, I just to understand what you're saying on the margins for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit",131,"Okay. That's helpful. And then maybe just to go into the financial side for a second. Calvin, I just to understand what you're saying on the margins for 2016. The gross margin range seems to imply that on an underlying basis, when you take out the benefit of the medical device tax, you're seeing a deterioration from where you sort of exited the second half of 2015. What are the factors influencing that math? And then on the OpEx side, the 9% to 13%, represents a pretty decent acceleration from what we saw this year. Can you maybe help put some of those investments into context? Where those dollars are going and whether 2016 represents a new normal year of investment spending or there's something particular that you're after this year?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. Like Gary said on the call, we're focused on reducing our cost of the new products and we've been managing our f",218,"Sure, David. I'll take you through some of the gross profit commentary and let Gary take you through some of the investments on the OpEx side. Like Gary said on the call, we're focused on reducing our cost of the new products and we've been managing our fixed costs very carefully. We're pleased with the progress we've been making throughout 2015. Our second half 2015 gross profit benefited from favorable product mix, essentially 0 product charges and other favorable outcomes. In 2016, we do expect to deliver continued cost reductions on the newer products, including the Xi stapler, Vessel Sealer and Xi endoscopes. At the same time, as compared with the second half of 2015, we'd expect a higher proportion of 2016 sales to be of the newer products. We'd expect a lower proportion of dual console system sales, probably a higher proportion of system sales involving trade-ins and probably some product charges, at some point, maybe more aligned with historical norms from the past. And while FX is not likely to be as strong a headwind as it was in 2015, it does appear as though it will have some negative impact on revenue and margins. And then lastly, I'd say that from a competitive side, any pressure there, the impacts that are unknown at this stage."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On the investment side, as I had mentioned in the script, we think that there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically. And we've been working on that for years,",169,"On the investment side, as I had mentioned in the script, we think that there's significant opportunity to improve what surgeons can see during cases, improving imaging through a variety of means technologically. And we've been working on that for years, and we'll continue to do so. I think there's great potential there. On the instrumentation side, we're expanding our stapling line and our advanced energy lines. The reception has been quite good. Those are not single instruments. They're really families of instruments, and we're filling out those families as we go. We feel good about it and think it's important we'll continue to invest there. And we think that there are opportunities in robotics in terms of both structure, things like Sp and other things that can change different segments of the market. They can allow us to enter other procedures that we're not currently in today or access other regions of the world that may have different needs. And so we'll continue to invest in those things."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of David Lewis with Morgan Stanley.",15,"And we do have a question from the line of David Lewis with Morgan Stanley."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I want to come back to margins here for a second. The spread on margins, Marshall or Calvin, the sort of 68% to 69.50%, it's a wider spread. I don't think you gave us the spreads for the last year. So what defines sort of the upper end and lower end of",121,"So I want to come back to margins here for a second. The spread on margins, Marshall or Calvin, the sort of 68% to 69.50%, it's a wider spread. I don't think you gave us the spreads for the last year. So what defines sort of the upper end and lower end of those ranges? And I guess, secondarily, when I think about these product manufacturing improvements you're making, which seemed to have a substantial impact on gross margins in the second half of the year, I guess, I would presume those advantages or those costs would be a bigger tailwind in '16 over '15. Is that kind of a correct statement? Those 2 questions, and I have a quick follow-up."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So to characterize the -- reductions, they had some impact in the second half of 2016. They -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the costs. I think the",167,"So to characterize the -- reductions, they had some impact in the second half of 2016. They -- or '15, sorry. They will have a more significant impact in '16 and '17. And we -- as Calvin had said, we'll continue to focus on reducing the costs. I think the bigger improvement during 2015 had to do with the lack of product charges that we mentioned in Q1. And as we move forward, the range is really -- the breadth of the range is really reflective of the items that Calvin gave you, which is that we expect to see a higher proportion of newer products. The extent of that, we'll see. We expect to see a lower proportion of dual consoles and a higher proportion of trade-ins. The mix of systems is always difficult to predict. And frankly, geographic mix also has an implication here. And as I said in my script, there's quite a bit of lumpiness to some of the -- those geographic markets."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, Gary, a quick strategic and margin question for you as well. So the expenses we saw a couple of years ago, you made a selective decision to sort of reinvest. Is that -- I mean, this is a 50% increase in OpEx spending relative to '15, 400 t",118,"Okay. And then, Gary, a quick strategic and margin question for you as well. So the expenses we saw a couple of years ago, you made a selective decision to sort of reinvest. Is that -- I mean, this is a 50% increase in OpEx spending relative to '15, 400 to 500 basis points above. Is it -- do you see this sort of similarly as sort of the opportunity to reinvest? And is the investment spend heavier on SG&A or R&D? And then the follow-up just is on Sp, as you mentioned, in light of what's happening with Single-Site procedures, does that change your thinking of the opportunity around Sp? Sorry for the couple of questions there."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. Yes, in terms of the balance of investment, it really is targeted in a couple of areas. R&D is clearly one area that will get investment and then support for international markets and some of those things are more structural, not necessarily just sa",206,"Sure. Yes, in terms of the balance of investment, it really is targeted in a couple of areas. R&D is clearly one area that will get investment and then support for international markets and some of those things are more structural, not necessarily just sales folks but clinical trials and other things. So that's where the balance or the bulk of that increase is going to lay in. And we think we have technologies that are important, and we think we have process that we can bring that's important and that will serve us well in the long term in the future. With regard to Sp vis--vis Single-Site, we think that Sp really enters and adds value in a different place than Single-Site does. Single-Site tended to work on a little bit more limited workspace, a little bit more constrained set of procedures. Sp is both broader and more capable. Price points are a little bit different. So when you think about Sp, when we think transoral, transanal, colorectal, places where there's specimen removal. So we look at those things, and we think about it. Sp is less oriented towards cosmetic benefits and more oriented towards being able to reach complex structures where you need to."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Tao Levy with Wedbush.",13,"And we have a question from the line of Tao Levy with Wedbush."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe we can start with U.S. system utilization. When you do the math, you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace whereby hospitals are -- could potentially accelerate the a",61,"So maybe we can start with U.S. system utilization. When you do the math, you're reaching peak levels here in the U.S. in terms of averages. And so what's the dynamic currently in the marketplace whereby hospitals are -- could potentially accelerate the addition of new systems in order to, again, meet your procedure growth expectations that you've laid out?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing that's important to remember in the United -- around the world but in the U.S. as well is there's not a single customer profile t",199,"Yes, I think as we look at -- make sure I interpret the question right. I think as we look at utilization patterns, one thing that's important to remember in the United -- around the world but in the U.S. as well is there's not a single customer profile that fits them all, so the average does not cover all the endpoints. And so you -- we definitely see some integrated delivery networks who are very interested in optimizing procedures per system per year and trying to drive that up to get better capital utilization, and we will help them do that. We'd see other health systems that, maybe in the exact same market, who are really interested in driving convenience for patients and for their surgeons and are willing to invest in capital once they get to kind of a minimum hurdle rate for procedure use or utilization, and so we see both. Predicting which of those strategies is going to dominate into the year is always a little bit hard. And at the end of the day, we really focus the organization on great utilization and great support, whichever strategy our customer wants to take us down."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, right. And just my follow-up, you've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the company. So maybe you could highlight a couple of the interes",54,"Okay, right. And just my follow-up, you've talked a couple of times about investing more and more into imaging. And aside from Firefly, we haven't seen anything very significant come out of the company. So maybe you could highlight a couple of the interesting projects within imaging that we should be paying attention to."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think I -- first statement is I beg to differ. But I look at the imaging platform that we brought out with Xi and it's a fundamentally different technology basis. Distal chip imaging, it gives us room to do some things from a usability, reach and",257,"Sure. I think I -- first statement is I beg to differ. But I look at the imaging platform that we brought out with Xi and it's a fundamentally different technology basis. Distal chip imaging, it gives us room to do some things from a usability, reach and workflow point of view that were very hard to do otherwise, and so we continue down that pathway. So for example, in Xi, you can move a scope arm to arm. There's not a dedicated robot to hold one endoscope. So that gives you the idea of port hopping, the ability to look around the abdomen differently. The other thing that distal chip imaging gets you is the ability to articulate your endoscope, which is a part of the Sp product line, is endoscopic articulation. We continue to invest in that set of technologies and expand our leadership position there because I think that both -- you can get better image quality and more flexibility and better price points by doing that technology. So that's one set of investments. The other set is as you've mentioned with Firefly, the ability to look and see things that you can't see easily with a white light, so the ability to look and see beneath tissue or to highlight tissue structure. And there are a set of technologies there that are useful and we're investing in, but those are longer term. They take a while to develop, and as we get further down the pipeline, we'll share with you where we are."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from the line of Ben Andrew with William Blair.",14,"And we have a question from the line of Ben Andrew with William Blair."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","On the initial Sp use, Gary, that you talked about, and you listed a few applications there, should we assume that that's where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is that l",61,"On the initial Sp use, Gary, that you talked about, and you listed a few applications there, should we assume that that's where we'll see kind of some initial clinical work? And when might we see results from those either published or discussed? Is that later this year or next year that maybe leads to next steps of commercializing the product?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Right. Yes, in terms of the first question, those are places where we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are our initial experience -- or we expect to have our initial experiences. I",90,"Right. Yes, in terms of the first question, those are places where we are intending to explore, so colorectal and transoral. We will also explore other places in time, but those are our initial experience -- or we expect to have our initial experiences. In terms of time lines, I'm not ready yet to tell you when in the year it will happen. We're still in conversations with regulatory bodies about pathway, and so as we get some clarity there, then we'll describe it to you later in the year."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. In that same vein, if you look out 3 or 4 years, can the Sp platform be a material percentage of the company's volumes? Or is this something that probably remains a niche, given the price point and we shouldn't really think differently about kind of",57,"Okay. In that same vein, if you look out 3 or 4 years, can the Sp platform be a material percentage of the company's volumes? Or is this something that probably remains a niche, given the price point and we shouldn't really think differently about kind of the distribution and maybe 5% or 10%, if you will?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multi-quad",150,"I think that it offers surgeons a different way to think about getting into the body and a different approach. It can deliver a lot of capability in a small package parallel into the body, and it can move about the body quite easily in terms of multi-quadrant access. So I think it's hard to predict long term. I think, for sure, near term, there are niches that I think it matters. Whether those niches grow into bigger opportunities, I think, remains to be seen. Having said that, the history of Intuitive and the history of technology is that as you bring raw technology into the hands of experts and they start to use it and develop it, a way leads to way. And I believe that. I think that we'll see things that develop as surgeons get deep with it. How big that gets? Impossible to predict right now."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then lastly for me, the range of procedure guidance is a little wide to start the year, obviously. And let's just try to isolate one effect, if we can. China, so if we don't see another authorization for system sales, is that a material impact w",73,"Okay. And then lastly for me, the range of procedure guidance is a little wide to start the year, obviously. And let's just try to isolate one effect, if we can. China, so if we don't see another authorization for system sales, is that a material impact within the range? Is that a percentage point or 2 in terms of a potential swing? Or how should we look at, for example, China, specifically?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to continue to be on driving growth in general surgery in our international markets, including China. When you look at the breadth of the range, to your question, there'",88,"Thanks for the question, Ben. When it comes to procedure guidance, our focus is going to continue to be on driving growth in general surgery in our international markets, including China. When you look at the breadth of the range, to your question, there's far bigger impacts than just the system authorization in China when it comes to the mature procedures in the U.S. and the rates of growth that we may see there that benefited us in '15 and, certainly, across a much wider range of markets."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Matt O'Brien with Piper Jaffray.",16,"And we do have a question from the line of Matt O'Brien with Piper Jaffray."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","This is actually JP, in for Matt. I just want to get back to the margin kind of profile for next year and ask it in a more simple way. So if you exclude the 70 basis points that you gained from the med tax credit, given the guidance you gave for OpEx next",68,"This is actually JP, in for Matt. I just want to get back to the margin kind of profile for next year and ask it in a more simple way. So if you exclude the 70 basis points that you gained from the med tax credit, given the guidance you gave for OpEx next year, would we be expecting the adjusted EBIT margins to actually be down year-over-year?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I mean, I think there are a lot of layered assumptions that go into the model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors, certainly, underlying the overall assumptions there. I think what we tried",75,"Yes. I mean, I think there are a lot of layered assumptions that go into the model, and we don't have specific guidance as it relates to that. Revenue would be one of the factors, certainly, underlying the overall assumptions there. I think what we tried to do is to lay out a lot of the factors that would be impacting the gross margin as well as the investment we're making on the expense side."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And if I could ask one on the recent clearance of the Integrated Table Motion. How is that sale going to be? And how are you guys going to get revenue from that? Is that going to be sales from Trumpf Medical, and you guys have got a piece of the r",59,"Got it. And if I could ask one on the recent clearance of the Integrated Table Motion. How is that sale going to be? And how are you guys going to get revenue from that? Is that going to be sales from Trumpf Medical, and you guys have got a piece of the revenue? Or how will that work?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Actually, Trumpf will sell the table in an independent transaction to the hospital. What we get out of it is we sell a software upgrade package for the table that allows it to be -- to operate in an integrated fashion.",42,"Yes. Actually, Trumpf will sell the table in an independent transaction to the hospital. What we get out of it is we sell a software upgrade package for the table that allows it to be -- to operate in an integrated fashion."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think for us the key here is we're working to make the operation more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms and redock during the procedure, make it more effici",67,"Yes. I think for us the key here is we're working to make the operation more efficient, right? This will make the ability for surgeons to reposition the patient without having to withdraw the robot arms and redock during the procedure, make it more efficient and, therefore, benefit certain groups of procedures and hopefully drive adoption. And I think that's really the key benefit from our perspective."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We do have a question from the line of Bob Hopkins from Bank of America.",15,"We do have a question from the line of Bob Hopkins from Bank of America."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I wanted to ask a question about 2016 revenue growth to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories where you see the potential for acceleratin",92,"So I wanted to ask a question about 2016 revenue growth to start. Can you give us a sense as to where you see incremental opportunities for acceleration? So what are the areas where you see or product categories where you see the potential for accelerating revenue growth or entirely new growth drivers in 2016 versus what you experienced in '15? And obviously, we're well aware what the major growth drivers are. I'm kind of curious about the things that potentially are available to you in '16 that weren't available in '15."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. As you know, we look at '16 in a couple of places. I think that we have opportunity in OUS markets and various places that are important to us. Now there are some structural things that we have to overcome and invest in, and sometimes a reimbursement",161,"Yes. As you know, we look at '16 in a couple of places. I think that we have opportunity in OUS markets and various places that are important to us. Now there are some structural things that we have to overcome and invest in, and sometimes a reimbursement and sometimes they're other parts of market access. And we'll do that, but I think the opportunity there is quite good. I think in terms of other verticals, we are working on a 30-millimeter stapler. The 30-millimeter stapler is really targeted at thoracic procedures. Xi system design is -- part of its design intent was to facilitate thoracic procedures, and we're in early days there. So as time goes on, I don't think that's something that's going to leap out of the gate in the beginning part of the year, but things that we're investing in from a product and support point of view that should build momentum over the next multiple quarters."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then, Marshall, to follow up on 2 quick things, on the revenue per procedure number, you highlighted that's been very stable within a range. But it feels like the cadence of new products will pick up as we move forward there. Can we expect that line i",113,"And then, Marshall, to follow up on 2 quick things, on the revenue per procedure number, you highlighted that's been very stable within a range. But it feels like the cadence of new products will pick up as we move forward there. Can we expect that line item to start moving back up towards the old highs as we go forward here? And then the other quick thing I wanted to ask of you is that I appreciate the comment that 70% of revenues now come from disposables. Can you give us a rough sense as to what the relative profitability of that disposable stream is versus the capital side of the business?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So first, talking about the range of I&A of revenue per procedure, we would hope that we'd be able to add to that number through increases in the advanced instrument -- instrumentation, including stapling and vessel sealing. As I said, that's been so",96,"Yes. So first, talking about the range of I&A of revenue per procedure, we would hope that we'd be able to add to that number through increases in the advanced instrument -- instrumentation, including stapling and vessel sealing. As I said, that's been somewhat muted or offset by the effects of foreign exchange over the last few quarters. But there's a -- there are other factors that could change that. I don't know what the historical high you were speaking about was, but I do think that there is room for it to grow going forward."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","It was about $2,000, I think.",6,"It was about $2,000, I think."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Remember, that number has in it stocking orders and some timing of other things. So longer term, as you have a bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of th",70,"Yes. Remember, that number has in it stocking orders and some timing of other things. So longer term, as you have a bigger and bigger installed base, the relative value of stocking orders is going to go down, and that has nothing to do with the sort of the pure economics of the exchange. The other question was around recurrent revenue. And remember, it's not just instruments. It's also service."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","About 50% is kind of the instruments and accessories of revenue, and 20% would be the service element to get to the 70% of recurring.",25,"About 50% is kind of the instruments and accessories of revenue, and 20% would be the service element to get to the 70% of recurring."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the margins on instruments and accessories are better than systems, and so as we get a quarter where we have a higher mix of systems, then the margins are going to be lower.",34,"And the margins on instruments and accessories are better than systems, and so as we get a quarter where we have a higher mix of systems, then the margins are going to be lower."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And that trend is likely to be durable that I&A and service will be higher-margin systems.",17,"And that trend is likely to be durable that I&A and service will be higher-margin systems."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Brandon Henry with RBC Capital Markets.",16,"And we do have a question from the line of Brandon Henry with RBC Capital Markets."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive has now shown kind of 2 years of strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think this strong performance is in 2016?",36,"So Intuitive has now shown kind of 2 years of strong U.S. urology growth. Can you discuss the reasons for this outperformance in urology and how sustainable you think this strong performance is in 2016?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Brandon, thanks for the question. A year ago, you saw a turnaround in the volumes of da Vinci Prostatectomy in the U.S. kind of the midpoint of the year, and the back half of the year started to see some growth. And that sustained throughout 2015. An",146,"Yes. Brandon, thanks for the question. A year ago, you saw a turnaround in the volumes of da Vinci Prostatectomy in the U.S. kind of the midpoint of the year, and the back half of the year started to see some growth. And that sustained throughout 2015. And the rate of growth has been, certainly, above what we believe the incidence rates of prostate cancer to be in the country. And also within U.S. urology is growth in partial nephrectomy as well, which has been pretty consistent and sustained, given the profile of what da Vinci technology brings to that procedure from both a clinical outcomes and cost effectiveness perspective. As we look at 2016, our baseline assumption is that the high levels of growth that we've seen over the last 6 quarters are likely to begin returning more towards the incidence rates of the disease."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then one quick question on Sp. Can you talk about why you decided to develop Sp as, essentially, an add on to the Xi platform and not as its own stand-alone platform? And then maybe also talk about your expectations for Sp instrumentation at lau",64,"Okay. And then one quick question on Sp. Can you talk about why you decided to develop Sp as, essentially, an add on to the Xi platform and not as its own stand-alone platform? And then maybe also talk about your expectations for Sp instrumentation at launch. Do you anticipate having a Vessel Sealer and a stapler at launch that will work with Sp?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the reason to make it compatible with Xi, I think it's really a straightforward thing, which is a lot of the components are shared in terms of surgeon's console and imaging systems. We want the customer experience to be seamless for our customers.",163,"Yes, on the reason to make it compatible with Xi, I think it's really a straightforward thing, which is a lot of the components are shared in terms of surgeon's console and imaging systems. We want the customer experience to be seamless for our customers. We think there are surgeons who go back and forth between Sps and Xis, and what that means is that you want the user experience to be common. We also make it easier for hospital departments to acquire capital if they already have a dual console or an Xi and they want just to add the Sp cart capability that makes the capital hurdle for them lower. And so it strengthens the Xi ecosystem, and I think that is a good idea and it's well received. So that has made sense for us. We haven't yet announced what our instrument kit be -- will be for Sp. And when we get to that point, we'll let you now."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Richard Newitter with Leerink Partners.",15,"And we do have a question from the line of Richard Newitter with Leerink Partners."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or, essentially, a limited launch by the end of this year? Does that mean that that's kind of your official launch in th",54,"Maybe just one on Sp and then I had one on the rotating bed. On Sp, Gary, did you say that you're moving into clinical kind of testing or, essentially, a limited launch by the end of this year? Does that mean that that's kind of your official launch in the end of 2016?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We don't expect material revenues in '16. We are planning on clinical experiences in '16.",16,"We don't expect material revenues in '16. We are planning on clinical experiences in '16."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for their device base",104,"Okay. Got it. And then on Sp, on the approval process, I know you said that it's kind of in discussion with the FDA right now. There is a competitor of yours that has a device that they're saying that they think they can get approval for their device based on larger kind of buckets or broader definitions of categories like urological procedures or general abdominal procedures. Can you help us understand if this is something that you've heard the FDA say to you as well? Or is it more nuanced than that and you need to go much more specific by individual procedures?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So the issue of kind of broad claim language versus narrower claim language is actually -- was part of the discussion at the FDA workshop. And I can refer you there to those minutes, and you'll see pretty much what the exchange has been. The issue, I",231,"Yes. So the issue of kind of broad claim language versus narrower claim language is actually -- was part of the discussion at the FDA workshop. And I can refer you there to those minutes, and you'll see pretty much what the exchange has been. The issue, I would not view that as something that's architecture dependent or only offered to a certain company. That has to do -- and in other words the FDA is going to respond to these kind of products in like manner as far as I can tell. And so that comes down to FDA asked for a certain amount of data based on the kinds of things you want to talk your customer about. And if you just want to talk about broad things and not specific things, then they ask for one set of data. And the more specific you get, the more data they ask for around that set of specifics. So in general, it's a matching of data requirements with claims. And so they're describing to you a strategy around what they -- they can do from a data requirement point of view. I think the playing field will be  level here. And to the extent that customers need a certain amount of information, then it's just going to be for all of us to go create that data and deliver it."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And just lastly, on the bed, can you help us understand what procedures, if any, or certain types of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and procedur",66,"Got it. And just lastly, on the bed, can you help us understand what procedures, if any, or certain types of surgeons that might have been on the sidelines for whom this product might kind of push them over the fence and really drive adoption and procedures that otherwise might have been slower to adopt? Are there any specific procedures that, that could really open up?"
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I -- those -- general surgeons routinely use bed motion to do 2 things: to use gravity as a retractor, so it's an extra hand using gravity; and for the anesthesiologist to manage the patient in terms of positioning with regard to other vital signs an",121,"Yes, I -- those -- general surgeons routinely use bed motion to do 2 things: to use gravity as a retractor, so it's an extra hand using gravity; and for the anesthesiologist to manage the patient in terms of positioning with regard to other vital signs and things like that. So in procedures where you're trying to manage bowel, for example, it's really helpful to have table motion, and that is clearly something that jumps out. However, once we've had it, we've now received CE mark in Europe and we've had it trialed in different specialties, I think its appeal is broad. So we thought about it upfront, initially, around general surgery. I think its appeal will be broader than that."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we do have a question from the line of Rick Wise with Stifel.",14,"And we do have a question from the line of Rick Wise with Stifel."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, you'll be our last questioner.",6,"Rick, you'll be our last questioner."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. I appreciate it, Gary. The -- maybe just to start here, Gary, you said several times in the course of your prepared remarks and in the Q&A that robotics is in its infancy. Just a big picture for a second, for you, are you emphasizing it because perh",115,"Okay. I appreciate it, Gary. The -- maybe just to start here, Gary, you said several times in the course of your prepared remarks and in the Q&A that robotics is in its infancy. Just a big picture for a second, for you, are you emphasizing it because perhaps this next wave of pipeline products that you've talked about and maybe some you haven't talked about are getting you more confident or excited about the potential for another growth reacceleration or an inflection point in the adoption of robotic surgery? It just -- I appreciate that the numbers of systems placed relative to hospitals are small, but just wondered if there was anything more there."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think a couple of things that excite me and lead me to believe there's a lot of opportunity -- a couple. One of them is that I think in the architectures we're in today, our focus -- and in the markets for which we have clearance, there's still a",249,"Sure. I think a couple of things that excite me and lead me to believe there's a lot of opportunity -- a couple. One of them is that I think in the architectures we're in today, our focus -- and in the markets for which we have clearance, there's still a lot of procedures that are being done open and have opportunity to be done minimally invasively with our products. And I think that is -- comes down to execution and delivery of some of the things we have in the pipeline. Having said that, I think that as you just stand back and look out over the next decade and ask do we think that robotic-assisted surgery can impact more procedures and more types of procedures than are -- they are being impacted today, I think the answer to that is absolutely yes. Some things are things like Sp, products that look different, Sp won't be the last set of products that look different. We think there are opportunities for other products and technologies that can really make a difference in surgeons delivering great care. And so we're excited about it and we're investing in it. And I think ask just about any surgeon: do you think that the use of computation analytics and robotics is going to improve your practice over time or become less important? And the answer is pretty uniform that those kinds of technologies should help them if they're well delivered and well executed."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. Two last quick ones, I'll ask at the same time. Instrument and accessories growth, I think for the first time in at least 5 quarters, maybe longer, certainly since '12, annually grew -- did grow faster than procedures. I mean, is there something",118,"Got you. Two last quick ones, I'll ask at the same time. Instrument and accessories growth, I think for the first time in at least 5 quarters, maybe longer, certainly since '12, annually grew -- did grow faster than procedures. I mean, is there something that we should read into that with implications for the next couple of years? Or is it just stocking, given the flattish revenues per procedure? And the second one, I'll throw it at you at the same time. The bed approval, you launched it in Europe in '15. And just maybe, did your early experience there, did it drive utilization or procedures or Xi or capital sales? Any color there would be welcome."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. On the revenue per procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 to 18 40. It did kind of tick over to a growth this last",104,"Yes. On the revenue per procedure, I don't think there's much more than what we said. There's a lot of factors that impact that particular metric. It has been running in a pretty tight range, 18 30 to 18 40. It did kind of tick over to a growth this last quarter as we saw utilization of advanced instruments kind of more than offset some of the headwinds mostly from exchange. But again, they're -- a lot of those factors could vary in the future in terms of procedure mix, customer efficiency, buying pattern, foreign exchange. So it's really a lot of factors there."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Executives","On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. Thanks, Rick. That was our last question. As we've said previously, while we focus o",213,"On Xi, the surgeon feedback has been outstanding. Too soon to tell in terms of number of sites and duration as to what the changes in trends are, but we'll be watching. Thanks, Rick. That was our last question. 
As we've said previously, while we focus on financial metrics such as revenues, profits and cash flow during the conference call, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. I hope the following comments from Dr. Solomon [ph], a general surgeon from Orlando, Florida, gives you some sense of the impact our products have in surgery. ""The advanced technologies and improved dexterity of the da Vinci Xi System have allowed me to perform complex minimally invasive operations with a statistically measurable improvement in outcomes. My patients are clearly and reproducibly benefiting from less pain, a shorter length of hospital stay, less time off work and lower short- and long-term complications."" We've built our company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the products we think that truly make a difference. This concludes today's call. Thank you for your participation, and we look forward to talking to you again in 3 months."
30239,319152206,920154,"Intuitive Surgical, Inc., Q4 2015 Earnings Call, Jan 21, 2016",2016-01-21,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And ladies and gentlemen, that does conclude your conference for today. Thank you for your participation and for using the AT&T Executive TeleConference Service. You may now disconnect.",28,"And ladies and gentlemen, that does conclude your conference for today. Thank you for your participation and for using the AT&T Executive TeleConference Service. You may now disconnect."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded, and I'll now turn the meeting over to our host, Senior Director",50,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded, and I'll now turn the meeting over to our host, Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance.",255,"Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our first quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our first quarter financial results. Patrick will discuss marketing and clinical highlights, then I'll provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. Turning firs",768,"Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. 
Turning first to procedures. Global procedure growth for the quarter was nearly 17%, led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States, continued growth in U.S. urology and modest growth in U.S. gynecology. Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair, followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of da Vinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance. Procedure growth was variable by country in Europe with solid performance in the United Kingdom and Germany offsetting slower growth in the Nordic countries. Performance in the quarter was helped by an extra procedure day in some regions relative to Q1 of 2015. Patrick will review procedure trends in greater detail later in the call. 
We placed 110 da Vinci systems in the quarter, up from 99 in Q1 of 2015. Customers continue to purchase our Xi systems over less expensive and less capable Si models by a factor of approximately 3:1. Capital performance was strong in the United States, offsetting capital softness in Europe and the exploration of our quota in China. Lastly, customer leasing and lease-to-own arrangements are making up a greater percentage of new system placements. Marshall will take you through our finances in more detail later in the call. 
Our operations teams remain focused on optimizing our manufacturing, design and supply chains for our newer products. Our teams continue to execute against their goals with steady improvements in reducing product cost for our new systems advanced instruments in the quarter. Product cost reductions exceeded our expectations, and we expect them to continue to improve in 2016 and 2017. 
Our offerings make up an ecosystem designed to meet our customers' needs in building and running outstanding robotic surgery programs. These ecosystems include systems instruments and accessories, training technologies and coursework, service offerings and program optimization and analytics support. As a result of the set of products and services that surround our systems, recurring revenue in the quarter comprised 75% of total company revenue. 
Highlights of the first quarter operating results are as follows: Procedures grew nearly 17% over the first quarter of last year. We shipped 110 da Vinci Surgical Systems, up from 99 in the first quarter of 2015. Revenue for the quarter was $595 million, up 12% over the prior year. Pro forma gross profit margin was 70% compared to 65.6% in the first quarter of last year. Instrument and accessory revenue increased to $322 million, up 16%. Total recurring revenue in the quarter was $447 million, representing 75% of total revenue. We generated a pro forma operating profit of $229 -- $229 million in the quarter, up 24% from the first quarter of last year, and pro forma net income was $170 million, up 27% from Q1 of 2015. 
We continue to enable our Xi platform with new product launches. Our launch of intraoperative table motion is proceeding well, with order flows that has met our expectations and with strong customer feedback on its utility, particularly in general surgery. In the quarter, we also launched our 30-millimeter excise stapler designed to facilitate stapling in thoracic procedures and our Xi Single-Site instrument and accessory kit. Both our 30-millimeter stapler and our Xi Single-Site instruments have started clinical use with positive feedback on their utility. Our Sp program remains on track. 
As our business is strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that substantial opportunity exists to enable better outcomes and to expand our access to our technologies globally. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we're focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our Sp product into initial clinical use. Third, driving our organizational capabilities in markets in Europe and Asia. And finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I will be describing a results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the busin",1363,"Thank you, Gary. I will be describing a results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We've posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
First quarter revenue was $595 million, an increase of 12% compared with $532 million for the first quarter of 2015 and a decrease of 12% compared with the seasonally stronger fourth quarter of $677 million. First quarter 2016 procedures of approximately 176,000 increased nearly 17% compared with the first quarter of 2015 and decreased slightly compared with the fourth quarter procedures of approximately 177,000. Year-over-year procedure growth was driven by general surgery procedures in the U.S. and urology worldwide and otherwise likely benefit from an additional calendar day associated with leap year. 
Revenue highlights are as follows: instrument and accessory revenue of $322 million increased 16% compared with last year and decreased 1% compared with the fourth quarter of 2015. These changes generally reflect changes in procedures. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,830 per procedure. This metric continues to fluctuate in a tight range of approximately 100 -- $1,830 and $1,840 per procedure. Relative to the first quarter of 2015, the current quarter reflects higher sales of advanced instruments, offset by the impact of customer buying patterns and foreign exchange. System revenue of $148 million increased 5% compared with last year and decreased 36% compared with last quarter. The increase relative to the prior year primarily reflects increased revenue associated with operating lease activities and slightly higher average system selling prices. The decrease relative to the fourth quarter primarily reflects seasonally lower unit sales and slightly lower ASP, partially offset by increased revenue associated with operating lease activities. 
110 systems were placed in the first quarter compared with 99 systems in the first quarter of 2015 and 158 systems last quarter. Approximately 77% of the systems shipped in the quarter were Xis, which is comparable to prior quarters.  Hospitals financed approximately 37% of the systems placed in the first quarter, up from 17% less quarter. We directly financed 31 systems, including 19 operating leases. As of the end of the first quarter, there were 62 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the first quarter of 2015 and $3 million in the fourth quarter. We also generated approximately $6 million of revenue during the quarter from lease buyouts compared with $2 million of revenue in the fourth quarter and no lease buyout revenue in the first quarter of last year. We exclude the impact of operating leases from our system Sp calculations. 
Globally, our average system price of $1,500,000 was approximately $30,000 higher than the first quarter of 2015 ASP and approximately $50,000 lower than the ASP last quarter. Relative to the prior year, the increase reflects a proportionately lower trade-in volume and favorable geographic mix, partially offset by an unfavorable product mix. The decrease relative to the fourth quarter reflects proportionately higher trade-in volume and lower mix of Xi dual consoles, partially offset by a favorable geographic mix. 
Service revenue of $125 million increased 9% year-over-year and increased approximately 4% compared with the fourth quarter of 2015. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. Outside of the U.S., results were as follows: first quarter revenue outside of the U.S. of $164 million increased 9% compared with $150 million for the first quarter of 2015 and decreased 25% compared with seasonally stronger fourth quarter, up to $219 million. The increase compared with the previous year is comprised of a 14% growth in recurring revenue, which is driven by procedure growth of 22% and increased systems revenue of 2%. The decrease compared to the fourth quarter reflects seasonally strong fourth quarter systems placements, partially offset by a 5% growth in recurring revenue. Outside the U.S., we placed 36 systems in the first quarter compared with 36 in the first quarter of 2015 and 75 last quarter. Current quarter system sales included 5 into China and 8 into Japan. System placements outside of the U.S. will continue to be lumpy as some of these markets are in their early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns, and sales into some markets are constrained by government regulation. 
Moving on to the remainder of the P&L. The pro forma gross margin for the first quarter was 70% compared with 65.6% for the first quarter of 2015 and 69.6% for the fourth quarter of 2015. Compared with the first quarter of 2015, the higher gross margin reflects reduction of product and product repair cost, improved manufacturing operations efficiencies, the elimination of the medical device tax, lower costs associated with product field actions and related inventory charges and a higher mix of instrument and accessory revenue. The medical device tax has been suspended for the next 2 years and reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products, our ability to further reduce product costs, manufacturing efficiency, cost associated with product field actions, and in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses, which exclude legal settlements and accruals for legal claims, stock compensation expense and amortization of purchased IP increased 14% compared with the first quarter of 2015 and increased 5% compared with last quarter. The increases over prior periods reflect increased investments in advanced imaging, advanced instrumentation and next-generation robotics, increased headcount and higher payroll taxes associated with stock option exercises. Our pro forma effective tax rate for the first quarter was 27.4% compared with an effective tax rate of 28.9% for the first quarter of 2015 and 24.9% last quarter. In late December 2015, Congress retroactively approved the 2015 Federal Research and Development Credit and made the R&D tax credit permanent going forward. The entire 2015 R&D tax credit was included in the fourth quarter. While no benefit was reflected in the first quarter of 2015 and a proportional benefit is reflected in the first quarter of 2016, other than the impact of the R&D credit, fluctuations in our tax rate between this quarter and the first and fourth quarters of 2015 primarily reflect changes in the mix of U.S. and OUS income. Our first quarter 2016 pro forma net income was $170 million or $4.42 per share compared with $135 million or $3.57 per share for the first quarter 2015 and $224 million or $5.89 per share for the fourth quarter of 2015. Note that fully diluted shares outstanding increased by approximately 400,000 shares relative to the fourth quarter, resulting primarily from the increase in our share price. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $595 million for the first quarter of 2016 compared with $532 million for the first quarter of 2015 and $677 million for the fourth quarter of 2015. GAAP net income was $136 million or $3.54 per share for the first quarter of 2016 compared with $97 million or $2.57 per share for the first quarter of 2015 and $190 million or $4.99 per share for the fourth quarter of 2015. 
We ended the year with cash and investments of $3.8 billion, up from $3.3 billion as of December 31, 2015. The increase primarily -- was primarily driven by proceeds from stock option exercises and cash generated from operations. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. [indiscernible] first quarter procedure growth of nearly 17%. U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, proce",772,"Thanks, Marshall. [indiscernible] first quarter procedure growth of nearly 17%. U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure growth outpaced our expectations. First quarter growth in our mature procedures continued at levels similar to the second half of 2015, generating majority of the procedure outperformance relative to our expectation. General surgery procedure growth also exceeded our expectations. In U.S. urology, first quarter growth in da Vinci prostatectomy and kidney procedures continued in similar rates at the second half of 2015. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect prostatectomy growth to return to levels similar to prostate cancer incidence rates over time. 
In U.S. gynecology, first quarter procedures grew modestly year-over-year with growth led by malignant and complex hysterectomy. Continuing the trend from 2015, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic-oncologists during the first quarter. Similar to the fourth quarter, U.S. Single-Site gynecology procedure growth declined compared to the first quarter of 2015. First quarter growth in U.S. general surgery procedure adoption remained strong, led by a robust growth in hernia repair and continued adoption of colorectal procedures. Cholecystectomy procedures were roughly flat in the quarter with growth in multiform procedures offsetting declines in Single-Site procedures. 
Q1 was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I have selected a couple of studies that you may find interesting. With the launch of our 30-millimeter stapler, surgeon interest in the use of da Vinci for thoracic surgery is growing. A new study comparing open video-assisted thoracic surgery or VATS and da Vinci surgery for [indiscernible] was published by Dr. Yang and colleagues from Memorial Sloan Kettering Cancer Center in the Anals of Surgery. [indiscernible] perspective database, including 2,400 surgeries to treat stage I non-small cell lung cancer patient, [indiscernible] match 470 patients across da Vinci, VATS and open surgery, the study found that da Vinci and minimally invasive VATS approach has enabled a shorter chest tube duration and length of hospital stay compared to open surgery. da Vinci surgery results are also credited with improved lymph node yields as compared to both open surgery and VATS, an important clinical outcome for determining next steps in the patient's treatment pathway. 
As it related to expansion of da Vinci lung resections, the authors highlighted that nearly 57% of pulmonary lobectomies in the U.S. are treated with open surgery, and they see promise in expanding patient access to minimally invasive surgery through da Vinci technology. 
Turning abroad. Procedures growth outside of the United States was approximately 22% in the first quarter, led by the global adoption of da Vinci prostatectomy with solid contributions from kidney procedures and colorectal resection. Compared to the second half of 2015, procedure growth slowed in both Europe and Asia during the quarter, in part due to the timing of the Easter holiday. Historically, our OUS procedure growth rates have been lumpy and less predictable in the short term. We're focused on improving our OUS procedure performance. In Japan, there were positive developments relating to reimbursement in the quarter. The MHLW approved for reimbursement of partial nephrectomy at a premium rate relative to open surgery and also approved clinical trial enrollment to begin supporting [indiscernible] exhibition for da Vinci malignant hysterectomy. 
A recent study funded by Intuitive and published in BJU International by Professor Hughes and colleagues from the University of Chester collected data from the United Kingdom, help statistics database including more than 20,000 prostatectomy patients and 2,000 partial nephrectomy patients to assess health resource utilization and cost following da Vinci, open and laparoscopic procedures. The database showed that from 2008 to 2013, the use of da Vinci surgery increased from 15% to 50% of prostatectomies and 1% to 22% of partial nephrectomies by displacing open surgery. During the first year after the operation, da Vinci surgery was shown to reduce inpatient admissions, hospital bed days and total costs for both prostatectomy and partial nephrectomy compared to open surgery. At 3 years post operation, the study showed similar outcomes from prostatectomy and was insufficient to draw conclusions for partial nephrectomy. Laparoscopic surgery outcomes were at the approximate midpoint between da Vinci and open surgery on resource utilization and costs for both procedures. The authors concluded, ""Our analysis suggest that there are substantial savings associated with robotic-assisted surgery when compared with open and laparoscopic interventions."" 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015.",311,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015. Now based upon favorable U.S. dVP and gynecology macro trends and U.S. general surgery growth, we are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 12% to 14%. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 69% and 70% of net revenue. 
Turning to operating expenses. As we have described, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. On our last call, we forecast to grow pro forma 2016 operating expenses between 9% and 13% above 2015 levels. We are now increasing our estimate for operating expenses to a range of between 12% and 15% above 2015. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect our 2016 other income, which is comprised mostly of interest income, to be in the upper end of the $20 million to $25 million range forecasts on our last call. With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Two questions. First of all, congrats on the great momentum of the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth. One, can you give us a sense of what you think you gr",89,"Two questions. First of all, congrats on the great momentum of the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth. One, can you give us a sense of what you think you grew in the quarter on same-day selling basis? But then much more importantly, just give us a sense as to specifically which surgery types accelerated in the U.S. and what drove the growth. What caused the acceleration? Why did things get better?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but exact science. From a tailwinds at leap year, that benefited the quarter and some modest benefit from the timing of the year as bein",136,"Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but exact science. From a tailwinds at leap year, that benefited the quarter and some modest benefit from the timing of the year as being on a Friday rather than a Thursday. And from a headwind perspective, you had the timing of Easter, which moved from the second quarter into the first quarter, but that has more of an impact on OUS geographies. From what accelerated, the mature procedures sustained pretty strong growth in the quarter, as we saw throughout 2015, which is a little bit of a surprise to us relative to our original expectation. And general surgery continues to be strong and growing off of a larger base, which has more impact on US procedures outcome."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then -- well, for the follow-up, I want to ask Gary a question about OpEx expand because I think it's an important comment from you guys. Your spending in the quarter was as high, exactly as you said it would be. And now you're raising that spen",107,"Okay. And then -- well, for the follow-up, I want to ask Gary a question about OpEx expand because I think it's an important comment from you guys. Your spending in the quarter was as high, exactly as you said it would be. And now you're raising that spend level even further. So can you just talk about where the incremental spend is going? What kind of new incremental technology announcements could that lead to? You mentioned a couple on the call. But I'm just really curious as to where the spending is going and when we could expect more visibility on the output from that spending."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So on the spend, I think the acceleration is really board confidence, confidence in the long-term viability of some of the markets and the things we're pursuing. You'll see it really cut into a couple of buckets. Some of these investments in the OUS",178,"Sure. So on the spend, I think the acceleration is really board confidence, confidence in the long-term viability of some of the markets and the things we're pursuing. You'll see it really cut into a couple of buckets. Some of these investments in the OUS markets where we think that we can do more by investing more. And we've been talking to you about that. The other side is on R&D. In terms of categories, we talk about it before, but we believe in them deeply. Advanced imaging, the ability to see beyond what you can just see with your naked eye, new robotic architectures that allow surgeons to get into and out of the body in different ways into different places that they could reach prior as well as analytics and over-the-shoulder guidance. All things that we've been investing and some things that we are accelerating. So asked -- we won't do product announcements on this call as we get deeper into those things and already to share them more probably with you, of course, we will."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then lastly, just to get a sense, [indiscernible] positive hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from the reimbursement perspective?",31,"And then lastly, just to get a sense, [indiscernible] positive hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from the reimbursement perspective?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Bob. The NHLW approved for the clinical trial to begin enrollment supporting malignant hysterectomy under [indiscernible] process.",18,"Yes, Bob. The NHLW approved for the clinical trial to begin enrollment supporting malignant hysterectomy under [indiscernible] process."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] Our next question comes from Tycho Peterson, JPMorgan.",10,"[Operator Instructions] Our next question comes from Tycho Peterson, JPMorgan."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I'm just wondering if you could talk a little bit about table motion. How many systems are installed that are capable of what percentage systems, I guess, have the option included. And if you just talk a little bit about how it flows through the gross mar",60,"I'm just wondering if you could talk a little bit about table motion. How many systems are installed that are capable of what percentage systems, I guess, have the option included. And if you just talk a little bit about how it flows through the gross margins as well and in terms of software upgrade from your perspective, right?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're pretty, pretty pleased with the level of adoption for our table motion, where the -- information relating that the surgeons that are pleased with its usage and performance. We're not going to be disclosing every quarter just how many tables we",63,"Yes. We're pretty, pretty pleased with the level of adoption for our table motion, where the -- information relating that the surgeons that are pleased with its usage and performance. We're not going to be disclosing every quarter just how many tables we delivered. So I won't go there. I'll just tell you that, again, we're pretty pleased with the level of adoption."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Maybe...",2,"Maybe..."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","With revenue on the margin side.",6,"With revenue on the margin side."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The margins. So we're providing is a software update to the Xi that enables the table motion. The table itself is being purchased from Trump.",26,"Yes. The margins. So we're providing is a software update to the Xi that enables the table motion. The table itself is being purchased from Trump."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","[indiscernible]",1,"[indiscernible]"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the -- and so our billing is 100% margin.",10,"And the -- and so our billing is 100% margin."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess maybe whatever's getting [indiscernible] degree to which this is going to drive a bullish in the demand for Xi now that you have that plus the full instrument set. Can you maybe just talk about how you see that flowing through the Xi demand?",48,"And I guess maybe whatever's getting [indiscernible] degree to which this is going to drive a bullish in the demand for Xi now that you have that plus the full instrument set. Can you maybe just talk about how you see that flowing through the Xi demand?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much",160,"Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much fuller and richer ecosystem. We think that helps. It's very hard to forecast how much it is, how many people sit and wait until the next step. But we think those things at clinical value, for sure. 30-millimeter stapler in thoracic procedures is a big win. Likewise, table motion for a lot of the more complex procedures. So we think that's growing, and there are a group of hospitals that use Si with Single-Site that if there are a single-system hospital, they own only just one and they have a robust Single-Site program, this allows them to consider Xi as an upgrade. It's hard to quantify, but we think, directionally, it's really strong."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then follow-up. Can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year.",28,"Okay. And then follow-up. Can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There are some other countries where",163,"Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There are some other countries where it's going a little slower. Sometimes it's a local economy issue. Sometimes it's more of where we are in maturity. Some of these countries, we're pretty well adopted in the mature procedures and they're really at the beginnings of emerging procedures. So it depends country by country. On the capital side, I think there's 2 things going on. A little bit of environment is one. And a little bit of a wait and see on competitive offerings as they come out. And we're navigating that pretty well. In terms of head-to-head comparisons with our technology, our systems are coming out great, but it can put a delay in the pipeline, and we're seeing a little bit of that in Europe."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Really, the only thing I'd add is Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year from Q1.",41,"Really, the only thing I'd add is Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year from Q1."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from David Lewis with Morgan Stanley.",9,"Our next question from David Lewis with Morgan Stanley."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just 2 quick ones here. Marshall, just coming back to address margin guidance. So [indiscernible] have been stronger for 5 consecutive quarters, and the guidance sort of implies no improvement throughout the year, which seems, I guess, less likely to us j",80,"Just 2 quick ones here. Marshall, just coming back to address margin guidance. So [indiscernible] have been stronger for 5 consecutive quarters, and the guidance sort of implies no improvement throughout the year, which seems, I guess, less likely to us just given the cost improvements you already discuss. So can you just talk to gross margin for the rest of the balance of the year and why you think 70% here in the first quarter is the high watermark?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do in systems, and Q1 tends to be seasonally lower quarter for capital. And also, we see a growth in the ne",83,"Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do in systems, and Q1 tends to be seasonally lower quarter for capital. And also, we see a growth in the new product, particularly energy products, stapling, and vessel sealer going forward, and those also have lower margins than the base. So I think just based on product mix alone, we don't expect to sustain 70%."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then Gary, I -- honestly, people have asked about spending already and know that the R&D spend is the highest I've seen in 4 years. So you're obviously clearly going to continue to invest. I have no expectations you're going to talk to us about",90,"Okay. And then Gary, I -- honestly, people have asked about spending already and know that the R&D spend is the highest I've seen in 4 years. So you're obviously clearly going to continue to invest. I have no expectations you're going to talk to us about future instrumentation and system announcements, but I think the enigma from all shareholders actually is imaging because that sort of more future-looking. Is there any chance we get updates or at least even any update on the strategy for advanced imaging this year?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, a fair question. In general, we have been making early investments in advanced imaging. And it's not one thing. As you know, we have Firefly, which is a molecular imaging product. We also have invested in raw imaging hardware capabilities, which we'l",94,"Yes, a fair question. In general, we have been making early investments in advanced imaging. And it's not one thing. As you know, we have Firefly, which is a molecular imaging product. We also have invested in raw imaging hardware capabilities, which we'll continue to do. As -- what we like to do is, as we have milestones that make sense, whether it's talking to regulatory bodies or engaging in clinical work, those tend to be good anchors to discuss with you. And as those arrive, then we'll share with you what we're thinking."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Ann could those arrive potentially in '16 for advanced imaging or unlikely?",12,"Ann could those arrive potentially in '16 for advanced imaging or unlikely?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think when we get there, we'll let you know.",10,"I think when we get there, we'll let you know."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we'll go next to David Roman with Goldman Sachs.",11,"And we'll go next to David Roman with Goldman Sachs."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it at stages this year there were sort of positive, as a tipping point, but this incr",84,"I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it at stages this year there were sort of positive, as a tipping point, but this incremental enthusiasm from the physician community around this procedure. Can you may be sort of talk about what you think specifically is stimulating that demand? And why are confident in that continuing on a go-forward basis?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of the market not all patients are",200,"There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of the market not all patients are suffering from the same level of disease. And then in more complex cases, if it's bilateral or prior abdominal surgeries of these patients, large herniated sac, the raw clinical capability of our products is being touted as an supported by surgeons as being important to them, a better quality of intervention, consumable cost in line with what their expectations are. So there, I think that we're feeling pretty good. The second thing we can do is analyze the kind of the reorder rates from surgeons as they go forward. So as you get through the trial periods, you're seeing kind of where as they learned and get deeper and deeper into it, whether they apply and how often do they keep buying our products? And that has been supportive as well. So as to those 2 things come together, we start to feel better about it. And that's what's behind that sort of comments."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","All right. That's helpful. And as my follow-up on the operating lease side. It looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess may be, a, could you talk to sort of some the dynamics underpinning",80,"All right. That's helpful. And as my follow-up on the operating lease side. It looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess may be, a, could you talk to sort of some the dynamics underpinning that? And then, b, based on your disclosures, it looks people are buying out these operating leases relatively quickly. So it's maybe help us understand is that true and why that's the case?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get to capital approval process and those a",96,"Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get to capital approval process and those are a couple of the ones you've seen bought out in this quarter. Most of the cap -- most of the leases of the operating leases are longer-term, being 4- and 5-year terms and will drive the recurring revenue going forward. Like we said, this quarter was around $4 million."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from Ben Andrew with William Blair.",9,"Our next question from Ben Andrew with William Blair."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make? A",69,"Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make? And are you planning to make that are different than what you've done before to try to lever that we've been considered specifically call that out."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So I think the -- it -- making a great robotic surgery program is really the integration of all of those things. And they're multiyear efforts to build that sort of programs from peer-to-peer networks that do advance coursework and teaching to validated l",214,"So I think the -- it -- making a great robotic surgery program is really the integration of all of those things. And they're multiyear efforts to build that sort of programs from peer-to-peer networks that do advance coursework and teaching to validated learning pathways and simulation. Those validations are both multiyear efforts to get right to the full instrument kit from vessel sealing and stapling and so on. And so we're pretty thoughtful about balancing that sort of investments. The things that have gotten really stronger and interesting in the last couple of years have been our ability to analyze data, look at national benchmarking, look at regional base benchmarking and share that information with a customers so that they can make good decisions. Sometimes those decisions are good for them and not great for Intuitive in the near term. If they optimize their program, we may get [indiscernible] revenue per procedure the long term, but we think, long term, it's better for everybody. And so we've been making those analytics and those investments and then communicating with hospitals. So we really have been plugging in each of those settings. And we do think it makes for an ecosystem that makes a lot of value for the customer and builds relationship with them."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And perhaps a quick one for you. And we think about the extra selling day is maybe as 1.5 percentage points of procedure growth. I know there's offsets with Easter, et cetera, but it's in that range of what the bump what's net?",43,"And perhaps a quick one for you. And we think about the extra selling day is maybe as 1.5 percentage points of procedure growth. I know there's offsets with Easter, et cetera, but it's in that range of what the bump what's net?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Ben. I'll let you do kind of your math on the specific percentage, but as it relates to the benefited, really just think of it as more in the U.S. because the favorability of leap year and New Year's gets mostly washed out by year -- Easter, particul",51,"Yes, Ben. I'll let you do kind of your math on the specific percentage, but as it relates to the benefited, really just think of it as more in the U.S. because the favorability of leap year and New Year's gets mostly washed out by year -- Easter, particularly in Europe."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Rick Wise with Stifel.",10,"And we have a question from Rick Wise with Stifel."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wonder -- talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and I guess the significant turnaround from the headwind you faced over the last couple of years. Also, u",86,"I wonder -- talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and I guess the significant turnaround from the headwind you faced over the last couple of years. Also, urology acting better. Have you worked through some of the challenges in each? And are we actually going to return to more sustainable growth in U.S. gynecology after a year or more or 2 of training and education, et cetera?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Let me speak to a couple of the factors, and I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy. The biggest one being prostatectomy. We know that the",299,"Let me speak to a couple of the factors, and I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy. The biggest one being prostatectomy. We know that there was a bolus of patients that went into watchful waiting, some of whom will have disease progression and come back for definitive treatment. How long that bolus lasts is a little bit hard for us to predict. The second thing are the possibility of share changes between some of the treatment modalities, surgery versus radiation, versus watchful waiting. That data tends to lag. Hard to get it in real time. There may be some share change, although there is it's probably modest. And then there's just demographics. It's demographics changes you have more folks getting diagnosed with prostate cancer over time. So those are the 3 things rolling through and sort of projecting how they balance out is what the challenge is. On the gynecology side, the thing that were's seeing in our experience is that you're seeing more surgery being done by high-volume gynecologists, in general, just not robotic surgery but laparoscopy and others. We're seeing consolidation in the marketplace into folks who are either oncologists or more routine surgeons. We think that's good for the world, and we think that's good for Intuitive. Those more dedicated surgeons tend to be our customers. We see them tackling more procedures in concentrated fashions, and so that's kind of what's happening in gynecology. Likewise, I think there's a demographic element here that's likely to find the bottom and then start to drift up. That unknown is nonsurgical approaches and in-office approaches. Those are kind of the factors at play. Patrick, I'll let you go from there."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes -- no, I think you described the nephrology [indiscernible] I think the problem in GYN market. Well, Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwind for us on ye",45,"Yes -- no, I think you described the nephrology [indiscernible] I think the problem in GYN market. Well, Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwind for us on year-over-year comparison [indiscernible]"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess my follow-up question -- and it might've been you, Patrick, who mentioned it. I think somebody described OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're goin",68,"And I guess my follow-up question -- and it might've been you, Patrick, who mentioned it. I think somebody described OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're going about that? What kind of initiatives are underway? And what you would hope what we should expect might come from those initiatives?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'll take that one, Rick. Well, the opportunity in Europe depends to be country by country. So we're looking to do something different or better tends to be making sure that we have staff that is supporting local efforts and local needs, that they're",116,"Yes. I'll take that one, Rick. Well, the opportunity in Europe depends to be country by country. So we're looking to do something different or better tends to be making sure that we have staff that is supporting local efforts and local needs, that they're working in local language, that they understand the health care systems in intimate ways that are specific to that country. And so where we see opportunity, we'll invest there and build that out, we have been. Where we made investments, we've seen growth. And so when we see some areas of opportunity, we think we have a playbook. Now we have to go executing that playbook. That's been our perspective there."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Matt O'Brien with Piper Jaffray.",12,"And we have a question from Matt O'Brien with Piper Jaffray."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Was hoping to start on the general surgery side. And it sounds like, again, like a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are",91,"Was hoping to start on the general surgery side. And it sounds like, again, like a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are you seeing any kind of the divergence or inflection in either ventral or inguinal? And are those procedures at this point getting a sizable enough to start to sway hospital decision making as to adding additional systems in order to meet that demand?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Matt. Thanks for your question. Both ventral and inguinal hernia procedures will continue to exhibit robust growth. Inguinal hernia is a bigger overall procedural category. It's just more commonly performed. The rates of adoption that we're seeing in",115,"Yes, Matt. Thanks for your question. Both ventral and inguinal hernia procedures will continue to exhibit robust growth. Inguinal hernia is a bigger overall procedural category. It's just more commonly performed. The rates of adoption that we're seeing in both procedures is encouraging, and the surgeon populations that are performing them are continuing to increase the volumes of procedures that they're doing. So it looks promising. And certainly, from an overall volume perspective, it had some influence because the numbers are getting to the point where it matters to create access for the surgeons to be able to continue to perform procedures that they are absorbing systems worth of activity in some of their institutions."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals evaluate some competitive systems that are hitting those markets. Just curious, do you think that's something that will linger here throughout 201",124,"Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals evaluate some competitive systems that are hitting those markets. Just curious, do you think that's something that will linger here throughout 2016 as most systems are fully rolled out? Or do you think it will be a fairly quick process of kind of taking a peak and doing that now and you could see a snapback in terms of the numbers of systems placed? I mean, specifically, did you see 10, 15 hospitals kind of delay they're evaluating both systems and then out of those 10 hospitals, 9 of them ended up buying da Vinci in the late last quarter or even earlier this quarter?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The -- I think is a little bit hard to predict how fast it will go through. I guess, our anecdotal experience have been -- some of them quick looks and making evaluation and come signs up with us and others are going through a little bit longer proce",183,"Yes. The -- I think is a little bit hard to predict how fast it will go through. I guess, our anecdotal experience have been -- some of them quick looks and making evaluation and come signs up with us and others are going through a little bit longer process. So with regards to a ""Snapback"" I wouldn't bake that in. I think it will play out a little longer than there. Having said that, our -- the response of our customers after they have evaluated the other offerings and come back to talk to us has been fantastic. So our confidence that we have good offerings, and we can meet customers' needs is very high. There go through the process and I think as new and different technologies come to market, not just the ones that are they today, we think this will be part of the new normal a little bit for Europe as people go shopping and making decisions. Our goal is to make sure that they find our products to be of very high value. So far, so good."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Larry Keusch, Raymond James.",10,"And we have a question from Larry Keusch, Raymond James."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Wondered if we could just -- first question start with the trade-in. I think there were 42, as you mentioned this quarter, and I think the prior quarters have been sort of averaging closer to 30. So I'm just trying understand perhaps what is driving the h",62,"Wondered if we could just -- first question start with the trade-in. I think there were 42, as you mentioned this quarter, and I think the prior quarters have been sort of averaging closer to 30. So I'm just trying understand perhaps what is driving the higher trade-in. And then what's the ultimate opportunity to drive trade-ins in the over system base?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's nothing specific of this quarter that I would call it as it relates to trade-in. I think we have the numbers right. It came off of our additional detail reported in the press release. Wouldn't call anything out specifically. I think it -- las",83,"Yes. There's nothing specific of this quarter that I would call it as it relates to trade-in. I think we have the numbers right. It came off of our additional detail reported in the press release. Wouldn't call anything out specifically. I think it -- last quarter, it was around in the high 30s, and it's been there for a little while. I don't know that it will probably fluctuate in that range. I'm sorry. I don't have any specific comments on it."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then for Gary, maybe just an update on Sp. And you mentioned some in your prepared comments. But where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?",45,"Okay. And then for Gary, maybe just an update on Sp. And you mentioned some in your prepared comments. But where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So we are in discussions with the FDA on trial type and the influence, and we have clinical sites that are getting prepped of the product from an engineering and design and validation point of view is right on track and looks really good. We're not expect",73,"So we are in discussions with the FDA on trial type and the influence, and we have clinical sites that are getting prepped of the product from an engineering and design and validation point of view is right on track and looks really good. We're not expecting anything of substance in terms of revenue this year. We do expect them in clinical use in the second half, and that's what we're working towards."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Jason Mills with Canaccord Genuity.",11,"And we have a question from Jason Mills with Canaccord Genuity."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","My first question has to do with -- I'm just try to understand better your [indiscernible] as it relates to managing the P&L. So -- what it -- what -- getting is higher procedural volume guidance and higher operating expense guidance. And would seem -- wh",136,"My first question has to do with -- I'm just try to understand better your [indiscernible] as it relates to managing the P&L. So -- what it -- what -- getting is higher procedural volume guidance and higher operating expense guidance. And would seem -- what we're seeing -- what we seem to be seeing is some leverage to the operating line. But I'm just curious, Gary, if you could talk about -- Marshall, if you talk about your dogmas over the next couple of years and sort of are you looking for operating margins expansion? Is that what your objective is? Are you managing the business to top line growth and trying to manage expenses as best as you can to get there? Could you talk about your dogmas or early demands in the P&L?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we are seeking high operational efficiency and leverage. You see that in product cost reduction and some of the things that we're doing in man",206,"Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we are seeking high operational efficiency and leverage. You see that in product cost reduction and some of the things that we're doing in manufacturing. There are other places in operation where we think we can find leverage. At the same time, we want a turnaround and reinvest those savings and opportunity. And we see a lot of opportunity. And I think that opportunity should be pursued. So it will be a little bit lumpy. We're trying to be balanced. I wouldn't say that our approach is hard over one or hard over the other. It's not revenue above all else, and it's not profit above all else. We try to the balance in that approach. Maybe a little bit lumpy. I think opportunities happen when they happen. You can be overly cautious in this one. And so we -- we'll maintain the fiscal discipline. That's been part of our history, and we'll keep it. Having said that, want to make sure that we invest some of the benefits of the company has gained into expanding the opportunity we've seen in front of us."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","That's helpful. My second and final question, having to do with your cash balance and use of cash. When -- very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it be fai",82,"That's helpful. My second and final question, having to do with your cash balance and use of cash. When -- very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it be fair to assume that you'll do modest -- maybe modest to moderate share repurchases going forward? Or well -- we'll we see maybe less over the next 2 years than we saw in the last 2 years?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","In terms of just how we think about capital allocation, right, we are thoughtful and about it, as you expect. We think buybacks are one leg or one tool in capital allocation. We really start with,  can we reinvest in the business and drive long-term growt",156,"In terms of just how we think about capital allocation, right, we are thoughtful and about it, as you expect. We think buybacks are one leg or one tool in capital allocation. We really start with,  can we reinvest in the business and drive long-term growth and opportunity? Buybacks, if there are times we've been typically patient and opportunistic. And we think because of the volatility of our stock, there are times that makes a lot of sense for us. And in conversations with shareholders, and where we are thoughtful and listening to them, that we have considered dividends and we will consider them in the future. So we look at those 3 things and try to trade them off. And we think for the long term, we're thinking about capital allocation, we're not trying to do signaling or messaging. We're trying to build value for the business and for the shareholders in the long term."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Vijay Kumar with Evercore.",10,"And we have a question from Vijay Kumar with Evercore."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe one on the OUS placements. I know, China, I think on the last quarter you said they had about 8 systems. Can we expect sort of renewed sort of a -- I guess, a contract from the government for 8? How should we think about OUS from a systems perspe",66,"So maybe one on the OUS placements. I know, China, I think on the last quarter you said they had about 8 systems. Can we expect sort of renewed sort of a -- I guess, a contract from the government for 8? How should we think about OUS from a systems perspective given that China [indiscernible] at the end of [indiscernible] systems that they can import?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. They're still  one out there. I don't know if it will happen. And we have",195,"So I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. They're still  one out there. I don't know if it will happen. And we have to go through a tender process, and that tender process had already begun. As far as additional quotas, we're -- it's a part of the overall budget -- government budget process in China. And so when it gets completed, and I don't have [indiscernible] tells me what it will be completed, then we're still under the quota system and still whether this is the under the quota system, how many will be awarded. And there's no way to predict that in the -- in advance. As far as the rest of the world goes, as I -- in my remarks, I mentioned that it's fourth quarter is a seasonally strong quarter. If you look at where we came out for this quarter, it's pretty comparable to last year for the first quarter, but it's going to be lumpy, market by market, depending on circumstances."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And maybe one follow-up for Gary. I know the clinical trial, I mean R&D expense were up 25% in the Q. Does that number include any clinical trial expenses? Look, I'm just trying to get a sense for as you talked about Japan you're starting clinical",56,"Great. And maybe one follow-up for Gary. I know the clinical trial, I mean R&D expense were up 25% in the Q. Does that number include any clinical trial expenses? Look, I'm just trying to get a sense for as you talked about Japan you're starting clinical trial sort of any potential impact in that number."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's some -- we're doing -- we've said before we're in the middle of gathering data or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinical trial",58,"Yes. There's some -- we're doing -- we've said before we're in the middle of gathering data or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinical trials, we'll tell you about them when we think it's appropriate."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And our next question is from Tao Levy from Wedbush.",10,"And our next question is from Tao Levy from Wedbush."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So we've talked a lot about sort of the hernia, colorectal surgery. But you've mentioned a couple of times thoracic surgery and the benefit that -- particularly Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportunitie",82,"So we've talked a lot about sort of the hernia, colorectal surgery. But you've mentioned a couple of times thoracic surgery and the benefit that -- particularly Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportunities within thoracic? Should we think of it as a colorectal-type opportunity, where it's moving in the right direction, but it's a little bit slower? Or could it potentially be more like a hernia or a hysterectomy opportunity?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'll start and ask Patrick to join in. Just -- from the starting place, these are typically cancer procedures and typically complex. Mediastinal cancers, lung cancers. They -- the products that that we have, Xi moves in the right direction. This inst",140,"Yes. I'll start and ask Patrick to join in. Just -- from the starting place, these are typically cancer procedures and typically complex. Mediastinal cancers, lung cancers. They -- the products that that we have, Xi moves in the right direction. This instrumentation we're bringing along moves us in the right direction terms of providing surgeons with the tools they're looking for for efficient procedures. And I think we're at the beginnings of that. The way to think about the market is there are some minimally invasive surgery done manually, video-assisted thoracic surgery. Some institutions do a lot of it with good results. Others do very little of it. If you look at national averages rather than institutional numbers, you see a lot of open surgery done, and we think that that's the opportunity. I'll let Patrick characterize it through."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, still -- it's still pretty early days, the foundation. We've got a small team in the U.S. focused on it. But our focus can just been driving general surgery growth in hernia colorectal resection. And internationally, you know how we still focus on dr",99,"Yes, still -- it's still pretty early days, the foundation. We've got a small team in the U.S. focused on it. But our focus can just been driving general surgery growth in hernia colorectal resection. And internationally, you know how we still focus on driving dVP adoption and some emerging procedures in countries where urology is deeply penetrated. Anyway, when you look around internationally, it is a cancer that is very common in Asia and other parts, so it's a very big opportunity for us, but perhaps a little bit around the corner from what we currently focus on."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. Great. And then my follow-up. You mentioned focusing on on urology internationally, and I understand that it's still relatively underpenetrated. But it is just the same procedure that you keep on going after internationally. Should we be worried t",65,"Got it. Great. And then my follow-up. You mentioned focusing on on urology internationally, and I understand that it's still relatively underpenetrated. But it is just the same procedure that you keep on going after internationally. Should we be worried that some of the other procedures that are catching on here in the U.S. in the last 3 years aren't moving the needle yet internationally?"
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That will be a last question. I'll answer that and then we'll move on. If it depends by country. For example, nice adoption thoracic surgery in China. We see a pretty different mix of procedures in Korea than we see in the United States. So you have to an",238,"That will be a last question. I'll answer that and then we'll move on. If it depends by country. For example, nice adoption thoracic surgery in China. We see a pretty different mix of procedures in Korea than we see in the United States. So you have to answer it country by country. I don't think there's a systemic worry here that that somehow we're stuck at [indiscernible] able to move any further. I do think that it's important for folks on the phone to realize that the profile of procedures in each country is going to differ based on the C state, based on how the reversed system works and the relative priorities of their health care system. So we see that reflected. We do see multiple procedure adoption in different countries just differ somewhat thereafter. 
That was our last question. As we've said previously, we focus on financial metrics such as revenues, profits and cash flows during these conference calls, organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand and that we remain committed to driving the vital few things that really make a difference. This concludes today's call. Thank you for your participation and support on this extraordinary journey to improve surgery. And I'll look forward speaking with you again in 3 months."
30239,328482491,959598,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Thank you. And ladies and gentlemen, we thank you for using AT&T Executive Teleconference Service. You may now disconnect.",19,"Thank you. And ladies and gentlemen, we thank you for using AT&T Executive Teleconference Service. You may now disconnect."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director",50,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance.",256,"Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our first quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our first quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. Turning firs",768,"Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. 
Turning first to procedures. Global procedure growth for the quarter was nearly 17% led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States, continued growth in U.S. urology and modest growth in U.S. gynecology. Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair, followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of da Vinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance. Procedure growth was variable by country in Europe, with solid performance in the United Kingdom and Germany offsetting slower growth in the Nordic countries. Performance in the quarter was helped by an extra procedure day in some regions relative to Q1 of 2015. Patrick will review procedure trends in greater detail later in the call. 
We placed 110 da Vinci systems in the quarter, up from 99 in Q1 of 2015. Customers continue to purchase our Xi Systems over less expensive and less capable Si models by a factor of approximately 3:1. Capital performance was strong in the United States, offsetting capital softness in Europe and the exploration of our quota in China. Lastly, customer leasing and lease-to-own arrangements are making up a greater percentage of new system placements. Marshall will take you through our finances in more detail later in the call. 
Our operations teams remain focused on optimizing our manufacturing design and supply chains for our newer products. Our teams continue to execute against their goals with steady improvements in reducing product costs for our new systems and advanced instruments in the quarter. Product cost reductions exceeded our expectations, and we expect them to continue to improve in 2016 and 2017. 
Our offerings make up an ecosystem designed to meet our customers' needs in building and running outstanding robotic surgery programs. These ecosystems include systems instruments and accessories, training technologies and peer-to-peer coursework, service offerings and program optimization and analytics support. As a result of the set of products and services that surround our systems, recurring revenue in the quarter comprised 75% of total company revenue. 
Highlights of the first quarter operating results are as follows: Procedures grew nearly 17% over the first quarter of last year. We shipped 110 da Vinci Surgical Systems, up from 99 in the first quarter of 2015. Revenue for the quarter was $595 million, up 12% over the prior year. Pro forma gross profit margin was 70% compared to 65.6% in the first quarter of last year. Instrument and accessory revenue increased to $322 million, up 16%. Total recurring revenue in the quarter was $447 million, representing 75% of total revenue. We generated a pro forma operating profit of $229 million in the quarter, up 24% from the first quarter of last year; and pro forma net income was $170 million, up 27% from Q1 of 2015. 
We continue to enable our Xi platform with new product launches. Our launch of intraoperative Table Motion is proceeding well, with order flow that has met our expectations and with strong customer feedback on its utility, particularly in general surgery. In the quarter, we also launched our 30-millimeter Xi stapler designed to facilitate stapling in thoracic procedures and our Xi Single-Site instrument and accessory kit. Both our 30-millimeter stapler and our Xi Single-Site instruments have started clinical use with positive feedback on their utility. Our Sp program remains on track. 
As our business is strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that substantial opportunity exists to enable better outcomes and to expand our access to our technologies globally. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we're focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our Sp product into initial clinical use; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I will be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the bus",1365,"Thank you, Gary. I will be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
First quarter revenue was $595 million, an increase of 12% compared with $532 million for the first quarter of 2015 and a decrease of 12% compared with the seasonally stronger fourth quarter of $677 million. First quarter 2016 procedures of approximately 176,000 increased nearly 17% compared with the first quarter of 2015 and decreased slightly compared with the fourth quarter procedures of approximately 177,000. Year-over-year procedure growth was driven by general surgery procedures in the U.S. and urology worldwide. It otherwise likely benefited from an additional calendar day associated with leap year. 
Revenue highlights are as follows: Instrument and accessory revenue of $322 million increased 16% compared with last year and decreased 1% compared with the fourth quarter of 2015. These changes generally reflect changes in procedures. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,830 per procedure. This metric continues to fluctuate in a tight range of approximately 100 -- $1,830 and $1,840 per procedure. Relative to the first quarter of 2015, the current quarter reflects higher sales of advanced instruments, offset by the impact of customer buying patterns and foreign exchange. System revenue of $148 million increased 5% compared with last year and decreased 36% compared with last quarter. The increase relative to the prior year primarily reflects increased revenue associated with operating lease activities and slightly higher average system selling prices. The decrease relative to the fourth quarter primarily reflects seasonally lower unit sales and slightly lower ASPs, partially offset by increased revenue associated with operating lease activities. 110 systems were placed in the first quarter compared with 99 systems in the first quarter of 2015 and 158 systems last quarter. Approximately 77% of the systems shipped in the quarter were Xis, which is comparable to prior quarters. Hospitals financed approximately 37% of the systems placed in the first quarter, up from 17% less quarter. We directly financed 31 systems, including 19 operating leases. As of the end of the first quarter, there were 62 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the first quarter of 2015 and $3 million in the fourth quarter. We also generated approximately $6 million of revenue during the quarter from lease buyouts compared with $2 million of revenue in the fourth quarter and no lease buyout revenue in the first quarter of last year. We excluded the impact of operating leases from our system ASP calculations. 
Globally, our average system price of $1,500,000 was approximately $30,000 higher than the first quarter of 2015 ASP and approximately $50,000 lower than the ASP last quarter. Relative to the prior year, the increase reflects a proportionately lower trade-in volume and favorable geographic mix, partially offset by an unfavorable product mix. The decrease relative to the fourth quarter reflects proportionately higher trade-in volume and lower mix of Xi dual consoles, partially offset by a favorable geographic mix. 
Service revenue of $125 million increased 9% year-over-year and increased approximately 4% compared with the fourth quarter of 2015. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: First quarter revenue outside of the U.S. of $164 million increased 9% compared with $150 million for the first quarter of 2015 and decreased 25% compared with seasonally stronger fourth quarter, up to $219 million. The increase compared with the previous year is comprised of a 14% growth in recurring revenue, which is driven by procedure growth of 22% and increased systems revenue of 2%. The decrease compared to the fourth quarter reflects seasonally strong fourth quarter systems placements, partially offset by a 5% growth in recurring revenue. Outside the U.S., we placed 36 systems in the first quarter compared with 36 in the first quarter of 2015 and 75 last quarter. Current quarter system sales included 5 into China and 8 into Japan. System placements outside of the U.S. will continue to be lumpy as some of these markets are in their early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns; and sales into some markets are constrained by government regulation. 
Moving on to the remainder of the P&L. The pro forma gross margin for the first quarter was 70% compared with 65.6% for the first quarter of 2015 and 69.6% for the fourth quarter of 2015. Compared with the first quarter of 2015, the higher gross margin reflects reduction of product and product repair costs, improved manufacturing operations efficiencies, the elimination of the medical device tax, lower costs associated with product field actions and related inventory charges and a higher mix of instrument and accessory revenue. The medical device tax has been suspended for the next 2 years and reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products, our ability to further reduce product costs, manufacturing efficiency, costs associated with product field actions and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses, which exclude legal settlements and accruals for legal claims, stock compensation expense and amortization of purchased IP, increased 14% compared with the first quarter of 2015 and increased 5% compared with last quarter. The increases over prior periods reflect increased investments in advanced imaging, advanced instrumentation and next-generation robotics; increased headcount and higher payroll taxes associated with stock option exercises. Our pro forma effective tax rate for the first quarter was 27.4% compared with an effective tax rate of 28.9% for the first quarter of 2015 and 24.9% last quarter. In late December 2015, Congress retroactively approved the 2015 federal research and development credit and made the R&D tax credit permanent going forward. The entire 2015 R&D tax credit was included in the fourth quarter. While no benefit was reflected in the first quarter of 2015 and a proportional benefit is reflected in the first quarter of 2016, other than the impact of the R&D credit, fluctuations in our tax rate between this quarter and the first and fourth quarters of 2015 primarily reflect changes in the mix of U.S. and OUS income. 
Our first quarter 2016 pro forma net income was $170 million or $4.42 per share compared with $135 million or $3.57 per share for the first quarter of 2015 and $224 million or $5.89 per share for the fourth quarter of 2015. Note that fully diluted shares outstanding increased by approximately 400,000 shares relative to the fourth quarter, resulting primarily from the increase in our share price. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $595 million for the first quarter of 2016 compared with $532 million for the first quarter of 2015 and $677 million for the fourth quarter of 2015. GAAP net income was $136 million or $3.54 per share for the first quarter of 2016 compared with $97 million or $2.57 per share for the first quarter of 2015 and $190 million or $4.99 per share for the fourth quarter of 2015. 
We ended the year with cash and investments of $3.8 billion, up from $3.3 billion as of December 31, 2015. The increase primarily -- was primarily driven by proceeds from stock option exercises and cash generated from operations. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure grow",782,"Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure growth outpaced our expectations. First quarter growth in our mature procedures continued at levels similar to the second half of 2015, generating majority of the procedure outperformance relative to our expectation. General surgery procedure growth also exceeded our expectations. In U.S. urology, first quarter growth in da Vinci prostatectomy and kidney procedures continued in similar rates as the second half of 2015. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect the prostatectomy growth to return to levels similar to prostate cancer incidence rates over time. 
In U.S. gynecology, first quarter procedures grew modestly year-over-year with growth led by malignant and complex hysterectomy. Continuing the trend from 2015, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic-oncologists during the first quarter. Similar to the fourth quarter, U.S. Single-Site gynecology procedure growth declined compared to the first quarter of 2015. First quarter growth in U.S. general surgery procedure adoption remained strong, led by a robust growth in hernia repair and continued adoption of colorectal procedures. Cholecystectomy procedures were roughly flat in the quarter with growth in multiport procedures offsetting declines in Single-Site procedures. 
Q1 was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I had selected a couple of studies that you may find interesting. With the launch of our 30-millimeter stapler, surgeon interest in the use of da Vinci for thoracic surgery is growing. A new study comparing open video-assisted thoracic surgery or VATS and da Vinci surgery for pulmonary lobectomy was published by Dr. Yang [ph] and colleagues from Memorial Sloan Kettering Cancer Center in the Annals of Surgery. Using a prospective database including 2,400 surgeries to treat stage I non-small cell lung cancer patients, the officers propensity matched 470 patients across da Vinci, VATS and open surgery. The study found that da Vinci and minimally invasive VATS approaches enabled a shorter chest tube duration and length of hospital stay compared to open surgery. da Vinci surgery was also credited with improved lymph node yields as compared to both open surgery and VATS, an important clinical outcome for determining next steps in the patient's treatment pathway. 
As it related to the expansion of da Vinci lung resections, the authors highlighted that nearly 57% of pulmonary lobectomies in the U.S. are treated with open surgery, and they see promise in expanding patient access to minimally invasive surgery through da Vinci technology. 
Turning abroad. Procedures growth outside of the United States was approximately 22% in the first quarter, led by the global adoption of da Vinci prostatectomy with solid contributions from kidney procedures and colorectal resections. Compared to the second half of 2015, procedure growth slowed in both Europe and Asia during the quarter, in part due to the timing of the Easter holiday. Historically, our OUS procedure growth rates have been lumpy and less predictable in the short term. We are focused on improving our OUS procedure performance. 
In Japan, there were positive developments relating to reimbursement in the quarter. The MHLW approved for reimbursement of partial nephrectomy at a premium rate relative to open surgery and also approved clinical trial enrollment to begin supporting a Senshin Iryo B submission for da Vinci malignant hysterectomy. 
A recent study funded by Intuitive and published in BJU International by Professor Hughes and colleagues from University of Chester collected data from the United Kingdom Health Episode Statistics database, including more than 20,000 prostatectomy patients and 2,000 partial nephrectomy patients to assess health resource utilization and costs following da Vinci, open and laparoscopic procedures. The database showed that from 2008 to 2013, the use of da Vinci surgery increased from 15% to 50% of prostatectomies and 1% to 22% of partial nephrectomies by displacing open surgery. During the first year after the operation, da Vinci surgery was shown to reduce inpatient admissions, hospital bed days and total costs for both prostatectomy and partial nephrectomy compared to open surgery. At 3 years post operation, the study showed similar outcomes for prostatectomy and was insufficient to draw conclusions for partial nephrectomy. Laparoscopic surgery outcomes were at the approximate midpoint between da Vinci and open surgery on resource utilization and costs for both procedures. The authors concluded, ""Our analysis suggests that there are substantial savings associated with robotic-assisted surgery when compared with open and laparoscopic interventions."" 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015.",311,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015. Now based upon favorable U.S. dVP and gynecology macro trends and U.S. general surgery growth, we are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 12% to 14%. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 69% and 70% of net revenue. 
Turning to operating expenses. As we have described, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. On our last call, we forecast to grow pro forma 2016 operating expenses between 9% and 13% above 2015 levels. We are now increasing our estimate for operating expenses to a range of between 12% and 15% above 2015. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect our 2016 other income, which is comprised mostly of interest income, to be in the upper end of the $20 million to $25 million range forecast on our last call. With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you th",92,"Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you think you grew in the quarter on a same-day selling basis? But then much more importantly, just give us a sense as to specifically which surgery types accelerated in the U.S. And what drove the growth? What caused the acceleration? Why did things get better?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter and some modest benefit from the timing of the year",141,"Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter and some modest benefit from the timing of the year as being on a Friday rather than a Thursday. And from a headwind perspective, you had the timing of Easter, which moved from the second quarter into the first quarter, but that has more of an impact on the OUS geographies. From what accelerated, the mature procedures sustained pretty strong growth in the quarter as they saw throughout 2015, which is a little bit of a surprise to us relative to our initial expectation. And general surgery continues to be strong and growing off of a larger base, which has more impact on the U.S. procedure growth [ph]."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level",108,"Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level even further. So can you just talk about where the incremental spend is going? What kind of new incremental technology announcements could that lead to? You mentioned a couple on the call, but I'm just really curious as to where the spending is going and when we could expect to get more visibility on the output from that spending."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So on the spend, I think the acceleration is really borne of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments",185,"Sure. So on the spend, I think the acceleration is really borne of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments in OUS markets where we think that we can do more by investing more, and we've been talking to you about that. The other side is on R&D. And in terms of the categories, we've talked about it before, but we believe in them deeply. Advanced imaging, the ability to see beyond what you can just see with your naked eye; new robotic architectures that allow surgeons to get into and out of the body in different ways into different places that they can't reach prior as well as analytics and over-the-shoulder guidance are all things that we've been investing in and some things that we're accelerating. So as -- we won't do product announcements on this call. As we get deeper into those things and are ready to share them more broadly with you, of course we will."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?",38,"And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process.",21,"Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] Our next question from Tycho Peterson, JPMorgan.",9,"[Operator Instructions] Our next question from Tycho Peterson, JPMorgan."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through the",61,"I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through the gross margins as well? It's mainly a software upgrade from your perspective, right?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how man",65,"Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how many tables we've delivered, so I won't go there. I'll just tell you that, again, we're pretty pleased with the level of adoption."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Can you maybe...",4,"Can you maybe..."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Obviously, the revenue on the margin side.",7,"Obviously, the revenue on the margin side."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf.",27,"Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the -- and so our billing is 100% margin.",10,"And the -- and so our billing is 100% margin."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand",52,"And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much",163,"Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much fuller and richer ecosystem. We think that helps. It's very hard to forecast how much it is, how many people sit and wait until the next step, but we think those things add clinical value. For sure, the 30-millimeter stapler in thoracic procedures is a big win; likewise, Table Motion for a lot of the more complex procedures. So we think that's strong and there are a group of hospitals that use Si with Single-Site that if they are single-system hospital, they own only -- own just one and they have a robust Single-Site program. This allows them to consider Xi as an upgrade. So it's hard to quantify, but we think directionally, it's really strong."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year.",28,"Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where i",165,"Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where it's going a little slower. Sometimes it's a local economy issue. Sometimes it's more of where we are in maturity. Some -- in some of these countries, we're pretty well adopted in the mature procedures and they're really at the beginnings of emerging procedures. So it depends country by country. On the capital side, I think there's 2 things going on. A little bit of environment is one and a little bit of a wait and see on competitive offerings as they come out, and we're navigating that pretty well. In terms of head-to-head comparisons with our technology, our systems are coming out great. But it can put a delay in the pipeline, and we're seeing a little bit of that in Europe."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year of Q1.",45,"The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year of Q1."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from David Lewis with Morgan Stanley.",9,"Our next question from David Lewis with Morgan Stanley."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies no improvement throughout the year, which seems, I guess, less likely to us, just given",79,"Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies no improvement throughout the year, which seems, I guess, less likely to us, just given the cost improvements you've already discussed. So can we just talk to gross margin progression throughout the balance of the year and why you think 70% here in the first quarter is the high watermark?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and that Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in th",84,"Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and that Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in the new product, particularly energy products, stapling and vessel sealing going forward, and those also have lower margins than the base. So I think just based on product mix alone, we don't expect to sustain 70%."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're obviously clearly going to continue to invest. I have no expectations you're going to talk to us",93,"Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're obviously clearly going to continue to invest. I have no expectations you're going to talk to us about future instrumentation and system announcements, but I think the enigma for most shareholders actually is advanced imaging because that's sort of more future-looking. Is there any chance we get incremental updates or at least even any update on the strategy for advanced imaging this year?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in",102,"Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in raw imaging hardware capabilities, which we'll continue to do. As -- what we like to do is, as we have milestones that make sense, whether it's talking to regulatory bodies or engaging in clinical work, those tend to be good anchors to discuss with you. And as those arrive, then we'll share with you what we're thinking."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And could those arrive potentially in '16 for advanced imaging or unlikely?",12,"And could those arrive potentially in '16 for advanced imaging or unlikely?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think when we get there, we'll let you know.",10,"I think when we get there, we'll let you know."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we'll go next to David Roman with Goldman Sachs.",11,"And we'll go next to David Roman with Goldman Sachs."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted Gary just to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year. They were sort of a positive as a tipping point but ju",85,"I wanted Gary just to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year. They were sort of a positive as a tipping point but just incremental enthusiasm from the physician community around this procedure. Can you maybe sort of talk about what you think specifically is stimulating that demand and why you're confident in that continuing on a go-forward basis?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suf",198,"There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suffering the same level of disease. And in the more complex cases, if it's bilateral or prior abdominal surgeries of these patients, large herniated sac, the raw clinical capability of our products is being touted as and supported by surgeons as being important to them, a better quality of intervention, consumable cost in line with what their expectations are. So there, I think that we're feeling pretty good. The second thing we can do is analyze the kind of the reorder rates from surgeons as they go forward. So as you get through the trial periods, you're seeing kind of where as they learn it and get deeper and deeper into it, where do they apply it and how often do they keep buying our products? And that has been supportive as well. So those 2 things come together, we start feeling better about it. And that's what's behind that sort of comments."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of th",87,"All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of the dynamics underpinning that? And then, b, based on your disclosures, it looks like people are buying out these operating leases relatively quickly, and so it's -- maybe help us understand is that true and why that's the case."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and",99,"Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and those are a couple of the ones you've seen bought out in this quarter. Most of the cap -- most of the leases -- of the operating leases are longer term, being 4- and 5-year terms, and will drive a recurring revenue going forward. Like we said, this quarter was around $4 million."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from Ben Andrew with William Blair.",9,"Our next question from Ben Andrew with William Blair."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make an",69,"Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make and are you planning to make that are different than what you've done before to try to lever that because you did specifically call that out?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to vali",217,"Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to validated learning pathways and simulation. Those validations are all multiyear efforts to get right to the full instrument kit from vessel sealing and stapling and so on. And so we're pretty thoughtful about balancing that sort of investments. The things that have gotten really stronger and interesting in the last couple of years have been our ability to analyze data, look at national benchmarking, look at regional base benchmarking and share that information with our customers so that they can make good decisions. Sometimes those decisions are good for them and not great for Intuitive in the near term. If they optimize their program, we may get [indiscernible] revenue per procedure in the near term, but we think long term, it's better for everybody. And so we've been making those analytics and those investments and then communicating with hospitals. So we really have been plugging in each of those settings, and I do think it makes for an ecosystem that creates a lot of value for the customer and builds our relationship with them."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was then?",45,"And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was then?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is just -- think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, p",54,"Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is just -- think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, particularly in Europe."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Rick Wise with Stifel.",10,"And we have a question from Rick Wise with Stifel."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also,",87,"I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also, urology acting better. Have we worked through some of the challenges in each? And are we actually going to return to more sustainable growth in U.S. gynecology after a year or more or 2 of training and education, et cetera?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We kno",308,"Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We know that there was a bolus of patients that went into watchful waiting, some of whom will have disease progression and come back to definitive treatment. How long that bolus lasts is a little bit hard for us to predict. The second thing are the possibility of share changes between some of the treatment modalities, surgery versus radiation versus watchful waiting. That data tends to lag. Hard to get it in real time. There may be some share change, although if there is, it's probably modest. And then there's just demographics. As demographics changes, you have more folks getting diagnosed with prostate cancer over time. So those are the 3 things that are rolling through and sort of projecting how they balance out is what the challenge is. On the gynecology side, the thing that were's seeing in our experience is that you're seeing more surgery being done by high-volume gynecologists, in general, just -- not just robotic surgery but laparoscopy and others. We're seeing a consolidation in the marketplace into folks who are either GYN-oncologists or more routine surgeons. We think that's good for the world, and we think that's good for Intuitive. Those more dedicated surgeons tend to be our customers. We see them tackling more procedures in concentrated fashions, and so that's kind of what's happened in gynecology. Likewise, I think there's a demographic element here that's likely to find the bottom and then start to drift up. The unknown is nonsurgical approaches and in-office approaches. And those are kind of the factors at play. Patrick, I'll let you go from there."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwi",56,"Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwind to us on a year-over-year comparison basis, I think like myomectomy."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're",69,"And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're going about that? What kind of initiatives are under way? And what you would hope or we should expect might come from those initiatives?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they'",118,"Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they're working in local language, that they understand the health care systems in intimate ways that are specific to that country. And so where we see opportunity, we'll invest there and build that out. We have been. Where we've made investments, we've seen growth. And so where we see some areas of opportunity, we think we have a playbook. Now we have to go execute against that playbook. That's been our perspective there."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Matt O'Brien with Piper Jaffray.",12,"And we have a question from Matt O'Brien with Piper Jaffray."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I was hoping to start on the general surgery side, and it sounds like, again, a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are yo",88,"I was hoping to start on the general surgery side, and it sounds like, again, a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are you seeing any kind of divergence or inflection in either ventral or inguinal? And are those procedures at this point getting sizable enough to start to sway hospital decision-making as to adding additional systems in order to meet that demand?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're s",116,"Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're seeing in both procedure is encouraging and the surgeon populations that are performing them are continuing to increase the volumes of procedures that they're doing. So it looks promising and certainly, from an overall volume perspective, had some influence because just the numbers are getting to the point where it matters to create access for these surgeons to be able to continue to perform procedures that they are absorbing systems worth of activity at some of their institutions."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throu",129,"Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throughout 2016 as most systems are fully rolled out? Or do you think that will be a fairly quick process of kind of taking a peak and maybe they're doing that now and we could see a snapback in terms of the numbers of systems placed? I mean, specifically, did you see 10, 15 hospitals kind of delay as they are evaluating both systems and then out of those 10 hospitals, 9 of them ended up buying da Vinci late last quarter or even early this quarter?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making evaluation and come sign up with us and others are going through a little bit longer pr",185,"Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making evaluation and come sign up with us and others are going through a little bit longer process. So with regards to a ""snapback"", I wouldn't bake that in. I think it will play out a little longer than that. Having said that, our -- the response of our customers after they have evaluated the other offerings and come back to talk to us has been fantastic. So our confidence that we have good offerings and we can meet these customers' needs is very high. They all go through that process. And I think as new and different technologies come to market, not just the ones that are there today, I think this will be part of the new normal a little bit for Europe is people cross-shopping and making decisions, and our goal is to make sure that they find our products to be of very high value. So far, so good."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Larry Keusch, Raymond James.",10,"And we have a question from Larry Keusch, Raymond James."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I Wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving th",63,"I Wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving the higher trade-in. And then what's the ultimate opportunity to drive trade-ins in your older system base?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our the detail we provided with the press release. I wouldn't call anything out specifically. I think it",86,"Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our the detail we provided with the press release. I wouldn't call anything out specifically. I think it -- last quarter, it was around, in the high 30s, and it's been there for a little while. I don't know that -- it will probably fluctuate in that range. I'm sorry. I don't have any specific comments on it."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?",44,"Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So we are in discussions with FDA on trial type and end points, and we have clinical sites that are getting the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anything of",69,"So we are in discussions with FDA on trial type and end points, and we have clinical sites that are getting the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anything of substance in terms of revenue this year. We do expect them in clinical use in the second half, and that's what we're working towards."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Jason Mills with Canaccord Genuity.",11,"And we have a question from Jason Mills with Canaccord Genuity."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it s",143,"My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it seem -- what we're seeing -- what we seem to be seeing is some leverage to the operating line, but I'm just curious, Gary, if you could talk about -- Marshall, if you could talk about the -- your dogmas over the next couple of years and sort of, are you looking for operating margin expansion? Is that what your objective is? Are you managing the business to top line growth and trying to manage expenses as best as you can to get there? Could you just talk about your dogmas as it relates to management of the P&L?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufact",208,"Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufacturing. There are other places in operation where we think we can find leverage. At the same time, we want to turn around and reinvest those savings and opportunity. And we see a lot of opportunity, and I think that opportunity should be pursued. So it will be a little bit lumpy. We're trying to be balanced. I wouldn't say that our approach is hard over one or hard over the other. It's not revenue above all else, and it's not profit above all else. We're trying to be balanced in that approach. And it may be a little bit lumpy. I think opportunities happen when they happen. You can be overly cautious and miss them, and so we will maintain the fiscal discipline. That's been part of our history, and we'll keep it. Having said that, we want to make sure that we reinvest some of the benefits that the company has gained into expanding the opportunity we see in front of us."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it",81,"That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it be fair to assume that you'll do modest -- maybe modest to moderate share repurchases going forward? Or will we see maybe less over the next 2 years than we saw in the last 2 years?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool in capital allocation. We really start with can we reinvest in the business and drive long-term growt",156,"In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool in capital allocation. We really start with can we reinvest in the business and drive long-term growth and opportunity. Buybacks, if there are times, we've been typically patient and opportunistic. And we think because of the volatility of our stock, there are times that, that makes a lot of sense for us. And in conversations with shareholders and where we are thoughtful and listened, then we have considered dividends and we will consider them in the future. So we look at those 3 things and try to trade them off. And we think for the long term, when we're thinking about capital allocation, we're not trying to do signaling or messaging. We're trying to build value for the business and for the shareholders in the long term."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Vijay Kumar with Evercore.",10,"And we have a question from Vijay Kumar with Evercore."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems persp",70,"So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems perspective, given that China, they're probably at the end of -- in their amount of systems that they can import?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there are about 6 systems left under quota. We sold 5 this quarter. They're still one out there. I don't know if it will happen. And we ha",203,"Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there are about 6 systems left under quota. We sold 5 this quarter. They're still one out there. I don't know if it will happen. And we have to go through a tender process, and that tender process had already begun. As far as additional quotas, we're -- it's a part of the overall budget -- government budget process in China. And so when that gets completed, and I don't have a magic ball that tells me when it will be completed, then we'll know whether we're still under the quota system and we'll know whether if we are under the quota system, how many will be awarded. And there's no way to predict that in the -- in advance. As far as the rest of the world goes, as I -- in my remarks, I mentioned that it's -- fourth quarter is a seasonally strong quarter. If you look at where we came out for this quarter, it's pretty comparable to last year for the first quarter, but it's going to be lumpy market by market, depending on circumstances."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan starting",58,"Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan starting clinical trial sort of any potential impact in that number."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinica",60,"Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinical trials, we'll tell you about them when we think it's appropriate."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And our next question from Tao Levy with Wedbush.",9,"And our next question from Tao Levy with Wedbush."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times the thoracic surgery and the benefit that -- and particularly the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opp",84,"We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times the thoracic surgery and the benefit that -- and particularly the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportunities within thoracic? Should we think of it as a colorectal-type opportunity where it's moving in the right direction but it's a little bit slower? Or could it potentially be more like a hernia or a hysterectomy opportunity?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from the starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right",150,"Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from the starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right direction. Some of the instrumentation we're bringing along moves us in the right direction in terms of providing surgeons with the tools they are looking for, for efficient procedures, and I think we're at the beginnings of that. The way to think about the market is there are some minimally invasive surgery done manually, video-assisted thoracic surgery. Some institutions do a lot of it with good results. Others do very little of it. If you look at national averages rather than institutional numbers, you see a lot of open surgery done. And we think that, that's the opportunity. I'll let Patrick characterize it through."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly",101,"Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly focused on driving dVP adoption and some emerging procedures in countries where urology is deeply penetrated. And when you look around internationally, it is a cancer that is very common in Asia and other parts. So it's a very big opportunity for us, and we're perhaps a little bit around the corner from what we're currently focused on."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried",65,"Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried that some of the other procedures that are catching on here in the U.S. over the last few years aren't moving the needle yet internationally?"
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we se",258,"Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we see in the United States. So you have to answer it country by country. I don't think there's a systemic worry here that, that somehow we're stuck at prostatectomy and won't be able to move any further. I do think that it's important for folks on the phone to realize that the profile of procedures in each country is going to differ based on disease state based on how the reimbursement system works and the relative priorities of their health care system, so we see that reflected. We do see multiple procedure adoption in different countries. It just differs on what they're after. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the vital few things that really make a difference. 
This concludes today's call. Thank you for your participation and support on this extraordinary journey to improve surgery, and I look forward to speaking with you again in 3 months."
30239,328482491,959643,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect.",20,"Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director",50,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance.",256,"Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our first quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our first quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. Turning firs",769,"Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. 
Turning first to procedures. Global procedure growth for the quarter was nearly 17% led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States, continued growth in U.S. urology and modest growth in U.S. gynecology. Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair, followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of da Vinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance. Procedure growth was variable by country in Europe, with solid performance in the United Kingdom and Germany offsetting slower growth in the Nordic countries. Performance in the quarter was helped by an extra procedure day in some regions relative to Q1 of 2015. Patrick will review procedure trends in greater detail later in the call. 
We placed 110 da Vinci systems in the quarter, up from 99 in Q1 of 2015. Customers continued to purchase our Xi Systems over less expensive and less capable Si models by a factor of approximately 3:1. Capital performance was strong in the United States, offsetting capital softness in Europe and the exploration of our quota in China. Lastly, customer leasing and lease-to-own arrangements are making up a greater percentage of new system placements. Marshall will take you through our finances in more detail later in the call. 
Our operations teams remain focused on optimizing our manufacturing design and supply chains for our newer products. Our teams continued to execute against their goals with steady improvements in reducing product costs for our new systems and advanced instruments in the quarter. Product cost reductions exceeded our expectations, and we expect them to continue to improve in 2016 and 2017. 
Our offerings make up an ecosystem designed to meet our customers' needs in building and running outstanding robotic surgery programs. These ecosystems include systems instruments and accessories, training technologies and peer-to-peer coursework, service offerings and program optimization and analytics support. As a result of the set of products and services that surround our systems, recurring revenue in the quarter comprised 75% of total company revenue. 
Highlights of the first quarter operating results are as follows: procedures grew nearly 17% over the first quarter of last year. We shipped 110 da Vinci Surgical Systems, up from 99 in the first quarter of 2015. Revenue for the quarter was $595 million, up 12% over the prior year. Pro forma gross profit margin was 70% compared to 65.6% in the first quarter of last year. Instrument and accessory revenue increased to $322 million, up 16%. Total recurring revenue in the quarter was $447 million, representing 75% of total revenue. We generated a pro forma operating profit of $229 million in the quarter, up 24% from the first quarter of last year; and pro forma net income was $170 million, up 27% from Q1 of 2015. 
We continued to enable our Xi platform with new product launches. Our launch of intraoperative Table Motion is proceeding well, with order flow that has met our expectations and with strong customer feedback on its utility, particularly in general surgery. In the quarter, we also launched our 30-millimeter Xi stapler designed to facilitate stapling in thoracic procedures and our Xi Single-Site instrument and accessory kit. Both our 30-millimeter stapler and our Xi Single-Site instruments have started clinical use with positive feedback on their utility. Our Sp program remains on track. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that substantial opportunity exists to enable better outcomes and to expand our -- access to our technologies globally. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we're focused on the following: first, expanding the use of da Vinci in general in thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our Sp product into initial clinical use; third, driving our organizational capabilities end markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the busin",1368,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
First quarter revenue was $595 million, an increase of 12% compared with $532 million for the first quarter of 2015 and a decrease of 12% compared with the seasonally stronger fourth quarter of $677 million. First quarter 2016 procedures of approximately 176,000 increased nearly 17% compared with the first quarter of 2015 and decreased slightly compared with the fourth quarter procedures of approximately 177,000. Year-over-year procedure growth was driven by general surgery procedures in the U.S. and urology worldwide. It otherwise likely benefited from an additional calendar day associated with leap year. 
Revenue highlights are as follows: Instrument and accessory revenue of $322 million increased 16% compared with last year and decreased 1% compared with the fourth quarter of 2015. These changes generally reflect changes in procedures. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,830 per procedure. This metric continues to fluctuate in a tight range of approximately 100 -- $1,830 and $1,840 per procedure. Relative to the first quarter of 2015, the current quarter reflects higher sales of advanced instruments, offset by the impact of customer buying patterns and foreign exchange. System revenue of $148 million increased 5% compared with last year and decreased 36% compared with last quarter. The increase relative to the prior year primarily reflects increased revenue associated with operating lease activities and slightly higher average system selling prices. The decrease relative to the fourth quarter primarily reflects seasonally lower unit sales and slightly lower ASPs, partially offset by increased revenue associated with operating lease activities. 110 systems were placed in the first quarter compared with 99 systems in the first quarter of 2015 and 158 systems last quarter. Approximately 77% of the systems shipped in the quarter were Xis, which is comparable to prior quarters. Hospitals financed approximately 37% of the systems placed in the first quarter, up from 17% less quarter. We directly financed 31 systems, including 19 operating leases. As of the end of the first quarter, there were 62 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the first quarter of 2015 and $3 million in the fourth quarter. We also generated approximately $6 million of revenue during the quarter from lease buyouts compared with $2 million of revenue in the fourth quarter and no lease buyout revenue in the first quarter of last year. We excluded the impact of operating leases from our system ASP calculations. 
Globally, our average system price of $1,500,000 was approximately $30,000 higher than the first quarter of 2015 ASP and approximately $50,000 lower than the ASP last quarter. Relative to the prior year, the increase reflects a proportionately lower trade-in volume and favorable geographic mix, partially offset by an unfavorable product mix. The decrease relative to the fourth quarter reflects proportionately higher trade-in volume and lower mix of Xi dual consoles, partially offset by a favorable geographic mix. 
Service revenue of $125 million increased 9% year over year and increased approximately 4% compared with the fourth quarter of 2015. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: first quarter revenue outside of the U.S. of $164 million increased 9% compared with $150 million for the first quarter of 2015 and decreased 25% compared with seasonally stronger fourth quarter, up to $219 million. The increase compared with the previous year is comprised of a 14% growth in recurring revenue, which is driven by a procedure growth of 22% and increased systems revenue of 2%. The decrease compared to the fourth quarter reflects seasonally strong fourth quarter systems placements, partially offset by a 5% growth in recurring revenue. Outside the U.S., we placed 36 systems in the first quarter compared with 36 in the first quarter of 2015 and 75 last quarter. Current quarter system sales included 5 into China and 8 into Japan. System placements outside of the U.S. will continue to be lumpy as some of these markets are in their early stages of adoption; some markets are highly seasonal, reflecting budget cycles or vacation patterns; and sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the first quarter was 70% compared with 65.6% for the first quarter of 2015 and 69.6% for the fourth quarter of 2015. Compared with the first quarter of 2015, the higher gross margin reflects a reduction of product and product repair costs, improved manufacturing operations efficiencies, the elimination of the medical device tax, lower costs associated with product field actions and related inventory charges and a higher mix of instrument and accessory revenue. The medical device tax has been suspended for the next 2 years and reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products, our ability to further reduce product costs, manufacturing efficiency, costs associated with product field actions and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses, which exclude legal settlements and accruals for legal claims, stock compensation expense and amortization of purchased IP, increased 14% compared with the first quarter of 2015 and increased 5% compared with last quarter. The increases over prior periods reflect increased investments in advanced imaging, advanced instrumentation and next-generation robotics; increased headcount and higher payroll taxes associated with stock option exercises. Our pro forma effective tax rate for the first quarter was 27.4% compared with an effective tax rate of 28.9% for the first quarter of 2015 and 24.9% last quarter. In late December 2015, Congress retroactively approved the 2015 federal research and development credit and made the R&D tax credit permanent going forward. The entire 2015 R&D tax credit was included in the fourth quarter, while no benefit was reflected in the first quarter of 2015 and a proportional benefit is reflected in the first quarter of 2016. Other than the impact of the R&D credit, fluctuations in our tax rate between this quarter and the first and fourth quarters of 2015 primarily reflect changes in the mix of U.S. and OUS income. 
Our first quarter 2016 pro forma net income was $170 million or $4.42 per share compared with $135 million or $3.57 per share for the first quarter of 2015 and $224 million or $5.89 per share for the fourth quarter of 2015. Note that fully diluted shares outstanding increased by approximately 400,000 shares relative to the fourth quarter, resulting primarily from the increase in our share price. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $595 million for the first quarter of 2016 compared with $532 million for the first quarter of 2015 and $677 million for the fourth quarter of 2015. GAAP net income was $136 million or $3.54 per share for the first quarter of 2016 compared with $97 million or $2.57 per share for the first quarter of 2015 and $190 million or $4.99 per share for the fourth quarter of 2015. 
We ended the year with cash and investments of $3.8 billion, up from $3.3 billion as of December 31, 2015. The increase primarily -- was primarily driven by proceeds from stock option exercises and cash generated from operations. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure grow",783,"Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure growth outpaced our expectations. First quarter growth in our mature procedures continued at levels similar to the second half of 2015, generating majority of the procedure outperformance relative to our expectation. General surgery procedure growth also exceeded our expectations. In U.S. urology, first quarter growth in da Vinci prostatectomy and kidney procedures continued at similar rates as the second half of 2015. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect the prostatectomy growth to return to levels similar to prostate cancer incidence rates over time. 
In U.S. gynecology, first quarter procedures grew modestly year over year with growth led by malignant and complex hysterectomy. Continuing the trend from 2015, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic-oncologists during the first quarter. Similar to the fourth quarter, U.S. Single-Site gynecology procedure growth declined compared to the first quarter of 2015. First quarter growth in U.S. general surgery procedure adoption remained strong, led by a robust growth in hernia repair and continued adoption of colorectal procedures. Cholecystectomy procedures were roughly flat in the quarter with growth in multiport procedures offsetting declines in Single-Site procedures. 
Q1 was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I selected a couple of studies that you may find interesting. With the launch of our 30-millimeter stapler, surgeon interest in the use of da Vinci for thoracic surgery is growing. A new study comparing open video-assisted thoracic surgery or VATS and da Vinci surgery for pulmonary lobectomy was published by Dr. Yang and colleagues from Memorial Sloan Kettering Cancer Center in the Annals of Surgery. Using a prospective database including 2,400 surgeries to treat stage I non-small cell lung cancer patients, the officers propensity matched 470 patients across da Vinci, VATS and open surgery. The study found that da Vinci and minimally invasive VATS approaches enabled a shorter chest tube duration and length of hospital stay compared to open surgery. da Vinci surgery was also credited with improved lymph node yields as compared to both open surgery and VATS, an important clinical outcome for determining next steps in the patient's treatment pathway. 
As it related to the expansion of da Vinci lung resections, the authors highlighted that nearly 57% of pulmonary lobectomies in the U.S. are treated with open surgery, and they see promise in expanding patient access to minimally invasive surgery through da Vinci technology. 
Turning abroad. Procedures growth outside of the United States was approximately 22% in the first quarter, led by the global adoption of da Vinci prostatectomy with solid contributions from kidney procedures and colorectal resections. Compared to the second half of 2015, procedure growth slowed in both Europe and Asia during the quarter, in part due to the timing of the Easter holiday. Historically, our OUS procedure growth rates have been lumpy and less predictable in the short term. We are focused on improving our OUS procedure performance. 
In Japan, there were positive developments relating to reimbursement in the quarter. The MHLW approved for reimbursement of partial nephrectomy at a premium rate relative to open surgery and also approved clinical trial enrollment to begin supporting a Senshin Iryo B submission for da Vinci malignant hysterectomy. 
A recent study funded by Intuitive and published in BJU International by Professor Hughes and colleagues from the University of Chester collected data from the United Kingdom Health Episode Statistics database, including more than 20,000 prostatectomy patients and 2,000 partial nephrectomy patients to assess health resource utilization and costs following da Vinci, open and laparoscopic procedures. The database showed that from 2008 to 2013, the use of da Vinci surgery increased from 15% to 50% of prostatectomies and 1% to 22% of partial nephrectomies by displacing open surgery. During the first year after the operation, da Vinci surgery was shown to reduce inpatient admissions, hospital bed days and total costs for both prostatectomy and partial nephrectomy compared to open surgery. At 3 years post operation, the study showed similar outcomes for prostatectomy and was insufficient to draw conclusions for partial nephrectomy. Laparoscopic surgery outcomes were at the approximate midpoint between da Vinci and open surgery on resource utilization and costs for both procedures. The authors concluded, ""Our analysis suggests that there are substantial savings associated with robotic-assisted surgery when compared with open and laparoscopic interventions.""
This concludes my remarks. I'll now turn the call over to Calvin."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015.",311,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015. Now based upon favorable U.S. dVP and gynecology macro trends and U.S. general surgery growth, we are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 12% to 14%. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 69% and 70% of net revenue. 
Turning to operating expenses. As we have described, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. On our last call, we forecast to grow pro forma 2016 operating expenses between 9% and 13% above 2015 levels. We are now increasing our estimate for operating expenses to a range of between 12% and 15% above 2015. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect our 2016 other income, which is comprised mostly of interest income, to be in the upper end of the $20 million to $25 million range forecast on our last call. With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you th",92,"Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you think you grew in the quarter on a same-day selling basis? But then much more importantly, just give us a sense as to specifically which surgery types accelerated in the U.S. And what drove the growth? What caused the acceleration? Why did things get better?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter, and some modest benefit from the time of the year",141,"Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter, and some modest benefit from the time of the year as being on a Friday rather than a Thursday. And from a headwind perspective, you had the timing of Easter, which moved from the second quarter into the first quarter, but that had more of an impact on the OUS geographies. From what accelerated, the mature procedures sustained pretty strong growth in the quarter as they saw throughout 2015, which is a little bit of a surprise to us relative to our initial expectation. And general surgery continues to be strong and growing off of a larger base, which has more impact on the U.S. procedure drum pump."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level",108,"Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level even further. So can you just talk about where the incremental spend is going? What kind of new incremental technology announcements could that lead to? You mentioned a couple on the call, but I'm just really curious as to where the spending is going and when we could expect to get more visibility on the output from that spending."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So on the spend, I think the acceleration is really board of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments",185,"Sure. So on the spend, I think the acceleration is really board of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments in OUS markets where we think that we can do more by investing more, and we've been talking to you about that. The other side is on R&D. And in terms of the categories, we've talked about it before, but we believe in them deeply. Advanced imaging, the ability to see beyond what you can just see with your naked eye; new robotic architectures that allow surgeons to get into and out of the body in different ways into different places that they could reach prior as well as analytics and over-the-shoulder guidance, all things that we have been investing in and some things that we're accelerating. So as -- we won't do product announcements on this call. As we get deeper into those things and are ready to share them more broadly with you, of course we will."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?",38,"And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process.",21,"Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] Our next question from Tycho Peterson, JPMorgan.",9,"[Operator Instructions] Our next question from Tycho Peterson, JPMorgan."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through to",61,"I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through to gross margins as well? It's mainly a software upgrade from your perspective, right?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how man",65,"Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how many tables we've delivered, so I won't go there. I'll just tell you that, again, we're pretty pleased with the level of adoption."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Can you maybe...",4,"Can you maybe..."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Obviously, the revenue on the margin side.",7,"Obviously, the revenue on the margin side."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf.",27,"Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the -- and so our billing is 100% margin.",10,"And the -- and so our billing is 100% margin."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand",52,"And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much",164,"Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much fuller and richer ecosystem. We think that helps. It's very hard to forecast how much it is, how many people sit and wait until the next step, but we think those things add clinical value for sure. The 30-millimeter stapler in thoracic procedures is a big win; likewise, Table Motion for a lot of the more complex procedures. So we think that's strong and there are a group of hospitals that use Si with Single-Site that if they are a single-system hospital, they own only -- own just one and they have a robust Single-Site program. This allows them to consider Xi as an upgrade. So it's hard to quantify, but we think directionally, it's really strong."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year.",28,"Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where i",163,"Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where it's going a little slower. Sometimes it's a local economy issue. Sometimes it's more of where we are in maturity. Some -- in some of these countries, we're pretty well adopted in the mature procedures and they're really at the beginnings of emerging procedures. So it depends country by country. On the capital side, I think there's 2 things going on: a little bit of environment is one and a little bit of a wait-and-see on competitive offerings as they come out, and we're navigating that pretty well. In terms of head-to-head comparisons with our technology, our systems are coming out great. But it can put a delay in the pipeline, and we're seeing a little bit of that in Europe."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year Q1.",44,"The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year Q1."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from David Lewis with Morgan Stanley.",9,"Our next question from David Lewis with Morgan Stanley."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies you had no improvement throughout the year, which seems, I guess, less likely to us, ju",81,"Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies you had no improvement throughout the year, which seems, I guess, less likely to us, just given the cost improvements you've already discussed. So can we just talk to gross margin progression throughout the balance of the year and why you think 70% here in the first quarter is the high watermark?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in the new",83,"Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in the new product, particularly energy products, stapling and vessel sealing going forward, and those also have lower margins than the base. So I think just based on product mix alone, we don't expect to sustain 70%."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're clearly obviously going to continue to invest. I have no expectations you're going to talk to us",93,"Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're clearly obviously going to continue to invest. I have no expectations you're going to talk to us about future instrumentation and system announcements, but I think the enigma for most shareholders actually is advanced imaging because that's sort of more future-looking. Is there any chance we get incremental updates or at least even any update on the strategy for advanced imaging this year?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in",102,"Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in raw imaging hardware capabilities, which we'll continue to do. As -- what we like to do is, as we have milestones that make sense, whether it's talking to regulatory bodies or engaging in clinical work, those tend to be good anchors to discuss with you. And as those arrive, then we'll share with you what we're thinking."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And could those arrive potentially in '16 for advanced imaging or unlikely?",12,"And could those arrive potentially in '16 for advanced imaging or unlikely?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think when we get there, we'll let you know.",10,"I think when we get there, we'll let you know."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we'll go next to David Roman with Goldman Sachs.",11,"And we'll go next to David Roman with Goldman Sachs."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year there was sort of a positive as a tipping point but just inc",84,"I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year there was sort of a positive as a tipping point but just incremental enthusiasm from the physician community around this procedure. Can you maybe sort of talk about what you think specifically is stimulating that demand and why you're confident in that continuing on a go-forward basis?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suf",199,"There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suffering the same level of disease. And in the more complex cases, if it's bilateral or prior abdominal surgeries of these patients, large herniated sac, the raw clinical capability of our products is being touted as -- and supported by surgeons as being important to them, a better quality of intervention, consumable costs in line with what their expectations are. So there, I think that we're feeling pretty good. The second thing we can do is analyze the kind of the reorder rates from surgeons as they go forward. So as you get through the trial periods, you're seeing kind of where as they learn it and get deeper and deeper into it, where do they apply it and how often do they keep buying our products? And that has been supportive as well. So those 2 things come together, we start feeling better about it. And that's what's behind that sort of comments."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of th",87,"All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of the dynamics underpinning that? And then, b, based on your disclosures, it looks like people are buying out these operating leases relatively quickly, and so it's -- maybe help us understand is that true and why that's the case."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and",99,"Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and those are a couple of the ones you've seen bought out in this quarter. Most of the cap -- most of the leases -- of the operating leases are longer term, being 4- and 5-year terms, and will drive a recurring revenue going forward. Like we said, this quarter was around $4 million."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from Ben Andrew with William Blair.",9,"Our next question from Ben Andrew with William Blair."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make an",69,"Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make and are you planning to make that are different than what you've done before to try to lever that because you did specifically call that out?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to vali",217,"Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to validated learning pathways and simulation. Those validations are all multiyear efforts to get right to the full instrument kit from vessel sealing and stapling and so on. And so we're pretty thoughtful about balancing that sort of investments. The things that have gotten really stronger and interesting in the last couple of years have been our ability to analyze data, look at national benchmarking, look at regional base benchmarking and share that information with our customers so that they can make good decisions. Sometimes those decisions are good for them and not great for Intuitive in the near term. If they optimize their program, we may get [indiscernible] revenue per procedure in the near term, but we think long term, it's better for everybody. And so we've been making those analytics and those investments and then communicating with hospitals. So we really have been plugging in each of those settings, and I do think it makes for an ecosystem that creates a lot of value for the customer and builds our relationship with them."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was net?",45,"And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was net?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is -- just think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, p",54,"Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is -- just think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, particularly in Europe."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Rick Wise with Stifel.",10,"And we have a question from Rick Wise with Stifel."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also,",87,"I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also, urology acting better. Have we worked through some of the challenges in each? And are we actually going to return to more sustainable growth in U.S. gynecology after a year or more or 2 of training and education, et cetera?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We kno",308,"Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We know that there was a bolus of patients that went into watchful waiting, some of whom will have disease progression and come back to definitive treatment. How long that bolus lasts is a little bit hard for us to predict. The second thing are the possibility of share changes between some of the treatment modalities, surgery versus radiation versus watchful waiting. That data tends to lag. Hard to get it in real time. There may be some share change, although if there is, it's probably modest. And then there's just demographics. As demographics changes, you have more folks getting diagnosed with prostate cancer over time. So those are the 3 things that are rolling through and sort of projecting how they balance out is what the challenge is. On the gynecology side, the thing that we're seeing in our experience is that you're seeing more surgery being done by high-volume gynecologists, in general, just -- not just robotic surgery but laparoscopy and others. We're seeing a consolidation in the marketplace into folks who are either GYN-oncologists or more routine surgeons. We think that's good for the world, and we think that's good for Intuitive. Those more dedicated surgeons tend to be our customers. We see them tackling more procedures in concentrated fashions, and so that's kind of what's happened in gynecology. Likewise, I think there's a demographic element here that's likely to find the bottom and then starts to drift up. The unknown is nonsurgical approaches and in-office approaches. And those are kind of the factors at play. Patrick, I'll let you go from there."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwi",55,"Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwind to us on a year-over-year comparison basis, things like myomectomy."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're",69,"And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're going about that? What kind of initiatives are under way? And what you would hope or we should expect might come from those initiatives?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they'",119,"Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they're working in the local language, that they understand the health care systems in intimate ways that are specific to that country. And so where we see opportunity, we'll invest there and build that out. We have been. Where we've made investments, we've seen growth. And so where we see some areas of opportunity, we think we have a playbook. Now we have to go execute against that playbook. That's been our perspective there."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Matt O'Brien with Piper Jaffray.",12,"And we have a question from Matt O'Brien with Piper Jaffray."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I was hoping to start on the general surgery side, and it sounds like, again, you had a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth",90,"I was hoping to start on the general surgery side, and it sounds like, again, you had a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are you seeing any kind of divergence or inflection in either ventral or inguinal? And are those procedures at this point getting sizable enough to start to sway hospital decision-making as to adding additional systems in order to meet that demand?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're s",116,"Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're seeing in both procedures is encouraging and the surgeon populations that are performing them are continuing to increase the volumes of procedures that they're doing. So it looks promising and certainly, from an overall volume perspective, had some influence because just the numbers are getting to the point where it matters to create access for these surgeons to be able to continue to perform procedures that they are absorbing systems' worth of activity at some of their institutions."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throu",129,"Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throughout 2016 as most systems are fully rolled out? Or do you think that will be a fairly quick process of kind of taking a peak and maybe they're doing that now and we could see a snapback in terms of the numbers of systems placed? I mean, specifically, did you see 10, 15 hospitals kind of delay as they were evaluating both systems and then out of those 10 hospitals, 9 of them ended up buying da Vinci late last quarter or even early this quarter?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making a evaluation and come sign up with us and others are going through a little bit longer",186,"Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making a evaluation and come sign up with us and others are going through a little bit longer process. So with regards to a ""snapback"", I wouldn't bake that in. I think it will play out a little longer than that. Having said that, our -- the response of our customers after they have evaluated the other offerings and come back to talk to us has been fantastic. So our confidence that we have good offerings and we can meet these customers' needs is very high. They all go through that process. And I think as new and different technologies come to market, not just the ones that are there today, I think this will be part of the new normal a little bit for Europe is people cross-shopping and making decisions, and our goal is to make sure that they find our products to be of very high value. So far, so good."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Larry Keusch, Raymond James.",10,"And we have a question from Larry Keusch, Raymond James."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter's has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving",63,"I wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter's has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving the higher trade-in. And then what's the ultimate opportunity to drive trade-ins in your older system base?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our -- the detail we provided with the press release. I wouldn't call anything out specifically. I think",87,"Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our -- the detail we provided with the press release. I wouldn't call anything out specifically. I think it -- last quarter, it was around, in the high 30s, and it's been there for a little while. I don't know that -- it will probably fluctuate in that range. I'm sorry. I don't have any specific comments on it."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?",44,"Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So we are in discussions with FDA on trial type and end points and we have clinical sites that are getting prepped the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anyth",70,"So we are in discussions with FDA on trial type and end points and we have clinical sites that are getting prepped the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anything of substance in terms of revenue this year. We do expect them in clinical use in the second half, and that's what we're working towards."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Jason Mills with Canaccord Genuity.",11,"And we have a question from Jason Mills with Canaccord Genuity."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it s",141,"My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it seem -- what we're seeing -- what we seem to be seeing is some leverage to the operating line, but I'm just curious, Gary, if you could talk about -- Marshall, if you could talk about the -- your dogmas over the next couple of years and sort of, are you looking for operating margin expansion? Is that what your objective is? Are you managing the business to top line growth and trying to manage expenses as best you can to get there? Could you talk about your dogmas as it relates to management of the P&L?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufact",209,"Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufacturing. There are other places in the operation where we think we can find leverage. At the same time, we want to turn around and reinvest those savings and opportunity. And we see a lot of opportunity, and I think that opportunity should be pursued. So it will be a little bit lumpy. We're trying to be balanced. I wouldn't say that our approach is hard over one or hard over the other. It's not revenue above all else, and it's not profit above all else. We're trying to be balanced in that approach. And it may be a little bit lumpy. I think opportunities happen when they happen. You can be overly cautious and miss them, and so we will maintain a fiscal discipline. That's been part of our history, and we'll keep it. Having said that, we want to make sure that we reinvest some of the benefits that the company has gained into expanding the opportunity we see in front of us."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it",81,"That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it be fair to assume that you'll do modest -- maybe modest to moderate share repurchases going forward? Or will we see maybe less over the next 2 years than we saw in the last 2 years?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool into capital allocation. We really start with, can we reinvest in the business and drive long-term gr",157,"In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool into capital allocation. We really start with, can we reinvest in the business and drive long-term growth and opportunity. Buybacks, if -- there are times, we've been typically patient and opportunistic. And we think because of the volatility of our stock, there are times that, that makes a lot of sense for us. And in conversations with shareholders and where we are thoughtful and listen, then we have considered dividends and we will consider them in the future. So we look at those 3 things and try to trade them off. And we think for the long term, when we're thinking about capital allocation, we're not trying to do signaling or messaging. We're trying to build value for the business and for the shareholders in the long term."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Vijay Kumar with Evercore.",10,"And we have a question from Vijay Kumar with Evercore."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of a renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems per",69,"So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of a renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems perspective, given that China, they're probably at the end of the amount of systems that they can import?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. There's still 1 out there. I don't know if it will happen. And they h",208,"Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. There's still 1 out there. I don't know if it will happen. And they have to go through a tender process, and that tender process had to have already begun. As far as additional quotas, we're -- it's a part of the overall budget -- government budget process in China. And so when that gets completed, and I don't have a magic ball that tells me when it will be completed, then we'll know whether we're still under the quota system and we'll know whether -- if we are under the quota system, how many will be awarded. And there's no way to predict that in the -- in advance. As far as the rest of the world goes, as I -- in my remarks, I mentioned that it's -- fourth quarter is a seasonally strong quarter. If you look at where we came out for this quarter, it was pretty comparable to last year for the first quarter, but it's going to be lumpy market by market, depending on the circumstances."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan, in start",59,"Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan, in starting clinical trial sort of any potential impact on that number?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinica",60,"Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinical trials, we'll tell you about them when we think it's appropriate."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And our next question from Tao Levy with Wedbush.",9,"And our next question from Tao Levy with Wedbush."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times thoracic surgery and the benefit that, in particular, the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportuniti",82,"We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times thoracic surgery and the benefit that, in particular, the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportunities within thoracic? Should we think of it as a colorectal-type opportunity where it's moving in the right direction but it's a little bit slower? Or could it potentially be more like a hernia or a hysterectomy opportunity?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from a starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right d",150,"Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from a starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right direction. Some of the instrumentation we're bringing along moves us in the right direction in terms of providing surgeons with the tools they are looking for, for efficient procedures, and I think we're at the beginnings of that. The way to think about the market is there are some minimally invasive surgery done manually, video-assisted thoracic surgery. Some institutions do a lot of it with good results. Others do very little of it. If you look at national averages rather than institutional numbers, you see a lot of open surgery done. And we think that, that's the opportunity. I'll let Patrick characterize it through."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly",100,"Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly focused on driving dVP adoption and some emerging procedures in countries where urology is deeply penetrated. And when you look around internationally, it is a cancer that is very common in Asia and other parts. So it's a very big opportunity for us though perhaps a little bit around the corner from what we're currently focused on."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried",65,"Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried that some of the other procedures that are catching on here in the U.S. over the last few years aren't moving the needle yet internationally?"
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we se",258,"Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we see in the United States. So you have to answer it country by country. I don't think there's a systemic worry here that, that somehow we're stuck at prostatectomy and won't be able to move any further. I do think that it's important for folks on the phone to realize that the profile of procedures in each country is going to differ based on disease state based on how the reimbursement system works and the relative priorities of their health care system, so we see that reflected. We do see multiple procedure adoption in different countries. It just differs on what they're after. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. Thank you for your participation and support on this extraordinary journey to improve surgery, and I look forward to speaking with you again in 3 months."
30239,328482491,959659,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect.",20,"Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director",50,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q1 2016 Earnings Release Call. [Operator Instructions] As a reminder, the conference is being recorded. And I'll now turn the meeting over to our host, Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance.",256,"Thank you. Good afternoon, and welcome to Intuitive Surgical's First Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Senior Director of Finance. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements. 
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our first quarter results as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our first quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. Turning firs",769,"Good afternoon, and thank you for joining us on the call today. Our first quarter company performance was strong with excellent global procedure growth, solid capital placements, improving product margins and important new product launches. 
Turning first to procedures. Global procedure growth for the quarter was nearly 17% led by growth in general surgery, growth in the use of da Vinci Surgical Systems outside the United States, continued growth in U.S. urology and modest growth in U.S. gynecology. Trends in U.S. general surgery growth continued with strong growth in inguinal hernia repair and ventral hernia repair, followed by continued growth in colorectal surgery. Customer feedback and commitment to the use of da Vinci in performing inguinal hernia repair for complex conditions has been encouraging in the quarter, increasing our confidence in its long-term acceptance. Procedure growth was variable by country in Europe, with solid performance in the United Kingdom and Germany offsetting slower growth in the Nordic countries. Performance in the quarter was helped by an extra procedure day in some regions relative to Q1 of 2015. Patrick will review procedure trends in greater detail later in the call. 
We placed 110 da Vinci systems in the quarter, up from 99 in Q1 of 2015. Customers continued to purchase our Xi Systems over less expensive and less capable Si models by a factor of approximately 3:1. Capital performance was strong in the United States, offsetting capital softness in Europe and the exploration of our quota in China. Lastly, customer leasing and lease-to-own arrangements are making up a greater percentage of new system placements. Marshall will take you through our finances in more detail later in the call. 
Our operations teams remain focused on optimizing our manufacturing design and supply chains for our newer products. Our teams continued to execute against their goals with steady improvements in reducing product costs for our new systems and advanced instruments in the quarter. Product cost reductions exceeded our expectations, and we expect them to continue to improve in 2016 and 2017. 
Our offerings make up an ecosystem designed to meet our customers' needs in building and running outstanding robotic surgery programs. These ecosystems include systems instruments and accessories, training technologies and peer-to-peer coursework, service offerings and program optimization and analytics support. As a result of the set of products and services that surround our systems, recurring revenue in the quarter comprised 75% of total company revenue. 
Highlights of the first quarter operating results are as follows: procedures grew nearly 17% over the first quarter of last year. We shipped 110 da Vinci Surgical Systems, up from 99 in the first quarter of 2015. Revenue for the quarter was $595 million, up 12% over the prior year. Pro forma gross profit margin was 70% compared to 65.6% in the first quarter of last year. Instrument and accessory revenue increased to $322 million, up 16%. Total recurring revenue in the quarter was $447 million, representing 75% of total revenue. We generated a pro forma operating profit of $229 million in the quarter, up 24% from the first quarter of last year; and pro forma net income was $170 million, up 27% from Q1 of 2015. 
We continued to enable our Xi platform with new product launches. Our launch of intraoperative Table Motion is proceeding well, with order flow that has met our expectations and with strong customer feedback on its utility, particularly in general surgery. In the quarter, we also launched our 30-millimeter Xi stapler designed to facilitate stapling in thoracic procedures and our Xi Single-Site instrument and accessory kit. Both our 30-millimeter stapler and our Xi Single-Site instruments have started clinical use with positive feedback on their utility. Our Sp program remains on track. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that substantial opportunity exists to enable better outcomes and to expand our -- access to our technologies globally. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we're focused on the following: first, expanding the use of da Vinci in general in thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our Sp product into initial clinical use; third, driving our organizational capabilities end markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the busin",1368,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe the business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
First quarter revenue was $595 million, an increase of 12% compared with $532 million for the first quarter of 2015 and a decrease of 12% compared with the seasonally stronger fourth quarter of $677 million. First quarter 2016 procedures of approximately 176,000 increased nearly 17% compared with the first quarter of 2015 and decreased slightly compared with the fourth quarter procedures of approximately 177,000. Year-over-year procedure growth was driven by general surgery procedures in the U.S. and urology worldwide. It otherwise likely benefited from an additional calendar day associated with leap year. 
Revenue highlights are as follows: Instrument and accessory revenue of $322 million increased 16% compared with last year and decreased 1% compared with the fourth quarter of 2015. These changes generally reflect changes in procedures. Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,830 per procedure. This metric continues to fluctuate in a tight range of approximately 100 -- $1,830 and $1,840 per procedure. Relative to the first quarter of 2015, the current quarter reflects higher sales of advanced instruments, offset by the impact of customer buying patterns and foreign exchange. System revenue of $148 million increased 5% compared with last year and decreased 36% compared with last quarter. The increase relative to the prior year primarily reflects increased revenue associated with operating lease activities and slightly higher average system selling prices. The decrease relative to the fourth quarter primarily reflects seasonally lower unit sales and slightly lower ASPs, partially offset by increased revenue associated with operating lease activities. 110 systems were placed in the first quarter compared with 99 systems in the first quarter of 2015 and 158 systems last quarter. Approximately 77% of the systems shipped in the quarter were Xis, which is comparable to prior quarters. Hospitals financed approximately 37% of the systems placed in the first quarter, up from 17% less quarter. We directly financed 31 systems, including 19 operating leases. As of the end of the first quarter, there were 62 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the first quarter of 2015 and $3 million in the fourth quarter. We also generated approximately $6 million of revenue during the quarter from lease buyouts compared with $2 million of revenue in the fourth quarter and no lease buyout revenue in the first quarter of last year. We excluded the impact of operating leases from our system ASP calculations. 
Globally, our average system price of $1,500,000 was approximately $30,000 higher than the first quarter of 2015 ASP and approximately $50,000 lower than the ASP last quarter. Relative to the prior year, the increase reflects a proportionately lower trade-in volume and favorable geographic mix, partially offset by an unfavorable product mix. The decrease relative to the fourth quarter reflects proportionately higher trade-in volume and lower mix of Xi dual consoles, partially offset by a favorable geographic mix. 
Service revenue of $125 million increased 9% year over year and increased approximately 4% compared with the fourth quarter of 2015. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: first quarter revenue outside of the U.S. of $164 million increased 9% compared with $150 million for the first quarter of 2015 and decreased 25% compared with seasonally stronger fourth quarter, up to $219 million. The increase compared with the previous year is comprised of a 14% growth in recurring revenue, which is driven by a procedure growth of 22% and increased systems revenue of 2%. The decrease compared to the fourth quarter reflects seasonally strong fourth quarter systems placements, partially offset by a 5% growth in recurring revenue. Outside the U.S., we placed 36 systems in the first quarter compared with 36 in the first quarter of 2015 and 75 last quarter. Current quarter system sales included 5 into China and 8 into Japan. System placements outside of the U.S. will continue to be lumpy as some of these markets are in their early stages of adoption; some markets are highly seasonal, reflecting budget cycles or vacation patterns; and sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the first quarter was 70% compared with 65.6% for the first quarter of 2015 and 69.6% for the fourth quarter of 2015. Compared with the first quarter of 2015, the higher gross margin reflects a reduction of product and product repair costs, improved manufacturing operations efficiencies, the elimination of the medical device tax, lower costs associated with product field actions and related inventory charges and a higher mix of instrument and accessory revenue. The medical device tax has been suspended for the next 2 years and reduced our 2015 gross margin by approximately 70 basis points. Future margins will fluctuate based on the mix of our newer products, our ability to further reduce product costs, manufacturing efficiency, costs associated with product field actions and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses, which exclude legal settlements and accruals for legal claims, stock compensation expense and amortization of purchased IP, increased 14% compared with the first quarter of 2015 and increased 5% compared with last quarter. The increases over prior periods reflect increased investments in advanced imaging, advanced instrumentation and next-generation robotics; increased headcount and higher payroll taxes associated with stock option exercises. Our pro forma effective tax rate for the first quarter was 27.4% compared with an effective tax rate of 28.9% for the first quarter of 2015 and 24.9% last quarter. In late December 2015, Congress retroactively approved the 2015 federal research and development credit and made the R&D tax credit permanent going forward. The entire 2015 R&D tax credit was included in the fourth quarter, while no benefit was reflected in the first quarter of 2015 and a proportional benefit is reflected in the first quarter of 2016. Other than the impact of the R&D credit, fluctuations in our tax rate between this quarter and the first and fourth quarters of 2015 primarily reflect changes in the mix of U.S. and OUS income. 
Our first quarter 2016 pro forma net income was $170 million or $4.42 per share compared with $135 million or $3.57 per share for the first quarter of 2015 and $224 million or $5.89 per share for the fourth quarter of 2015. Note that fully diluted shares outstanding increased by approximately 400,000 shares relative to the fourth quarter, resulting primarily from the increase in our share price. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP revenue was $595 million for the first quarter of 2016 compared with $532 million for the first quarter of 2015 and $677 million for the fourth quarter of 2015. GAAP net income was $136 million or $3.54 per share for the first quarter of 2016 compared with $97 million or $2.57 per share for the first quarter of 2015 and $190 million or $4.99 per share for the fourth quarter of 2015. 
We ended the year with cash and investments of $3.8 billion, up from $3.3 billion as of December 31, 2015. The increase primarily -- was primarily driven by proceeds from stock option exercises and cash generated from operations. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure grow",783,"Thanks, Marshall. Of our first quarter procedure growth of nearly 17%, U.S. procedures grew approximately 15% and OUS procedures grew approximately 22%. In the U.S., even though growth benefited from favorable operating days in the quarter, procedure growth outpaced our expectations. First quarter growth in our mature procedures continued at levels similar to the second half of 2015, generating majority of the procedure outperformance relative to our expectation. General surgery procedure growth also exceeded our expectations. In U.S. urology, first quarter growth in da Vinci prostatectomy and kidney procedures continued at similar rates as the second half of 2015. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect the prostatectomy growth to return to levels similar to prostate cancer incidence rates over time. 
In U.S. gynecology, first quarter procedures grew modestly year over year with growth led by malignant and complex hysterectomy. Continuing the trend from 2015, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic-oncologists during the first quarter. Similar to the fourth quarter, U.S. Single-Site gynecology procedure growth declined compared to the first quarter of 2015. First quarter growth in U.S. general surgery procedure adoption remained strong, led by a robust growth in hernia repair and continued adoption of colorectal procedures. Cholecystectomy procedures were roughly flat in the quarter with growth in multiport procedures offsetting declines in Single-Site procedures. 
Q1 was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I selected a couple of studies that you may find interesting. With the launch of our 30-millimeter stapler, surgeon interest in the use of da Vinci for thoracic surgery is growing. A new study comparing open video-assisted thoracic surgery or VATS and da Vinci surgery for pulmonary lobectomy was published by Dr. Yang and colleagues from Memorial Sloan Kettering Cancer Center in the Annals of Surgery. Using a prospective database including 2,400 surgeries to treat stage I non-small cell lung cancer patients, the officers propensity matched 470 patients across da Vinci, VATS and open surgery. The study found that da Vinci and minimally invasive VATS approaches enabled a shorter chest tube duration and length of hospital stay compared to open surgery. da Vinci surgery was also credited with improved lymph node yields as compared to both open surgery and VATS, an important clinical outcome for determining next steps in the patient's treatment pathway. 
As it related to the expansion of da Vinci lung resections, the authors highlighted that nearly 57% of pulmonary lobectomies in the U.S. are treated with open surgery, and they see promise in expanding patient access to minimally invasive surgery through da Vinci technology. 
Turning abroad. Procedures growth outside of the United States was approximately 22% in the first quarter, led by the global adoption of da Vinci prostatectomy with solid contributions from kidney procedures and colorectal resections. Compared to the second half of 2015, procedure growth slowed in both Europe and Asia during the quarter, in part due to the timing of the Easter holiday. Historically, our OUS procedure growth rates have been lumpy and less predictable in the short term. We are focused on improving our OUS procedure performance. 
In Japan, there were positive developments relating to reimbursement in the quarter. The MHLW approved for reimbursement of partial nephrectomy at a premium rate relative to open surgery and also approved clinical trial enrollment to begin supporting a Senshin Iryo B submission for da Vinci malignant hysterectomy. 
A recent study funded by Intuitive and published in BJU International by Professor Hughes and colleagues from the University of Chester collected data from the United Kingdom Health Episode Statistics database, including more than 20,000 prostatectomy patients and 2,000 partial nephrectomy patients to assess health resource utilization and costs following da Vinci, open and laparoscopic procedures. The database showed that from 2008 to 2013, the use of da Vinci surgery increased from 15% to 50% of prostatectomies and 1% to 22% of partial nephrectomies by displacing open surgery. During the first year after the operation, da Vinci surgery was shown to reduce inpatient admissions, hospital bed days and total costs for both prostatectomy and partial nephrectomy compared to open surgery. At 3 years post operation, the study showed similar outcomes for prostatectomy and was insufficient to draw conclusions for partial nephrectomy. Laparoscopic surgery outcomes were at the approximate midpoint between da Vinci and open surgery on resource utilization and costs for both procedures. The authors concluded, ""Our analysis suggests that there are substantial savings associated with robotic-assisted surgery when compared with open and laparoscopic interventions.""
This concludes my remarks. I'll now turn the call over to Calvin."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015.",311,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 9% to 12% above the approximately 652,000 procedures performed in 2015. Now based upon favorable U.S. dVP and gynecology macro trends and U.S. general surgery growth, we are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 12% to 14%. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 68% and 69.5% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 69% and 70% of net revenue. 
Turning to operating expenses. As we have described, we will be increasing our investments in key areas that will enable and drive the future of robotic-assisted surgery. On our last call, we forecast to grow pro forma 2016 operating expenses between 9% and 13% above 2015 levels. We are now increasing our estimate for operating expenses to a range of between 12% and 15% above 2015. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect our 2016 other income, which is comprised mostly of interest income, to be in the upper end of the $20 million to $25 million range forecast on our last call. With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and OUS profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] We have a question from Bob Hopkins with Bank of America.",13,"[Operator Instructions] We have a question from Bob Hopkins with Bank of America."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you th",92,"Okay. Two questions, but first of all, congrats on the great momentum in the business. I have a question on U.S. procedure volume growth and then on your comments on OpEx spend. First on procedure volume growth, one, can you give us a sense of what you think you grew in the quarter on a same-day selling basis? But then much more importantly, just give us a sense as to specifically which surgery types accelerated in the U.S. And what drove the growth? What caused the acceleration? Why did things get better?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter, and some modest benefit from the time of the year",141,"Bob, thanks for the question. From a same-day selling perspective, estimating the impact of operating days is anything but an exact science. From a tailwinds, you had leap year that benefited the quarter, and some modest benefit from the time of the year as being on a Friday rather than a Thursday. And from a headwind perspective, you had the timing of Easter, which moved from the second quarter into the first quarter, but that had more of an impact on the OUS geographies. From what accelerated, the mature procedures sustained pretty strong growth in the quarter as they saw throughout 2015, which is a little bit of a surprise to us relative to our initial expectation. And general surgery continues to be strong and growing off of a larger base, which has more impact on the U.S. procedure drum pump."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level",108,"Okay. And then -- well, for the follow-up, I want to ask Gary a question on OpEx spend because I think it's an important comment from you guys. Your spending in the quarter was high, exactly as you said it would be and now you're raising that spend level even further. So can you just talk about where the incremental spend is going? What kind of new incremental technology announcements could that lead to? You mentioned a couple on the call, but I'm just really curious as to where the spending is going and when we could expect to get more visibility on the output from that spending."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So on the spend, I think the acceleration is really board of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments",185,"Sure. So on the spend, I think the acceleration is really board of confidence, confidence in the long-term viability of some of the markets and some of the things we're pursuing. You'll see it really cut into a couple of buckets. Some of it is investments in OUS markets where we think that we can do more by investing more, and we've been talking to you about that. The other side is on R&D. And in terms of the categories, we've talked about it before, but we believe in them deeply. Advanced imaging, the ability to see beyond what you can just see with your naked eye; new robotic architectures that allow surgeons to get into and out of the body in different ways into different places that they could reach prior as well as analytics and over-the-shoulder guidance, all things that we have been investing in and some things that we're accelerating. So as -- we won't do product announcements on this call. As we get deeper into those things and are ready to share them more broadly with you, of course we will."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?",38,"And then lastly, just to get a sense, I thought I heard something about -- positive about hysterectomy in Japan. It went by pretty quickly. Is there some positive momentum on hysterectomy in Japan from a reimbursement perspective?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process.",21,"Yes, Bob. The MHLW approved for a clinical trial to begin enrollment supporting malignant hysterectomy under the Senshin Iryo B process."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] Our next question from Tycho Peterson, JPMorgan.",9,"[Operator Instructions] Our next question from Tycho Peterson, JPMorgan."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through to",61,"I'm just wondering if you could talk a little bit about Table Motion. How many systems are installed that are capable? Or what percentage of systems, I guess, have the option included? And if you could just talk a little bit about how it flows through to gross margins as well? It's mainly a software upgrade from your perspective, right?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how man",65,"Yes. We're pretty, pretty pleased with the level of adoption for our Table Motion. We're -- the information we're getting back from surgeons is they're pleased with its usage and its performance. We're not going to be disclosing every quarter just how many tables we've delivered, so I won't go there. I'll just tell you that, again, we're pretty pleased with the level of adoption."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Can you maybe...",4,"Can you maybe..."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Obviously, the revenue on the margin side.",7,"Obviously, the revenue on the margin side."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf.",27,"Yes. The margins, so what we're providing is a software update to the Xi that enables the Table Motion. The table itself is being purchased from Trumpf."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","[indiscernible].",1,"[indiscernible]."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And the -- and so our billing is 100% margin.",10,"And the -- and so our billing is 100% margin."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand",52,"And I guess, maybe what I was getting at is the degree to which this is going to drive a bullish demand for Xi now that you have that plus the full instrument set. Could you maybe just talk a little bit about how you see that flowing through the Xi demand?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much",164,"Yes. I think that it -- each one of these steps, the 30-millimeter Xi stapler, the Integrated Table Motion, now the Xi instrument kit is rounding out that Xi platform. And we have some more to do. It's not all complete, but it's definitely becoming a much fuller and richer ecosystem. We think that helps. It's very hard to forecast how much it is, how many people sit and wait until the next step, but we think those things add clinical value for sure. The 30-millimeter stapler in thoracic procedures is a big win; likewise, Table Motion for a lot of the more complex procedures. So we think that's strong and there are a group of hospitals that use Si with Single-Site that if they are a single-system hospital, they own only -- own just one and they have a robust Single-Site program. This allows them to consider Xi as an upgrade. So it's hard to quantify, but we think directionally, it's really strong."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year.",28,"Okay. And then follow-up, can you just comment on Europe? It looks like that was a little soft. Maybe just talk about the outlook there for the year."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where i",163,"Yes. Europe was definitely a variable both in procedures and in systems. On the procedure side, we had some strength in some countries where they're moving along, and we think there's opportunity to do that and better. There's some other countries where it's going a little slower. Sometimes it's a local economy issue. Sometimes it's more of where we are in maturity. Some -- in some of these countries, we're pretty well adopted in the mature procedures and they're really at the beginnings of emerging procedures. So it depends country by country. On the capital side, I think there's 2 things going on: a little bit of environment is one and a little bit of a wait-and-see on competitive offerings as they come out, and we're navigating that pretty well. In terms of head-to-head comparisons with our technology, our systems are coming out great. But it can put a delay in the pipeline, and we're seeing a little bit of that in Europe."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year Q1.",44,"The only other thing I'd add is that there's -- Europe has become very seasonal. And so if you look at Q4, it was extremely strong relative to the previous couple of quarters, and Q1 is more comparable to the previous year Q1."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from David Lewis with Morgan Stanley.",9,"Our next question from David Lewis with Morgan Stanley."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies you had no improvement throughout the year, which seems, I guess, less likely to us, ju",81,"Just 2 quick ones here. Marshall, just coming back to gross margin guidance, so your GMs have been stronger for 5 consecutive quarters and the guidance sort of implies you had no improvement throughout the year, which seems, I guess, less likely to us, just given the cost improvements you've already discussed. So can we just talk to gross margin progression throughout the balance of the year and why you think 70% here in the first quarter is the high watermark?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in the new",83,"Sure. So one of the biggest factors we see going forward is product mix. So know that we have higher margins on instruments and accessories than we do on systems and Q1 tends to be seasonally a lower quarter for capital. And also, we see growth in the new product, particularly energy products, stapling and vessel sealing going forward, and those also have lower margins than the base. So I think just based on product mix alone, we don't expect to sustain 70%."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're clearly obviously going to continue to invest. I have no expectations you're going to talk to us",93,"Okay. And then, Gary, I -- obviously, people have asked about spending already and I know that the R&D spend is the highest you've seen in 4 years. So you're clearly obviously going to continue to invest. I have no expectations you're going to talk to us about future instrumentation and system announcements, but I think the enigma for most shareholders actually is advanced imaging because that's sort of more future-looking. Is there any chance we get incremental updates or at least even any update on the strategy for advanced imaging this year?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in",102,"Yes, that's a fair question. In general, we have been making early investments in advanced imaging. And what I'd tell you there is that it's not one thing. As you know, we have Firefly, which is a molecular imaging-based product. We also have invested in raw imaging hardware capabilities, which we'll continue to do. As -- what we like to do is, as we have milestones that make sense, whether it's talking to regulatory bodies or engaging in clinical work, those tend to be good anchors to discuss with you. And as those arrive, then we'll share with you what we're thinking."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And could those arrive potentially in '16 for advanced imaging or unlikely?",12,"And could those arrive potentially in '16 for advanced imaging or unlikely?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think when we get there, we'll let you know.",10,"I think when we get there, we'll let you know."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we'll go next to David Roman with Goldman Sachs.",11,"And we'll go next to David Roman with Goldman Sachs."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year there was sort of a positive as a tipping point but just inc",84,"I wanted Gary to come back to some of the early part of your prepared remarks where you discussed the continued momentum that you're seeing in hernia. And it seemed like it's at stages this year there was sort of a positive as a tipping point but just incremental enthusiasm from the physician community around this procedure. Can you maybe sort of talk about what you think specifically is stimulating that demand and why you're confident in that continuing on a go-forward basis?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suf",199,"There's 2 ways that our confidence has been building. One of them is around the clinical outcomes and anecdotes that we hear, and that comes to -- as we've talked about before, inguinal hernia particularly is the segment of market not all patients are suffering the same level of disease. And in the more complex cases, if it's bilateral or prior abdominal surgeries of these patients, large herniated sac, the raw clinical capability of our products is being touted as -- and supported by surgeons as being important to them, a better quality of intervention, consumable costs in line with what their expectations are. So there, I think that we're feeling pretty good. The second thing we can do is analyze the kind of the reorder rates from surgeons as they go forward. So as you get through the trial periods, you're seeing kind of where as they learn it and get deeper and deeper into it, where do they apply it and how often do they keep buying our products? And that has been supportive as well. So those 2 things come together, we start feeling better about it. And that's what's behind that sort of comments."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of th",87,"All right. That's helpful. And then just for my follow-up on the operating lease side, it looks like this is sort of a higher quarter for percentage of total coming from operating leases. So I guess maybe, a, can you talk sort of the -- through some of the dynamics underpinning that? And then, b, based on your disclosures, it looks like people are buying out these operating leases relatively quickly, and so it's -- maybe help us understand is that true and why that's the case."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and",99,"Sure. So the operating leases is our way of being able to be flexible with the customer and meet the customers' needs in terms of demand. Some of the leases are shorter term and basically bridge their ability to get through a capital approval process, and those are a couple of the ones you've seen bought out in this quarter. Most of the cap -- most of the leases -- of the operating leases are longer term, being 4- and 5-year terms, and will drive a recurring revenue going forward. Like we said, this quarter was around $4 million."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our next question from Ben Andrew with William Blair.",9,"Our next question from Ben Andrew with William Blair."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make an",69,"Gary, a question on the ecosystem. One of the most material competitive advantages you guys have is kind of the embedding of the technology and your training and all the other things throughout the health care system. What investments can you guys make and are you planning to make that are different than what you've done before to try to lever that because you did specifically call that out?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to vali",217,"Yes. I think the -- it's -- making a great robotic surgery program is really the integration of all of those things, and there are multiyear efforts to build that sort of programs from peer-to-peer networks that do advanced coursework and teaching to validated learning pathways and simulation. Those validations are all multiyear efforts to get right to the full instrument kit from vessel sealing and stapling and so on. And so we're pretty thoughtful about balancing that sort of investments. The things that have gotten really stronger and interesting in the last couple of years have been our ability to analyze data, look at national benchmarking, look at regional base benchmarking and share that information with our customers so that they can make good decisions. Sometimes those decisions are good for them and not great for Intuitive in the near term. If they optimize their program, we may get [indiscernible] revenue per procedure in the near term, but we think long term, it's better for everybody. And so we've been making those analytics and those investments and then communicating with hospitals. So we really have been plugging in each of those settings, and I do think it makes for an ecosystem that creates a lot of value for the customer and builds our relationship with them."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was net?",45,"And Patrick, a quick one for you. Can we think about the extra selling day as maybe as 1.5 percentage points of procedure growth? I know there's some offsets with Easter, et cetera, but is it in that range of what the bump was net?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is -- just think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, p",54,"Yes, Ben. I'll let you kind of do your math on the specific percentage. But as it relates to the benefit, it really is -- just think of it more as in the U.S. because the favorability of leap year and New Year's gets -- it's mostly washed out by Easter, particularly in Europe."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Rick Wise with Stifel.",10,"And we have a question from Rick Wise with Stifel."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also,",87,"I wanted to talk a little bit more about U.S. urology and U.S. gynecology. I was really intrigued with the modest growth in -- on the gynecology side and, I guess, the significant turnaround from the headwind you faced over the last couple of years. Also, urology acting better. Have we worked through some of the challenges in each? And are we actually going to return to more sustainable growth in U.S. gynecology after a year or more or 2 of training and education, et cetera?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We kno",308,"Yes. Let me speak to a couple of the factors, and then I'll let Patrick take it from there. As we look at urology, you've got like 3 main procedures in urology: prostatectomy, partial nephrectomy and cystectomy, the biggest one being prostatectomy. We know that there was a bolus of patients that went into watchful waiting, some of whom will have disease progression and come back to definitive treatment. How long that bolus lasts is a little bit hard for us to predict. The second thing are the possibility of share changes between some of the treatment modalities, surgery versus radiation versus watchful waiting. That data tends to lag. Hard to get it in real time. There may be some share change, although if there is, it's probably modest. And then there's just demographics. As demographics changes, you have more folks getting diagnosed with prostate cancer over time. So those are the 3 things that are rolling through and sort of projecting how they balance out is what the challenge is. On the gynecology side, the thing that we're seeing in our experience is that you're seeing more surgery being done by high-volume gynecologists, in general, just -- not just robotic surgery but laparoscopy and others. We're seeing a consolidation in the marketplace into folks who are either GYN-oncologists or more routine surgeons. We think that's good for the world, and we think that's good for Intuitive. Those more dedicated surgeons tend to be our customers. We see them tackling more procedures in concentrated fashions, and so that's kind of what's happened in gynecology. Likewise, I think there's a demographic element here that's likely to find the bottom and then starts to drift up. The unknown is nonsurgical approaches and in-office approaches. And those are kind of the factors at play. Patrick, I'll let you go from there."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwi",55,"Yes -- no, I think you described the urology situation well. The other thing to bear in mind in the GYN market is while Single-Site procedures have been declining, some of the other benign procedures have been stabilizing and are creating less of a headwind to us on a year-over-year comparison basis, things like myomectomy."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're",69,"And I guess, my follow-up question, and it might have been you, Patrick, who mentioned it. I think somebody described the OUS procedure growth as it can be lumpy and, ""We're working to improve the performance there."" Can you talk a little about how you're going about that? What kind of initiatives are under way? And what you would hope or we should expect might come from those initiatives?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they'",119,"Yes. I'll take that one, Rick. The opportunity in Europe tends to be country by country. So where we're looking to do something different or better, it tends to be making sure that we have staff that is supporting local efforts and local needs, that they're working in the local language, that they understand the health care systems in intimate ways that are specific to that country. And so where we see opportunity, we'll invest there and build that out. We have been. Where we've made investments, we've seen growth. And so where we see some areas of opportunity, we think we have a playbook. Now we have to go execute against that playbook. That's been our perspective there."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Matt O'Brien with Piper Jaffray.",12,"And we have a question from Matt O'Brien with Piper Jaffray."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I was hoping to start on the general surgery side, and it sounds like, again, you had a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth",90,"I was hoping to start on the general surgery side, and it sounds like, again, you had a very good quarter. But I'm just curious if either of the various ventral -- or I'm sorry, the various hernia cases are really leading the charge in some of that growth. Are you seeing any kind of divergence or inflection in either ventral or inguinal? And are those procedures at this point getting sizable enough to start to sway hospital decision-making as to adding additional systems in order to meet that demand?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're s",116,"Yes. Matt, thanks for the question. Certainly, both ventral and inguinal hernia procedures continue to exhibit robust growth. Inguinal hernia is a bigger overall procedure category. It's just more commonly performed, but the rates of adoption that we're seeing in both procedures is encouraging and the surgeon populations that are performing them are continuing to increase the volumes of procedures that they're doing. So it looks promising and certainly, from an overall volume perspective, had some influence because just the numbers are getting to the point where it matters to create access for these surgeons to be able to continue to perform procedures that they are absorbing systems' worth of activity at some of their institutions."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throu",129,"Okay. That's very helpful. And then, Gary, your commentary about the ways that we saw in Europe as hospitals are evaluating some competitive systems that are hitting those markets is curious to me. Do you think that's something that will linger here throughout 2016 as most systems are fully rolled out? Or do you think that will be a fairly quick process of kind of taking a peak and maybe they're doing that now and we could see a snapback in terms of the numbers of systems placed? I mean, specifically, did you see 10, 15 hospitals kind of delay as they were evaluating both systems and then out of those 10 hospitals, 9 of them ended up buying da Vinci late last quarter or even early this quarter?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making a evaluation and come sign up with us and others are going through a little bit longer",186,"Yes. The -- I think that it's a little bit hard to predict how fast it will go through. I guess, our anecdotal experience has been some have been quick looks in making a evaluation and come sign up with us and others are going through a little bit longer process. So with regards to a ""snapback"", I wouldn't bake that in. I think it will play out a little longer than that. Having said that, our -- the response of our customers after they have evaluated the other offerings and come back to talk to us has been fantastic. So our confidence that we have good offerings and we can meet these customers' needs is very high. They all go through that process. And I think as new and different technologies come to market, not just the ones that are there today, I think this will be part of the new normal a little bit for Europe is people cross-shopping and making decisions, and our goal is to make sure that they find our products to be of very high value. So far, so good."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Larry Keusch, Raymond James.",10,"And we have a question from Larry Keusch, Raymond James."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter's has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving",63,"I wondered if we could just, first question, start with the trade-ins. I think there were 42, as you mentioned this quarter, and I think the prior quarter's has been sort of averaging closer to 30. So I'm just trying to understand perhaps what is driving the higher trade-in. And then what's the ultimate opportunity to drive trade-ins in your older system base?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our -- the detail we provided with the press release. I wouldn't call anything out specifically. I think",87,"Yes. There's nothing specific about this quarter that I would call out as it relates to trade-ins. I think you have the numbers right. It came off of our -- the detail we provided with the press release. I wouldn't call anything out specifically. I think it -- last quarter, it was around, in the high 30s, and it's been there for a little while. I don't know that -- it will probably fluctuate in that range. I'm sorry. I don't have any specific comments on it."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?",44,"Okay. And then for Gary, maybe just an update on Sp. You mentioned some in your prepared comments, but where are we in getting those evaluations going? And is it conceivable that we could see commercial units perhaps by the end of the year?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So we are in discussions with FDA on trial type and end points and we have clinical sites that are getting prepped the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anyth",70,"So we are in discussions with FDA on trial type and end points and we have clinical sites that are getting prepped the product. From the engineering and design and validation point of view, it's right on track, looks really good. We're not expecting anything of substance in terms of revenue this year. We do expect them in clinical use in the second half, and that's what we're working towards."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Jason Mills with Canaccord Genuity.",11,"And we have a question from Jason Mills with Canaccord Genuity."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it s",141,"My first question has to do with -- I'm just trying to understand better your dogmas as it relates to managing the P&L. So what it's -- obviously, we're getting here is higher procedural volume guidance and higher operating expense guidance. And what it seem -- what we're seeing -- what we seem to be seeing is some leverage to the operating line, but I'm just curious, Gary, if you could talk about -- Marshall, if you could talk about the -- your dogmas over the next couple of years and sort of, are you looking for operating margin expansion? Is that what your objective is? Are you managing the business to top line growth and trying to manage expenses as best you can to get there? Could you talk about your dogmas as it relates to management of the P&L?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufact",209,"Yes. So my first statement is kind of a caution of beware of averages. So there are places in the business where we're seeking high operational efficiency and leverage. You see that in product cost reductions and some of the things we're doing in manufacturing. There are other places in the operation where we think we can find leverage. At the same time, we want to turn around and reinvest those savings and opportunity. And we see a lot of opportunity, and I think that opportunity should be pursued. So it will be a little bit lumpy. We're trying to be balanced. I wouldn't say that our approach is hard over one or hard over the other. It's not revenue above all else, and it's not profit above all else. We're trying to be balanced in that approach. And it may be a little bit lumpy. I think opportunities happen when they happen. You can be overly cautious and miss them, and so we will maintain a fiscal discipline. That's been part of our history, and we'll keep it. Having said that, we want to make sure that we reinvest some of the benefits that the company has gained into expanding the opportunity we see in front of us."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it",81,"That's helpful. My second and final question is having to do with your cash balance and use of cash. You've been very proficient at buying back stock in the past. Given where the share price is juxtaposed to significantly expanding cash balance, would it be fair to assume that you'll do modest -- maybe modest to moderate share repurchases going forward? Or will we see maybe less over the next 2 years than we saw in the last 2 years?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool into capital allocation. We really start with, can we reinvest in the business and drive long-term gr",157,"In terms of just how we think about capital allocation, we are thoughtful and serious about it as you'd expect. We think buybacks are one leg or one tool into capital allocation. We really start with, can we reinvest in the business and drive long-term growth and opportunity. Buybacks, if -- there are times, we've been typically patient and opportunistic. And we think because of the volatility of our stock, there are times that, that makes a lot of sense for us. And in conversations with shareholders and where we are thoughtful and listen, then we have considered dividends and we will consider them in the future. So we look at those 3 things and try to trade them off. And we think for the long term, when we're thinking about capital allocation, we're not trying to do signaling or messaging. We're trying to build value for the business and for the shareholders in the long term."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And we have a question from Vijay Kumar with Evercore.",10,"And we have a question from Vijay Kumar with Evercore."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of a renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems per",69,"So maybe one on the OUS placements. I know China, I think on the last quarter, you said they had about 8 systems. Can we expect sort of a renewed sort of a -- I guess, a contract from the government, right? How should we think about OUS from a systems perspective, given that China, they're probably at the end of the amount of systems that they can import?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. There's still one out there. I don't know if it will happen. And they",208,"Yes, so I'll speak to China first and then to other locations next. As far as China goes, when we left last quarter, there were about 6 systems left under quota. We sold 5 this quarter. There's still one out there. I don't know if it will happen. And they have to go through a tender process, and that tender process had to have already begun. As far as additional quotas, we're -- it's a part of the overall budget -- government budget process in China. And so when that gets completed, and I don't have a magic ball that tells me when it will be completed, then we'll know whether we're still under the quota system and we'll know whether -- if we are under the quota system, how many will be awarded. And there's no way to predict that in the -- in advance. As far as the rest of the world goes, as I -- in my remarks, I mentioned that it's -- fourth quarter is a seasonally strong quarter. If you look at where we came out for this quarter, it was pretty comparable to last year for the first quarter, but it's going to be lumpy market by market, depending on the circumstances."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan, in start",59,"Great. And then maybe one follow-up for Gary. I know that clinical trials, I mean, R&D expenses were up 25% in the Q. Does that number include any clinical trial expenses? Because I'm just trying to get a sense for -- and as you talk about Japan, in starting clinical trial sort of any potential impact on that number?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinica",60,"Yes, there's some -- we're doing -- we've said before we're in the middle of gathering data for -- or evidence for gastrectomy in Japan. That doesn't go into R&D. That's actually in our SG&A numbers. And if we were doing -- I mean, as far as other clinical trials, we'll tell you about them when we think it's appropriate."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And our next question from Tao Levy with Wedbush.",9,"And our next question from Tao Levy with Wedbush."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times thoracic surgery and the benefit that, in particular, the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportuniti",82,"We've talked a lot about the sort of hernia, colorectal surgery, but you've mentioned a couple of times thoracic surgery and the benefit that, in particular, the Xi might bring to that procedure. Can you sort of maybe summarize some of the key opportunities within thoracic? Should we think of it as a colorectal-type opportunity where it's moving in the right direction but it's a little bit slower? Or could it potentially be more like a hernia or a hysterectomy opportunity?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from a starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right d",150,"Yes, just -- so I'll start, and I'll ask Patrick to join in. The -- just from a starting place, these are typically cancer procedures and typically complex mediastinal cancers, lung cancers. They -- the product set that we have, Xi moves us in the right direction. Some of the instrumentation we're bringing along moves us in the right direction in terms of providing surgeons with the tools they are looking for, for efficient procedures, and I think we're at the beginnings of that. The way to think about the market is there are some minimally invasive surgery done manually, video-assisted thoracic surgery. Some institutions do a lot of it with good results. Others do very little of it. If you look at national averages rather than institutional numbers, you see a lot of open surgery done. And we think that, that's the opportunity. I'll let Patrick characterize it through."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly",100,"Yes. Tao, it's still pretty early days. We're in the foundation. We've got a small team in the U.S. focused on it, but our focus continues to be on driving general surgery growth in hernia and colorectal resections. And internationally, we're still highly focused on driving dVP adoption and some emerging procedures in countries where urology is deeply penetrated. And when you look around internationally, it is a cancer that is very common in Asia and other parts. So it's a very big opportunity for us though perhaps a little bit around the corner from what we're currently focused on."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried",65,"Got you. Great. And then as my follow-up, you mentioned focusing on urology internationally. And I understand that it's still relatively underpenetrated, but it is just the same procedure that you keep on going after internationally. Should we be worried that some of the other procedures that are catching on here in the U.S. over the last few years aren't moving the needle yet internationally?"
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we se",258,"Thanks. Tao, that will be our last question. I'll answer that and then we'll move on. The -- I think it depends by country. So we see, for example, nice adoption of thoracic surgery in China. We see a pretty different mix of procedures in Korea than we see in the United States. So you have to answer it country by country. I don't think there's a systemic worry here that, that somehow we're stuck at prostatectomy and won't be able to move any further. I do think that it's important for folks on the phone to realize that the profile of procedures in each country is going to differ based on disease state based on how the reimbursement system works and the relative priorities of their health care system, so we see that reflected. We do see multiple procedure adoption in different countries. It just differs on what they're after. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. Thank you for your participation and support on this extraordinary journey to improve surgery, and I look forward to speaking with you again in 3 months."
30239,328482491,960199,"Intuitive Surgical, Inc., Q1 2016 Earnings Call, Apr 19, 2016",2016-04-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect.",20,"Thank you. And ladies and gentlemen, we thank you for using AT&T Executive TeleConference Service, and you may now disconnect."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ca",56,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to your host, Calvin Darling, Senior Director of Finance, Investor Relations of Intuitive Surgical. Please go ahead, sir."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on April 19, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. 
In addition, today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our second quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our",736,"Good afternoon, and thank you for joining us on the call today. 
In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our new products. 
Turning first to procedures. Global procedure growth for the quarter was nearly 16%, with prior quarter trends continuing. Drivers of growth included U.S. general surgery, growth in the use of da Vinci Surgical Systems outside the United States and modest growth in U.S. urology and gynecology. In renal hernia repair and hernia repair growth remained strong, and growth in colorectal surgery was solid. Procedure growth was variable by country in Europe, with accelerating growth in Germany. Both the Nordics and France experienced modest improvement relative to Q1 growth rates. In the U.K., growth decelerated slightly from Q1. In Asia, procedural growth in Japan was solid again in the quarter, while growth in Korea was robust and accelerated over Q1 growth rate. Growth in procedures in China was also strong. Patrick will review procedure trends in greater detail later in the call. 
We placed 130 da Vinci systems in the quarter, up from 118 in Q2 of 2015. Our most capable model, da Vinci Xi, represented roughly 3/4 of new capital placements. System placement orders included an increase in dual consoles and the addition of Integrated Table Motion, leading to higher feature content on average than Q1. 
Placements in Europe and Asia increased over Q1, while U.S. placements were slightly up relative to last quarter. Marshall will take you through our finances in more detail later in the call.
Our operations teams have performed well over the past several quarters and remain focused on optimizing our manufacturing design and supply chains. Q2 was another strong quarter of operations efficiency and cost reduction performance. We plan to continue these optimization efforts as they provide significant financial flexibility for us in coming years. 
Turning to highlights of our second quarter operating results. Procedures grew nearly 16% over the second quarter of last year. We shipped 130 da Vinci Surgical Systems, up from 118 in the second quarter of 2015. Revenue for the quarter was $670 million, up 14% from the prior year. Pro forma gross profit margin was 71.9% compared to 68% in the second quarter of last year. Instrument and accessory revenue increased to $339 million, up 14%. Total recurring revenue in the quarter was $467 million, representing 70% of total revenue. We generated a pro forma operating profit of $297 million in the quarter, up 30% from the second quarter of last year. And pro forma net income was $220 million, up 28% from Q2 of 2015.
Recent launches of Xi products, including Xi intraoperative table motion, have been well-received, as has expansion of advanced instrument lines, including our stapling products. We are continuing to invest in these line extensions to increase the value and utility of our Xi offering. We have also increased investment in advanced imaging, including significant refinements in our intraoperative 3D endoscopes, image processing for real-time and preoperative images and infrared imaging. 
Our single port, or SP program, is progressing to plan. As SP approaches clinical readiness, we are conducting in-house validations and initiating work with clinical trial sites and regulatory agencies. We expect first markets to include head and neck surgery, urology and colorectal surgery. Over time, I expect this list of applications to evolve. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that a substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. We expect quarter-over-quarter variation in spending and increased fixed expenses in the back half of this year. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we remain focused on the following: first, expanding the use of da Vinci in general surgery in thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our Xi product into clinical use; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive of value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1200,"Thank you, Gary. 
I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. 
We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion.
Second quarter 2016 revenue was $670 million, an increase of 14% compared with $586 million for the second quarter of 2015 and an increase of 13% compared with first quarter revenue of $595 million. Second quarter 2016 procedures increased nearly 16% compared with the second quarter of 2015 and increased 7% compared with last quarter. Procedure growth has been driven by general surgery in the U.S. and urology worldwide. Revenue highlights are as follows: instrument and accessory revenue of $339 million increased 14% compared with last year and increased 5% compared with first quarter of 2016. Growth in instruments and accessory revenue generally reflect procedure growth. Instrument and accessory revenue realized per procedure, including stocking orders, was approximately $1,810 per procedure. This metric has fluctuated in a tight range over the past couple of years. The slight decrease in the second quarter relative to the second quarter of 2015 and the first quarter of 2016 primarily reflects the impact of customer buying patterns, partially offset by increased usage of our stapling and vessel sealer products. While instrument and accessory usage per procedure has been relatively constant, customer buying patterns fluctuate in the short term.
System revenue of $203 million increased 15% compared with the second quarter of 2015 and increased 37% compared with last quarter. These increases primarily reflect higher average system selling prices, higher system placements and revenue associated with lease buyout transactions. 
130 systems were placed in the second quarter compared with 118 systems in the second quarter of 2015 and 110 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 19 last quarter and 5 systems in the second quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the second quarter, there were 66 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the second quarter of 2015 and $4 million in the last quarter. We also generated approximately $13 million of revenue during the quarter from lease buyouts compared with $6 million in the first quarter and $4 million in the second quarter of last year. We excluded the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system selling price of $1.56 million was approximately $60,000 higher than both the second quarter of 2015 and last quarter. The increase compared with prior quarters reflect a higher mix of dual console system and sales of table motion. We introduced intraoperative table motion in Europe in the third quarter of 2015 and early this year in the U.S. During the first and second quarters, we recognized $1 million and $6 million of table motion software, respectively. Both the mix of dual consoles and a number of table motion placements will fluctuate quarter-to-quarter.
Service revenue of $128 million increased 13% year-over-year and increased approximately 3% compared with the first quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. Outside of the U.S., results were as follows: second quarter revenue outside of the U.S. of $185 million increased 10% compared with $168 million for the second quarter of 2015 and increased 13% compared with the first quarter of $164 million. The increase compared with the previous years comprise of 16% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 2%. The increase compared to the first quarter reflects systems revenue growth of 30% and recurring revenue growth of 4%. 
Outside the U.S., we placed 51 systems in the second quarter compared with 46 in the second quarter of 2015 and 36 systems last quarter. Current quarter system sales included 22 into Europe, 4 into China and 13 into Japan. System placements outside the U.S. will continue to be lumpy. As some of these markets are in the early stages of adoption, some markets are highly seasonal, reflecting the budget cycles or vacation patterns. And sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the second quarter of 2016 was 71.9% compared with 68% for the second quarter of 2015 and 70% for the first quarter of 2016. Compared with the first quarter of 2016, the higher gross margin reflects reduction in product costs, favorable costs associated with our scope exchange program, manufacturing efficiencies and higher dual console mix, lease buyouts and table motion sales. Future margins will fluctuate based on the mix of our newer products, the mix of systems and instrument accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs, improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 9% compared with the second quarter of 2015 and decreased nearly $2 million compared with last quarter. The increase over the second quarter of 2015 reflects increased investments in advanced imaging, advanced instrumentation in next-generation robotics and increased headcount. The decrease compared with the prior quarter reflects lower payroll taxes, partially offset by increased headcount costs, particularly in our product operations area.
Our pro forma effective tax rate for the second quarter was 27.8% compared with an effective tax rate of 25.6% for the second quarter of 2015 and 27.4% last quarter. The increase in the tax rate compared with 2015 reflects onetime benefits reflected in 2015. Our second quarter 2016 pro forma net income was $220 million or $5.62 per share compared with $173 million or $4.57 per share for the second quarter of 2015 and $170 million or $4.42 per share for the first quarter of 2016. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP net income was $185 million or $4.71 per share for the second quarter of 2016 compared with $135 million or $3.56 per share for the second quarter of 2015 and $136 million or $3.54 per share for the first quarter of 2016. We ended the quarter with cash and investments of $4.2 billion, up from $3.8 billion as of March 31, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we'll continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Although our second quarter procedure growth was nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compar",1028,"Thanks, Marshall. 
Although our second quarter procedure growth was nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to approximately 15% in the second half of 2015 and approximately 13% in the first half of 2016 [ph]. We expect our procedure growth rate to moderate in the second half of 2016. 
In the United States, second quarter procedure growth continued to outpace our expectations. Second quarter growth in our mature procedures slowed modestly compared to the first quarter. General and thoracic procedure growth remained robust. In U.S. urology, second quarter growth in da Vinci protastectomy and kidney procedures slowed modestly compared to the first quarter of 2016. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect prostatectomy growth to return to levels similar to prostate cancer diagnoses overtime.
In U.S. gynecology, second quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Similar to the first quarter, U.S. Single-Site gynecology procedures declined compared to the second quarter of 2015. In the U.S., procedures for benign gynecologic conditions slightly grew during the first half of 2016, exceeding our expectations. Second quarter U.S. general surgery procedure adoption remained strong, led by robust growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and surgeon retention and expansion remains encouraging. Cholecystectomy procedures slightly declined in the quarter, with growth in multiport procedures nearly offsetting declines in Single-Site procedures.
Second quarter was another quarter with a large number of clinical publications and presentations evaluating da Vinci surgery. Of these, I selected a few studies that you may find interesting. Intuitive is among the founding partners for the American Hernia Society Quality Collaborative Initiative, or the AHSQC. And this quarter, 2 primary analyses comparing da Vinci to open or laparoscopic complex central hernia repair were brought forward. The first was a podium presentation at the American Hernia Society Annual Meeting by Dr. Palouse from Vanderbilt comparing da Vinci to open retromuscular hernia repair. This patient matched analysis involving data for multiple institutions found that da Vinci reduced hospital length of stay by 3 days without significant differences in surgical site infections, readmissions or reoperations. In addition, a paper was published in Surgical Endoscopy by Dr. Warren and colleagues from the University of South Carolina. The authors used their institution submissions to AHSQC to compare da Vinci to laparoscopic retromuscular hernia repair. Their study found that with a longer operative time, da Vinci reduced the hospital length of stay by 1 day and also enabled a greater percentage of patients to receive [indiscernible] closure and extra [indiscernible] placement of mesh to which the authors attribute a reduced likelihood of hernia recurrence for [indiscernible] lesions. 
Next, as Marshall mentioned earlier, sales of our intraoperative table motion technology were strong in the quarter. During the quarter, the first clinical publication reviewing this technology was published in the International Journal of Colorectal Disease by Dr. Morelli and colleagues from the University of Pisa. In a small case series of colorectal resections, surgeons used table motion to reposition the patient an average of 3 to 4x per procedure. The author suggested that the technology may improve patient's safety by reducing the amount of time in extreme patient physicians and stated ""The da Vinci Xi, plus the new operating table, gives the potential to optimize gravity exposure and provide a quick access to different surgical objectives, as is important for colorectal surgery.""
Turning abroad. Procedure growth outside of the United States was approximately 25% in the second quarter, led by the global adoption of da Vinci prostatectomy, with solid contributions from kidney procedures and colorectal resections. Compared to the first quarter of 2016, second quarter procedure growth improved in Europe and was similar to the first quarter in Asia. Outside of the U.S., second quarter procedure performance varied by country, with strong growth in Germany, China and South Korea. In certain countries where our urology businesses has become more mature, such as the United Kingdom and Nordic countries, procedures continue to grow at a slower rate. Emerging procedures are in an early stage in these markets, and we are engaged with a broad range of stakeholders working to enable procedure adoption in the gynecologic and general surgery. In Japan, partial nephrectomy growth accelerated in the first quarter following approval of national reimbursement. 
During the quarter, a meta-analysis sponsored by the South Korean National Evidence-based Healthcare Collaborating Agency, or NEHCA, was published in the Annals of Surgical Treatment and Research and reviewed da Vinci and laparoscopic colorectal colon cancer reception. The meta-analysis included nearly 700 patients and found that with a longer operative time, da Vinci surgery result in a more rapid return of normal diet and valve function of, lower blood loss and a shorter hospital stay. This government-sponsored health technology adds to the number of HTAs that have evaluated da Vinci surgery and a broad range of procedures over the years.
I will conclude my remarks by highlighting one of the largest population-based studies on the impact of da Vinci prostatectomy published in the Journal of Urology by Dr. Pearson colleagues from the University of Chicago. Using data from the National Cancer Database, study includes nearly 100,000 prostatectomy patients treated with either da Vinci or open surgery. After matching the patient populations for risk factors, da Vinci surgery was shown to reduce positive surgical margins across low-, medium- and higher-risk cohorts as well as reduced use of radiation therapy, 30-day readmissions and 30-day mortality compared to open surgery. 
Dr. Kupfer from Indiana University published a letter of alongside the study titled Robotic Versus Open Prostatectomy and the Controversy, in which he stated that any debate of a robotic prostatectomy should be put to rest. 
This concludes my remarks. I will now turn the call over to Calvin."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015.",347,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015. We are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 14% to 15%.
In regards to certain forward-looking metrics, we have the following expectations. We anticipate fewer lease buyouts and lower upgrade and other systems revenue in Q3 and Q4 than we saw in Q2. Second half 2016 system ASPs will likely be lower than Q2, driven by product and channel mix. We expect a directionally higher proportion of our system placements in Q3 and Q4 to come from operating leases than we saw in Q2.
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 69% and 70% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 70% and 71% of net revenue. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will accelerate in the second half of 2016. We continue to forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels.
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income to total approximately $30 million in 2016, higher than the $20 million to $25 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Ben Andrew with William Blair.",16,"[Operator Instructions] 
And our first question comes from the line of Ben Andrew with William Blair."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, maybe just start up by talking about the increase investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may see",59,"Gary, maybe just start up by talking about the increase investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may see some payouts. I recall, it took about a year for the European investments to kick in."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investments and scale rather than just the upfront D. So you're seeing some grow",228,"Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investments and scale rather than just the upfront D. So you're seeing some growth in that. We have some other technology investments that are a little broader. We've talked about imaging, and that's kind of a multistep process. Some of it is on the acquisition side, new [indiscernible] of endoscopes. Some of it is on the software side, and some of it is in the ability to enhance our imaging portfolio. Some of those things will become commercial in future quarters. Some of them are a little longer, multi-year types of investments. With regard to investments outside of R&D, we've been growing our investments in regions around the world where we think there's real opportunity from Japan to Germany and France and others. That will continue. I think that some of those investments are doing well for us. We have opportunity to perform better than we have thus far. And so the right kinds of investments there are sometimes in clinical data and clinical trials, sometimes in other market development efforts, sometimes in our resources and headcount. And again, those things can be effective from a couple of quarters out to multi-years out, depending on what the activity is."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to matur",47,"Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to mature in certain geographies?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multi-year process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some ca",79,"I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multi-year process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cases, we need interactions with payers and reimbursement. So we -- I don't think you have to wait years to see the early indicators, but full penetration is often more than a year of process."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then finally, in the SP, you did head and neck. Can you be more precise? Would that be sleep  apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?",37,"Great. And then finally, in the SP, you did head and neck. Can you be more precise? Would that be sleep  apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for th",140,"Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for that. There may be benign indications. Part of what we're talking to regulatory bodies about are clinical requirements for them to make some of those assessments and varies from what happens in Europe to what happens in the U.S., what happens in Asia. So that will play out in time. But think of head and neck starting point is towards. It may have other applications in neck surgery over time. I think that SP is a pretty powerful platform. And where we start and where it evolves to will differ. Surgeons get a chance to experience it for themselves."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And next question is from the line of Tycho Peterson of JPMorgan.",12,"And next question is from the line of Tycho Peterson of JPMorgan."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","First question, Gary, can you maybe just provide a little bit more clarity on SP timelines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue cont",66,"First question, Gary, can you maybe just provide a little bit more clarity on SP timelines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue contributor in '17. So can you maybe just talk a little bit about how we should think about the rollout next year."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be material revenue contributor in '17. A lot of that will be buildi",90,"Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be material revenue contributor in '17. A lot of that will be building the foundation, the evidence foundation, some of the clinical work. And then, I think, '18, it starts to become more of a material contributor for us. As we get our clearances and start to solidify that timeline, we'll call them up more for you."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about timelines around t",54,"Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about timelines around the trials for 30-day, 1-year and 2-year follow-up?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Turn that to Patrick.",4,"Turn that to Patrick."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publication that I mentioned on the call from the HSQC is among the investments we've made in helping support s",57,"Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publication that I mentioned on the call from the HSQC is among the investments we've made in helping support surgeons bring forward the outcomes that they're getting with da Vinci compared to the alternatives."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just last one, you had noted some delays in Europe around tenders from competitive they got. Anything changed from your perspective this quarter?",26,"Okay. And then just last one, you had noted some delays in Europe around tenders from competitive they got. Anything changed from your perspective this quarter?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to",61,"Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to engage the customer at different levels depending on what their needs are. So nothing new to report."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of David Lewis of Morgan Stanley.",13,"And the next question from the line of David Lewis of Morgan Stanley."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just a couple of quick questions. Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you just give",92,"Just a couple of quick questions. Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you just give us a broader sense of what the word analytics means to you, Intuitive? And then on imaging. Is the next disclosure we're likely to see in advanced imaging approval or simply an announcement of an imaging clinical study? And then I had a quick financial follow-up."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Okay. I think analytics has multiple components in it. As you may now, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems our online. They report that information to us mostly around the system performan",319,"Okay. I think analytics has multiple components in it. As you may now, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems our online. They report that information to us mostly around the system performance itself, whether itself is doing rather than, say, patient information. That data can be turned into insights for the company and for our customers, and we have been doing that for some time now. So there's that type of analytics. Going forward, I think that it is our computational structures get more powerful, we can bring some of that intelligence more real-time. So rather than off-line insights, you can start generating real-time insights. That's a multi-year pathway. I think it's interesting and challenging. I think there is long-term potential in it. But we're moving down that pathway, making sure that we have good access and fast access and low latency access to our devices in the field and then bringing to bear information that can help surgeons as they're performing their procedure. And you'll see from us in future years a series of products that come out using that set of kind of digital pipeline. Turning to imaging. There are a couple of different things. We are releasing endoscopes that are fairly regular equipped and improving that set of technologies. We made a technology change in the type of imaging we use when we switched to Xi that has allowed for faster durations for us in the kinds of imaging we do. So there's that kind of thing that's going on, kind of a regular heartbeat. Our customers are pretty well aware of where those things are. There are other things that we've talked about, other indications for our fluorescence. We're more likely to talk to you about what's happening clinically there than to announce a launch. So you'll have some warning prior to launch."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down but the first time. And in several quarters, I think",122,"Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down but the first time. And in several quarters, I think you said operating leases will pick back up in the back half of the year. So sort of what's the driver there? And then just on mix or ASPs going lower precisions in the back half. I'm assuming that's tied to your view of different geographies less Xis or less consoles, dual consoles. Just give us some flavor on some of those 2 dynamics, why you're so confident operating leases tick back up and ASPs tick down."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be working pretty well for both. This last quarter, we just saw a fewer number than the previous qu",184,"Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be working pretty well for both. This last quarter, we just saw a fewer number than the previous quarter. The previous quarter, if you recall, was 19. We would expect it to be more likely Q1 than it was Q2. So that's the increase that Calvin was referring to. As far as ASPs go, seasonally, systems revenue is stronger in Q4. Systems drive a slightly lower gross margin than do instruments and accessories. So that makes alone will cause margins to go down. We also would expect a little bit better performance, again, due to seasonal factors in the non-U.S. markets for the OUS. And so that mix also will drive revenues down a little. And then we expect to continue to see growth in stapling and vessel sealing in our newer technology products, and those also drive slightly lower margins. So a lot of mix will cause margins to go down in the next couple of quarters."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Marshall, none of these things seem to me to be new dynamics. These seem to be  sort of ordinary operating damage for Intuitive. Is that sort of how you see it?",31,"Marshall, none of these things seem to me to be new dynamics. These seem to be  sort of ordinary operating damage for Intuitive. Is that sort of how you see it?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","For the most part, the seasonal things are, I think -- the new thing is that as we drive the new product revenues, that's increases over previous quarters.",28,"For the most part, the seasonal things are, I think -- the new thing is that as we drive the new product revenues, that's increases over previous quarters."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And David, if we're talking about margins, one thing that kind of different in the second quarter was on the service side. You saw a pretty marked increase in the service gross profit in the second quarter. And during the quarter, we are able to utilize m",103,"And David, if we're talking about margins, one thing that kind of different in the second quarter was on the service side. You saw a pretty marked increase in the service gross profit in the second quarter. And during the quarter, we are able to utilize more refurbished scopes for our scope replacement programs with customers. We're going to be expanding the program as the base builds out in the second half, and it's going to require a much higher proportion of new scopes at higher costs and lower margin to replenish. So that's something that'll be a headwind in the second half."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Bob Hopkins of Bank of America.",15,"And the next question is from the line of Bob Hopkins of Bank of America."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'll be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces",114,"So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'll be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces here. So just from a top-down perspective, from where you sit today, when you look forward at the business, should we be thinking about low 70s gross margin as something that can be sustained over time? Just give us a sense in what you just been learning here in the first half of this year as it relates to a more sustainable outlook for gross margins longer term."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I do",129,"Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I don't want to get into where we think it will go long term. Long term, those same moving parts will cause us not to have high confidence in exactly where it will come out, although know that we'll manage things very diligently. As you know, last year, we put in some programs to reduce the costs of Xi and Xi-related products. And those have been successful, and that's part of what we're seeing here in the year-to-year improvement."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","But I mean, in terms of thinking about the biggest moving pieces, one of the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin look like for the company.",45,"But I mean, in terms of thinking about the biggest moving pieces, one of the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin look like for the company."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I don't think we put a stake on the ground, and I don't think I'm prepared to do that right now.",22,"Yes. I don't think we put a stake on the ground, and I don't think I'm prepared to do that right now."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. No, well, we can take it off-line. And then Gary, one of the things I wanted to ask about, 2 quick things. One just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm just",138,"Okay. No, well, we can take it off-line. And then Gary, one of the things I wanted to ask about, 2 quick things. One just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm just curious now at this almost 20% of the market cap in cash. Are there sizable M&A targets out there that you're kind of considering and that's why there hasn't been anything incremental done with the cash? Just would love to get an updated view there. And then you mentioned on the topic of advanced imaging and timelines for new products, you said some of these approvals could come in future quarters. I mean, I was just curious, when you made that comment, were you talking about advanced imaging specifically?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, let's speak to cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We'",303,"Well, let's speak to cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're seeing, I think, great momentum on the clinical side in terms of clinical acceptance. We have a couple of things going on. We have some new platforms we want to bring to the market that, I think, are outstanding, are very well-done and well-conceived. That will take some investment for us to do. The other thing is that we see proliferation of folks who want to enter with competitive offerings. And that's both an opportunity for us and requirement for some diligence. And the opportunity is some of those technologies are interesting. It may be interesting to us. Other ones are things where we may want to speed up or just our strategy as the market evolves. As we think about the cash probably, our first thought is can we use that cash productively to drive future growth organically? Our second thought is are there M&A opportunities that, for the long term, are good for the company? To answer the both of those, are there opportunities? The third, are there other ways we can deploy the capital with a long-term view for the benefit of the shareholders? And that might be in buybacks or dividends or other things. So we're disciplined about thinking about capital allocation. I think this is a special time in the company's history. And we're walking through how we think about cash with a fair amount of discipline and diligence. You had asked a question on product releases. Why don't you ask it again just to make sure I hit it?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could get into future quarters. I was just curious whether that was a broad comment or whether you were specifically seek",49,"Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could get into future quarters. I was just curious whether that was a broad comment or whether you were specifically seeking to advantaged imaging."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A broad comment. There are some imaging things that are kind of near product things that look a lot like what we have today, and there's some long-term imaging investments. And so the submission pipeline and our regulatory interactions are pretty full pip",43,"A broad comment. There are some imaging things that are kind of near product things that look a lot like what we have today, and there's some long-term imaging investments. And so the submission pipeline and our regulatory interactions are pretty full pipeline."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Larry Keusch with Raymond James.",14,"And the next question is from the line of Larry Keusch with Raymond James."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take it out several years, what would be the benefits to the surge",64,"Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take it out several years, what would be the benefits to the surgeon at that time with these technologies embedded versus what's available today in Xi?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery in general, not just Intuitive, h",243,"Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery in general, not just Intuitive, how much better in terms of outcomes and lower complications is the top 10th [ph] percentile surgeon versus the average surgeon? And the spread is quite big, as you look at that. There's a lot of variability in surgical performance. And so you ask the question, what drives that variability? Why? And some of it, not all of it, but some of it is that what you're looking for individual images is subtle. Where are nerves, where are cancer boundaries, where are the arteries, what's the right tissue dissection plane. Those things are subtle and take a long time for people to internalize and the best to do it better. And so what we're trying to do here is find technology that make it easier for other surgeons to be as good as the best, and we think that matters. Imaging will play a large role in this. So forward a decade, what you'd really like to be able to do is mark tissues of interest in real-time, paint for the surgeon what the elements and boundaries are that allow for a good dissection or a proper dissection or best margin performance. And that's what's really driving our investments."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us",81,"Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us understand what that means. And then on China, you did a number of systems in the quarter. Just wanted to figure out where we were with the quota, those kind of one-off now in any given quarter."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when w",201,"So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when we see fluctuations and what they're buying versus what they are using, there are times when they use more than they buy and times when they buy more than they use. And it just happens, and it's going to fluctuate quarter-to-quarter. And that was my comment in the short term. And so what we saw this quarter was they used more than they purchased. And so I don't have a great explanation for it beyond  that. That's just what we see. On the other hand, we do have distributors that buy in bulk because of their holding inventory to sell to there and customers. And we do see fluctuations in those numbers as well. So the combination of the 2 direct hospitals that we sell to as well as distributors, we can actually measure or identify what is customer buying pattern. I don't think that you don't see anything there that alarms us in one way or another."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And China?",3,"Okay. And China?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","China. China, we sold 4 systems this quarter. Both systems were sold to military hospitals. The quota that we were selling to and a couple the past year is expired at the end of December. And we're awaiting for the government to approve a new quota. We do",57,"China. China, we sold 4 systems this quarter. Both systems were sold to military hospitals. The quota that we were selling to and a couple the past year is expired at the end of December. And we're awaiting for the government to approve a new quota. We don't have great information as to when that will occur."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas.",12,"Describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget p",96,"Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget process this year has been delayed, so that's what we are not sure exactly when they'll approve that and then when we'll get a quota for it. Military hospitals buy independent of those public hospitals, and we've been selling to military hospitals all along, frankly, and have a number of placements at them."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next question from the line of Brandon Henry of RBC Capital Markets.",12,"Next question from the line of Brandon Henry of RBC Capital Markets."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories. What were",71,"Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories. What were the drivers of the year-over-year increase in gross margins in the first half of the year for 2016 versus the first half of the year in 2015?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'm not sure we can list out item-by-item a specific contribution, but we have been focusing on obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months",166,"Yes. I'm not sure we can list out item-by-item a specific contribution, but we have been focusing on obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months into the year. We're at 71% on a year-to-date basis, and that coincides with the upper end of the 70% to 70% -- 70% to 71% guidance range. But Q2 was an exceptionally strong quarter for gross margin, and I think we wanted to leave some specific comments there, specifically on the product side. We would expect a higher proportion of sales of newer products, as was described in lower proportion of dual console sales and probably more sales through distributors at lower pricing and lower margins. And I think I already mentioned previously on the service side, we had some real benefits on the scope exchange in the second quarter, which are unlikely to continue in the second half."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then separately, I think you guys mentioned a slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for protastectomy growth in the updated guidance range? Are we now k",55,"Okay. And then separately, I think you guys mentioned a slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for protastectomy growth in the updated guidance range? Are we now kind of through the bolus of patients that previously deferred treatment?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Brad. Tough to know where exactly you are with patient population that may have differed treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all through",127,"Yes, Brad. Tough to know where exactly you are with patient population that may have differed treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all throughout 2015. How much of that is associated with having more through any potential bolus that may be out there is difficult to predict, though, I think as you for to say a few times in the past that, over time, we do expect that prostatectomy volumes are likely to return towards the rate of diagnosis. And our recent history and the recent growth rates we've seen in 2015 and the first half of 2016, we believe, exceed that growth rate."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of Rick Wise of Stifel, Nicolaus.",13,"And the next question from the line of Rick Wise of Stifel, Nicolaus."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me start off with procedures again. I just wanted to make sure I understood that comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you w",57,"Let me start off with procedures again. I just wanted to make sure I understood that comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you will, slowing? Can you just help us better understand your thinking there?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We cont",69,"Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We continue to expect and will continue to drive growth in U.S. general surgery and overseas markets and urology and early-stage procedures."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well-received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3%",72,"Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well-received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3% converted? 50%? And is this a tailwind now, leaving, aside all the other moving factors, is it a positive tailwind now for a year or 2 or 3?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to",75,"Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to table motion. It was roughly split 50-50 between new installations and systems in the field. So again, it was a strong quarter, but I think we'll see how it heads."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it",71,"The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it will be a go-forward. So you can look at history to sort of give you a guide as to how much that is."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. and then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there.",37,"Yes. and then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I listened to",119,"And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I listened to the looming competition from Medtronic, their Analyst Day, your friends at [indiscernible], we're very focused on lowering per-procedure robotic cost to -- it seems like, in your words, laparoscopic levels. How do you react? How do you deal? How do you compete with that approach, given their entrenched instrument kit abilities? And will your new platform is addressed that per-procedure cost aspect of positioning you to better address some of these factors?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. I think you're going t",241,"Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. I think you're going to have to show benefit over laparoscopy, what can be done that lap can't do. And that's going to require some innovation and some technology, and the technologies are going to have to be paid for. So I think, over time, it's closer than have to come out and show what it is that they plan to do to make that happen. As we look at it, I do think there are opportunities for Intuitive to manage different price points. We have already, in terms of our capital line. And it's also true in our instrument line, and we continue to do that. So I think customers will have choice, and the choice will be, what price point do they want to enter and what benefit and value do they find at that price point. Intuitive will offer multiple price points. We will give them that opportunity. We have already, and we will continue to. And what value they find what price point will be their decision. And there, so far, have been really just 1 or 2 companies who have been out there having those conversations and driving it. I think we understand reasonably well."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Tao Levy with Wedbush Securities.",14,"And the next question is from the line of Tao Levy with Wedbush Securities."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more ef",51,"Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more effectively versus in prior years?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operationa",185,"I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operational efficiency at the hospital level or health system level that has been driving it. I think it's great. It's been great for our customers, and we support it. I think that the second thing is that some of the new procedure categories we're coming in to allow for higher volume procedures, Single-Sites. So more repeatable, shorter-procedure durations give you higher utilizations, just kind of the nature of the mix of product that's coming in. And lastly, I think, in some of the markets, we're seeing, referral consolidations. So low-volume surgeons are referring to higher-volume surgeons, essentially passing patients to those a few more. And that also drives utilization. We're kind of multiple factors there that have supported the growth. I don't know that it goes on forever. I don't think there's if it growth in utilization possible. But so far, so good."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And then just lastly, the percent of your applicable procedure's better currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?",38,"Got you. And then just lastly, the percent of your applicable procedure's better currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some g",106,"Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some gynecologic procedures, vessel sealers. There's still a lot of runway left. And in particular, as you think about the white results there on the available on our excise at the Xi installed base becomes larger, up more opportunities for to be used in thoracic procedures. There's going to be plenty of runway ahead of the installed base continues to move towards our new technology."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","[indiscernible] procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?",20,"[indiscernible] procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Not at this time.",4,"Not at this time."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Richard Newitter of the ring partners.",15,"And the next question is from the line of Richard Newitter of the ring partners."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to now is,",88,"I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to now is, do you think or can you tell us what procedures or new incremental procedures does this potentially open up for you? Or could you begin to see it open up where you aren't already being used today?"
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something that's f",183,"Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something that's fundamental capability that's good in one place comp and stub application in others, and I suspect we'll see that. And as we get more data on it, we're happy to share it with you. 
That was our last question. As we've said previously, will we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits on the human hand, and I assure that we remain committed to driving the vital few things that truly make a difference. This concludes today's call. I thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months. Thank you."
30239,365727306,1008131,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ok thank you. That concludes our conference for today. Thank you for your participation, and for using AT&T Executive TeleConference service. You may now disconnect.",25,"Ok thank you. That concludes our conference for today. Thank you for your participation, and for using AT&T Executive TeleConference service. You may now disconnect."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ca",56,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to your host, Calvin Darling, Senior Director of Finance, Investor Relations of Intuitive Surgical. Please go ahead, sir."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on April 19, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. 
In addition, today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our second quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our",737,"Good afternoon, and thank you for joining us on the call today. 
In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our new products. 
Turning first to procedures. Global procedure growth for the quarter was nearly 16%, with prior quarter trends continuing. Drivers of growth included U.S. general surgery, growth in the use of da Vinci Surgical Systems outside the United States and modest growth in U.S. urology and gynecology. Inguinal hernia repair and ventral hernia repair growth remained strong, and growth in colorectal surgery was solid. Procedure growth was variable by country in Europe, with accelerating growth in Germany. Both the Nordics and France experienced modest improvement relative to Q1 growth rates. In the U.K., growth decelerated slightly from Q1. In Asia, procedural growth in Japan was solid again in the quarter, while growth in Korea was robust and accelerated over Q1 growth rate. Growth in procedures in China was also strong. Patrick will review procedure trends in greater detail later in the call. 
We placed 130 da Vinci systems in the quarter, up from 118 in Q2 of 2015. Our most capable model, da Vinci Xi, represented roughly 3/4 of new capital placements. System placement orders included an increase in dual consoles and the addition of Integrated Table Motion, leading to higher feature content on average than Q1. 
Placements in Europe and Asia increased over Q1, while U.S. placements were slightly up relative to last quarter. Marshall will take you through our finances in more detail later in the call.
Our operations teams have performed well over the past several quarters and remain focused on optimizing our manufacturing design and supply chains. Q2 was another strong quarter of operations efficiency and cost reduction performance. We plan to continue these optimization efforts as they provide significant financial flexibility for us in coming years. 
Turning to highlights of our second quarter operating results. Procedures grew nearly 16% over the second quarter of last year. We shipped 130 da Vinci Surgical Systems, up from 118 in the second quarter of 2015. Revenue for the quarter was $670 million, up 14% from the prior year. Pro forma gross profit margin was 71.9% compared to 68% in the second quarter of last year. Instrument and accessory revenue increased to $339 million, up 14%. Total recurring revenue in the quarter was $467 million, representing 70% of total revenue. We generated a pro forma operating profit of $297 million in the quarter, up 30% from the second quarter of last year. And pro forma net income was $220 million, up 28% from Q2 of 2015.
Recent launches of Xi products, including Xi intraoperative table motion, have been well-received, as has expansion of advanced instrument lines, including our stapling products. We are continuing to invest in these line extensions to increase the value and utility of our Xi offering. We have also increased investment in advanced imaging, including significant refinements in our intraoperative 3D endoscopes, image processing for real-time and preoperative images and near-infrared fluorescence imaging. 
Our single port, or SP program, is progressing to plan. As SP approaches clinical readiness, we are conducting in-house validations and initiating work with clinical trial sites and regulatory agencies. We expect first markets to include head and neck surgery, urology and colorectal surgery. Over time, I expect this list of applications to evolve. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that a substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. We expect quarter-to-quarter variation in spending and increased fixed expenses in the back half of this year. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we remain focused on the following: first, expanding the use of da Vinci in general surgery and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our SP product into initial clinical use; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe",1197,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website, so that there's no confusion.
Second quarter 2016 revenue was $670 million, an increase of 14% compared with $586 million for the second quarter of 2015 and an increase of 13% compared with first quarter revenue of $595 million. Second quarter 2016 procedures increased nearly 16% compared with the second quarter of 2015 and increased 7% compared with last quarter. 
Procedure growth has been driven by general surgery in the U.S. and urology worldwide. Revenue highlights are as follows: instrument and accessory revenue of $339 million increased 14% compared with last year and increased 5% compared with first quarter of 2016. Growth in instruments and accessory revenue generally reflect procedure growth. Instrument and accessory revenue realized per procedure, including stocking orders, was approximately $1,810 per procedure. This metric has fluctuated in a tight range over the past couple of years. The slight decrease in the second quarter relative to the second quarter of 2015 and the first quarter of 2016 primarily reflects the impact of customer buying patterns, partially offset by increased usage of our stapling and vessel sealer products. While instrument and accessory usage per procedure has been relatively constant, customer buying patterns fluctuate in the short term.
System revenue of $203 million increased 15% compared with the second quarter of 2015 and increased 37% compared with last quarter. These increases primarily reflect higher average system selling prices, higher system placements and revenue associated with lease buyout transactions. 
130 systems were placed in the second quarter compared with 118 systems in the second quarter of 2015 and 110 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 19 last quarter and 5 systems in the second quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the second quarter, there were 66 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the second quarter of 2015 and $4 million in the last quarter. We also generated approximately $13 million of revenue during the quarter from lease buyouts compared with $6 million in the first quarter and $4 million in the second quarter of last year. We excluded the impact of operating leases and lease buyouts from our system ASP calculation. 
Globally, our average system selling price of $1.56 million was approximately $60,000 higher than both the second quarter of 2015 and last quarter. The increase compared with prior quarters reflect a higher mix of dual-console system and sales of table motion. We introduced intraoperative table motion in Europe in the third quarter of 2015 and early this year in the U.S. During the first and second quarters, we recognized $1 million and $6 million of table motion software, respectively. Both the mix of dual consoles and a number of table motion placements will fluctuate quarter-to-quarter.
Service revenue of $128 million increased 13% year-over-year and increased approximately 3% compared with the first quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. Outside of the U.S., results were as follows: second quarter revenue outside of the U.S. of $185 million increased 10% compared with $168 million for the second quarter of 2015 and increased 13% compared with the first quarter of $164 million. The increase compared with the previous years comprise of 16% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 2%. The increase compared to the first quarter reflects systems revenue growth of 30% and recurring revenue growth of 4%. 
Outside the U.S., we placed 51 systems in the second quarter compared with 46 in the second quarter of 2015 and 36 systems last quarter. Current quarter system sales included 22 into Europe, 4 into China and 13 into Japan. System placements outside the U.S. will continue to be lumpy. As some of these markets are in the early stages of adoption, some markets are highly seasonal, reflecting budget cycles or vacation patterns. And sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the second quarter of 2016 was 71.9% compared with 68% for the second quarter of 2015 and 70% for the first quarter of 2016. Compared with the first quarter of 2016, the higher gross margin reflects reduction in product costs, favorable costs associated with our scope exchange program, manufacturing efficiencies and higher dual-console mix, lease buyouts and table motion sales. Future margins will fluctuate based on the mix of our newer products, the mix of systems and instrument accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs, improve manufacturing efficiency and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses increased 9% compared with the second quarter of 2015 and decreased nearly $2 million compared with last quarter. The increase over the second quarter of 2015 reflects increased investments in advanced imaging, advanced instrumentation and next-generation robotics and increased headcount. The decrease compared with the prior quarter reflects lower payroll taxes, partially offset by increased headcount costs, particularly in our product operations area.
Our pro forma effective tax rate for the second quarter was 27.8% compared with an effective tax rate of 25.6% for the second quarter of 2015 and 27.4% last quarter. The increase in the tax rate compared with 2015 reflects onetime benefits reflected in 2015. Our second quarter 2016 pro forma net income was $220 million or $5.62 per share compared with $173 million or $4.57 per share for the second quarter of 2015 and $170 million or $4.42 per share for the first quarter of 2016. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP net income was $185 million or $4.71 per share for the second quarter of 2016 compared with $135 million or $3.56 per share for the second quarter of 2015 and $136 million or $3.54 per share for the first quarter of 2016. We ended the quarter with cash and investments of $4.2 billion, up from $3.8 billion as of March 31, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we'll continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlight."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to app",1033,"Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to approximately 15% in the second half of 2015 and approximately 13% in the first half of 2015. We expect our procedure growth rate to moderate in the second half of 2016. 
In the United States, second quarter procedure growth continued to outpace our expectations. Second quarter growth in our mature procedures slowed modestly compared to the first quarter. General and thoracic procedure growth remained robust. In U.S. urology, second quarter growth in da Vinci prostatectomy and kidney procedures slowed modestly compared to the first quarter of 2016. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect prostatectomy growth to return to levels similar to prostate cancer diagnoses over time.
In U.S. gynecology, second quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Similar to the first quarter, U.S. Single-Site gynecology procedures declined compared to the second quarter of 2015. In the U.S., procedures for benign gynecologic conditions slightly grew during the first half of 2016, exceeding our expectations. Second quarter U.S. general surgery procedure adoption remained strong, led by robust growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and surgeon retention and expansion remains encouraging. Cholecystectomy procedures slightly declined in the quarter, with growth in multiport procedures nearly offsetting declines in Single-Site procedures.
Second quarter was another quarter with a large number of clinical publications and presentations evaluating da Vinci surgery. Of these, I selected a few studies that you may find interesting. Intuitive is among the founding partners for the American Hernia Society Quality Collaborative initiative, or the AHSQC. In this quarter, 2 preliminary analyses comparing da Vinci to open or laparoscopic complex ventral hernia repair were brought forward. The first was a podium presentation at the American Hernia Society annual meeting by Dr. Poulose from Vanderbilt comparing da Vinci to open retromuscular hernia repair. This patient matched analysis involving data for multiple institutions found that da Vinci reduced hospital length of stay by 3 days without significant differences in surgical site infections, readmissions or reoperations. In addition, a paper was published in Surgical Endoscopy by Dr. Warren and colleagues from the University of South Carolina. The authors used their institution submissions to AHSQC to compare da Vinci to laparoscopic retromuscular hernia repair. Their study found that with a longer operative time, da Vinci reduced the hospital length of stay by 1 day and also enabled a greater percentage of patients to receive fascial closure and extraperitoneal placement of mesh to which the authors attribute a reduced likelihood of hernia recurrence for bowel adhesion.
Next, as Marshall mentioned earlier, sales of our intraoperative table motion technology were strong in the quarter. During the quarter, the first clinical publication reviewing this technology was published in the International Journal of Colorectal Disease by Dr. Morelli [ph] and colleagues from the University of Pisa. In a small case series of colorectal resections, surgeons used table motion to reposition the patient an average of 3x to 4x per procedure. The author suggested that the technology may improve patient's safety by reducing the amount of time in extreme patient physicians and stated ""The da Vinci Xi, plus the new operating table, gives the potential to optimize gravity exposure and provide a quick access to different surgical objectives that is important in colorectal surgery.""
Turning abroad. Procedure growth outside of the United States was approximately 25% in the second quarter, led by the global adoption of da Vinci prostatectomy, with solid contributions from kidney procedures and colorectal resections. Compared to the first quarter of 2016, second quarter procedure growth improved in Europe and was similar to the first quarter in Asia. Outside of the U.S., second quarter procedure performance varied by country, with strong growth in Germany, China and South Korea. In certain countries where our urology businesses has become more mature, such as the United Kingdom and Nordic countries, procedures continue to grow at a slower rate. Emerging procedures are in an early stage in these markets, and we are engaged with a broad range of stakeholders working to enable procedure adoption in the gynecologic and general surgery. In Japan, partial nephrectomy growth accelerated in the first quarter, following approval of national reimbursement. 
During the quarter, a meta-analysis sponsored by the South Korean National Evidence-based Healthcare Collaborating Agency, or NECA, was published in the Annals of Surgical Treatment and Research. It reviewed da Vinci and laparoscopic colon reception -- colon cancer reception. The meta-analysis included nearly 700 patients and found that with a longer operative time, da Vinci surgery resulted in a more rapid return of normal diet and bowel function, lower blood loss and a shorter hospital stay. This government-sponsored health technology assessment adds to the number of HTAs that have evaluated da Vinci surgery and a broad range of procedures over the years.
I will conclude my remarks by highlighting one of the largest population-based studies on the impact of da Vinci prostatectomy published in the Journal of Urology by Dr. Pearson [ph] colleagues from the University of Chicago. Using data from the National Cancer Data Base, the study includes nearly 100,000 prostatectomy patients treated with either da Vinci or open surgery. After matching the patient populations for risk factors, da Vinci surgery was shown to reduce positive surgical margins across low-, medium- and high-risk cohorts as well as reduced use of radiation therapy, 30-day readmissions and 30-day mortality compared to open surgery. 
Dr. Cope [ph] from Indiana University published a letter alongside the study titled Robotic Versus Open Prostatectomy and the Controversy, in which he stated that any debate of a robotic prostatectomy should be put to rest. 
This concludes my remarks. I will now turn the call over to Calvin."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015.",347,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015. We are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 14% to 15%.
In regards to certain forward-looking metrics, we have the following expectations. We anticipate fewer lease buyouts and lower upgrade and other systems revenue in Q3 and Q4 than we saw in Q2. Second half 2016 system ASPs will likely be lower than Q2, driven by product and channel mix. We expect a directionally higher proportion of our system placements in Q3 and Q4 to come from operating leases than we saw in Q2.
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 69% and 70% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 70% and 71% of net revenue. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will accelerate in the second half of 2016. We continue to forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels.
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income to total approximately $30 million in 2016, higher than the $20 million to $25 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair.",16,"[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may se",59,"Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may see some payoffs. I recall, it took about a year for the European investments to kick in."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growt",228,"Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growth in that. We have some other technology investments that are a little broader. We've talked about imaging, and that's kind of a multistep process. Some of it is on the acquisition side, new kinds of endoscopes. Some of it is on the software side, and some of it is in the ability to enhance [indiscernible] imaging portfolio. Some of those things will become commercial in future quarters. Some of them are a little longer, multiyear types of investments. With regard to investments outside of R&D, we've been growing our investments in regions around the world where we think there's real opportunity from Japan to Germany and France and others. That will continue. I think that some of those investments are doing well for us. We have opportunity to perform better than we have thus far. And so the right kinds of investments there are sometimes in clinical data and clinical trials, sometimes in other market development efforts, sometimes in our resources and headcount. And again, those things can be effective from a couple of quarters out to multiyears out, depending on what the activity is."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to matur",47,"Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to mature in certain geographies?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cas",79,"I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cases, we need interactions with payers and reimbursement. So we -- I don't think you have to wait years to see the early indicators, but full penetration is often more than a year of process."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?",38,"Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for th",140,"Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for that. There may be benign indications. Part of what we're talking to regulatory bodies about are clinical requirements for them to make some of those assessments and varies from what happens in Europe to what happens in the U.S., what happens in Asia. So that will play out in time. But think of head and neck starting point is torus. It may have other applications in neck surgery over time. I think that SP is a pretty powerful platform. And where we start and where it evolves to will differ. Surgeons get a chance to experience it for themselves."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And next question is from the line of Tycho Peterson of JPMorgan.",12,"And next question is from the line of Tycho Peterson of JPMorgan."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue con",67,"First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue contributor in '17. So can you maybe just talk a little bit about how we should think about the rollout next year."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be buil",92,"Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be building the foundation, the evidence foundation, some of the clinical work. And then, I think, '18, it starts to become more of a material contributor for us. As we get our clearances and start to solidify that time line, we'll call that up more for you."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around",55,"Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around the trials for 30-day, 1-year and 2-year follow-up?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I'll turn that to Patrick.",6,"I'll turn that to Patrick."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publication that I mentioned on the call from the AHSQC is among the investments we've made in helping support",57,"Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publication that I mentioned on the call from the AHSQC is among the investments we've made in helping support surgeons bring forward the outcomes that they're getting with da Vinci compared to the alternatives."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?",26,"Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to",61,"Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to engage the customer at different levels depending on what their needs are. So nothing new to report."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of David Lewis of Morgan Stanley.",13,"And the next question from the line of David Lewis of Morgan Stanley."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you",95,"Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you just give us a broader sense of what the word analytics means to you, Intuitive? And then on imaging. Is the next disclosure we're likely to see in advanced imaging approval or simply an announcement of an imaging clinical study? And then I had a quick financial follow-up."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performa",319,"Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performance itself, whether is itself is doing rather than, say, patient information. That data can be turned into insights for the company and for our customers, and we have been doing that for some time now. So there's that type of analytics. Going forward, I think that is our computational structures get more powerful. We can bring some of that intelligence more real-time. So rather than off-line insights, you can start generating real-time insights. That's a multiyear pathway. I think it's interesting and challenging. I think there is long-term potential in it. But we're moving down that pathway, making sure that we have good access and fast access and low-latency access to our devices in the field and then bringing to bear information that can help surgeons as they're performing their procedure. And you'll see from us in future years a series of products that come out using that set of kind of digital pipeline. Turning to imaging. There are a couple of different things. We are releasing endoscopes that are fairly regular equipped [ph] and improving that set of technologies. We made a technology change in the type of imaging we use when we switched to Xi that has allowed for faster durations for us in the kinds of imaging we do. So there's that kind of thing that's going on, kind of a regular heartbeat. Our customers are pretty well aware of where those things are. There are other things that we've talked about, other indications for our fluorescence. We're more likely to talk to you about what's happening clinically there than to announce a launch. So you'll have some warning prior to launch."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I t",123,"Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I think you said operating leases will pick back up in the back half of the year. So sort of what's the driver there? And then just on mix or ASPs going lower precisions in the back half. I'm assuming that's tied to your view of different geographies less Xis or less consoles, dual consoles. Just give us some flavor on some of those 2 dynamics, why you're so confident operating leases tick back up and ASPs tick down."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both of them. And this last quarter, we just saw a fewer number t",193,"Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both of them. And this last quarter, we just saw a fewer number than the previous quarter. The previous quarter, if you recall, was 19. We would expect it to be more like Q1 than it was Q2. So that's the increase that Calvin was referring to. As far as ASPs go, seasonally, systems revenue is stronger in Q4. Systems drive a slightly lower gross margin than do instruments and accessories. So that mix alone will cause margins to go down. We also would expect a little bit better performance, again, due to seasonal factors in the non-U.S. markets or the -- outside the U.S. And so that mix also will drive revenues down a little. And then we expect to continue to see growth in stapling and vessel sealing in our newer technology products, and those also drive slightly lower margins. So a lot of mix will cause margins to go down in the next couple of quarters."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?",31,"Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters.",28,"For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to u",106,"And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to utilize more refurbished scopes for our scope replacement programs with customers. We're going to be expanding the program as the base builds out in the second half, and it's going to require a much higher proportion of new scopes at higher costs and lower margin to replenish. So that's something that will be a headwind in the second half."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Bob Hopkins of Bank of America.",15,"And the next question is from the line of Bob Hopkins of Bank of America."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces",114,"So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces here. So just from a top-down perspective, from where you sit today, when you look forward at the business, should we be thinking about low 70s gross margin as something that can be sustained over time? Just give us a sense in what you just been learning here in the first half of this year as it relates to a more sustainable outlook for gross margins longer term."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I do",129,"Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I don't want to get into where we think it will go long term. Long term, those same moving parts will cause us not to have high confidence in exactly where they will come out, although know that we'll manage things very diligently. As you know, last year, we put in some programs to reduce the costs of Xi and Xi-related products. And those have been successful, and that's part of what we're seeing here in the year-to-year improvement."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","But I mean, in terms of thinking about the biggest moving pieces, one of the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company.",46,"But I mean, in terms of thinking about the biggest moving pieces, one of the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now.",23,"Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm j",140,"Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm just curious now at this almost 20% of the market cap in cash. Are there sizable M&A targets out there that you're kind of considering, and that's why there hasn't been anything incremental done with the cash? Just would love to get an updated view there. And then you mentioned on the topic of advanced imaging and time lines for new products, you said some of these approvals could come in future quarters. I mean, I was just curious, when you made that comment, were you talking about advanced imaging specifically?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're",304,"Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're seeing, I think, great momentum on the clinical side in terms of clinical acceptance. We have a couple of things going on. We have some new platforms we want to bring to the market that, I think, are outstanding, are very well done and well-conceived. That will take some investment for us to do. The other thing is that we see proliferation of folks who want to enter the market with competitive offerings. And that's both an opportunity for us and requirement for some diligence. And the opportunity is some of those technologies are interesting. It may be interesting to us. Other ones are things where we may want to speed up or adjust our strategy as the market evolves. As we think about the cash broadly, our first thought is can we use the cash productively to drive future growth organically? Our second thought is are there M&A opportunities that, for the long term, are good for the company? To answer the both of those, are there opportunities? The third, are there other ways we can deploy the capital with a long-term view for the benefit of shareholders? And that might be in buybacks or dividends or other things. So we're disciplined about thinking about capital allocation. I think this is a special time in the company's history. And we're walking through how we think about cash with a fair amount of discipline and diligence. You had asked a question on product releases. Why don't you ask it again just to make sure I hit it?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specific",52,"Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specifically speaking to advanced imaging."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are pretty full",44,"A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are pretty full pipeline."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Larry Keusch of Raymond James.",14,"And the next question is from the line of Larry Keusch of Raymond James."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the sur",64,"Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the surgeon at that time with these technologies embedded versus what's available today in Xi?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive,",245,"Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive, how much better in terms of outcomes and lower complications is the top 10th percentile surgeon versus the average surgeon? And the spread is quite big, as you look at that. There's a lot of variability in surgical performance. And so you ask the question, what drives that variability? Why? And some of it, not all of it, but some of it is that what you're looking for individual images are subtle. Where are nerves, where are cancer boundaries, where are the arteries, what's the right tissue dissection plane. Those things are subtle and take a long time for people to internalize and the best to do it better. And so what we're trying to do here is find technology that make it easier for other surgeons to be as good as the best, and we think that matters. Imaging will play a large role in this. So play forward a decade, what you'd really like to be able to do is mark tissues of interest in real time, paint for the surgeon what the elements and boundaries are that allow for a good dissection or the proper dissection or the best margin performance. And that's what's really directing our investments."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us",81,"Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us understand what that means. And then on China, you did a number of systems in the quarter. Just wanted to figure out where we were with the quota, those kind of one-offs now in any given quarter."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when w",199,"So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when we see fluctuations and what they're buying versus what they're using, there are times when they use more than they buy and times when they buy more than they use. And it just happens, and it's going to fluctuate quarter-to-quarter. And that was my comment in the short term. And so what we saw this quarter was they used more than they purchased. And so I don't have a great explanation for it beyond  that. That's just what we see. On the other hand, we do have distributors that buy in bulk because their holding inventory to sell to their end customers. And we do see fluctuations in those numbers as well. So the combination of the 2 direct hospitals that we sell to as well as distributors, we can actually measure or identify what is customer buying pattern. I don't think -- we don't see anything there that alarms us in one way or another."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And China?",3,"Okay. And China?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past year is expired at the end of December. And we're awaiting for the government to approve a new quota. We do",57,"China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past year is expired at the end of December. And we're awaiting for the government to approve a new quota. We don't have great information as to when that will occur."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas.",14,"You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget p",95,"Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget process this year has been delayed, so that's why we're not sure exactly when they'll approve that and then when we'll get a quota for it. Military hospitals buy independent of those public hospitals, and we've been selling to military hospitals all along, frankly, and have a number of placements at them."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next question from the line of Brandon Henry of RBC Capital Markets.",12,"Next question from the line of Brandon Henry of RBC Capital Markets."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories. What were",71,"Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories. What were the drivers of the year-over-year increase in gross margins in the first half of the year for 2016 versus the first half of the year in 2015?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months int",166,"Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months into the year. We're at 71% on a year-to-date basis, and that coincides with the upper end of the 70% to 70% -- 70% to 71% guidance range. But Q2 was an exceptionally strong quarter for gross margin, and I think we wanted to leave some specific comments there, specifically on the product side. We would expect a higher proportion of sales of newer products, as was described in lower proportion of dual-console sales and probably more sales through distributors at lower pricing and lower margins. And I think I already mentioned previously on the service side, we had some real benefits on the scope exchange in the second quarter, which are unlikely to continue in the second half."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're no",54,"Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're now kind of through the bolus of patients that previously deferred treatment?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all th",128,"Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all throughout 2015. How much of that is associated with having worked through any potential bolus that may be out there is difficult to predict, though, I think as you've heard us say a few times in the past that, over time, we do expect that prostatectomy volumes are likely to return towards the rate of diagnosis. And our recent history and the recent growth rates we've seen in 2015 and the first half of 2016, we believe, exceed that growth rate."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of Rick Wise of Stifel, Nicolaus.",13,"And the next question from the line of Rick Wise of Stifel, Nicolaus."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you wi",57,"Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you will, slowing? Can you just help us better understand your thinking there?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We cont",70,"Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We continue to expect and will continue to drive growth in U.S. general surgery and overseas markets in urology and early-stage [indiscernible] procedures."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3%",73,"Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3% converted? 50%? And is this a tailwind now, leaving, aside all the other moving factors, is it a positive tailwind now for a year or 2 or 3?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to",75,"Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to table motion. It was roughly split 50-50 between new installations and systems in the field. So again, it was a strong quarter, but I think we'll see how it heads."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it",72,"The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it will be a go forward. So you can look at history to sort of give you a guide as to how much that is."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there.",37,"Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I li",121,"Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I listened to the looming competition from Medtronic, their Analyst Day and your friends at Verb, they are very focused on lowering per-procedure robotic cost to -- it seems like, in their words, laparoscopic levels. How do you react? How do you deal? How do you compete with that approach, given their entrenched instrument capabilities? And will your new platforms address that per-procedure cost aspect of positioning you to better address some of these factors?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're goin",247,"Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're going to have to show benefit over laparoscopy, what can be done that lap can't do. And that's going to require some innovation and some technology, and the technologies are going to have to be paid for. So I think, over time, folks are going to have to come out and show what it is that they plan to do to make that happen. As we look at it, I do think there are opportunities for Intuitive to manage different price points. We have already, in terms of our capital line, and it's also true in our instrument line, and we can continue to do that. So I think customers will have choice. And the choice will be, at what price point do they want to enter and what benefit and value do they find at that price point. Intuitive will offer multiple price points. We will give them that opportunity. We have already, and we will continue to. And what value they find at what price point will be their decision. And there, so far, have been really just 1 or 2 companies who have been out there having those conversations and driving it. I think we understand it reasonably well."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Tao Levy of Wedbush Securities.",14,"And the next question is from the line of Tao Levy of Wedbush Securities."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more ef",51,"Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more effectively versus in prior years?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operationa",190,"I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operational efficiency at the hospital level or health system level that has been driving it. I think it's great. It's been great for our customers, and we support it. I think that the second thing is that some of the new procedure categories we're coming in to allow for higher volume procedures, [indiscernible] Single-Sites. So more repeatable, shorter-procedure durations give you higher utilizations, just kind of the nature of the mix of product that's coming in. And lastly, I think, in some of the markets, we're seeing referral consolidations. So low-volume surgeons are referring to higher-volume surgeons, essentially passing patients to those who do more. And that also drives up utilization. So there are kind of multiple factors there that have supported the growth. I don't know that it goes on forever. I don't think there's -- if there's growth in utilization, possible. But so far, so good."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And then just lastly, the percent of your applicable procedure's better currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?",38,"Got you. And then just lastly, the percent of your applicable procedure's better currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some g",110,"Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some gynecologic procedures, vessel sealers. There's still a lot of runway left. And in particular, as you think about the white reloads there only available on our Xi systems at the Xi installed base becomes larger, hoping to have more opportunities for those -- to be used in thoracic procedures. There's going to be plenty of runway ahead if the installed base continues to move towards our newest technology."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","[indiscernible] procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?",20,"[indiscernible] procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Not at this time.",4,"Not at this time."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Richard Newitter of Leerink Partners.",14,"And the next question is from the line of Richard Newitter of Leerink Partners."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to now is,",88,"I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to now is, do you think or can you tell us what procedures or new incremental procedures does this potentially open up for you? Or could you begin to see it open up where you aren't already being used today?"
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something",185,"Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something that's fundamental capability that's good in one place tends to have application in others, and I suspect we'll see that. And as we get more data on it, we're happy to share it with you. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. This concludes today's call. I thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months. Thank you."
30239,365727306,1008204,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect.",25,"Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ca",56,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to your host, Calvin Darling, Senior Director of Finance, Investor Relations of Intuitive Surgical. Please go ahead, sir."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on April 19, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. 
In addition, today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our second quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our",737,"Good afternoon, and thank you for joining us on the call today. 
In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our new products. 
Turning first to procedures. Global procedure growth for the quarter was nearly 16%, with prior quarter trends continuing. Drivers of growth included U.S. general surgery, growth in the use of da Vinci Surgical Systems outside the United States and modest growth in U.S. urology and gynecology. Inguinal hernia repair and ventral hernia repair growth remained strong, and growth in colorectal surgery was solid. Procedure growth was variable by country in Europe, with accelerating growth in Germany. Both the Nordics and France experienced modest improvement relative to Q1 growth rates. In the U.K., growth decelerated slightly from Q1. In Asia, procedural growth in Japan was solid again in the quarter, while growth in Korea was robust and accelerated over Q1 growth rate. Growth in procedures in China was also strong. Patrick will review procedure trends in greater detail later in the call. 
We placed 130 da Vinci systems in the quarter, up from 118 in Q2 of 2015. Our most capable model, da Vinci Xi, represented roughly 3/4 of new capital placements. System placement orders included an increase in dual consoles and the addition of Integrated Table Motion, leading to higher feature content on average than Q1. 
Placements in Europe and Asia increased over Q1, while U.S. placements were slightly up relative to last quarter. Marshall will take you through our finances in more detail later in the call.
Our operations teams have performed well over the past several quarters and remain focused on optimizing our manufacturing, design and supply chains. Q2 was another strong quarter of operations efficiency and cost reduction performance. We plan to continue these optimization efforts as they provide significant financial flexibility for us in coming years. 
Turning to highlights of our second quarter operating results. Procedures grew nearly 16% over the second quarter of last year. We shipped 130 da Vinci Surgical Systems, up from 118 in the second quarter of 2015. Revenue for the quarter was $670 million, up 14% from the prior year. Pro forma gross profit margin was 71.9% compared to 68% in the second quarter of last year. Instrument and accessory revenue increased to $339 million, up 14%. Total recurring revenue in the quarter was $467 million, representing 70% of total revenue. We generated a pro forma operating profit of $297 million in the quarter, up 30% from the second quarter of last year. And pro forma net income was $220 million, up 28% from Q2 of 2015.
Recent launches of Xi products, including Xi intraoperative table motion, have been well-received, as has expansion of advanced instrument lines, including our stapling products. We are continuing to invest in these line extensions to increase the value and utility of our Xi offering. We have also increased investment in advanced imaging, including significant refinements in our intraoperative 3D endoscopes, image processing for real-time and preoperative images and near-infrared fluorescence imaging. 
Our single port, or SP program, is progressing to plan. As SP approaches clinical readiness, we are conducting in-house validations and initiating work with clinical trial sites and regulatory agencies. We expect first markets to include head and neck surgery, urology and colorectal surgery. Over time, I expect this list of applications to evolve. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that a substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. We expect quarter-to-quarter variation in spending and increased fixed expenses in the back half of this year. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we remain focused on the following: first, expanding the use of da Vinci in general surgery and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our SP product into initial clinical use; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe",1197,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website, so that there's no confusion.
Second quarter 2016 revenue was $670 million, an increase of 14% compared with $586 million for the second quarter of 2015 and an increase of 13% compared with first quarter revenue of $595 million. Second quarter 2016 procedures increased nearly 16% compared with the second quarter of 2015 and increased 7% compared with last quarter. 
Procedure growth has been driven by general surgery in the U.S. and urology worldwide. Revenue highlights are as follows: instrument and accessory revenue of $339 million increased 14% compared with last year and increased 5% compared with first quarter of 2016. Growth in instruments and accessory revenue generally reflect procedure growth. Instrument and accessory revenue realized per procedure, including stocking orders, was approximately $1,810 per procedure. This metric has fluctuated in a tight range over the past couple of years. The slight decrease in the second quarter relative to the second quarter of 2015 and the first quarter of 2016 primarily reflects the impact of customer buying patterns, partially offset by increased usage of our stapling and vessel sealer products. While instrument and accessory usage per procedure has been relatively constant, customer buying patterns fluctuate in the short term.
System revenue of $203 million increased 15% compared with the second quarter of 2015 and increased 37% compared with last quarter. These increases primarily reflect higher average system selling prices, higher system placements and revenue associated with lease buyout transactions. 
130 systems were placed in the second quarter compared with 118 systems in the second quarter of 2015 and 110 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 19 last quarter and 5 systems in the second quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the second quarter, there were 66 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the second quarter of 2015 and $4 million in the last quarter. We also generated approximately $13 million of revenue during the quarter from lease buyouts compared with $6 million in the first quarter and $4 million in the second quarter of last year. We exclude the impact of operating leases and lease buyouts from our system ASP calculation. 
Globally, our average system selling price of $1.56 million was approximately $60,000 higher than both the second quarter of 2015 and last quarter. The increase compared with prior quarters reflect a higher mix of dual-console system and sales of table motion. We introduced intraoperative table motion in Europe in the third quarter of 2015 and early this year in the U.S. During the first and second quarters, we recognized $1 million and $6 million of table motion software, respectively. Both the mix of dual consoles and a number of table motion placements will fluctuate quarter-to-quarter.
Service revenue of $128 million increased 13% year-over-year and increased approximately 3% compared with the first quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. Outside of the U.S., results were as follows: second quarter revenue outside of the U.S. of $185 million increased 10% compared with $168 million for the second quarter of 2015 and increased 13% compared with the first quarter of $164 million. The increase compared with the previous years comprise of 16% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 2%. The increase compared to the first quarter reflects systems revenue growth of 30% and recurring revenue growth of 4%. 
Outside the U.S., we placed 51 systems in the second quarter compared with 46 in the second quarter of 2015 and 36 systems last quarter. Current quarter system sales included 22 into Europe, 4 into China and 13 into Japan. System placements outside the U.S. will continue to be lumpy. As some of these markets are in the early stages of adoption, some markets are highly seasonal, reflecting budget cycles or vacation patterns. And sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the second quarter of 2016 was 71.9% compared with 68% for the second quarter of 2015 and 70% for the first quarter of 2016. Compared with the first quarter of 2016, the higher gross margin reflects reduction in product costs, favorable costs associated with our scope exchange program, manufacturing efficiencies and higher dual-console mix, lease buyouts and table motion sales. Future margins will fluctuate based on the mix of our newer products, the mix of systems and instrument accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs, improve manufacturing efficiency and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses increased 9% compared with the second quarter of 2015 and decreased nearly $2 million compared with last quarter. The increase over the second quarter of 2015 reflects increased investments in advanced imaging, advanced instrumentation and next-generation robotics and increased headcount. The decrease compared with the prior quarter reflects lower payroll taxes, partially offset by increased headcount costs, particularly in our product operations area.
Our pro forma effective tax rate for the second quarter was 27.8% compared with an effective tax rate of 25.6% for the second quarter of 2015 and 27.4% last quarter. The increase in the tax rate compared with 2015 reflects onetime benefits reflected in 2015. Our second quarter 2016 pro forma net income was $220 million or $5.62 per share compared with $173 million or $4.57 per share for the second quarter of 2015 and $170 million or $4.42 per share for the first quarter of 2016. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP net income was $185 million or $4.71 per share for the second quarter of 2016 compared with $135 million or $3.56 per share for the second quarter of 2015 and $136 million or $3.54 per share for the first quarter of 2016. We ended the quarter with cash and investments of $4.2 billion, up from $3.8 billion as of March 31, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we'll continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlight."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to app",1033,"Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to approximately 15% in the second half of 2015 and approximately 13% in the first half of 2015. We expect our procedure growth rate to moderate in the second half of 2016. 
In the United States, second quarter procedure growth continued to outpace our expectations. Second quarter growth in our mature procedures slowed modestly compared to the first quarter. General and thoracic procedure growth remained robust. In U.S. urology, second quarter growth in da Vinci prostatectomy and kidney procedures slowed modestly compared to the first quarter of 2016. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect prostatectomy growth to return to levels similar to prostate cancer diagnoses over time.
In U.S. gynecology, second quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Similar to the first quarter, U.S. Single-Site gynecology procedures declined compared to the second quarter of 2015. In the U.S., procedures for benign gynecologic conditions slightly grew during the first half of 2016, exceeding our expectations. Second quarter U.S. general surgery procedure adoption remained strong, led by robust growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and surgeon retention and expansion remains encouraging. Cholecystectomy procedures slightly declined in the quarter, with growth in multiport procedures nearly offsetting declines in Single-Site procedures.
Second quarter was another quarter with a large number of clinical publications and presentations evaluating da Vinci surgery. Of these, I selected a few studies that you may find interesting. Intuitive is among the founding partners for the American Hernia Society Quality Collaborative initiative, or the AHSQC. In this quarter, 2 preliminary analyses comparing da Vinci to open or laparoscopic complex ventral hernia repair were brought forward. The first was a podium presentation at the American Hernia Society annual meeting by Dr. Poulose from Vanderbilt comparing da Vinci to open retromuscular hernia repair. This patient matched analysis involving data for multiple institutions found that da Vinci reduced hospital length of stay by 3 days without significant differences in surgical site infections, readmissions or reoperations. In addition, a paper was published in Surgical Endoscopy by Dr. Warren and colleagues from the University of South Carolina. The authors used their institution submissions to AHSQC to compare da Vinci to laparoscopic retromuscular hernia repair. Their study found that with a longer operative time, da Vinci reduced the hospital length of stay by 1 day and also enabled a greater percentage of patients to receive fascial closure and extraperitoneal placement of mesh to which the authors attribute a reduced likelihood of hernia recurrence for bowel adhesion.
Next, as Marshall mentioned earlier, sales of our intraoperative table motion technology were strong in the quarter. During the quarter, the first clinical publication reviewing this technology was published in the International Journal of Colorectal Disease by Dr. Morelli [ph] and colleagues from the University of Pisa. In a small case series of colorectal resections, surgeons used table motion to reposition the patient an average of 3x to 4x per procedure. The author suggested that the technology may improve patient's safety by reducing the amount of time in extreme patient physicians and stated ""The da Vinci Xi, plus the new operating table, gives the potential to optimize gravity exposure and provide a quick access to different surgical objectives that is important in colorectal surgery.""
Turning abroad. Procedure growth outside of the United States was approximately 25% in the second quarter, led by the global adoption of da Vinci prostatectomy, with solid contributions from kidney procedures and colorectal resections. Compared to the first quarter of 2016, second quarter procedure growth improved in Europe and was similar to the first quarter in Asia. Outside of the U.S., second quarter procedure performance varied by country, with strong growth in Germany, China and South Korea. In certain countries where our urology businesses has become more mature, such as the United Kingdom and Nordic countries, procedures continue to grow at a slower rate. Emerging procedures are in an early stage in these markets, and we are engaged with a broad range of stakeholders working to enable procedure adoption in the gynecologic and general surgery. In Japan, partial nephrectomy growth accelerated in the first quarter, following approval of national reimbursement. 
During the quarter, a meta-analysis sponsored by the South Korean National Evidence-based Healthcare Collaborating Agency, or NECA, was published in the Annals of Surgical Treatment and Research. It reviewed da Vinci and laparoscopic colon reception -- colon cancer reception. The meta-analysis included nearly 700 patients and found that with a longer operative time, da Vinci surgery resulted in a more rapid return of normal diet and bowel function, lower blood loss and a shorter hospital stay. This government-sponsored health technology assessment adds to the number of HTAs that have evaluated da Vinci surgery and a broad range of procedures over the years.
I will conclude my remarks by highlighting one of the largest population-based studies on the impact of da Vinci prostatectomy published in the Journal of Urology by Dr. Pearson [ph] colleagues from the University of Chicago. Using data from the National Cancer Data Base, the study includes nearly 100,000 prostatectomy patients treated with either da Vinci or open surgery. After matching the patient populations for risk factors, da Vinci surgery was shown to reduce positive surgical margins across low-, medium- and high-risk cohorts as well as reduced use of radiation therapy, 30-day readmissions and 30-day mortality compared to open surgery. 
Dr. Cope [ph] from Indiana University published a letter alongside the study titled Robotic Versus Open Prostatectomy: End the Controversy, in which he stated that any debate of a robotic prostatectomy should be put to rest. 
This concludes my remarks. I will now turn the call over to Calvin."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015.",347,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015. We are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 14% to 15%.
In regards to certain forward-looking metrics, we have the following expectations. We anticipate fewer lease buyouts and lower upgrade and other systems revenue in Q3 and Q4 than we saw in Q2. Second half 2016 system ASPs will likely be lower than Q2, driven by product and channel mix. We expect a directionally higher proportion of our system placements in Q3 and Q4 to come from operating leases than we saw in Q2.
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 69% and 70% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 70% and 71% of net revenue. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will accelerate in the second half of 2016. We continue to forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels.
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income to total approximately $30 million in 2016, higher than the $20 million to $25 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair.",16,"[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may se",59,"Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may see some payoffs. I recall, it took about a year for the European investments to kick in."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growt",229,"Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growth in that. We have some other technology investments that are a little broader. We've talked about imaging, and that's kind of a multistep process. Some of it is on the acquisition side, new kinds of endoscopes. Some of it is on the software side, and some of it is in the ability to enhance our florescence imaging portfolio. Some of those things will become commercial in future quarters. Some of them are a little longer, multiyear types of investments. With regard to investments outside of R&D, we've been growing our investments in regions around the world where we think there's real opportunity from Japan to Germany and France and others. That will continue. I think that some of those investments are doing well for us. We have opportunity to perform better than we have thus far. And so the right kinds of investments there are sometimes in clinical data and clinical trials, sometimes in other market development efforts, sometimes in our resources and headcount. And again, those things can be effective from a couple of quarters out to multi-years out, depending on what the activity is."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to matur",47,"Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to mature in certain geographies?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cas",79,"I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cases, we need interactions with payers and reimbursement. So we -- I don't think you have to wait years to see the early indicators, but full penetration is often more than a year of process."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?",38,"Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for th",140,"Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for that. There may be benign indications. Part of what we're talking to regulatory bodies about are clinical requirements for them to make some of those assessments and varies from what happens in Europe to what happens in the U.S., what happens in Asia. So that will play out in time. But think of head and neck starting point is torus. It may have other applications in neck surgery over time. I think that SP is a pretty powerful platform. And where we start and where it evolves to will differ. Surgeons get a chance to experience it for themselves."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And next question is from the line of Tycho Peterson of JPMorgan.",12,"And next question is from the line of Tycho Peterson of JPMorgan."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue con",67,"First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue contributor in '17. So can you maybe just talk a little bit about how we should think about the rollout next year."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be buil",92,"Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be building the foundation, the evidence foundation, some of the clinical work. And then, I think, '18, it starts to become more of a material contributor for us. As we get our clearances and start to solidify that time line, we'll call that up more for you."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around",55,"Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around the trials for 30-day, 1-year and 2-year follow-up?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I'll turn that to Patrick.",6,"I'll turn that to Patrick."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publications that I mentioned on the call from the AHSQC is among the investments we've made in helping support",57,"Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publications that I mentioned on the call from the AHSQC is among the investments we've made in helping support surgeons bring forward the outcomes that they're getting with da Vinci compared to the alternatives."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?",26,"Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to",61,"Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to engage the customer at different levels depending on what their needs are. So nothing new to report."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of David Lewis of Morgan Stanley.",13,"And the next question from the line of David Lewis of Morgan Stanley."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you",96,"Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you just give us a broader sense of what the word analytics means to you at Intuitive? And then on imaging. Is the next disclosure we're likely to see an advanced imaging approval or simply an announcement of an imaging clinical study? And then I had a quick financial follow-up."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performa",318,"Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performance itself, whether is itself is doing rather than, say, patient information. That data can be turned into insights for the company and for our customers, and we have been doing that for some time now. So there's that type of analytics. Going forward, I think that as our computational structures get more powerful. We can bring some of that intelligence more real-time. So rather than off-line insights, you can start generating real-time insights. That's a multiyear pathway. I think it's interesting and challenging. I think there is long-term potential in it. But we're moving down that pathway, making sure that we have good access and fast access and low-latency access to our devices in the field and then bringing to bear information that can help surgeons as they're performing their procedure. And you'll see from us in future years a series of products that come out using that set of kind of digital pipeline. Turning to imaging. There are a couple of different things. We are releasing endoscopes at a fairly regular clip and improving that set of technologies. We made a technology change in the type of imaging we use when we switched to Xi that has allowed for faster durations for us in the kinds of imaging we do. So there's that kind of thing that's going on, kind of a regular heartbeat. Our customers are pretty well aware of where those things are. There are other things that we've talked about, other indications for our fluorescence. We're more likely to talk to you about what's happening clinically there than to announce a launch. So you'll have some warning prior to launch."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I t",124,"Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I think you said operating leases will pick back up in the back half of the year. So sort of what's the driver there? And then just on mix or ASPs going lower for systems in the back half. I'm assuming that's tied to your view of different geographies less Xis or less consoles, dual consoles. Just give us some flavor on some of those 2 dynamics, why you're so confident operating leases tick back up and ASPs tick down."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both them and us. Last quarter, we just saw a fewer number than t",192,"Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both them and us. Last quarter, we just saw a fewer number than the previous quarter. The previous quarter, if you recall, was 19. We would expect it to be more like Q1 than it was Q2. So that's the increase that Calvin was referring to. As far as ASPs go, seasonally, systems revenue is stronger in Q4. Systems drive a slightly lower gross margin than do instruments and accessories. So that mix alone will cause margins to go down. We also would expect a little bit better performance, again, due to seasonal factors in the non-U.S. markets or the -- outside the U.S. And so that mix also will drive revenues down a little. And then we expect to continue to see growth in stapling and vessel sealing in our newer technology products, and those also drive slightly lower margins. So a lot of mix will cause margins to go down in the next couple of quarters."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?",31,"Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters.",28,"For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to u",106,"And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to utilize more refurbished scopes for our scope replacement programs with customers. We're going to be expanding the program as the base builds out in the second half, and it's going to require a much higher proportion of new scopes at higher costs and lower margin to replenish. So that's something that will be a headwind in the second half."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Bob Hopkins of Bank of America.",15,"And the next question is from the line of Bob Hopkins of Bank of America."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces",114,"So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces here. So just from a top-down perspective, from where you sit today, when you look forward at the business, should we be thinking about low 70s gross margin as something that can be sustained over time? Just give us a sense in what you just been learning here in the first half of this year as it relates to a more sustainable outlook for gross margins longer term."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I do",129,"Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I don't want to get into where we think it will go long term. Long term, those same moving parts will cause us not to have high confidence in exactly where they will come out, although know that we'll manage things very diligently. As you know, last year, we put in some programs to reduce the costs of Xi and Xi-related products. And those have been successful, and that's part of what we're seeing here in the year-to-year improvement."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","But I mean, in terms of thinking about the biggest moving pieces, what are the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company.",46,"But I mean, in terms of thinking about the biggest moving pieces, what are the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now.",23,"Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm j",140,"Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm just curious now at this almost 20% of the market cap in cash. Are there sizable M&A targets out there that you're kind of considering, and that's why there hasn't been anything incremental done with the cash? Just would love to get an updated view there. And then you mentioned on the topic of advanced imaging and time lines for new products, you said some of these approvals could come in future quarters. I mean, I was just curious, when you made that comment, were you talking about advanced imaging specifically?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're",304,"Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're seeing, I think, great momentum on the clinical side in terms of clinical acceptance. We have a couple of things going on. We have some new platforms we want to bring to the market that, I think, are outstanding, are very well done and well-conceived. That will take some investment for us to do. The other thing is that we see proliferation of folks who want to enter the market with competitive offerings. And that's both an opportunity for us and requirement for some diligence. And the opportunity is some of those technologies are interesting. It may be interesting to us. Other ones are things where we may want to speed up or adjust our strategy as the market evolves. As we think about the cash broadly, our first thought is can we use the cash productively to drive future growth organically? Our second thought is are there M&A opportunities that, for the long term, are good for the company? To answer the both of those, are there opportunities? The third, are there other ways we can deploy the capital with a long-term view for the benefit of shareholders? And that might be in buybacks or dividends or other things. So we're disciplined about thinking about capital allocation. I think this is a special time in the company's history. And we're walking through how we think about cash with a fair amount of discipline and diligence. You had asked a question on product releases. Why don't you ask it again just to make sure I hit it?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specific",52,"Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specifically speaking to advanced imaging."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are a pretty ful",45,"A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are a pretty full pipeline."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Larry Keusch of Raymond James.",14,"And the next question is from the line of Larry Keusch of Raymond James."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the sur",64,"Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the surgeon at that time with these technologies embedded versus what's available today in Xi?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive,",245,"Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive, how much better in terms of outcomes and lower complications is the top 10th percentile surgeon versus the average surgeon? And the spread is quite big, as you look at that. There's a lot of variability in surgical performance. And so you ask the question, what drives that variability? Why? And some of it, not all of it, but some of it is that what you're looking for individual images are subtle. Where are nerves, where are cancer boundaries, where are the arteries, what's the right tissue dissection plane. Those things are subtle and take a long time for people to internalize and the best to do it better. And so what we're trying to do here is find technology that make it easier for other surgeons to be as good as the best, and we think that matters. Imaging will play a large role in this. So play forward a decade, what you'd really like to be able to do is mark tissues of interest in real time, paint for the surgeon what the elements and boundaries are that allow for a good dissection or the proper dissection or the best margin performance. And that's what's really directing our investments."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us",81,"Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us understand what that means. And then on China, you did a number of systems in the quarter. Just wanted to figure out where we were with the quota, those kind of one-offs now in any given quarter."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when w",199,"So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when we see fluctuations and what they're buying versus what they're using, there are times when they use more than they buy and times when they buy more than they use. And it just happens, and it's going to fluctuate quarter-to-quarter. And that was my comment in the short term. And so what we saw this quarter was they used more than they purchased. And so I don't have a great explanation for it beyond that. That's just what we see. On the other hand, we do have distributors that buy in bulk because their holding inventory to sell to their end customers. And we do see fluctuations in those numbers as well. So the combination of the 2 direct hospitals that we sell to as well as distributors, we can actually measure or identify what is customer buying pattern. I don't think -- we don't see anything there that alarms us in one way or another."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And China?",3,"Okay. And China?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past years expired at the end of December. And we're awaiting for the government to approve a new quota. We don'",56,"China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past years expired at the end of December. And we're awaiting for the government to approve a new quota. We don't have great information as to when that will occur."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas.",14,"You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget p",95,"Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget process this year has been delayed, so that's why we're not sure exactly when they'll approve that and then when we'll get a quota for it. Military hospitals buy independent of those public hospitals, and we've been selling to military hospitals all along, frankly, and have a number of placements at them."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next question from the line of Brandon Henry of RBC Capital Markets.",12,"Next question from the line of Brandon Henry of RBC Capital Markets."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories what were t",71,"Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories what were the drivers of the year-over-year increase in gross margins in the first half of the year for 2016 versus the first half of the year in 2015?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months int",166,"Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months into the year. We're at 71% on a year-to-date basis, and that coincides with the upper end of the 70% to 70% -- 70% to 71% guidance range. But Q2 was an exceptionally strong quarter for gross margin, and I think we wanted to leave some specific comments there, specifically on the product side. We would expect a higher proportion of sales of newer products, as was described in lower proportion of dual-console sales and probably more sales through distributors at lower pricing and lower margins. And I think I already mentioned previously on the service side, we had some real benefits on the scope exchange in the second quarter, which are unlikely to continue in the second half."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're no",54,"Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're now kind of through the bolus of patients that previously deferred treatment?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all th",128,"Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all throughout 2015. How much of that is associated with having worked through any potential bolus that may be out there is difficult to predict, though, I think as you've heard us say a few times in the past that, over time, we do expect that prostatectomy volumes are likely to return towards the rate of diagnosis. And our recent history and the recent growth rates we've seen in 2015 and the first half of 2016, we believe, exceed that growth rate."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of Rick Wise of Stifel, Nicolaus.",13,"And the next question from the line of Rick Wise of Stifel, Nicolaus."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you wi",57,"Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you will, slowing? Can you just help us better understand your thinking there?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We cont",70,"Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We continue to expect and will continue to drive growth in U.S. general surgery and overseas markets in urology and early-stage origin procedures."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3%",73,"Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3% converted? 50%? And is this a tailwind now, leaving, aside all the other moving factors, is it a positive tailwind now for a year or 2 or 3?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to",75,"Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to table motion. It was roughly split 50-50 between new installations and systems in the field. So again, it was a strong quarter, but I think we'll see how it heads."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it",72,"The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it will be a go forward. So you can look at history to sort of give you a guide as to how much that is."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there.",37,"Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I li",121,"Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I listened to the looming competition from Medtronic, their Analyst Day and your friends at Verb, they are very focused on lowering per-procedure robotic cost to -- it seems like, in their words, laparoscopic levels. How do you react? How do you deal? How do you compete with that approach, given their entrenched instrument capabilities? And will your new platforms address that per-procedure cost aspect of positioning you to better address some of these factors?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're goin",247,"Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're going to have to show benefit over laparoscopy, what can be done that lap can't do. And that's going to require some innovation and some technology, and the technologies are going to have to be paid for. So I think, over time, folks are going to have to come out and show what it is that they plan to do to make that happen. As we look at it, I do think there are opportunities for Intuitive to manage different price points. We have already, in terms of our capital line, and it's also true in our instrument line, and we can continue to do that. So I think customers will have choice. And the choice will be, at what price point do they want to enter and what benefit and value do they find at that price point. Intuitive will offer multiple price points. We will give them that opportunity. We have already, and we will continue to. And what value they find at what price point will be their decision. And there, so far, have been really just 1 or 2 companies who have been out there having those conversations and driving it. I think we understand it reasonably well."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Tao Levy of Wedbush Securities.",14,"And the next question is from the line of Tao Levy of Wedbush Securities."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more ef",51,"Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more effectively versus in prior years?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operationa",192,"I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operational efficiency at the hospital level or health system level that has been driving it. I think it's great. It's been great for our customers, and we support it. I think that the second thing is that some of the new procedure categories we're coming in to allow for higher volume procedures out of single sites. So more repeatable, shorter-procedure durations give you higher utilizations, just kind of the nature of the mix of product that's coming in. And lastly, I think, in some of the markets, we're seeing referral consolidations. So low-volume surgeons are referring to higher-volume surgeons, essentially passing patients to those who do more. And that also drives up utilization. So there are kind of multiple factors there that have supported the growth. I don't know that it goes on forever. I don't think there's -- if there's growth in utilization, possible. But so far, so good."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And then just lastly, the percent of your applicable procedures that are currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?",39,"Got you. And then just lastly, the percent of your applicable procedures that are currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some g",110,"Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some gynecologic procedures, vessel sealers. There's still a lot of runway left. And in particular, as you think about the white reloads there only available on our Xi systems at the Xi installed base becomes larger, hoping to have more opportunities for those -- to be used in thoracic procedures. There's going to be plenty of runway ahead as the installed base continues to move towards our newest technology."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","You don't have a procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?",24,"You don't have a procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Not at this time.",4,"Not at this time."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Richard Newitter of Leerink Partners.",14,"And the next question is from the line of Richard Newitter of Leerink Partners."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to know is",88,"I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to know is, do you think or can you tell us what procedures or new incremental procedures does this potentially open up for you? Or could you begin to see it open up where you aren't already being used today?"
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something",186,"Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something that's a fundamental capability that's good in one place tends to have application in others, and I suspect we'll see that. And as we get more data on it, we're happy to share it with you. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. This concludes today's call. I thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months. Thank you."
30239,365727306,1008219,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect.",25,"Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Ca",56,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Q2 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to your host, Calvin Darling, Senior Director of Finance, Investor Relations of Intuitive Surgical. Please go ahead, sir."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Second Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on April 19, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. 
In addition, today's press release and supplementary financial data tables have been posted to our website. Today's format will consist of providing you with highlights of our second quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our second quarter financial results. Patrick will discuss marketing and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our",737,"Good afternoon, and thank you for joining us on the call today. 
In the second quarter, our company performance was strong, highlighted by sustained procedure growth across multiple geographies, improved margins and continued customer preference for our new products. 
Turning first to procedures. Global procedure growth for the quarter was nearly 16%, with prior quarter trends continuing. Drivers of growth included U.S. general surgery, growth in the use of da Vinci Surgical Systems outside the United States and modest growth in U.S. urology and gynecology. Inguinal hernia repair and ventral hernia repair growth remained strong, and growth in colorectal surgery was solid. Procedure growth was variable by country in Europe, with accelerating growth in Germany. Both the Nordics and France experienced modest improvement relative to Q1 growth rates. In the U.K., growth decelerated slightly from Q1. In Asia, procedural growth in Japan was solid again in the quarter, while growth in Korea was robust and accelerated over Q1 growth rate. Growth in procedures in China was also strong. Patrick will review procedure trends in greater detail later in the call. 
We placed 130 da Vinci systems in the quarter, up from 118 in Q2 of 2015. Our most capable model, da Vinci Xi, represented roughly 3/4 of new capital placements. System placement orders included an increase in dual consoles and the addition of Integrated Table Motion, leading to higher feature content on average than Q1. 
Placements in Europe and Asia increased over Q1, while U.S. placements were slightly up relative to last quarter. Marshall will take you through our finances in more detail later in the call.
Our operations teams have performed well over the past several quarters and remain focused on optimizing our manufacturing, design and supply chains. Q2 was another strong quarter of operations efficiency and cost reduction performance. We plan to continue these optimization efforts as they provide significant financial flexibility for us in coming years. 
Turning to highlights of our second quarter operating results. Procedures grew nearly 16% over the second quarter of last year. We shipped 130 da Vinci Surgical Systems, up from 118 in the second quarter of 2015. Revenue for the quarter was $670 million, up 14% from the prior year. Pro forma gross profit margin was 71.9% compared to 68% in the second quarter of last year. Instrument and accessory revenue increased to $339 million, up 14%. Total recurring revenue in the quarter was $467 million, representing 70% of total revenue. We generated a pro forma operating profit of $297 million in the quarter, up 30% from the second quarter of last year. And pro forma net income was $220 million, up 28% from Q2 of 2015.
Recent launches of Xi products, including Xi intraoperative table motion, have been well-received, as has expansion of advanced instrument lines, including our stapling products. We are continuing to invest in these line extensions to increase the value and utility of our Xi offering. We have also increased investment in advanced imaging, including significant refinements in our intraoperative 3D endoscopes, image processing for real-time and preoperative images and near-infrared fluorescence imaging. 
Our single port, or SP program, is progressing to plan. As SP approaches clinical readiness, we are conducting in-house validations and initiating work with clinical trial sites and regulatory agencies. We expect first markets to include head and neck surgery, urology and colorectal surgery. Over time, I expect this list of applications to evolve. 
As our business has strengthened, we have increased our mid- and long-term investments in research and development. We've been increasing our investments in imaging, analytics and new product architectures based on our belief that a substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. We expect quarter-to-quarter variation in spending and increased fixed expenses in the back half of this year. Calvin will take you through our projected spending later in the call. 
As we move forward in 2016, we remain focused on the following: first, expanding the use of da Vinci in general surgery and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including expanding our Xi line and taking our SP product into initial clinical use; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who will review financial highlights."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe",1197,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website, so that there's no confusion.
Second quarter 2016 revenue was $670 million, an increase of 14% compared with $586 million for the second quarter of 2015 and an increase of 13% compared with first quarter revenue of $595 million. Second quarter 2016 procedures increased nearly 16% compared with the second quarter of 2015 and increased 7% compared with last quarter. 
Procedure growth has been driven by general surgery in the U.S. and urology worldwide. Revenue highlights are as follows: instrument and accessory revenue of $339 million increased 14% compared with last year and increased 5% compared with first quarter of 2016. Growth in instruments and accessory revenue generally reflect procedure growth. Instrument and accessory revenue realized per procedure, including stocking orders, was approximately $1,810 per procedure. This metric has fluctuated in a tight range over the past couple of years. The slight decrease in the second quarter relative to the second quarter of 2015 and the first quarter of 2016 primarily reflects the impact of customer buying patterns, partially offset by increased usage of our stapling and vessel sealer products. While instrument and accessory usage per procedure has been relatively constant, customer buying patterns fluctuate in the short term.
System revenue of $203 million increased 15% compared with the second quarter of 2015 and increased 37% compared with last quarter. These increases primarily reflect higher average system selling prices, higher system placements and revenue associated with lease buyout transactions. 
130 systems were placed in the second quarter compared with 118 systems in the second quarter of 2015 and 110 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 19 last quarter and 5 systems in the second quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the second quarter, there were 66 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $1 million in the second quarter of 2015 and $4 million in the last quarter. We also generated approximately $13 million of revenue during the quarter from lease buyouts compared with $6 million in the first quarter and $4 million in the second quarter of last year. We exclude the impact of operating leases and lease buyouts from our system ASP calculation. 
Globally, our average system selling price of $1.56 million was approximately $60,000 higher than both the second quarter of 2015 and last quarter. The increase compared with prior quarters reflect a higher mix of dual-console system and sales of table motion. We introduced intraoperative table motion in Europe in the third quarter of 2015 and early this year in the U.S. During the first and second quarters, we recognized $1 million and $6 million of table motion software, respectively. Both the mix of dual consoles and a number of table motion placements will fluctuate quarter-to-quarter.
Service revenue of $128 million increased 13% year-over-year and increased approximately 3% compared with the first quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. Outside of the U.S., results were as follows: second quarter revenue outside of the U.S. of $185 million increased 10% compared with $168 million for the second quarter of 2015 and increased 13% compared with the first quarter of $164 million. The increase compared with the previous years comprise of 16% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 2%. The increase compared to the first quarter reflects systems revenue growth of 30% and recurring revenue growth of 4%. 
Outside the U.S., we placed 51 systems in the second quarter compared with 46 in the second quarter of 2015 and 36 systems last quarter. Current quarter system sales included 22 into Europe, 4 into China and 13 into Japan. System placements outside the U.S. will continue to be lumpy. As some of these markets are in the early stages of adoption, some markets are highly seasonal, reflecting budget cycles or vacation patterns. And sales into some markets are constrained by government regulations. 
Moving on to the remainder of the P&L. The pro forma gross margin for the second quarter of 2016 was 71.9% compared with 68% for the second quarter of 2015 and 70% for the first quarter of 2016. Compared with the first quarter of 2016, the higher gross margin reflects reduction in product costs, favorable costs associated with our scope exchange program, manufacturing efficiencies and higher dual-console mix, lease buyouts and table motion sales. Future margins will fluctuate based on the mix of our newer products, the mix of systems and instrument accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs, improve manufacturing efficiency and, in the long term, the potential reinstatement of the medical device tax. 
Pro forma operating expenses increased 9% compared with the second quarter of 2015 and decreased nearly $2 million compared with last quarter. The increase over the second quarter of 2015 reflects increased investments in advanced imaging, advanced instrumentation and next-generation robotics and increased headcount. The decrease compared with the prior quarter reflects lower payroll taxes, partially offset by increased headcount costs, particularly in our product operations area.
Our pro forma effective tax rate for the second quarter was 27.8% compared with an effective tax rate of 25.6% for the second quarter of 2015 and 27.4% last quarter. The increase in the tax rate compared with 2015 reflects onetime benefits reflected in 2015. Our second quarter 2016 pro forma net income was $220 million or $5.62 per share compared with $173 million or $4.57 per share for the second quarter of 2015 and $170 million or $4.42 per share for the first quarter of 2016. As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. 
I will now summarize our GAAP results. GAAP net income was $185 million or $4.71 per share for the second quarter of 2016 compared with $135 million or $3.56 per share for the second quarter of 2015 and $136 million or $3.54 per share for the first quarter of 2016. We ended the quarter with cash and investments of $4.2 billion, up from $3.8 billion as of March 31, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we'll continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlight."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to app",1033,"Thanks, Marshall. Of our second quarter procedure growth of nearly 16%, U.S. procedures grew approximately 13% and OUS procedures grew approximately 25%. During the first half of 2016, global procedure growth increased to approximately 16% compared to approximately 15% in the second half of 2015 and approximately 13% in the first half of 2015. We expect our procedure growth rate to moderate in the second half of 2016. 
In the United States, second quarter procedure growth continued to outpace our expectations. Second quarter growth in our mature procedures slowed modestly compared to the first quarter. General and thoracic procedure growth remained robust. In U.S. urology, second quarter growth in da Vinci prostatectomy and kidney procedures slowed modestly compared to the first quarter of 2016. We continue to believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market, and we expect prostatectomy growth to return to levels similar to prostate cancer diagnoses over time.
In U.S. gynecology, second quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci Hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Similar to the first quarter, U.S. Single-Site gynecology procedures declined compared to the second quarter of 2015. In the U.S., procedures for benign gynecologic conditions slightly grew during the first half of 2016, exceeding our expectations. Second quarter U.S. general surgery procedure adoption remained strong, led by robust growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and surgeon retention and expansion remains encouraging. Cholecystectomy procedures slightly declined in the quarter, with growth in multiport procedures nearly offsetting declines in Single-Site procedures.
Second quarter was another quarter with a large number of clinical publications and presentations evaluating da Vinci surgery. Of these, I selected a few studies that you may find interesting. Intuitive is among the founding partners for the American Hernia Society Quality Collaborative initiative, or the AHSQC. In this quarter, 2 preliminary analyses comparing da Vinci to open or laparoscopic complex ventral hernia repair were brought forward. The first was a podium presentation at the American Hernia Society annual meeting by Dr. Poulose from Vanderbilt comparing da Vinci to open retromuscular hernia repair. This patient matched analysis involving data for multiple institutions found that da Vinci reduced hospital length of stay by 3 days without significant differences in surgical site infections, readmissions or reoperations. In addition, a paper was published in Surgical Endoscopy by Dr. Warren and colleagues from the University of South Carolina. The authors used their institution submissions to AHSQC to compare da Vinci to laparoscopic retromuscular hernia repair. Their study found that with a longer operative time, da Vinci reduced the hospital length of stay by 1 day and also enabled a greater percentage of patients to receive fascial closure and extraperitoneal placement of mesh to which the authors attribute a reduced likelihood of hernia recurrence for bowel adhesion.
Next, as Marshall mentioned earlier, sales of our intraoperative table motion technology were strong in the quarter. During the quarter, the first clinical publication reviewing this technology was published in the International Journal of Colorectal Disease by Dr. Morelli [ph] and colleagues from the University of Pisa. In a small case series of colorectal resections, surgeons used table motion to reposition the patient an average of 3x to 4x per procedure. The author suggested that the technology may improve patient's safety by reducing the amount of time in extreme patient physicians and stated ""The da Vinci Xi, plus the new operating table, gives the potential to optimize gravity exposure and provide a quick access to different surgical objectives that is important in colorectal surgery.""
Turning abroad. Procedure growth outside of the United States was approximately 25% in the second quarter, led by the global adoption of da Vinci prostatectomy, with solid contributions from kidney procedures and colorectal resections. Compared to the first quarter of 2016, second quarter procedure growth improved in Europe and was similar to the first quarter in Asia. Outside of the U.S., second quarter procedure performance varied by country, with strong growth in Germany, China and South Korea. In certain countries where our urology businesses has become more mature, such as the United Kingdom and Nordic countries, procedures continue to grow at a slower rate. Emerging procedures are in an early stage in these markets, and we are engaged with a broad range of stakeholders working to enable procedure adoption in the gynecologic and general surgery. In Japan, partial nephrectomy growth accelerated in the first quarter, following approval of national reimbursement. 
During the quarter, a meta-analysis sponsored by the South Korean National Evidence-based Healthcare Collaborating Agency, or NECA, was published in the Annals of Surgical Treatment and Research. It reviewed da Vinci and laparoscopic colon reception -- colon cancer reception. The meta-analysis included nearly 700 patients and found that with a longer operative time, da Vinci surgery resulted in a more rapid return of normal diet and bowel function, lower blood loss and a shorter hospital stay. This government-sponsored health technology assessment adds to the number of HTAs that have evaluated da Vinci surgery and a broad range of procedures over the years.
I will conclude my remarks by highlighting one of the largest population-based studies on the impact of da Vinci prostatectomy published in the Journal of Urology by Dr. Pearson [ph] colleagues from the University of Chicago. Using data from the National Cancer Data Base, the study includes nearly 100,000 prostatectomy patients treated with either da Vinci or open surgery. After matching the patient populations for risk factors, da Vinci surgery was shown to reduce positive surgical margins across low-, medium- and high-risk cohorts as well as reduced use of radiation therapy, 30-day readmissions and 30-day mortality compared to open surgery. 
Dr. Cope [ph] from Indiana University published a letter alongside the study titled Robotic Versus Open Prostatectomy: End the Controversy, in which he stated that any debate of a robotic prostatectomy should be put to rest. 
This concludes my remarks. I will now turn the call over to Calvin."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015.",347,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 12% to 14% above the approximately 652,000 procedures performed in 2015. We are increasing our estimate for 2016. We now anticipate full year 2016 procedure growth within a range of 14% to 15%.
In regards to certain forward-looking metrics, we have the following expectations. We anticipate fewer lease buyouts and lower upgrade and other systems revenue in Q3 and Q4 than we saw in Q2. Second half 2016 system ASPs will likely be lower than Q2, driven by product and channel mix. We expect a directionally higher proportion of our system placements in Q3 and Q4 to come from operating leases than we saw in Q2.
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 69% and 70% of net revenue. We are now increasing our estimate. We now expect full year 2016 pro forma gross profit to be within a range of between 70% and 71% of net revenue. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will accelerate in the second half of 2016. We continue to forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels.
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015. We expect other income to total approximately $30 million in 2016, higher than the $20 million to $25 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, we continue to expect our 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair.",16,"[Operator Instructions] And our first question comes from the line of Ben Andrew of William Blair."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may se",59,"Gary, maybe just start up by talking about the increased investments in OpEx in the back half. Obviously, you guys have always been looking for opportunities there, but talk about more granularly about where those investments are coming and when we may see some payoffs. I recall, it took about a year for the European investments to kick in."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growt",229,"Sure. As we've said before, I think the messaging here has been pretty consistent. Some of the investments are in technology, things like SP starting to move into field-based investment and scale rather than just the upfront D. So you're seeing some growth in that. We have some other technology investments that are a little broader. We've talked about imaging, and that's kind of a multistep process. Some of it is on the acquisition side, new kinds of endoscopes. Some of it is on the software side, and some of it is in the ability to enhance our fluorescence imaging portfolio. Some of those things will become commercial in future quarters. Some of them are a little longer, multiyear types of investments. With regard to investments outside of R&D, we've been growing our investments in regions around the world where we think there's real opportunity from Japan to Germany and France and others. That will continue. I think that some of those investments are doing well for us. We have opportunity to perform better than we have thus far. And so the right kinds of investments there are sometimes in clinical data and clinical trials, sometimes in other market development efforts, sometimes in our resources and headcount. And again, those things can be effective from a couple of quarters out to multi-years out, depending on what the activity is."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to matur",47,"Okay. And then 2 more quick ones for me, please. In Europe, you talked about some of the investments in emerging procedures. Is that a protracted multi-year process to move beyond urology and the initial GYN procedures that you've kind of started to mature in certain geographies?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cas",79,"I think that you can see early success sooner than years, but I think broad adoption in many of these places is a multiyear process. It starts with leading surgeons and key opinion leaders and surgical society endorsements and goes from there. In some cases, we need interactions with payers and reimbursement. So we -- I don't think you have to wait years to see the early indicators, but full penetration is often more than a year of process."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?",38,"Great. And then finally, in the SP, you did say head and neck. Can you be more precise? Would that be sleep apnea? Or is this more thyroidectomy? Do you have some initial thoughts on where specifically, please?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for th",140,"Yes. So I think, at the beginning, it's really starting in the markets we're already participating in. So transoral, more than, for example, thyroidectomy, I think, this is more around surgery in the throat. And for sure, there's cancer indications for that. There may be benign indications. Part of what we're talking to regulatory bodies about are clinical requirements for them to make some of those assessments and varies from what happens in Europe to what happens in the U.S., what happens in Asia. So that will play out in time. But think of head and neck starting point is torus. It may have other applications in neck surgery over time. I think that SP is a pretty powerful platform. And where we start and where it evolves to will differ. Surgeons get a chance to experience it for themselves."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And next question is from the line of Tycho Peterson of JPMorgan.",12,"And next question is from the line of Tycho Peterson of JPMorgan."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue con",67,"First question, Gary, can you maybe just provide a little bit more clarity on SP time lines? I understand you're lining up the initial sites now. It sounds like from some of the recent discussions, you're really not expecting that to be much a revenue contributor in '17. So can you maybe just talk a little bit about how we should think about the rollout next year."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be buil",92,"Sure. So first step here is clearances and some clinical data to support that clearance. '17 will be really focused on data generation. While I expect some revenue, I don't think it will be a material revenue contributor in '17. A lot of that will be building the foundation, the evidence foundation, some of the clinical work. And then, I think, '18, it starts to become more of a material contributor for us. As we get our clearances and start to solidify that time line, we'll call that up more for you."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around",55,"Okay. And then just switching over to hernia. I think you'd talked in the past about doing some initial trial work. Can you maybe talk a little bit about where that stands in terms of any patient enrollment and how we should think about time lines around the trials for 30-day, 1-year and 2-year follow-up?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I'll turn that to Patrick.",6,"I'll turn that to Patrick."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publications that I mentioned on the call from the AHSQC is among the investments we've made in helping support",57,"Yes. So we have a number of different initiatives ongoing as it relates to sponsoring evidence development in hernia repair. The 2 presentation publications that I mentioned on the call from the AHSQC is among the investments we've made in helping support surgeons bring forward the outcomes that they're getting with da Vinci compared to the alternatives."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?",26,"Okay. And then just last one, you had noted some delays in Europe around tenders from competitive takeoffs. Just anything changed from your perspective this quarter?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to",61,"Nothing new to note. I think that tender offers and competitive interactions is the new normal. I think our teams are doing great. I think their performance has been effective. I think we're communicating well. We have a broad portfolio that allows us to engage the customer at different levels depending on what their needs are. So nothing new to report."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of David Lewis of Morgan Stanley.",13,"And the next question from the line of David Lewis of Morgan Stanley."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you",96,"Just a couple of quick questions. Let me -- Gary, one for you, and then I have kind of a clarifying financial question. So Gary, I appreciate the incrementally more detail you gave us in the pipeline this quarter. So 2 pieces. First is analytics. Can you just give us a broader sense of what the word analytics means to you at Intuitive? And then on imaging. Is the next disclosure we're likely to see an advanced imaging approval or simply an announcement of an imaging clinical study? And then I had a quick financial follow-up."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performa",318,"Okay. I think analytics has multiple components in it. As you may know, the majority of our systems are real-time connected to the Internet today. I think over 90% of systems are online. They report back information to us mostly around the system performance itself, whether is itself is doing rather than, say, patient information. That data can be turned into insights for the company and for our customers, and we have been doing that for some time now. So there's that type of analytics. Going forward, I think that as our computational structures get more powerful. We can bring some of that intelligence more real-time. So rather than off-line insights, you can start generating real-time insights. That's a multiyear pathway. I think it's interesting and challenging. I think there is long-term potential in it. But we're moving down that pathway, making sure that we have good access and fast access and low-latency access to our devices in the field and then bringing to bear information that can help surgeons as they're performing their procedure. And you'll see from us in future years a series of products that come out using that set of kind of digital pipeline. Turning to imaging. There are a couple of different things. We are releasing endoscopes at a fairly regular clip and improving that set of technologies. We made a technology change in the type of imaging we use when we switched to Xi that has allowed for faster durations for us in the kinds of imaging we do. So there's that kind of thing that's going on, kind of a regular heartbeat. Our customers are pretty well aware of where those things are. There are other things that we've talked about, other indications for our fluorescence. We're more likely to talk to you about what's happening clinically there than to announce a launch. So you'll have some warning prior to launch."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I t",124,"Okay, that's helpful. And then just Calvin or Marshall. Just thinking about the systems guidance in the back half of the year, a couple of components. I note this quarter that operating leases were down for the first time. And in several quarters, yet I think you said operating leases will pick back up in the back half of the year. So sort of what's the driver there? And then just on mix or ASPs going lower for systems in the back half. I'm assuming that's tied to your view of different geographies less Xis or less consoles, dual consoles. Just give us some flavor on some of those 2 dynamics, why you're so confident operating leases tick back up and ASPs tick down."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both them and us. Last quarter, we just saw a fewer number than t",192,"Sure. So philosophically, first of all, we provide our customers' leases to provide some flexibility and how they get into robotics, and it's proven out to be -- to work out pretty well for both them and us. Last quarter, we just saw a fewer number than the previous quarter. The previous quarter, if you recall, was 19. We would expect it to be more like Q1 than it was Q2. So that's the increase that Calvin was referring to. As far as ASPs go, seasonally, systems revenue is stronger in Q4. Systems drive a slightly lower gross margin than do instruments and accessories. So that mix alone will cause margins to go down. We also would expect a little bit better performance, again, due to seasonal factors in the non-U.S. markets or the -- outside the U.S. And so that mix also will drive revenues down a little. And then we expect to continue to see growth in stapling and vessel sealing in our newer technology products, and those also drive slightly lower margins. So a lot of mix will cause margins to go down in the next couple of quarters."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?",31,"Marshall, none of these things seem to me to be new dynamics. These seem to be sort of ordinary operating dynamics for Intuitive. Is that sort of how you see it?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters.",28,"For the most part, the seasonal things are, I think the -- the new thing is as we drive the new product revenues, that's increases over previous quarters."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to u",106,"And David, if we're talking about margins, the one thing that was kind of different in the second quarter was on the service side. You saw a pretty market increase in the service gross profit in the second quarter. And during the quarter, we are able to utilize more refurbished scopes for our scope replacement programs with customers. We're going to be expanding the program as the base builds out in the second half, and it's going to require a much higher proportion of new scopes at higher costs and lower margin to replenish. So that's something that will be a headwind in the second half."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Bob Hopkins of Bank of America.",15,"And the next question is from the line of Bob Hopkins of Bank of America."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces",114,"So Marshall, just to continue on this conversation around margins. Last quarter, you commented on mix and how you didn't think you'd be able to sustain 70%. And now the guidance is going up on gross margin, and I understand there's a lot of moving pieces here. So just from a top-down perspective, from where you sit today, when you look forward at the business, should we be thinking about low 70s gross margin as something that can be sustained over time? Just give us a sense in what you just been learning here in the first half of this year as it relates to a more sustainable outlook for gross margins longer term."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I do",129,"Yes. I think we've given you the guidance for the remainder of the year. We think that's the best crystal ball we have at this point. There are a lot of moving parts. Hard to predict exactly where each one will come out. And so I'll leave it at that. I don't want to get into where we think it will go long term. Long term, those same moving parts will cause us not to have high confidence in exactly where they will come out, although know that we'll manage things very diligently. As you know, last year, we put in some programs to reduce the costs of Xi and Xi-related products. And those have been successful, and that's part of what we're seeing here in the year-to-year improvement."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","But I mean, in terms of thinking about the biggest moving pieces, what are the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company.",46,"But I mean, in terms of thinking about the biggest moving pieces, what are the things that you have us focus on, as we think a little bit longer term, when we try to consider what a sustainable gross margin might look like for the company."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now.",23,"Yes. I don't think we put a stake in the ground, and I don't think that I'm prepared to do that right now."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm j",140,"Okay. No, well, we can take it offline. And then, Gary, one of the things I wanted to ask about, 2 quick things. One on just kind of eye-popping number of $4.2 billion now in cash on the balance sheet, and you get this question quite frequently. But I'm just curious now at this almost 20% of the market cap in cash. Are there sizable M&A targets out there that you're kind of considering, and that's why there hasn't been anything incremental done with the cash? Just would love to get an updated view there. And then you mentioned on the topic of advanced imaging and time lines for new products, you said some of these approvals could come in future quarters. I mean, I was just curious, when you made that comment, were you talking about advanced imaging specifically?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're",304,"Well, let's speak cash, and then we'll go to the organic side. Yes, we look at the cash and think we're in an interesting point in the company's evolution here. On the one hand, I think that customer acceptance of our products has been really high. We're seeing, I think, great momentum on the clinical side in terms of clinical acceptance. We have a couple of things going on. We have some new platforms we want to bring to the market that, I think, are outstanding, are very well done and well-conceived. That will take some investment for us to do. The other thing is that we see proliferation of folks who want to enter the market with competitive offerings. And that's both an opportunity for us and requirement for some diligence. And the opportunity is some of those technologies are interesting. It may be interesting to us. Other ones are things where we may want to speed up or adjust our strategy as the market evolves. As we think about the cash broadly, our first thought is can we use the cash productively to drive future growth organically? Our second thought is, are there M&A opportunities that, for the long term, are good for the company? To answer the both of those, are there opportunities? The third, are there other ways we can deploy the capital with a long-term view for the benefit of shareholders? And that might be in buybacks or dividends or other things. So we're disciplined about thinking about capital allocation. I think this is a special time in the company's history. And we're walking through how we think about cash with a fair amount of discipline and diligence. You had asked a question on product releases. Why don't you ask it again just to make sure I hit it?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specific",52,"Sure. You made a comment about the timing of new product releases, and you said some will take many years and some of those approvals could come in future quarters. And I was just curious as to whether that was a broad comment or whether you were specifically speaking to advanced imaging."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are a pretty ful",45,"A broad comment. There are some imaging things that are kind of newer product things that look a lot like what we have today, and there are some long-term imaging investments. And so the submission pipeline and our regulatory interactions are a pretty full pipeline."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Larry Keusch of Raymond James.",14,"And the next question is from the line of Larry Keusch of Raymond James."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the sur",64,"Gary, I just wanted to pick up on your last answer on the imaging. If you were to sort of think about all the efforts in analytics and imaging that the company's working on and you were to take this out several years, what would be the benefits to the surgeon at that time with these technologies embedded versus what's available today in Xi?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive,",245,"Yes. It's a good question. There's a couple of things that, I think, drive some of the variability that you see in surgery. So it's really interesting. If you ask the question, and there's some research out there, surgery, in general, not just Intuitive, how much better in terms of outcomes and lower complications is the top 10th percentile surgeon versus the average surgeon? And the spread is quite big, as you look at that. There's a lot of variability in surgical performance. And so you ask the question, what drives that variability? Why? And some of it, not all of it, but some of it is that what you're looking for individual images are subtle. Where are nerves, where are cancer boundaries, where are the arteries, what's the right tissue dissection plane. Those things are subtle and take a long time for people to internalize and the best to do it better. And so what we're trying to do here is find technology that make it easier for other surgeons to be as good as the best, and we think that matters. Imaging will play a large role in this. So play forward a decade, what you'd really like to be able to do is mark tissues of interest in real time, paint for the surgeon what the elements and boundaries are that allow for a good dissection or the proper dissection or the best margin performance. And that's what's really directing our investments."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us",81,"Okay, that's really helpful. And then for Marshall, I guess, 2 quick ones. The per-procedure revenue certainly was at a lower level than we've seen in some time. You definitely mentioned some customer buying patterns in there. So if you could just help us understand what that means. And then on China, you did a number of systems in the quarter. Just wanted to figure out where we were with the quota, those kind of one-offs now in any given quarter."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when w",199,"So as it relates to my comment on customer buying patterns, we're able to measure or look at what happens with instrument accessory usage. And from that, what we've determined is that the usage really hasn't changed a lot surgery-by-surgery. And so when we see fluctuations and what they're buying versus what they're using, there are times when they use more than they buy and times when they buy more than they use. And it just happens, and it's going to fluctuate quarter-to-quarter. And that was my comment in the short term. And so what we saw this quarter was they used more than they purchased. And so I don't have a great explanation for it beyond that. That's just what we see. On the other hand, we do have distributors that buy in bulk because their holding inventory to sell to their end customers. And we do see fluctuations in those numbers as well. So the combination of the 2 direct hospitals that we sell to as well as distributors, we can actually measure or identify what is customer buying pattern. I don't think -- we don't see anything there that alarms us in one way or another."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And China?",3,"Okay. And China?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past years expired at the end of December. And we're awaiting for the government to approve a new quota. We don'",56,"China. China, we sold 4 systems this quarter. Those systems were sold to military hospitals. The quota that we were selling to and a couple of past years expired at the end of December. And we're awaiting for the government to approve a new quota. We don't have great information as to when that will occur."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas.",14,"You might describe the differences between military hospitals and nonmilitary hospitals vis--vis quotas."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget p",95,"Yes. The quota system that we had was for public hospitals. And there is a process by which you -- we're classified as high technology, and there's a quota established by the government. It's in conjunction with their normal budget process. Their budget process this year has been delayed, so that's why we're not sure exactly when they'll approve that and then when we'll get a quota for it. Military hospitals buy independent of those public hospitals, and we've been selling to military hospitals all along, frankly, and have a number of placements at them."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next question from the line of Brandon Henry of RBC Capital Markets.",12,"Next question from the line of Brandon Henry of RBC Capital Markets."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories what were t",71,"Obviously, Intuitive has posted better-than-expected gross margin in the first half of the year, and I think we're all trying to figure out how sustainable that is. So can you help us trying to quantify or may be bucket into several categories what were the drivers of the year-over-year increase in gross margins in the first half of the year for 2016 versus the first half of the year in 2015?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months int",166,"Yes. I'm not sure we can list out item by item a specific contribution, but we have been focusing obviously on reducing costs for quite some time and managing our fixed cost, and we're really pleased with the progress. We look at where we sit 6 months into the year. We're at 71% on a year-to-date basis, and that coincides with the upper end of the 70% to 70% -- 70% to 71% guidance range. But Q2 was an exceptionally strong quarter for gross margin, and I think we wanted to leave some specific comments there, specifically on the product side. We would expect a higher proportion of sales of newer products, as was described in lower proportion of dual-console sales and probably more sales through distributors at lower pricing and lower margins. And I think I already mentioned previously on the service side, we had some real benefits on the scope exchange in the second quarter, which are unlikely to continue in the second half."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're no",54,"Okay. And then separately, I think you guys mentioned some slight slowing in prostatectomy growth in 2Q. Can you give us some more details on this comment and kind of discuss what's implied for prostatectomy growth and the updated guidance range? We're now kind of through the bolus of patients that previously deferred treatment?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all th",128,"Yes, Brad. It's tough to know where exactly you are with patient population that may have deferred treatment. What we saw in the quarter was just slight volume of growth from what we saw in the first quarter and the second half of 2015 or, frankly, all throughout 2015. How much of that is associated with having worked through any potential bolus that may be out there is difficult to predict, though, I think as you've heard us say a few times in the past that, over time, we do expect that prostatectomy volumes are likely to return towards the rate of diagnosis. And our recent history and the recent growth rates we've seen in 2015 and the first half of 2016, we believe, exceed that growth rate."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question from the line of Rick Wise of Stifel, Nicolaus.",13,"And the next question from the line of Rick Wise of Stifel, Nicolaus."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you wi",57,"Let me start off with procedures again. I just wanted to make sure I understood the comment about the second half procedure growth slowing. Yes, I see that comps are modestly tougher. Is it something about OUS? Is it the urology served recovery, if you will, slowing? Can you just help us better understand your thinking there?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We cont",70,"Rick, yes, you mentioned the growth rate comparisons get a little harder in the second half of the year. The mature procedure contributions that we saw in the first half of the year, we don't think will be as strong in the second half of the year. We continue to expect and will continue to drive growth in U.S. general surgery and overseas markets in urology and early-stage origin procedures."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3%",73,"Okay. Back on gross margin. Clearly, it sounds from your comments that table motion adoption, which has been, in your words, well received, has been one factor helping margins. Where are we in the sort of the penetration of the installed base? I mean, 3% converted? 50%? And is this a tailwind now, leaving, aside all the other moving factors, is it a positive tailwind now for a year or 2 or 3?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to",75,"Yes, I don't think I want to get into the specific units on this. We're really pleased with the progress we're making and the strong market response from the customers. I think Marshall mentioned in the script we had $6 million of revenue attributable to table motion. It was roughly split 50-50 between new installations and systems in the field. So again, it was a strong quarter, but I think we'll see how it heads."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it",72,"The history of selling package to the installed base rather than new installs is that you have a few quarters of strong performance, and then it tends to tail off. Folks who are going to be interest in it tend to move forward quickly. And then mostly, it will be a go forward. So you can look at history to sort of give you a guide as to how much that is."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there.",37,"Yes. And then we do have roughly around 750 or so da Vinci Xis out in the world at this point in time, and we made some good progress on that. There's still some more out there."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I li",121,"Got you. And just one last one for you, Gary, if I could. At SAGES this year, it was very clear that Intuitive is messaging around looking at total procedure costs in the hospital for robotics and how much economic sense it made, robotics makes. When I listened to the looming competition from Medtronic, their Analyst Day and your friends at Verb, they are very focused on lowering per-procedure robotic cost to -- it seems like, in their words, laparoscopic levels. How do you react? How do you deal? How do you compete with that approach, given their entrenched instrument capabilities? And will your new platforms address that per-procedure cost aspect of positioning you to better address some of these factors?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're goin",247,"Sure. I think the first thing of some of the messaging coming out around opportunities on price on per-procedure price, I think there's a big challenge for new entrants there, which is what benefit do you bring at which price point. So I think you're going to have to show benefit over laparoscopy, what can be done that lap can't do. And that's going to require some innovation and some technology, and the technologies are going to have to be paid for. So I think, over time, folks are going to have to come out and show what it is that they plan to do to make that happen. As we look at it, I do think there are opportunities for Intuitive to manage different price points. We have already, in terms of our capital line, and it's also true in our instrument line, and we can continue to do that. So I think customers will have choice. And the choice will be, at what price point do they want to enter and what benefit and value do they find at that price point. Intuitive will offer multiple price points. We will give them that opportunity. We have already, and we will continue to. And what value they find at what price point will be their decision. And there, so far, have been really just 1 or 2 companies who have been out there having those conversations and driving it. I think we understand it reasonably well."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Tao Levy of Wedbush Securities.",14,"And the next question is from the line of Tao Levy of Wedbush Securities."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more ef",51,"Your utilization per system in the U.S. keeps on hitting sort of new highs. And so I'm just wondering, where is the increase in capacity that the hospitals are finding? Where is that coming from? Are they utilizing the work week schedules a little more effectively versus in prior years?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operationa",192,"I think it's more than one thing for me. One is we're seeing health systems, integrated delivery networks, optimizing the placement of their products and optimizing the flow of patients and surgeons around that product. And so that's kind of an operational efficiency at the hospital level or health system level that has been driving it. I think it's great. It's been great for our customers, and we support it. I think that the second thing is that some of the new procedure categories we're coming in to allow for higher volume procedures out of single sites. So more repeatable, shorter-procedure durations give you higher utilizations, just kind of the nature of the mix of product that's coming in. And lastly, I think, in some of the markets, we're seeing referral consolidations. So low-volume surgeons are referring to higher-volume surgeons, essentially passing patients to those who do more. And that also drives up utilization. So there are kind of multiple factors there that have supported the growth. I don't know that it goes on forever. I don't think there's -- if there's growth in utilization, possible. But so far, so good."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got you. And then just lastly, the percent of your applicable procedures that are currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?",39,"Got you. And then just lastly, the percent of your applicable procedures that are currently using the robotic vessel sealer or stapler. Do you have sort of a rough metric of where that stands today that you can share?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some g",110,"Tao, certainly we have seen growth in our vessel sealer and stapler adoption each quarter over the past few years and particularly in procedures where there's a high value associated with using those, whether it be in colorectal resections, even in some gynecologic procedures, vessel sealers. There's still a lot of runway left. And in particular, as you think about the white reloads there only available on our Xi systems at the Xi installed base becomes larger, hoping to have more opportunities for those -- to be used in thoracic procedures. There's going to be plenty of runway ahead as the installed base continues to move towards our newest technology."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","You don't have a procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?",24,"You don't have a procedure -- sorry, a percent that you can share just to get a sense of how [indiscernible] runway is?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Not at this time.",4,"Not at this time."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","And the next question is from the line of Richard Newitter of Leerink Partners.",14,"And the next question is from the line of Richard Newitter of Leerink Partners."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to know is",88,"I just had a quick one follow-up on your table motion. It sounds like that product is certainly gaining traction. And I was just curious to know, is this feature being used in the way that you would have expected it to? And what I'd really like to know is, do you think or can you tell us what procedures or new incremental procedures does this potentially open up for you? Or could you begin to see it open up where you aren't already being used today?"
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something",186,"Yes. I think that early experience has been that it's a well-received, particularly by multi-quadrant general surgeons, which is really where Xi was positioned and one of the big motivations for table motion. As frequently happens in the space, something that's a fundamental capability that's good in one place tends to have application in others, and I suspect we'll see that. And as we get more data on it, we're happy to share it with you. 
That was our last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flows during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. This concludes today's call. I thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months. Thank you."
30239,365727306,1008817,"Intuitive Surgical, Inc., Q2 2016 Earnings Call, Jul 19, 2016",2016-07-19,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect.",25,"Okay, thank you. That concludes our conference for today. Thank you for your participation and for using AT&T Executive TeleConference service. You may now disconnect."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Se",51,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance a",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on July 20, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third quarter financial results. Patrick will discuss procedure and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. Global procedural growth was over 14% year-over-year in th",951,"Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. 
Global procedural growth was over 14% year-over-year in the quarter. Drivers of growth centered on U.S. general surgery and growth in the use of da Vinci Surgical Systems outside the United States. In the United States, year-over-year growth in ventral and inguinal hernia repair continues to be strong. U.S. colon resection and lung resection also contributed to solid growth. As we've stated in prior calls, we are expecting growth rates in mature procedures in the U.S. to moderate, and U.S. EBP is starting to follow this pattern, driven by the macroeconomic environment for prostate cancer diagnosis and treatment. 
In Europe, procedure growth tempered in the quarter, with some countries posting solid performance while growth softened in others. 
We're pleased with growth in procedures in Asia, with Korea and China, in particular, demonstrating continued strength. Patrick will review procedure trends in greater detail later in the call. 
We placed 134 da Vinci systems in the quarter, up from 117 in Q3 of 2015. While we offer a range of models and price points, our most capable model, da Vinci Xi, again represented roughly 3/4 of new capital placements. As we've said on previous calls, capital placements are lumpy, and this quarter was no exception. 
Healthy placements stood out in the U.S., while placements in our European regions softened relative to a year ago. Capital placements in Asia are particularly unpredictable, given environment constraints like reimbursements in Japan and quotas in China. Placements in Asia were in line with prior quarters. 
Turning to revenue and gross margin dynamics. We experienced some onetime tailwinds in the quarter that contributed to higher-than-expected net income. Marshall will take you through these events and our general finances in greater detail later in the call. 
Turning to highlights of our third quarter operating results. Procedures grew approximately 14% over the fourth -- third quarter of last year. We shipped 134 da Vinci Surgical Systems, up from 117 in the third quarter of 2015. Revenue for the quarter was $683 million, up 16% from the prior year. Pro forma gross profit margin was 73.1% compared to 16 -- 69.3% in the third quarter of last year. Instrument and accessory revenue increased to $348 million, up 17%. Total recurring revenue in the quarter was $478 million, representing 70% of total revenue. We generated a pro forma operating profit of $308 million in the quarter, up 28% from the third quarter of last year. And pro forma net income was $246 million, up 23% from Q3 of 2015. 
As we discussed with you on our last call, as our businesses strengthened, we have increased our mid- and long-term investments in creating our next generation of products and services. We've been increasing these investments based on our belief that our -- that substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. 
We continue to enhance features and expand access to our Xi suite of instruments, accessories and imaging products. In the third quarter, we added the ability to ship Xi Single-Site, Xi 30-millimeter stapler and Firefly to several countries. In addition, interoperative table motion uptake and performance is meeting our expectations. We are continuing to invest in the expansion and refinement of our base instrument, stapling and vessel sealing products for our Xi platform. 
New system platforms continue to make good progress. Our da Vinci single port is progressing in its in-house clinical evaluations and preparations for human clinical trials expected later this quarter. As we've discussed on our prior calls, we plan first markets to include head and neck surgery, urology and colorectal surgery. 
SP is a platform technology that allows high-dexterity access with great 3D vision to confined surgical spaces. Commentary by surgeons after in-house evaluations have indicated strong interest in the clinical potential of this platform. 
In the quarter, we also announced the creation of a joint venture with Fosun Pharma, owner of our current da Vinci partner in China. The JV's first objectives are to work with ISI and Fosun to produce products that address an acute need in the diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection and treatment are important. 
The technology underpinning the system is based on computer-controlled catheters, advanced image processing and sophisticated sensing. It incorporates a substantial set of proprietary intellectual property developed, owned or licensed by Intuitive over the past several years. This system is in its early stages of our human clinical experience, and final clearance and launch targets are not yet set. That said, the raw capability of the technology is compelling, and it has the potential to perform as a broader diagnostic and treatment platform over time. 
Bringing new platforms to the market represents a significant investment. We've added approximately 400 employees year-to-date and expect increased fixed investments and some lumpiness in spending in future quarters as these platforms move through design, validation, data collection and early launch. 
As we close 2016, we have focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including new clearances, additional clinical and economic validation, training centers and the expansion of our product offerings; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who'll review financial highlights."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1305,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. 
We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
Third quarter 2016 revenue was $683 million, an increase of 16% compared with $590 million for the third quarter of 2015 and an increase of 2% compared with the second quarter revenue of $670 million. Third quarter 2016 procedures increased 14% compared with the third quarter of 2015 and decreased 1% compared with last quarter. Procedure growth relative to last year has been driven by general surgery in the U.S. and urology worldwide. The decrease relative to the prior quarter primarily reflects seasonality. 
Revenue highlights are as follows.  Instrument and accessory revenue of $348 million increased 17% compared with last year and increased 3% compared with the second quarter of 2016. Growth in instruments and accessory revenue generally reflects procedure growth and increased sales of stapling and vessel sealing products. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,870 per procedure compared with $1,840 last year and $1,810 last quarter. The increase is relative to the third quarter of 2015 and last quarter reflects increased sales for stapling and vessel sealing products. The increase compared to the second quarter of 2016 also reflects the impact of customer buying patterns. 
System revenue of $205 million increased 18% compared with the third quarter of 2015 and increased 1% compared with last quarter. The year-over-year and quarter-over-quarter increases reflect higher system placements and higher revenue associated with lease buyouts, partially offset by lower average system selling prices. 
We generated approximately $13 million of revenue during the quarter from lease buyouts compared with $3 million in the third quarter of 2015 and $13 million last quarter. While lease buyouts are difficult to predict, we expect the level of fourth quarter lease buyouts to be below those of the third quarter.
134 systems were placed in the third quarter of 2016 compared with 117 systems in the third quarter of 2015 and 130 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 15 last quarter and 13 systems in the third quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the third quarter, there were 74 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $2 million in the third quarter of 2015 and approximately $4 million last quarter. We excluded the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system price was $1.53 million compared with $1.61 million last year and $1.56 million last quarter. The decreases compared with prior periods primarily reflect a lower mix of dual console systems, partially offset by a lower mix of trade-in systems in the third quarter of 2016. 
Service revenue of $130 million increased 10% year-over-year and increased approximately 1% compared with the second quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows. Third quarter revenue outside of the U.S. of $189 million increased 25% compared with $151 million for the third quarter of 2015 and increased 2% compared with $185 million for the second quarter. The increase compared with the previous year is comprised of a 26% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 24%. The increase compared to the second quarter reflects systems revenue growth of 2% and recurring revenue growth of 2% in a seasonally slower quarter. 
Outside the U.S., we placed 49 systems in the third quarter compared with 37 in the third quarter of 2015 and 51 systems last quarter. 
Current quarter system sales included 18 into Europe, 2 into China 11 into Japan and 18 in the rest of world markets. System placements outside of the U.S. will continue to be lumpy as some of the OUS markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns. And sales into some markets are constrained by government regulation.
Moving on to the remainder of the P&L. Pro forma gross margin for the third quarter of 2016 was 73.1% compared with 69.3% for the third quarter of 2015 and 71.9% for the second quarter of 2016. 
The pro forma gross margin for the third quarter of 2016 included $7.1 million of Medical Device Tax refunds. Without the Medical Device Tax refunds, our pro forma gross margin would have been the same as the second quarter or 72%. 
Compared with the third quarter of 2015, the higher gross margin reflects reduced product costs, the Medical Device Tax refunds and manufacturing efficiencies. 
Future margins will fluctuate based on the mix of our newer products, the mix of system and instrument and accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs and improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 14% compared with the third quarter of 2015 and increased approximately $6 million compared with last quarter. The increases reflect increased headcount, increased product development activities and investments in our OUS commercial organization. 
We added over 400 employees, primarily into product operations area, over the past year. The increase compared with the prior quarter primarily reflects increased headcount costs. 
Our pro forma effective tax rate for the third quarter was 22.7% compared with an effective rate of 18.4% for the third quarter of 2015 and 27.8% last quarter. The pro forma third quarter of 2016 tax rate reflected $16 million of tax benefits or $0.40 per share realized as a result of the statute limitation expirations in various jurisdictions. The third quarter of 2015 tax rate reflected $29 million or $0.77 per share related to a favorable tax court ruling involving an independent third party.  Our tax rate will fluctuate with changes in the mix of OUS and U.S. income and with the impact of one-time items. 
Our third quarter 2016 pro forma net income was $246 million or $6.19 per share compared with $199 million or $5.24 per share for the third quarter of 2015 and $220 million or $5.62 per share for the second quarter of 2016. 
Excluding onetime income tax and Medical Device Tax benefits, pro forma net income would have been $225 million or $5.65 per share.
As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results. 
GAAP net income was $211 million or $5.31 per share for the third quarter of 2016 compared with $167 million or $4.40 per share for the third quarter of 2015 and $185 million or $4.71 per share for the second quarter of 2016. 
We ended the quarter with cash and investments of $4.6 billion, up from $4.2 billion as of June 30, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. During the first 3 quarters of 2016, global procedure growth was nearly 16%. In",986,"Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. 
During the first 3 quarters of 2016, global procedure growth was nearly 16%. In the United States, taken together, growth in our mature procedures slowed in the third quarter compared to the first half of the year. General and thoracic procedure growth remained healthy. 
In U.S. urology, third quarter growth in da Vinci Prostatectomy slowed to low single-digit growth, a level that we believe to be similar to the overall rate of diagnoses of new prostate cancers. We believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market. 
In U.S. gynecology, third quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Procedures for benign gynecologic conditions grew modestly during the third quarter, continuing a trend from the first half of the year. 
Third quarter U.S. general and thoracic surgery procedure adoption remained strong, led by solid growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and existing surgeon retention and utilization remains encouraging. 
Cholecystectomy procedures declined in the quarter, with growth in multi-port procedures being offset by declines in Single-Site procedures. Early-stage adoption of lobectomies and other thoracic procedures is encouraging. 
Last month, at the global symposium on robotic-assisted and minimally invasive hernia repair, several new data sets comparing da Vinci to open and laparoscopic hernia repair were presented. Among the most notable presentation, Dr. Rosen from the Cleveland Clinic, presented new data on retromuscular ventral hernia repair from the American Hernia Society's Quality Collaborative or the AHSQC. 
In a prospective cohort of more than 400 patients, case match between da Vinci and open surgery, da Vinci surgery was shown to reduce the length of hospitalization by 2.5 days compared to open surgery, with similar levels of wound outcomes, readmissions and reoperations. Intuitive is a founding partner of AHSQC and we are supporting its expansion to include data for inguinal hernia repair. 
Turning abroad. Procedure growth outside of the United States was approximately 25% in the third quarter, led by the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures. Total procedure growth in Europe and Asia was similar to the first half of the year, though procedure performance varied by country.  Strong growth continued in China, South Korea, Japan and Germany. 
While adoption of da Vinci in urology is the primary driver of procedure growth outside of the United States, we are seeing multi-specialty adoption in certain countries. In China, roughly half of the year-to-date procedure growth has come from categories outside of urology. In South Korea, approximately 60% of the year-to-date procedures have come from categories outside of urology. 
We are investing in the development of clinical evidence to support the adoption of da Vinci surgery in markets around the world. Globally, we support several evidence initiatives and registries, including AHSQC, gynecologic oncology societal Registries in the U.S. and Europe and the colorectal registry in Europe. In the U.S., we are also supporting several comparative prospective and retrospective multicenter studies on hernia repair, colorectal surgery and thoracic surgery. Outside of the United States, we are sponsoring clinical studies in Japan to support reimbursements submissions for malignant hysterectomy and gastrectomy. In Europe, we provide support for studies in colorectal, thoracic and gynecological oncology. We are committed to developing evidence in key markets to support the adoption of da Vinci surgery where our technology can bring value to hospitals, surgeons, patients. 
Third quarter was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I've selected a few studies that you may find interesting. Dr. [indiscernible] and colleagues from Indiana University published a study in Surgical Endoscopy comparing da Vinci to laparoscopic colorectal procedures captured in the American College of Surgeons' national surgical quality improvement project or inscript database from 2011 through 2014. Including over 27,000 procedures across a range of colorectal resections, in exchange for approximately 45-minute longer operative time, da Vinci low anterior sections and right [indiscernible] showed a reduction in conversion rates. Left colectomies trended towards a reduction in conversion rates without statistical significance. Low anterior resections also showed a lower rate of sepsis with a higher rate of [indiscernible]. Across all cohorts, da Vinci surgery generated a reduction in length of hospital stay. 
The next study was published by Dr. Osman and colleagues from the University in Istanbul, Turkey, in the General of Surgical Laparoscopy, Endoscopy and Percutaneous Technologies. In the small case series, the author continues their performance in rectal resections on da Vinci Xi to da Vinci SI. They found that da Vinci Xi was associated with an approximate 40 minutes of reduced operative time. The reduction in operative time was attributable to an elimination of double docking and hybrid surgeries and the da Vinci Xi cohort. The surgeons also found that da Vinci Xi patient population experienced an increase in lymph nodes harvested and quicker return of [indiscernible] function with a 1 day longer length of hospital stay. The authors concluded ""The Xi generation appeared to allow short consult times, and its broader capabilities promise to make it a lot easier for surgeons to perform this complex robotic procedure."" 
While this study highlights the enhanced capabilities of da Vinci Xi per multi quadrant surgery such as rectal resection, our da Vinci SI installed bases remained stable in 2016 as customers continue to find value in its utilization. Taken together, procedures performed on da Vinci Si and Xi platforms represented over 95% of our third quarter procedures. 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015.",525,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016. 
Starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015. Now as we enter the fourth quarter, we continue to forecast full year procedure growth of 14% to 15%, likely towards the higher end of the range. 
With regard to Q4 2016 system placements, we directionally expect system placements for the quarter to follow recent seasonal trends. However, we anticipate system placements outside of the U.S. will continue to be lumpy as some of our U.S., OUS markets are in early stages of adoption and sales into some markets are constrained by government regulations. Recall, we placed 13 systems into China and 7 systems into Brazil in the fourth quarter of 2015. As the quota in China expired in 2015 and a new quota has not yet been issued, and as we are in the very early stages of adoption in Brazil, we do not expect comparables and placements into these markets in the fourth quarter of 2016. 
Also, we believe that the flexibility we have offered customers in the form of operating leases has been well received. As a result, as compared to prior periods, we expect a higher proportion of Q4 2016 placements to be under operating leases, with revenue recognized in future periods. 
Finally, we expect to see a lower number of lease buyouts in the fourth quarter compared to the previous 2 quarters, given the lower number of short-term leases that are outstanding at this time. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. We now expect our full year 2016 pro forma gross profit margin to be approximately 71.5% of net revenue. As Marshall indicated, the third quarter benefited from a $7.1 million Medical Device Tax refund. Excluding that benefit, our gross profit margin would have been 72%. We expect our fourth quarter margin to be directionally lower than the third quarter, primarily due to product mix. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will continue to accelerate. On our last call, we forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels. We are now refining this range to 13% to 14%. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015.
We expect other income to total approximately $33 million in 2016, higher than the $30 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, consistent with previous guidance, we expect our Q4 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America.",15,"[Operator Instructions] 
That will come from the line of Bob Hopkins from Bank of America."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I had 2 questions. First for Marshall, just to clarify a couple of things that were mentioned relating to the fourth [ph] quarter and then a question for Gary on the [indiscernible] agreement. But Marshall, I'll start with you. Just 2 quick clarificati",84,"So I had 2 questions. First for Marshall, just to clarify a couple of things that were mentioned relating to the fourth [ph] quarter and then a question for Gary on the [indiscernible] agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on the Medical Device Tax and the $7 million, could you explain why that is one-time? And then on the system sales guidance that you're providing, is that essentially suggesting that systems will be globally roughly flat in Q4?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. So the Medical Device Tax is the result -- refund is the result of -- when you originally compute the tax, there is some subjective areas, and we modified what we have previously filed. So we get a one-time refund and it's over. And they have -",122,"Yes, sure. So the Medical Device Tax is the result -- refund is the result of -- when you originally compute the tax, there is some subjective areas, and we modified what we have previously filed. So we get a one-time refund and it's over. And they have -- we've received the money, and there has been an audit. So we're all done with that. Second question has to do with the level of systems. I think what Calvin said was that the systems are seasonally stronger in Q4. What he was trying to set up, however, was that relative to the prior year, there's some hard comparables, given that we had some markets that are rather lumpy like China and Brazil."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Second question on [indiscernible]. I think Bob had a question on [indiscernible] before he got to us.",17,"Second question on [indiscernible]. I think Bob had a question on [indiscernible] before he got to us."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I just was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more",101,"So I just was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more color on what this is. Like, is this a new totally new system or just an add-on to Xi? Just should we think about it as being a couple of years away from commercialization? Or is it really longer-term project? I'm just sort of wondering if you could provide some perspective."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I'll give a little bit of an overview. We'll, of course, give you additional detail in the coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with",225,"I'll give a little bit of an overview. We'll, of course, give you additional detail in the coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with some special sensing technologies and some image analysis. Currently, the current configuration it's in, it's a stand-alone. Those types of technologies in the future could be integrated into other things, and we won't preclude ourselves from doing that. We do conceive of it as a way to access the body through natural orifices and other means, where you want to follow up a prescribed pathway to get to some deep place in the body and do something. Our first clinical interest is in biopsing lung cancers or biopsing suspicious lesions in the lung. We think that, that is important globally and particularly important in China. And as a result, the partnership with Fosun, who we've known through their [indiscernible] company for many years, made a lot of sense to us. And we're excited about it. We're not ready to give you commercial timelines yet. The technology is mature enough that we're in our initial human clinical experience. That's really the very beginnings for us. And as we get greater clarity on our launch timelines and thoughts, we'll share them with you."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Now we'll go to the line of David Lewis with Morgan Stanley.",13,"Now we'll go to the line of David Lewis with Morgan Stanley."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I you want to start a strategic question and maybe have 2 follow-up questions. It's great to be on this call, actually, the Intuitive story sort of poised for pretty significant change. I really think Intuitive has really been about one system. I kn",165,"Gary, I you want to start a strategic question and maybe have 2 follow-up questions. It's great to be on this call, actually, the Intuitive story sort of poised for pretty significant change. I really think Intuitive has really been about one system. I know you have multiple configurations, but in this quarter alone, Xi was still 75% of new placements. But if I think about the next 2 years, right, you're still going to have Xi and all those multiple Intuitive prior systems, you have XSP, and you're also now going to have this catheter-based sensing systems. So I wonder if you could help us understand you, are we right about this company as morphing these next 2 years? And how do these support sort of multiple platforms now, impact the addressable markets you can serve, your ability to accelerate growth and, obviously, just flat out R&D spending across these platforms? I know it's a big question, but I think it's an important one."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, fair enough. I think, as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional",316,"Yes, fair enough. I think, as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional technologies, open surgery, conventional laparoscopy or with Xi. So we think SP can broaden clinically what surgeons can do. I think that will start in niches and then will move out into broader applications as we gain clinical experience. It does increase our support load a little bit in terms of complexity with regard to the SP just because it's a new set of instruments and add-on accessories. But it's not an entirely new set of compositional platform and things like that. As you start thinking about that catheter-based technologies, again, that's a new set of technologies. You had kind of framed it in 2-year horizon. I would stretch that horizon out a little bit. I wouldn't anchor us there. I do think that takes us to different places. I think it allows access to parts of the body that you may not think of surgically. It may be more around diagnostics. And I think it will open up to practitioners' ways of approaching tissue that they just haven't thought about before. And that's why we're doing it. That -- you've seen us increase our R&D spend, and we've been both talking about in doing it. And part of it has been investing in these technologies. And I think it matters. I think as people look, as we look from the bottom of your feet to the top of you had to look for opportunities to get better outcomes, we think of a variety of technologies from access technologies to imaging technologies to computational technologies that can lower and make a difference, and that's where we're putting our mouth is."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and, frankly, kind of extraordinary. So as you head into '17, some of the comments you made, I don't",129,"And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and, frankly, kind of extraordinary. So as you head into '17, some of the comments you made, I don't think it's realistic for investors to expect 200 basis points of margin expansion in '17. Based on your comments on spending in which are going to have to just support these platforms, I mean, how should we sort of calibrate our thinking next year between sort of an extraordinary 2016 expansion and a more moderate 2015 margin expansion? Should we be thinking about something between those 2 poles [ph] as more appropriate than what we are seeing this year, which seems very outsized?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Clearly, we'll give you guidance in January of what 2017 is going to look like. But some of the variables that could occur, obviously, have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins and ex",163,"Clearly, we'll give you guidance in January of what 2017 is going to look like. But some of the variables that could occur, obviously, have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins and existing products. And so if there were -- as we introduce stapling, for example, we saw the decline in margins initially. As we approved the manufacturability and efficiency in the manufacturing process as we see improvement in markets. So I'm not going to predict what we're going to do next year. I'd just say that there are a lot of moving parts. Mix geographically also has an impact. Mix between systems and instruments and accessories has an impact. There's just a lot of variables that go into it. I think what you've seen this last year, though, is outstanding performance by our manufacturing group to reduce the costs of newer products that were lower margin a year ago."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just curious, just quickly lastly, on the ex-U.S. business on systems, I think the commentary on Brazil so and China, those seem kind of very short term in nature. Eventually, those tend to get raised. But in terms of the European business,",68,"Okay. And then just curious, just quickly lastly, on the ex-U.S. business on systems, I think the commentary on Brazil so and China, those seem kind of very short term in nature. Eventually, those tend to get raised. But in terms of the European business, did you see any impact from Brexit? Or do you just think this is a lumpiness that always occurs generally in your business?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think, the dynamics in U.K. in particular, it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there, AHS any anyway, tha",132,"Yes, I think, the dynamics in U.K. in particular, it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there, AHS any anyway, that AHS England has been looking at how to spend their money and try to cover budget shortfalls. So there's been pressure there for some time of Brexit likely doesn't help. With regard to Europe more broadly, it really is varying country-by-country. Some cases, we see reasonable growth and support other. Countries have been a little bit more of a struggle. And the response that really has been to increase our local presence, increase local data generation and be in close contact with government payers and private payers."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Tycho Peterson with JPMorgan.",12,"Next we'll go to the line of Tycho Peterson with JPMorgan."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I actually want to follow up on Dave's question on margins. As we think about the XI experience and the impact that had a gross margins, as we think forward to SP, is that a fair proxy in terms of magnitude of the impact on gross margin when that does rol",53,"I actually want to follow up on Dave's question on margins. As we think about the XI experience and the impact that had a gross margins, as we think forward to SP, is that a fair proxy in terms of magnitude of the impact on gross margin when that does roll out?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We're not at the stage where we've introduced a product that we're manufacturing them in bulk. But I think it's fair to say that SP's margins will be lower than our existing product portfolio. And it will work on it as we both over time and try to reduce",52,"We're not at the stage where we've introduced a product that we're manufacturing them in bulk. But I think it's fair to say that SP's margins will be lower than our existing product portfolio. And it will work on it as we both over time and try to reduce those costs."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of lunch, lower overall",66,"But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of lunch, lower overall quantities. So just based on magnitude, it's probably not going to have as big an impact on the overall margin."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Understood. And then can you comment on trade-ins? I know you called out in the footnotes. You've had 58 U.S., highest number ever. Just kind of a onetime thing any kind of went back and scrub the systems in the field?",41,"Understood. And then can you comment on trade-ins? I know you called out in the footnotes. You've had 58 U.S., highest number ever. Just kind of a onetime thing any kind of went back and scrub the systems in the field?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there was a footnote within our data table that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, w",122,"Yes, there was a footnote within our data table that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, weed perform the verification audit out of our installed base records, which identified 43 system, mostly older standard of S models, which have been retired. So we went and removed those retired systems from our installed base during the quarter. So I think the trade-out number was 33, and then most of the rest here was just kind of this adjustment we made to the base. So the trade-ins were pretty, I think, in line with previous periods."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Last one, I'll ask if we can capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but maybe just talk a little bit about capital deployment at this point.",37,"Okay. Last one, I'll ask if we can capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but maybe just talk a little bit about capital deployment at this point."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. I think, we think about capital deployment consistent with how we've talked about it before. We're in a period where there is now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. We're",159,"Yes, sure. I think, we think about capital deployment consistent with how we've talked about it before. We're in a period where there is now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. We're also that the additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products. And those technologies, it's nice to do tuck-ins and small licensing arrangements that we've done in the past, and we'll try to do those. But maybe we have to buy, to pay a greater dollar to get some of that technology in the future. So we want to have money for those things. Beyond that, to the extent that we have the right opportunity to buy back stock and return shares -- money to shareholders, we'll take that opportunity. But we'll do that opportunistically as we have in the past."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Ben Andrew with William Blair.",12,"Next, we'll go to the line of Ben Andrew with William Blair."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, looking at the relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of a second piece of that, from a regulatory perspective, what sort of time frames would you be looking",71,"Gary, looking at the relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of a second piece of that, from a regulatory perspective, what sort of time frames would you be looking at to get something through once you've finished developments and you've done some human testing through approval? Is it quicker there? Or is it similar to this U.S.?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the first question, I think, in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various pro",96,"Yes, on the first question, I think, in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various products in China, typically, in our past, it's been a little bit longer process than it has in the U.S. What that looks like going forward, in particular, for the new products we're talking about, I can't speak to it at this time. We just don't have enough information on it."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then you talked about international procedures being up about 25%, which is a strong number. But I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particular geographic pattern there? Was China demonstrably",61,"Okay. And then you talked about international procedures being up about 25%, which is a strong number. But I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particular geographic pattern there? Was China demonstrably or that plus the RW placements sort of got my attention relative to some emerging opportunities overseas."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Ben, this is Patrick. In certain international markets, we are deeply penetrated in urology. And where you have seen those penetration rates increase overtime, the rate of growth has decelerated and emerging procedures things colorectal and gynecology are",61,"Ben, this is Patrick. In certain international markets, we are deeply penetrated in urology. And where you have seen those penetration rates increase overtime, the rate of growth has decelerated and emerging procedures things colorectal and gynecology are still very small. So countries like the Nordic countries places like U.K. where we are pretty deep, you see those growth rates low."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And there's maybe for Patrick as well, but a competitive this morning talked about seeing some other general surgeries cases calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in herni",185,"Okay. And there's maybe for Patrick as well, but a competitive this morning talked about seeing some other general surgeries cases calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in hernia and kind of the trajectory of adoption relative to some of the historical adopting procedures, if you would.
Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population as they continue to do more procedures has been a strong point and the way in which the technology is going to be adopted. Now hernia repairs was not one thing. So there's a variety of patients subsets within, variety of different physician perspectives around the value that our technology can bring into the procedure. And so it's probably not quite like DPB in terms of the way you would think of it is been adopted, maybe a little more benign hysterectomy, given the alternative therapies and the heterogeneous landscape out there in terms of how they address these patients."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then last question for me, I guess, is the question, it's around the I&A, the revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there. But was oth",66,"Okay. And then last question for me, I guess, is the question, it's around the I&A, the revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there. But was other than stapling and sealing, was there anything in particular in there that caught your attention relative to the mix?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just kind of given a little historical perspective. If you look at prior to Q2 of 2016, our I&A revenue per procedure has been running within our really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actuall",226,"Yes, just kind of given a little historical perspective. If you look at prior to Q2 of 2016, our I&A revenue per procedure has been running within our really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actually dropped down to $1,810, and we talked about timing of orders being the main factor here. So as expected here in Q3, we saw orders rebound to offset Q2. And if you take the average of Q2 and Q3 right back at the $1,840, kind of in line with those trends over the past couple of years. As we said, though, we continue to see increasing utilization of the advanced instruments, including those stapler and vessel sealer. And moving forward as we anticipate continued growth in the procedure volumes in colorectal and thoracic surgery, areas where these products are more widely used, we would anticipate a slightly higher contribution to revenue per procedure on an organic consumption model, if you will. But it's important to remember that a variety of factors impact revenue per procedure, including the type or procedure performed, the efficiency of use and optimization, use of advanced instruments, stocking orders, timing and distributors. So there's a lot of factors here. So as a result, I&A can be lumpy, and future trends can be difficult to forecast in the end."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Amit Hazan with Citi.",12,"Next we'll go to the line of Amit Hazan with Citi."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for GDP, all the way down to low single digits, it sounds like, for this quarter. It's a pretty fast change and it w",101,"Maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for GDP, all the way down to low single digits, it sounds like, for this quarter. It's a pretty fast change and it would otherwise be something that will be slower trend line. Any more color you can add as to [indiscernible] why it's happening and maybe, more importantly, just the confidence you guys have that this quarter kind of marched that bottom and that incident rate growth is kind of your right way to throw for prostate."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedures like DPB is difficult. And we highlighted for peer to Tao the growth that we've seen with our rates growth that we thought were consistent wi",112,"Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedures like DPB is difficult. And we highlighted for peer to Tao the growth that we've seen with our rates growth that we thought were consistent with the rate of diagnoses. It's hard to say in a quarter where the rate at which we've seen growth change over the course of this year. The specifics behind it, the data you take typically comes to us years down the road. But we feel that what we saw in the quarter is probably more consistent diagnoses than perhaps what we've seen over the past handful of quarters."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to maybe ask this in a while, but throw this qu",122,"Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to maybe ask this in a while, but throw this question out, just one possible avenue. Just thinking about out-patient centers, ambulatory surgery centers, is there to what extent is there kind of an increase in the success that you're having in being able to place da Vinci outpatient centers? Is that becoming a focus for you at all? Or is that at all a part of maybe the slightly better rate of growth we're seeing in gynecology in the U.S?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think you're connecting 2 things I'm not sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher volume surgeons and higher volume centers. S",124,"Yes. So I think you're connecting 2 things I'm not sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher volume surgeons and higher volume centers. Separately, there is a trend toward a more out-patient work. We do see utilization of our systems in out-patient environments that tends to be more in existing integrated delivery networks, possibly out-patient departments as part of integrated plan. It's not something I'd call out as a major trend at this point. I'm not sure that I would quite blanket to GYN. It's possible, but I think there are a lot of factors there that sorting them is not possible yet."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","If you look at GYN overall and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery in the benign hysterectomy has enabled the majority of patients to now be treated on an out-patient basis. So minimally invasive surge",63,"If you look at GYN overall and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery in the benign hysterectomy has enabled the majority of patients to now be treated on an out-patient basis. So minimally invasive surgery is adopted with our technology. It will enable hospitals to manage these patients in a more out-patient oriented way."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","One last question for me on the system side. Just thinking through not just the fourth quarter, which is a little bit longer term, '17 if you want. But thinking about the installed base. Just really consistently growing about, 10% a year, with every quart",100,"One last question for me on the system side. Just thinking through not just the fourth quarter, which is a little bit longer term, '17 if you want. But thinking about the installed base. Just really consistently growing about, 10% a year, with every quarter since the grows about 10 -- on that 10% rate on an annual basis. Can you maybe just talk through the key drivers and maybe pressure points as we think about that number and the sustainability of that 10% growth in the installed base growth figure as we think through the next year or 2?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A couple of -- I think about it kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest",132,"A couple of -- I think about it kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest driver and where they see growth, I think, that they move forward. The places where that can be a little bit different or disconnected is in a very early market where you're just getting started. So a new reimbursement clearance or a new quote or a new procedure clearance doesn't follow a more mature trend. So those are the 2 things that are rolling around. I think the biggest one for us is customer belief, and utilization for future procedures as the best predictor of capital."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Rick Wise from Stifel, Nicolaus.",13,"Next we'll go to the line of Rick Wise from Stifel, Nicolaus."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, just maybe just going back to [indiscernible] briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and viable it is to Intuitive. Are there other similar opportunities to [indiscernible],",76,"Gary, just maybe just going back to [indiscernible] briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and viable it is to Intuitive. Are there other similar opportunities to [indiscernible], whether it be geographic or technology? Or I mean, is this a direction we should expect Intuitive to push looking for other technologies to bring into the ecosystem? Is that the right way to think about it?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think the idea that if there are technologies or other assets that we can bring, that we think will increase the value of robotic surgery program or a minimally invasive surgery program based on a computation to one of our customers, is that an opportun",136,"I think the idea that if there are technologies or other assets that we can bring, that we think will increase the value of robotic surgery program or a minimally invasive surgery program based on a computation to one of our customers, is that an opportunity for? Yes. They tend to develop in time. The underlying catheter-based technologies that we're talking about now, as you know, having followed us for some time, were really first acquired by us years ago. So the answer to that, yes, we're outlooking. Fosun has been a good partner. They have both a relationship with us through each [indiscernible], but they also understand the health care space extremely well in multiple dimensions. And so the short answer to that is we've been doing it and expect to continue to do it."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","A couple of more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings or early innings r",71,"A couple of more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings or early innings rather? And maybe particularly on colorectal, how do accelerate colorectal adoption? Do we need more clinical data? Can you talk through some of those issues?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So as we said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's la",225,"Sure. So as we said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's large value, distinct value for the procedure relative to alternatives and when the procedure is pretty will concentrated in the hands of well-trained surgeons. So take colorectal and separate it a little bit. In the case of rectal cancer, that's a complex set of procedures. Oncologic, of course, in nature, has been growing steadily. Not a super rapid rise relative to some prior adoptions but a steady adoption for us year. And data collection has been occurring. Data publication has been occurring. And we're doing okay there. I think in other parts of colon, sometimes it's for benign, sometimes it's in oncology. Those are typically done by different surgeons. And so they adopt a look at different rates. You look at hernia again, it's subsegmented, ventral hernia versus inguinal in some segments within inguinal. So we look at it. Ventral hernia and inguinal hernia, as we define the available markets for procedures for which we bring value, have adopted pretty nicely relative to past trends. Rectal has been on a slower adoption but a steady one. And colon is in the middle."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slow growth. Rebounded gynecology recovering. General surgery continuing to grow dramatically. We wrote that math with what we're",85,"And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slow growth. Rebounded gynecology recovering. General surgery continuing to grow dramatically. We wrote that math with what we're seeing internationally. Should we feel reasonably optimistic that something like mid-teens procedure growth, again with some variation, is that the right sustainable growth rate from here, given the growing installed base, given the geographic penetration and given the continuing evolution of Intuitive technology?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, we're not ready to give of our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January.",38,"Yes, we're not ready to give of our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We'll go to the line of Larry Biegelsen with Wells Fargo.",12,"We'll go to the line of Larry Biegelsen with Wells Fargo."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -",73,"So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -- sounds like -- is that a good rate to use going forward? And I had a couple of follow-ups."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's going to be variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We talk a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for interna",86,"Yes. There's going to be variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We talk a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for international to support the earlier phase growth there. So you look at it overall, we're within our guidance range. We refined our full year guidance to that 13% to 14%. So again, there'll be some quarter variability, but I think we're tracking to the overall platform."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which is Calvin walked through.",29,"And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which is Calvin walked through."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it. And when we think about the pipeline and potential launches of new products and functionality, should be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?",34,"Got it. And when we think about the pipeline and potential launches of new products and functionality, should be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, we've been launching a fair amount of interests. Things in various markets. We tend to tell you when they come out. We have not tagged a launch date either for SP or any other kind of major systems at this time.",42,"Well, we've been launching a fair amount of interests. Things in various markets. We tend to tell you when they come out. We have not tagged a launch date either for SP or any other kind of major systems at this time."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ram in ventral versus inguinal or both of them equally strong?",43,"Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ram in ventral versus inguinal or both of them equally strong?"
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything abo",118,"It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything about adoption I'd call out strongly at this time. I think both of them are moving through that first set of adopters, generating additional data. We're seeing more data now generally supportive and looks pretty good. I think that technique refinement and data generation is what the next round of surgeons rely upon to evaluate. And so we're seeing that kind of transition right now, clearly, in both of those hernia domains."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our final question will come from Brandon Henry with RBC Capital Markets.",12,"Our final question will come from Brandon Henry with RBC Capital Markets."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive again posted strong growth and operating margins this quarter. Can you discuss some of the product and that are driving these better margins and then inning you're in, in some of these cost initiatives? And then separately, the company's head",86,"So Intuitive again posted strong growth and operating margins this quarter. Can you discuss some of the product and that are driving these better margins and then inning you're in, in some of these cost initiatives? And then separately, the company's headcount has increased meaningfully over the last couple of quarters. Can you discuss where you're making the investments in headcount and how much of that increase in headcount can be attributed to the Fosun JV versus some other initiatives? And then I have a follow-up."
30239,402358121,1056478,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast there. On the first one in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as",341,"That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast there. On the first one in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it is a routine discipline of scanning through both operating processes and manufacturing processes and parts cost and working them down as they come. You do get the first -- the greatest help on those things in the first few years of a platform release, and then after that, it starts getting increasingly hard. Suffice it to say that it isn't possible to do it. In terms of headcount growth, it's a mixture of commercial growth a little bit more weighted outside the U.S. than U.S., some manufacturing growth to cover volumes of things like instruments and accessories and other things that have been increasing as well as some design help. The headcount growth as it relates to Fosun, we're not really to break out at this time. We have certainly made headcount investment over the last few years into the technologies that have underpinned that relationship. But it's not -- I wouldn't call it out as Fosun just yet. 
With that, I'll go ahead and close the call and will catch your next quarter on the next conference call. So that was the last question. As we've said previously, while we focus on financial metrics such as revenues, profits and cash flow during these conference calls, our organizational focus romance on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Se",51,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance a",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on July 20, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third quarter financial results. Patrick will discuss procedure and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. Global procedural growth was over 14% year-over-year in th",951,"Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. 
Global procedural growth was over 14% year-over-year in the quarter. Drivers of growth centered on U.S. general surgery and growth in the use of da Vinci Surgical Systems outside the United States. In the United States, year-over-year growth in ventral and inguinal hernia repair continues to be strong. U.S. colon resection and lung resection also contributed to solid growth. As we've stated in prior calls, we are expecting growth rates in mature procedures in the U.S. to moderate, and U.S. EBP is starting to follow this pattern, driven by the macroeconomic environment for prostate cancer diagnosis and treatment. 
In Europe, procedure growth tempered in the quarter, with some countries posting solid performance while growth softened in others. 
We're pleased with growth in procedures in Asia, with Korea and China, in particular, demonstrating continued strength. Patrick will review procedure trends in greater detail later in the call. 
We placed 134 da Vinci systems in the quarter, up from 117 in Q3 of 2015. While we offer a range of models and price points, our most capable model, da Vinci Xi, again represented roughly 3/4 of new capital placements. As we've said on previous calls, capital placements are lumpy, and this quarter was no exception. 
Healthy placements stood out in the U.S., while placements in our European regions softened relative to a year ago. Capital placements in Asia are particularly unpredictable, given environment constraints like reimbursements in Japan and quotas in China. Placements in Asia were in line with prior quarters. 
Turning to revenue and gross margin dynamics. We experienced some onetime tailwinds in the quarter that contributed to higher-than-expected net income. Marshall will take you through these events and our general finances in greater detail later in the call. 
Turning to highlights of our third quarter operating results. Procedures grew approximately 14% over the fourth -- third quarter of last year. We shipped 134 da Vinci Surgical Systems, up from 117 in the third quarter of 2015. Revenue for the quarter was $683 million, up 16% from the prior year. Pro forma gross profit margin was 73.1% compared to 16 -- 69.3% in the third quarter of last year. Instrument and accessory revenue increased to $348 million, up 17%. Total recurring revenue in the quarter was $478 million, representing 70% of total revenue. We generated a pro forma operating profit of $308 million in the quarter, up 28% from the third quarter of last year. And pro forma net income was $246 million, up 23% from Q3 of 2015. 
As we discussed with you on our last call, as our businesses strengthened, we have increased our mid- and long-term investments in creating our next generation of products and services. We've been increasing these investments based on our belief that our -- that substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. 
We continue to enhance features and expand access to our Xi suite of instruments, accessories and imaging products. In the third quarter, we added the ability to ship Xi Single-Site, Xi 30-millimeter stapler and Firefly to several countries. In addition, interoperative table motion uptake and performance is meeting our expectations. We are continuing to invest in the expansion and refinement of our base instrument, stapling and vessel sealing products for our Xi platform. 
New system platforms continue to make good progress. Our da Vinci single port is progressing in its in-house clinical evaluations and preparations for human clinical trials expected later this quarter. As we've discussed on our prior calls, we plan first markets to include head and neck surgery, urology and colorectal surgery. 
SP is a platform technology that allows high-dexterity access with great 3D vision to confined surgical spaces. Commentary by surgeons after in-house evaluations have indicated strong interest in the clinical potential of this platform. 
In the quarter, we also announced the creation of a joint venture with Fosun Pharma, owner of our current da Vinci partner in China. The JV's first objectives are to work with ISI and Fosun to produce products that address an acute need in the diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection and treatment are important. 
The technology underpinning the system is based on computer-controlled catheters, advanced image processing and sophisticated sensing. It incorporates a substantial set of proprietary intellectual property developed, owned or licensed by Intuitive over the past several years. This system is in its early stages of our human clinical experience, and final clearance and launch targets are not yet set. That said, the raw capability of the technology is compelling, and it has the potential to perform as a broader diagnostic and treatment platform over time. 
Bringing new platforms to the market represents a significant investment. We've added approximately 400 employees year-to-date and expect increased fixed investments and some lumpiness in spending in future quarters as these platforms move through design, validation, data collection and early launch. 
As we close 2016, we have focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including new clearances, additional clinical and economic validation, training centers and the expansion of our product offerings; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who'll review financial highlights."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1305,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. 
We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
Third quarter 2016 revenue was $683 million, an increase of 16% compared with $590 million for the third quarter of 2015 and an increase of 2% compared with the second quarter revenue of $670 million. Third quarter 2016 procedures increased 14% compared with the third quarter of 2015 and decreased 1% compared with last quarter. Procedure growth relative to last year has been driven by general surgery in the U.S. and urology worldwide. The decrease relative to the prior quarter primarily reflects seasonality. 
Revenue highlights are as follows.  Instrument and accessory revenue of $348 million increased 17% compared with last year and increased 3% compared with the second quarter of 2016. Growth in instruments and accessory revenue generally reflects procedure growth and increased sales of stapling and vessel sealing products. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,870 per procedure compared with $1,840 last year and $1,810 last quarter. The increase is relative to the third quarter of 2015 and last quarter reflects increased sales for stapling and vessel sealing products. The increase compared to the second quarter of 2016 also reflects the impact of customer buying patterns. 
System revenue of $205 million increased 18% compared with the third quarter of 2015 and increased 1% compared with last quarter. The year-over-year and quarter-over-quarter increases reflect higher system placements and higher revenue associated with lease buyouts, partially offset by lower average system selling prices. 
We generated approximately $13 million of revenue during the quarter from lease buyouts compared with $3 million in the third quarter of 2015 and $13 million last quarter. While lease buyouts are difficult to predict, we expect the level of fourth quarter lease buyouts to be below those of the third quarter.
134 systems were placed in the third quarter of 2016 compared with 117 systems in the third quarter of 2015 and 130 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 15 last quarter and 13 systems in the third quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the third quarter, there were 74 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $2 million in the third quarter of 2015 and approximately $4 million last quarter. We excluded the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system price was $1.53 million compared with $1.61 million last year and $1.56 million last quarter. The decreases compared with prior periods primarily reflect a lower mix of dual console systems, partially offset by a lower mix of trade-in systems in the third quarter of 2016. 
Service revenue of $130 million increased 10% year-over-year and increased approximately 1% compared with the second quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows. Third quarter revenue outside of the U.S. of $189 million increased 25% compared with $151 million for the third quarter of 2015 and increased 2% compared with $185 million for the second quarter. The increase compared with the previous year is comprised of a 26% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 24%. The increase compared to the second quarter reflects systems revenue growth of 2% and recurring revenue growth of 2% in a seasonally slower quarter. 
Outside the U.S., we placed 49 systems in the third quarter compared with 37 in the third quarter of 2015 and 51 systems last quarter. 
Current quarter system sales included 18 into Europe, 2 into China 11 into Japan and 18 in the rest of world markets. System placements outside of the U.S. will continue to be lumpy as some of the OUS markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns. And sales into some markets are constrained by government regulation.
Moving on to the remainder of the P&L. Pro forma gross margin for the third quarter of 2016 was 73.1% compared with 69.3% for the third quarter of 2015 and 71.9% for the second quarter of 2016. 
The pro forma gross margin for the third quarter of 2016 included $7.1 million of Medical Device Tax refunds. Without the Medical Device Tax refunds, our pro forma gross margin would have been the same as the second quarter or 72%. 
Compared with the third quarter of 2015, the higher gross margin reflects reduced product costs, the Medical Device Tax refunds and manufacturing efficiencies. 
Future margins will fluctuate based on the mix of our newer products, the mix of system and instrument and accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs and improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 14% compared with the third quarter of 2015 and increased approximately $6 million compared with last quarter. The increases reflect increased headcount, increased product development activities and investments in our OUS commercial organization. 
We added over 400 employees, primarily into product operations area, over the past year. The increase compared with the prior quarter primarily reflects increased headcount costs. 
Our pro forma effective tax rate for the third quarter was 22.7% compared with an effective rate of 18.4% for the third quarter of 2015 and 27.8% last quarter. The pro forma third quarter of 2016 tax rate reflected $16 million of tax benefits or $0.40 per share realized as a result of the statute limitation expirations in various jurisdictions. The third quarter of 2015 tax rate reflected $29 million or $0.77 per share related to a favorable tax court ruling involving an independent third party.  Our tax rate will fluctuate with changes in the mix of OUS and U.S. income and with the impact of onetime items. 
Our third quarter 2016 pro forma net income was $246 million or $6.19 per share compared with $199 million or $5.24 per share for the third quarter of 2015 and $220 million or $5.62 per share for the second quarter of 2016. 
Excluding onetime income tax and Medical Device Tax benefits, pro forma net income would have been $225 million or $5.65 per share.
As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results. 
GAAP net income was $211 million or $5.31 per share for the third quarter of 2016 compared with $167 million or $4.40 per share for the third quarter of 2015 and $185 million or $4.71 per share for the second quarter of 2016. 
We ended the quarter with cash and investments of $4.6 billion, up from $4.2 billion as of June 30, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. During the first 3 quarters of 2016, global procedure growth was nearly 16%. In",995,"Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. 
During the first 3 quarters of 2016, global procedure growth was nearly 16%. In the United States, taken together, growth in our mature procedures slowed in the third quarter compared to the first half of the year. General and thoracic procedure growth remained healthy. 
In U.S. urology, third quarter growth in da Vinci Prostatectomy slowed to low single-digit growth, a level that we believe to be similar to the overall rate of diagnoses of new prostate cancers. We believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market. 
In U.S. gynecology, third quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists during the second quarter. Procedures for benign gynecologic conditions grew modestly during the third quarter, continuing a trend from the first half of the year. 
Third quarter U.S. general and thoracic surgery procedure adoption remained strong, led by solid growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and existing surgeon retention and utilization remains encouraging. 
Cholecystectomy procedures declined in the quarter, with growth in multi-port procedures being offset by declines in Single-Site procedures. Early-stage adoption of lobectomies and other thoracic procedures is encouraging. 
Last month, at the global symposium on robotic-assisted and minimally invasive hernia repair, several new data sets comparing da Vinci to open and laparoscopic hernia repair were presented. Among the most notable presentation, Dr. Rosen from the Cleveland Clinic, presented new data on retromuscular ventral hernia repair from the American Hernia Society's Quality Collaborative or the AHSQC. 
In a prospective cohort of more than 400 patients, case match between da Vinci and open surgery, da Vinci surgery was shown to reduce the length of hospitalization by 2.5 days compared to open surgery, with similar levels of wound outcomes, readmissions and reoperations. Intuitive is a founding partner of AHSQC and we are supporting its expansion to include data for inguinal hernia repair. 
Turning abroad. Procedure growth outside of the United States was approximately 25% in the third quarter, led by the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures. Total procedure growth in Europe and Asia was similar to the first half of the year, though procedure performance varied by country.  Strong growth continued in China, South Korea, Japan and Germany. 
While adoption of da Vinci in urology is the primary driver of procedure growth outside of the United States, we are seeing multi-specialty adoption in certain countries. In China, roughly half of the year-to-date procedure growth has come from categories outside of urology. In South Korea, approximately 60% of the year-to-date procedures have come from categories outside of urology. 
We are investing in the development of clinical evidence to support the adoption of da Vinci surgery in markets around the world. Globally, we support several evidence initiatives and registries, including AHSQC, gynecologic oncology societal registries in the U.S. and Europe, and the colorectal registry in Europe. 
In the U.S., we are also supporting several comparative prospective and retrospective multicenter studies on hernia repair, colorectal surgery and thoracic surgery. Outside of the United States, we are sponsoring clinical studies in Japan to support reimbursement submissions for malignant hysterectomy and gastrectomy. In Europe, we provide support for studies in colorectal, thoracic and gynecological oncology. 
We are committed to developing local evidence in key markets to support the adoption of da Vinci surgery where our technology can bring value to hospitals, surgeons, patients. 
Third quarter was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I've selected a few studies that you may find interesting. Dr. Dalesh [ph] and colleagues from Indiana University published a study in Surgical Endoscopy comparing da Vinci to laparoscopic colorectal procedures captured in the American College of Surgeons' National Surgical Quality Improvement Project or inscript database from 2011 through 2014. 
Including over 27,000 procedures across a range of colon and rectal resections, in exchange for an approximately 45-minute longer operative time, da Vinci low anterior resections and right colectomies showed a reduction in conversion rates. Left colectomies trended towards a reduction in conversion rates without statistical significance. Low anterior resections also showed a lower rate of sepsis with a higher rate of diverting ostomy. Across all cohorts, da Vinci surgery generated a reduction in length of hospital stay. 
The next study was published by Dr. Ozben and colleagues from the Acibadem University in Istanbul, Turkey in the General of Surgical Laparoscopy, Endoscopy and Percutaneous Technologies. In a small case series, the authors compared their performance in performing rectal resections on da Vinci Xi to da Vinci SI. They found that da Vinci Xi was associated with an approximate 40 minutes of reduced operative time. The reduction in operative time was attributable to an elimination of double docking and hybrid surgeries in the da Vinci Xi cohort. The surgeons also found that da Vinci Xi patient population experienced an increase in lymph nodes harvested and quicker return of bowel function with a 1 day longer length of hospital stay. 
The authors concluded ""The Xi generation appeared to allow shorter console times, and its broader capabilities promise to make it a lot easier for surgeons to perform this complex robotic procedure."" 
While this study highlights the enhanced port flow capabilities of da Vinci Xi for multi-quadrant surgery such as rectal resection, our da Vinci SI installed bases remained stable in 2016 as customers continue to find value in its utilization. 
Taken together, procedures performed on da Vinci Si and Xi platforms represented over 95% of our third quarter procedures. 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015.",525,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. 
On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015. Now as we enter the fourth quarter, we continue to forecast full year procedure growth of 14% to 15%, likely towards the higher end of the range. 
With regard to Q4 2016 system placements, we directionally expect system placements for the quarter to follow recent seasonal trends. However, we anticipate system placements outside of the U.S. will continue to be lumpy as some of our U.S., OUS markets are in early stages of adoption and sales into some markets are constrained by government regulations. 
Recall, we placed 13 systems into China and 7 systems into Brazil in the fourth quarter of 2015. As the quota in China expired in 2015 and a new quota has not yet been issued and as we are in the very early stages of adoption in Brazil, we do not expect comparables and placements into these markets in the fourth quarter of 2016. 
Also, we believe that the flexibility we have offered customers in the form of operating leases has been well received. As a result, as compared to prior periods, we expect a higher proportion of Q4 2016 placements to be under operating leases, with revenue recognized in future periods. 
Finally, we expect to see a lower number of lease buyouts in the fourth quarter compared to the previous 2 quarters, given the lower number of short-term leases that are outstanding at this time. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. We now expect our full year 2016 pro forma gross profit margin to be approximately 71.5% of net revenue. 
As Marshall indicated, the third quarter benefited from a $7.1 million Medical Device Tax refund. Excluding that benefit, our gross profit margin would have been 72%. We expect our fourth quarter margin to be directionally lower than the third quarter, primarily due to product mix. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will continue to accelerate. On our last call, we forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels. We are now refining this range to 13% to 14%. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015.
We expect other income to total approximately $33 million in 2016, higher than the $30 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, consistent with previous guidance, we expect our Q4 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America.",15,"[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on",83,"So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on the Medical Device Tax and the $7 million, could you explain why that is onetime? And then on the system sales guidance that you're providing, is that essentially suggesting that systems will be globally roughly flat in Q4?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we have previously filed. So we get a onetime refund, and it's over. And they have",125,"Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we have previously filed. So we get a onetime refund, and it's over. And they have -- we've received the money, and there has been an audit, so we're all done with that. Second question had to do with the level of systems. No, I think that what Calvin said was that the systems are seasonally stronger in Q4. What he was trying to set up, however, was that relative to the prior year, there's some hard comparables, given that we had some markets that are rather lumpy like China and Brazil."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You got a second question on Fosun. I think Bob had a question on Fosun before he got to -- if you still have him. If not, well, come back around in queue.",33,"You got a second question on Fosun. I think Bob had a question on Fosun before he got to -- if you still have him. If not, well, come back around in queue."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little",105,"So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more color on what this is. Like, is this a new -- totally new system or just an add-on to Xi? Just -- should we think about it as being a couple of years away from commercialization? Or is it really a longer-term project? I'm just sort of wondering if you could provide some perspective."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along",226,"Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with some special sensing technologies and some image analysis. Currently -- the current configuration it's in, it's a stand alone. Those types of technologies in the future could be integrated into other things, and we won't preclude ourselves from doing that. We do conceive of it as a way to access the body through natural orifices and other means, where you want to follow a prescribed pathway to get to some deep place in the body and do something. Our first clinical interest is in biopsying lung cancers or biopsying suspicious lesions in the lung. We think that, that is important globally and particularly important in China. And as a result, the partnership with Fosun, who we've known through their Chindex company for many years, made a lot of sense to us. And we're excited about it. We're not ready to give you commercial timelines yet. The technology is mature enough that we're in our initial human clinical experience. That's really the very beginnings for us, and as we get greater clarity on our launch timelines and thoughts, we'll share them with you."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Now we'll go to the line of David Lewis with Morgan Stanley.",13,"Now we'll go to the line of David Lewis with Morgan Stanley."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I you want to start with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has usu",172,"Gary, I you want to start with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has usually been about one system. I know you have multiple configurations, but in this quarter alone, Xi was still 75% of new placements. But if I think about the next 2 years, right, you're still going to have Xi and all those multiple Intuitive prior systems. You have XSP, and you're also now going to have this catheter-based sensing systems. So I wonder if you could help us understand are we right to think about this company as morphing these next 2 years? And how does supporting sort of multiple platforms now impact the addressable markets you can serve, your ability to accelerate growth and, obviously, just flat out R&D spending across these platforms? I know it's a big question, but I think it's an important one."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with convention",323,"Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional technologies, open surgery, conventional laparoscopy or with Xi. So we think SP can broaden clinically what surgeons can do. I think that will start in niches and then will move out into broader applications as we gain clinical experience. It does increase our support load a little bit in terms of complexity, with regard to the SP, just because it's a new set of instruments and add-on accessories. But it's not an entirely new set of computational platform and things like that. As you start thinking about that catheter-based technologies, again, that's a new set of technology. So you had kind of framed it in a 2-year horizon. I would stretch that horizon out a little bit. I wouldn't anchor us there. I do think that takes us to different places. I think it allows access to parts of the body that you may not think of surgically. It may be more around diagnostics. And I think it will open up to practitioners' ways of approaching tissue that they just haven't thought about before. And that's why we're doing it. That -- you've seen us increase our R&D spend, and we've been both talking about it and doing it, and part of it has been investing in these technologies. And I think it matters. I think as people look -- as we look from the bottom of your feet to the top of your head and look for opportunities to get better outcomes, we think of a variety of technologies from access technologies to imaging technologies to computational technologies that can really make a difference, and that's -- we're putting our money where our mouth is."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and have been, frankly, kind of extraordinary. So as you head into '17, just on the spending comment",131,"And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and have been, frankly, kind of extraordinary. So as you head into '17, just on the spending comments you've made, I don't think it's realistic for investors to expect 200 basis points of margin expansion in '17. Based on your comments on spending, in which you're going to have to just support these platforms, I mean, how should we sort of calibrate our thinking next year between sort of an extraordinary 2016 expansion and a more moderate 2015 margin expansion? Should we be thinking about something between those 2 poles as more appropriate than what we are seeing this year, which seems very outsized?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Clearly, we'll give you guidance in January of what 2017 is going to look like. But some of the variables that could occur, obviously, have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than e",163,"Clearly, we'll give you guidance in January of what 2017 is going to look like. But some of the variables that could occur, obviously, have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than existing products. And so if there were -- as we introduce stapling, for example, we saw decline in margin initially as we improved the manufacturability and efficiency of the manufacturing process, as we see improvements in margins. So I'm not going to predict what we're going to do next year. I would just say that there are a lot of moving parts. Mix, geographically, also has an impact. Mix between systems and instruments and accessories has an impact. There's just a lot of variables that go into it. I think what you've seen this last year, though, is outstanding performance by our manufacturing group to reduce the cost of newer products that were lower margin a year ago."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the Europe",68,"Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the European business, did you see any impact from Brexit? Or do you just think this is lumpiness that always occurs generally in your business?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think, the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS, an",134,"Yes, I think, the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS, anyway, that NHS England has been looking at how to spend their money and trying to cover budget shortfalls. So there's been pressure there for some time. Brexit likely doesn't help. With regard to Europe, more broadly, it really is varying country-by-country. Some places, we see reasonable growth and support. Other countries have been a little bit more of a struggle. And the response to that really has been to increase local presence, increase local data generation and be in close contact with government payers and private payers."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Tycho Peterson from JPMorgan.",11,"Next, we'll go to the line of Tycho Peterson from JPMorgan."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I actually want to follow up on Dave's question earlier on margins. If we think about the XI experience and the impact that had a gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when",55,"I actually want to follow up on Dave's question earlier on margins. If we think about the XI experience and the impact that had a gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when that does roll out?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce",118,"We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce those costs.
But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall quantities. So just based on magnitude, it's probably not going to have as big an impact on the overall margin."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed the systems in the field?",46,"Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed the systems in the field?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we p",125,"Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we performed a verification audit out of our installed base records, which identified -- and identified 43 system, mostly older standard of S models, which had been retired. So we went and removed those retired systems from our installed base during the quarter. So I think the trade-out number was 33, and then most of the rest here was just kind of this adjustment we made to the base. So the trade-ins were pretty, I think, in line with previous periods."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Last one, I'll ask if we can throw in a capital deployment question because you're over $4.5 million now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?",42,"Okay. Last one, I'll ask if we can throw in a capital deployment question because you're over $4.5 million now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And w",165,"Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And we're also going to see additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products. And those technologies, it's nice to do tuck-ins and small licensing arrangements that we've done in the past, and we'll try to do those. But it may be that we have to buy -- to pay a greater dollar to get some of that technology in the future. So we want to have money for those things. Beyond that, to the extent that we have the right opportunity to buy back stock and return shares -- money to shareholders, we'll take that opportunity, but we'll do that opportunistically as we have in the past."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Ben Andrew with William Blair.",12,"Next, we'll go to the line of Ben Andrew with William Blair."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of just a second piece to that, from a regulatory perspective, what sort of timeframes would you b",72,"Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of just a second piece to that, from a regulatory perspective, what sort of timeframes would you be looking at to get something through once you've finished developments and you've done some human testing to approval? Is it quicker there? Or is it similar to the U.S.?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various p",96,"Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various products in China, typically, in our past, it's been a little bit longer process than it has in the U.S. What that looks like going forward, in particular, for the new products we're talking about, I can't speak to at this time. We just don't have enough information on it."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrabl",62,"Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrably or -- that, plus the ROW placements sort of got my attention relative to some emerging opportunities overseas."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things colorectal and gyne",64,"Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things colorectal and gynecologic oncology, are still fairly small. So countries like the Nordic countries, places like the U.K., where we're pretty deep, you see those growth rates slow."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, this is may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you a",69,"Okay. And then, this is may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in hernia and kind of the trajectory of adoption relative to some of the historical fast-adopting procedures, if you would."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology h",121,"Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology has been adopted. Now hernia repair, though, is not one thing. So there's a variety of patient subsets within it, variety of different physician perspectives around the value that our technology can bring in the procedure. And so it's probably not quite like dVP in terms of the way you would think of it as being adopted. Maybe a little more benign hysterectomy, given the alternative therapies and the heterogeneous landscape out there in terms of how they address these patients."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other",66,"Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other than stapling and vessel sealing, was there anything in particular in there that caught your attention relative to mix?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just kind of given a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actual",228,"Yes, just kind of given a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actually dropped down to $1,810, and we talked about timing of orders being the main factor here. So as expected here in Q3, we saw orders rebound to offset Q2. And if you take the average of Q2 and Q3, right back at the $1,840, kind of in line with those trends over the past couple of years. As we said, though, we continue to see increasing utilization of the advanced instruments, including the stapler and vessel sealer. And moving forward, as we anticipate continued growth in the procedure volumes in colorectal and thoracic surgery, areas where these products are more widely used, we would anticipate a slightly higher contribution to revenue per procedure on an organic consumption model, if you will. But it's important to remember that a variety of factors impact revenue per procedure, including the type or procedure performed, the efficiency of use and optimization, use of advanced instruments, stocking orders, timing and distributors. So there's a lot of factors here. So as a result, I&A, it can be lumpy, and future trends can be difficult to forecast in the end."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Amit Hazan with Citi.",12,"Next we'll go to the line of Amit Hazan with Citi."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast",113,"Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast change in what, otherwise, would seem to me to be something that would be a slower trend line. Any more color you can add as to what's happening now and why it's happening and maybe, more importantly, just the confidence you guys have that this quarter kind of marks that bottom and that incident rate growth is kind of your right rate of growth for prostate."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rate of growth that we've seen with our rates growth that we thought wer",120,"Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rate of growth that we've seen with our rates growth that we thought were consistent with the rate of diagnoses. It's hard to say in a quarter or the rate at which we've seen growth change over the course of this year. The specifics behind it, that data, it typically comes to us years down the road. But we feel that the -- what we saw in the quarter is probably more consistent with the rate of diagnoses than perhaps what we've seen over the past handful of quarters."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this i",134,"Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this in a while, so I'll just throw this question out, just one possible avenue. Just thinking about outpatient centers, ambulatory surgery centers, is there -- to what extent -- or is there kind of any increase in the success that you're having in being able to place da Vinci in outpatient centers? Is that becoming a focus for you at all? And is that at all a part of maybe the slightly better rates of growth we're seeing in gynecology in the U.S?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think you're connecting 2 things I'm not sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume centers. S",123,"Yes. So I think you're connecting 2 things I'm not sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume centers. Separately, there is a trend toward a more outpatient work. We do see utilization of our systems in outpatient environments, that tends to be more in existing integrated delivery networks, possible loaned outpatient departments as part of a integrated plan. It's not something I'd call out as a major trend at this point. I'm not sure that I would quite blanket GYN. It's possible, but I think there are a lot of factors there that sorting them is not possible yet."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive s",62,"If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive surgery is adopted with the technology, it will enable hospitals to manage these patients in a more outpatient-oriented way."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just one last question for me on the systems side. Just thinking through not just the fourth quarter, which is a little bit of longer term, and you can call it '17, if you want. But thinking about the installed base, it's been really consistently growing",110,"Just one last question for me on the systems side. Just thinking through not just the fourth quarter, which is a little bit of longer term, and you can call it '17, if you want. But thinking about the installed base, it's been really consistently growing now 10% a year. Almost every quarter, it seems like it grows about 10 -- on that 10% rate on an annual basis. Can you maybe just talk through the key drivers and maybe pressure points as we think about that number and the sustainability of that 10% growth in the installed base growth figure as we think through the next year or 2?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is",137,"A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest driver and where they see growth, I'd think, that they move forward. The places where that can be a little bit different or disconnected is in a very early market where you're just getting started. So a new reimbursement clearance or a new quote or a new procedure clearance don't -- doesn't follow the more mature trend. So those are the 2 things that are rolling around. I think the biggest one for us is customer belief and utilization for future procedures as the best predictor of capital."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Rick Wise from Stifel, Nicolaus.",12,"Next, we'll go to the line of Rick Wise from Stifel, Nicolaus."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geogra",76,"Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geographic or technology? Or I mean, is this a direction we should expect Intuitive to push looking for other technologies to bring into the ecosystem? Is that the right way to think about it?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity",136,"I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity for us? Yes. They tend to develop in time. The underlying catheter-based technologies that we're talking about now, as you know, having followed us for some time, were really first acquired by us years ago. So the answer to that is yes. We're out looking. Fosun has been a good partner. They have both a relationship with us through Chindex, but they also understand the healthcare space extremely well in multiple dimensions. And so the short answer to that is we've been doing it and expect to continue to do it."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings,",71,"A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings, rather? And maybe, particularly on colorectal, how do accelerate colorectal adoption? Do we need more clinical data? Can you talk through some of those issues?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's",223,"Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's large value, distinct value for the procedure relative to alternatives and when the procedure is pretty well concentrated in the hands of well-trained surgeons. So take colorectal and separate it a little bit. In the case of rectal cancer, that's a complex set of procedures. Oncologic, of course, in nature, has been growing steadily. Not at a super rapid rise relative to some prior adoptions, but a steady adoption for us. And data collection has been occurring, data publication has been occurring, and we're doing okay there. I think in other parts of colon, sometimes it's for benign, sometimes it's oncology. Those are typically done by different surgeons. And so they adopt at little bit different rates. You look at hernia, again, it's sub-segmented, ventral hernia versus inguinal and subsegments within inguinal. So we look at it. Ventral hernia and inguinal hernia, as we define the available markets for procedures for which we bring value, have adopted pretty nicely relative to past trends. Rectal has been on a slower adoption but a steady one, and colon is in the middle."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math wi",88,"And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math with what we're seeing internationally. Should we feel reasonably optimistic that something like mid-teens procedure growth, again, with some variation? Is that the right sustainable growth rate from here, given the growing installed base, given the geographic penetration and given the continuing evolution of Intuitive technology?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're not ready to give of our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January.",38,"Yes. We're not ready to give of our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We'll go to the line of Larry Biegelsen with Wells Fargo.",12,"We'll go to the line of Larry Biegelsen with Wells Fargo."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -",75,"So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -- it sounds like -- is that a good rate to use going forward? And I had a couple of follow ups."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for",116,"Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for international to support the earlier phase growth there. So you look at it overall, we're within our guidance range. We refined our full year guidance to that 13% to 14%. So again, there'll be some quarter variability, but I think we're tracking to the overall plan. And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin you walked through."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?",37,"Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time.",47,"Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?",43,"Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?"
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything abo",119,"It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything about adoption that I'd call out strongly at this time. I think both of them are moving through that first set of adopters, generating additional data. We're seeing more data now generally supportive. It looks pretty good. I think that technique refinement and data generation is what the next round of surgeons rely upon to evaluate. And so we're seeing that kind of transition right now, really, in both of those hernia domains."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our final question will come from Brandon Henry with RBC Capital Markets.",12,"Our final question will come from Brandon Henry with RBC Capital Markets."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive again posted strong growth and operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And",94,"So Intuitive again posted strong growth and operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And then separately, the company's headcount has increased meaningfully over the last couple of quarters. Can you discuss where you're making the investments in headcount? And then how much of that increase in headcount can be attributed to the Fosun JV versus some other initiatives? And then I have a follow up."
30239,402358121,1056540,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it i",341,"That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it is a routine discipline of scanning through both operating processes and manufacturing processes and parts costs and working them down as they come. You do get the first -- the greatest help on those things in the first few years of a platform release. And then after that, it starts getting increasingly hard. It's not specifically to say that it isn't possible to do it. On terms of headcount growth, it's a mixture of commercial growth, a little bit more weighted outside the U.S. than U.S., some manufacturing growth to cover volumes of things like instruments and accessories and other things that have been increasing as well as some design help. The headcount growth, as it relates to Fosun, we're not really to break out at this time. We have certainly made headcount investment over the last few years into the technologies that have underpinned that relationship. But it's not -- I wouldn't call it out as Fosun just yet. 
With that, I'll go ahead and close the call. And Brandon, we'll catch your next question on the next conference call. That was the last question. 
As we've said previously, while we focus on financial metrics, such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Se",51,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance a",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on July 20, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third quarter financial results. Patrick will discuss procedure and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. Global procedure growth was over 14% year-over-year in the",951,"Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. 
Global procedure growth was over 14% year-over-year in the quarter. Drivers of growth centered on U.S. general surgery and growth in the use of da Vinci Surgical Systems outside the United States. In the United States, year-over-year growth in ventral and inguinal hernia repair continues to be strong. U.S. colon resection and lung resection also contributed to solid growth. As we've stated in prior calls, we are expecting growth rates in mature procedures in the U.S. to moderate, and U.S. dVP is starting to follow this pattern, driven by the macroeconomic environment for prostate cancer diagnosis and treatment. 
In Europe, procedure growth tempered in the quarter, with some countries posting solid performance while growth softened in others. 
We're pleased with growth in procedures in Asia, with Korea and China, in particular, demonstrating continued strength. Patrick will review procedure trends in greater detail later in the call. 
We placed 134 da Vinci systems in the quarter, up from 117 in Q3 of 2015. While we offer a range of models and price points, our most capable model, da Vinci Xi, again represented roughly 3/4 of new capital placements. As we've said on previous calls, capital placements are lumpy, and this quarter was no exception. 
Healthy placements stood out in the U.S., while placements in our European regions softened relative to a year ago. Capital placements in Asia are particularly unpredictable, given environment constraints like reimbursements in Japan and quotas in China. Placements in Asia were in line with prior quarters. 
Turning to revenue and gross margin dynamics. We experienced some onetime tailwinds in the quarter that contributed to higher-than-expected net income. Marshall will take you through these events and our general finances in greater detail later in the call. 
Turning to highlights of our third quarter operating results. Procedures grew approximately 14% over the fourth -- third quarter of last year. We shipped 134 da Vinci Surgical Systems, up from 117 in the third quarter of 2015. Revenue for the quarter was $683 million, up 16% from the prior year. Pro forma gross profit margin was 73.1% compared to 16 -- 69.3% in the third quarter of last year. Instrument and accessory revenue increased to $348 million, up 17%. Total recurring revenue in the quarter was $478 million, representing 70% of total revenue. We generated a pro forma operating profit of $308 million in the quarter, up 28% from the third quarter of last year. And pro forma net income was $246 million, up 23% from Q3 of 2015. 
As we discussed with you on our last call, as our business has strengthened, we have increased our mid- and long-term investments in creating our next generation of products and services. We've been increasing these investments based on our belief that our -- that substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. 
We continue to enhance features and expand access to our Xi suite of instruments, accessories and imaging products. In the third quarter, we added the ability to ship Xi Single-Site, Xi 30-millimeter stapler and Firefly to several countries. In addition, interoperative table motion uptake and performance is meeting our expectations. We are continuing to invest in the expansion and refinement of our base instrument, stapling and vessel sealing products for our Xi platform. 
New system platforms continue to make good progress. Our da Vinci single port is progressing in its in-house clinical evaluations and preparations for human clinical trials expected later this quarter. As we've discussed on prior calls, we plan first markets to include head and neck surgery, urology and colorectal surgery. 
SP is a platform technology that allows high-dexterity access with great 3D vision to confined surgical spaces. Commentary by surgeons after in-house evaluations have indicated strong interest in the clinical potential of this platform. 
In the quarter, we also announced the creation of a joint venture with Fosun Pharma, owner of our current da Vinci partner in China. The JV's first objectives are to work with ISI and Fosun to produce products that address an acute need in the diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection and treatment are important. 
The technology underpinning the system is based on computer-controlled catheters, advanced image processing and sophisticated sensing. It incorporates a substantial set of proprietary intellectual property developed, owned or licensed by Intuitive over the past several years. This system is in its early stages of our human clinical experience, and final clearance and launch targets are not yet set. That said, the raw capability of the technology is compelling, and it has the potential to perform as a broader diagnostic and treatment platform over time. 
Bringing new platforms to the market represents a significant investment. We've added approximately 400 employees year-to-date and expect increased fixed investments and some lumpiness in spending in future quarters as these platforms move through design, validation, data collection and early launch. 
As we close 2016, we have focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including new clearances, additional clinical and economic validation, training centers and the expansion of our product offerings; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who'll review financial highlights."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1307,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. 
We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
Third quarter 2016 revenue was $683 million, an increase of 16% compared with $590 million for the third quarter of 2015 and an increase of 2% compared with the second quarter revenue of $670 million. Third quarter 2016 procedures increased 14% compared with the third quarter of 2015 and decreased 1% compared with last quarter. Procedure growth relative to last year has been driven by general surgery in the U.S. and urology worldwide. The decrease relative to the prior quarter primarily reflects seasonality. 
Revenue highlights are as follows: Instrument and accessory revenue of $348 million increased 17% compared with last year and increased 3% compared with the second quarter of 2016. Growth in instruments and accessory revenue generally reflects procedure growth and increased sales of stapling and vessel sealing products. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,870 per procedure compared with $1,840 last year and $1,810 last quarter. The increases relative to the third quarter of 2015 and last quarter reflect increased sales for our stapling and vessel sealing products. The increase compared to the second quarter of 2016 also reflects the impact of customer buying patterns. 
System revenue of $205 million increased 18% compared with the third quarter of 2015 and increased 1% compared with last quarter. The year-over-year and quarter-over-quarter increases reflect higher system placements and higher revenue associated with lease buyouts, partially offset by lower average system selling prices. 
We generated approximately $13 million of revenue during the quarter from lease buyouts compared with $3 million in the third quarter of 2015 and $13 million last quarter. While lease buyouts are difficult to predict, we expect the level of fourth quarter lease buyouts to be below those of the third quarter.
134 systems were placed in the third quarter of 2016 compared with 117 systems in the third quarter of 2015 and 130 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 15 last quarter and 13 systems in the third quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the third quarter, there were 74 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $2 million in the third quarter of 2015 and approximately $4 million last quarter. We exclude the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system price was $1.53 million compared with $1.61 million last year and $1.56 million last quarter. The decreases compared with prior periods primarily reflect a lower mix of dual console systems, partially offset by a lower mix of trade-in systems in the third quarter of 2016. 
Service revenue of $130 million increased 10% year-over-year and increased approximately 1% compared with the second quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: Third quarter revenue outside of the U.S. of $189 million increased 25% compared with $151 million for the third quarter of 2015 and increased 2% compared with $185 million for the second quarter. The increase compared with the previous year is comprised of a 26% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 24%. The increase compared to the second quarter reflects systems revenue growth of 2% and recurring revenue growth of 2% in a seasonally slower quarter. 
Outside the U.S., we placed 49 systems in the third quarter compared with 37 in the third quarter of 2015 and 51 systems last quarter. 
Current quarter system sales included 18 into Europe, 2 into China, 11 into Japan and 18 in the rest of world markets. System placements outside of the U.S. will continue to be lumpy as some of the OUS markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales into some markets are constrained by government regulation.
Moving on to the remainder of the P&L. Pro forma gross margin for the third quarter of 2016 was 73.1% compared with 69.3% for the third quarter of 2015 and 71.9% for the second quarter of 2016. 
The pro forma gross margin for the third quarter of 2016 included $7.1 million of Medical Device Tax refunds. Without the Medical Device Tax refunds, our pro forma gross margin would have been the same as the second quarter or 72%. 
Compared with the third quarter of 2015, the higher gross margin reflects reduced product costs, the Medical Device Tax refunds and manufacturing efficiencies. 
Future margins will fluctuate based on the mix of our newer products, the mix of system and instrument and accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs and improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 14% compared with the third quarter of 2015 and increased approximately $6 million compared with last quarter. The increases reflect increased headcount, increased product development activity and investments in our OUS commercial organization. 
We added over 400 employees, primarily in the product operations area, over the past year. The increase compared with the prior quarter primarily reflects increased headcount costs. 
Our pro forma effective tax rate for the third quarter was 22.7% compared with an effective rate of 18.4% for the third quarter of 2015 and 27.8% last quarter. The pro forma third quarter of 2016 tax rate reflected $16 million of tax benefits or $0.40 per share realized as a result of the statute of limitation expirations in various jurisdictions. The third quarter of 2015 tax rate reflected $29 million or $0.77 per share related to a favorable tax court ruling involving an independent third party. Our tax rate will fluctuate with changes in the mix of OUS and U.S. income and with the impact of onetime items. 
Our third quarter 2016 pro forma net income was $246 million or $6.19 per share compared with $199 million or $5.24 per share for the third quarter of 2015 and $220 million or $5.62 per share for the second quarter of 2016. 
Excluding onetime income tax and Medical Device Tax benefits, pro forma net income would have been $225 million or $5.65 per share.
As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results. 
GAAP net income was $211 million or $5.31 per share for the third quarter of 2016 compared with $167 million or $4.40 per share for the third quarter of 2015 and $185 million or $4.71 per share for the second quarter of 2016. 
We ended the quarter with cash and investments of $4.6 billion, up from $4.2 billion as of June 30, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. During the first 3 quarters of 2016, global procedure growth was nearly 16%. In",993,"Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. 
During the first 3 quarters of 2016, global procedure growth was nearly 16%. In the United States, taken together, growth in our mature procedures slowed in the third quarter compared to the first half of the year. General and thoracic procedure growth remained healthy. 
In U.S. urology, third quarter growth in da Vinci Prostatectomy slowed to low single-digit growth, a level that we believe to be similar to the overall rate of diagnoses of new prostate cancers. We believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market. 
In U.S. gynecology, third quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists during the third quarter. Procedures for benign gynecologic conditions grew modestly during the third quarter, continuing a trend from the first half of the year. 
Third quarter U.S. general and thoracic surgery procedure adoption remained strong, led by solid growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and existing surgeon retention and utilization remains encouraging. 
Cholecystectomy procedures declined in the quarter, with growth in multi-port procedures being offset by declines in Single-Site procedures. Early-stage adoption of lobectomies and other thoracic procedures is encouraging. 
Last month at the global symposium on robotic-assisted and minimally-invasive hernia repair, several new data sets comparing da Vinci to open and laparoscopic hernia repair were presented. Among the most notable presentations, Dr. Rosen from the Cleveland Clinic presented new data on retromuscular ventral hernia repair from the American Hernia Society's Quality Collaborative or the AHSQC. 
In a prospective cohort of more than 400 patients, case-matched between da Vinci and open surgery, da Vinci surgery was shown to reduce the length of hospitalization by 2.5 days compared to open surgery, with similar levels of wound outcomes, readmissions and reoperations. Intuitive is a founding partner of AHSQC and we are supporting its expansion to include data for inguinal hernia repair. 
Turning abroad. Procedure growth outside of the United States was approximately 25% in the third quarter, led by the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures. Total procedure growth in Europe and Asia was similar to the first half of the year, though procedure performance varied by country.  Strong growth continued in China, South Korea, Japan and Germany. 
While adoption of da Vinci in urology is the primary driver of procedure growth outside of the United States, we are seeing multi-specialty adoption in certain countries. In China, roughly half of the year-to-date procedure growth has come from categories outside of urology. In South Korea, approximately 60% of the year-to-date procedures have come from categories outside of urology. 
We are investing in the development of clinical evidence to support the adoption of da Vinci surgery in markets around the world. Globally, we support several evidence initiatives and registries, including AHSQC, gynecologic oncology societal registries in the U.S. and Europe, and the colorectal registry in Europe. 
In the U.S., we are also supporting several comparative prospective and retrospective multicenter studies on hernia repair, colorectal surgery and thoracic surgery. Outside of the United States, we are sponsoring clinical studies in Japan to support reimbursement submissions for malignant hysterectomy and gastrectomy. In Europe, we provide support for studies in colorectal, thoracic and gynecological oncology. 
We are committed to developing local evidence in key markets to support the adoption of da Vinci surgery where our technology can bring value to hospitals, surgeons, patients. 
Third quarter was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I've selected a few studies that you may find interesting. Dr. Dalesh [ph] and colleagues from Indiana University published a study in Surgical Endoscopy comparing da Vinci to laparoscopic colorectal procedures captured in the American College of Surgeons' National Surgical Quality Improvement Project or NSQIP database from 2011 through 2014. 
Including over 27,000 procedures across a range of colon and rectal resections, in exchange for an approximate 45-minute longer operative time, da Vinci low anterior resections and right colectomies showed a reduction in conversion rates. Left colectomies trended towards a reduction in conversion rates without statistical significance. Low anterior resections also showed a lower rate of sepsis with a higher rate of diverting ostomy. Across all cohorts, da Vinci surgery generated a reduction in length of hospital stay. 
The next study was published by Dr. Ozben and colleagues from the Acibadem University in Istanbul, Turkey in the Journal of Surgical Laparoscopy, Endoscopy and Percutaneous Technologies. In a small case series, the authors compared their performance in performing rectal resections on da Vinci Xi to da Vinci Si. They found that da Vinci Xi was associated with an approximate 40 minutes of reduced operative time. The reduction in operative time was attributable to an elimination of double docking and hybrid surgeries in the da Vinci Xi cohort. The surgeons also found the da Vinci Xi patient population experienced an increase in lymph nodes harvested and quicker return of bowel function with a 1 day longer length of hospital stay. 
The authors concluded ""The Xi generation appeared to allow shorter console times, and its broader capabilities promise to make it a lot easier for surgeons to perform this complex robotic procedure."" 
While this study highlights the enhanced workflow capabilities of da Vinci Xi for multi-quadrant surgery such as rectal resection, our da Vinci Si installed base has remained stable in 2016 as customers continue to find value in its utilization. 
Taken together, procedures performed on da Vinci Si and Xi platforms represented over 95% of our third quarter procedures. 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015.",526,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. 
On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015. Now as we enter the fourth quarter, we continue to forecast full year procedure growth of 14% to 15%, likely towards the higher end of the range. 
With regard to Q4 2016 system placements, we directionally expect system placements for the quarter to follow recent seasonal trends. However, we anticipate system placements outside of the U.S. will continue to be lumpy as some of our U.S. -- OUS markets are in early stages of adoption and sales into some markets are constrained by government regulations. 
Recall, we placed 13 systems into China and 7 systems into Brazil in the fourth quarter of 2015. As the quota in China expired in 2015 and a new quota has not yet been issued and as we are in the very early stages of adoption in Brazil, we do not expect comparables and placements into these markets in the fourth quarter of 2016. 
Also, we believe that the flexibility we have offered customers in the form of operating leases has been well received. As a result, as compared to prior periods, we expect a higher proportion of Q4 2016 placements to be under operating leases, with revenue recognized in future periods. 
Finally, we expect to see a lower number of lease buyouts in the fourth quarter compared to the previous 2 quarters, given the lower number of short-term leases that are outstanding at this time. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. We now expect our full year 2016 pro forma gross profit margin to be approximately 71.5% of net revenue. 
As Marshall indicated, the third quarter benefited from a $7.1 million Medical Device Tax refund. Excluding that benefit, our gross profit margin would have been 72%. We expect our fourth quarter margin to be directionally lower than the third quarter, primarily due to product mix. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will continue to accelerate. On our last call, we forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels. We are now refining this range to 13% to 14%. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015.
We expect other income to total approximately $33 million in 2016, higher than the $30 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, consistent with previous guidance, we expect our Q4 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America.",15,"[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on",83,"So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on the Medical Device Taxes and the $7 million, could you explain why that is onetime? And then on the system sales guidance that you're providing, is that essentially suggesting that systems will be globally roughly flat in Q4?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have",125,"Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have -- we've received the money, and there has been an audit, so we're all done with that. Second question had to do with the level of systems. Now, I think that what Calvin said was that the systems are seasonally stronger in Q4. What he was trying to set up, however, was that relative to the prior year, there's some hard comparables, given that we had some markets that are rather lumpy like China and Brazil."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue.",33,"You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little",109,"So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more color on what this is. Like, is this a new -- is this a new totally new system or just an add-on to Xi? Just -- should we think about it as being a couple of years away from commercialization? Or is it really a longer-term project? I'm just sort of wondering if you could provide some perspective."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along",226,"Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with some special sensing technologies and some image analysis. Currently -- the current configuration it's in, it's a stand alone. Those types of technologies in the future could be integrated into other things, and we won't preclude ourselves from doing that. We do conceive of it as a way to access the body through natural orifices and other means, where you want to follow a prescribed pathway to get to some deep place in the body and do something. Our first clinical interest is in biopsying lung cancers or biopsying suspicious lesions in the lung. We think that, that is important globally and particularly important in China. And as a result, the partnership with Fosun, who we've known through their Chindex company for many years, made a lot of sense to us. And we're excited about it. We're not ready to give you commercial timelines yet. The technology is mature enough that we're in our initial human clinical experience. That's really the very beginnings for us, and as we get greater clarity on our launch timelines and thoughts, we'll share them with you."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Now we'll go to the line of David Lewis with Morgan Stanley.",13,"Now we'll go to the line of David Lewis with Morgan Stanley."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has u",172,"Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has usually been about one system. I know you have multiple configurations, but in this quarter alone, Xi was still 75% of new placements. But if I think about the next 2 years, right, you're still going to have Xi and all those multiple Intuitive prior systems. You have XSP, and you're also now going to have this catheter-based sensing system. So I wonder if you could help us understand are we right to think about this company as morphing these next 2 years? And how does supporting sort of multiple platforms now impact the addressable markets you can serve, your ability to accelerate growth and, obviously, just flat out R&D spending across these platforms? I know it's a big question, but I think it's an important one."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with convention",322,"Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional technologies, open surgery, conventional laparoscopy or with Xi. So we think SP can broaden clinically what surgeons can do. I think that will start in niches and then we'll move out into broader applications as we gain clinical experience. It does increase our support load a little bit in terms of complexity with regard to the SP, just because it's a new set of instruments and add-on accessories. But it's not an entirely new set of computational platform and things like that. As you start thinking about the catheter-based technologies, again, that's a new set of technologies. You had kind of framed it in a 2-year horizon. I would stretch that horizon out a little bit. I wouldn't anchor us there. I do think that takes us to different places. I think it allows access to parts of the body that you may not think of surgically. It may be more around diagnostics. And I think it will open up to practitioners' ways of approaching tissue that they just haven't thought about before. And that's why we're doing it. That -- you've seen us increase our R&D spend, and we've been both talking about it and doing it, and part of it has been investing in these technologies. And I think it matters. I think as people look -- as we look from the bottom of your feet to the top of your head and look for opportunities to get better outcomes, we think of a variety of technologies from access technologies to imaging technologies to computational technologies that can really make a difference, and that's -- we're putting our money where our mouth is."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the sp",135,"And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the spending comments you've made, I don't think it's realistic for investors to expect 200 basis points of margin expansion in '17. Based on your comments on spending and what you're going to have to do to support these platforms, I mean, how should we sort of calibrate our thinking next year between sort of an extraordinary 2016 expansion and a more moderate 2015 margin expansion? Should we be thinking about something between those 2 poles as more appropriate than what we are seeing this year, which seems very outsized?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than ex",163,"Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than existing products. And so if there were -- as we introduced stapling, for example, we saw a decline in margin initially. As we improved the manufacturability and efficiency of the manufacturing processes, we've seen improvements in margins. So I'm not going to predict what we're going to do next year. I would just say that there are a lot of moving parts. Mix, geographically, also has an impact. Mix between systems and instruments and accessories has an impact. There's just a lot of variables that go into it. I think what you've seen this last year, though, is outstanding performance by our manufacturing group to reduce the cost of newer products that were lower margin a year ago."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the Europe",68,"Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the European business, did you see any impact from Brexit? Or do you just think this is lumpiness that always occurs generally in your business?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyw",134,"Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyway, that NHS England has been looking at how to spend their money and trying to cover budget shortfall. So there's been pressure there for some time. Brexit likely doesn't help. With regard to Europe more broadly, it really is varying country-by-country. Some places, we see reasonable growth and support. Other countries have been a little bit more of a struggle. And the response to that really has been to increase local presence, increase local data generation and be in close contact with government payers and private payers."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Tycho Peterson from JPMorgan.",11,"Next, we'll go to the line of Tycho Peterson from JPMorgan."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when",55,"I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when that does roll out?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce",52,"We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce those costs."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall",66,"But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall quantities. So just based on magnitude, it's probably not going to have as big an impact on the overall margin."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?",45,"Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we p",124,"Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we performed a verification audit of our installed base records, which identified -- and identified 43 system, mostly older standard and S models, which had been retired. So we went and removed those retired systems from our installed base during the quarter. So I think the trade-out number was 33, and then most of the rest here was just kind of this adjustment we made to the base. So the trade-ins were pretty, I think, in line with previous periods."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?",39,"Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And w",165,"Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And we're also going to see additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products. And those technologies, it's nice to do tuck-ins and small licensing arrangements that we've done in the past, and we'll try to do those. But it may be that we have to buy -- to pay a greater dollar to get some of that technology in the future. So we want to have money for those things. Beyond that, to the extent that we have the right opportunity to buy back stock and return shares -- money to shareholders, we'll take that opportunity, but we'll do that opportunistically as we have in the past."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Ben Andrew with William Blair.",12,"Next, we'll go to the line of Ben Andrew with William Blair."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be",73,"Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be looking at to get something through once you've finished developments and you've done some human testing to approval? Is it quicker there? Or is it similar to the U.S.?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various p",96,"Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various products in China, typically, in our past, it's been a little bit longer process than it has in the U.S. What that looks like going forward, in particular for the new products we're talking about, I can't speak to at this time. We just don't have enough information on it."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrabl",62,"Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrably or -- that, plus the ROW placements sort of got my attention relative to some emerging opportunities overseas."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and",65,"Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and gynecologic oncology, are still fairly small. So countries like the Nordic countries, places like the U.K., where we're pretty deep, you see those growth rates slow."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are",68,"Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in hernia and kind of the trajectory of adoption relative to some of the historical fast-adopting procedures, if you would."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology h",121,"Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology has been adopted. Now hernia repair, though, is not one thing. So there's a variety of patient subsets within, a variety of different physician perspectives around the value that our technology can bring in the procedure. And so it's probably not quite like dVP in terms of the way you would think of it as being adopted. Maybe a little more benign hysterectomy, given the alternative therapies and the heterogeneous landscape out there in terms of how they address these patients."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other",66,"Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other than stapling and vessel sealing, was there anything in particular in there that caught your attention relative to mix?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actua",229,"Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actually dropped down to $1,810, and we talked about timing of orders being the main factor here. So as expected here in Q3, we saw orders rebound to offset Q2. And if you take the average of Q2 and Q3, you're right back at the $1,840, kind of in line with those trends over the past couple of years. As we said, though, we continue to see increasing utilization of the advanced instruments, including the stapler and vessel sealer. And moving forward, as we anticipate continued growth in the procedure volumes in colorectal and thoracic surgery, areas where these products are more widely used, we would anticipate a slightly higher contribution to revenue per procedure on an organic consumption model, if you will. But it's important to remember that a variety of factors impact revenue per procedure, including the type or procedure performed, the efficiency of use and optimization, use of advanced instruments, stocking orders, timing and distributors. So there's a lot of factors here. So as a result, I&A, it can be lumpy, and future trends can be difficult to forecast in the end."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Amit Hazan with Citi.",12,"Next we'll go to the line of Amit Hazan with Citi."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast",113,"Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast change in what, otherwise, would seem to me to be something that would be a slower trend line. Any more color you can add as to what's happening now and why it's happening and maybe, more importantly, just the confidence you guys have that this quarter kind of marks that bottom and that incident rate growth is kind of your right rate of growth for prostate."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thoug",121,"Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thought were consistent with the rate of diagnoses. It's hard to say in the quarter or the rate at which we've seen growth change over the course of this year. The specifics behind it, that data, typically comes to us years down the road. But we feel that the -- what we saw in the quarter is probably more consistent with the rate of diagnoses than perhaps what we've seen over the past handful of quarters."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this i",137,"Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this in a while, so I'll just throw this question out, just as one possible avenue. Just thinking about outpatient centers, ambulatory surgery centers, is there -- to what extent -- or is there kind of any increase in the success that you're having in being able to place da Vincis in outpatient centers? Is that becoming more of a focus for you at all? And is that at all a part of maybe the slightly better rates of growth we're seeing in gynecology in the U.S?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume cent",126,"Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume centers. Separately, there is a trend toward more outpatient work. We do see utilization of our systems in outpatient environments; that tends to be more in existing integrated delivery networks, possible loaned [ph] outpatient departments as part of a integrated plan. It's not something I'd call out as a major trend at this point. I'm not sure that I would quite link it to GYN. It's possible, but I think there are a lot of factors there that sorting them is not possible yet."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive s",62,"If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive surgery is adopted with the technology, it will enable hospitals to manage these patients in a more outpatient-oriented way."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10%",108,"Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10% a year. Almost every quarter, it seems like it grows about 10 -- on that 10% rate on an annual basis. Can you maybe just talk through the key drivers and maybe pressure points as we think about that number and the sustainability of that 10% growth in the installed base growth figure as you think through the next year or 2?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is",137,"A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest driver and where they see growth, I think that they move forward. The places where that can be a little bit different or disconnected is in a very early market where you're just getting started. So a new reimbursement clearance or a new quote or a new procedure clearance don't -- doesn't follow the more mature trend. So those are the 2 things that are rolling around. I think the biggest one for us is customer belief and utilization for future procedures as the best predictor of capital."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Rick Wise from Stifel, Nicolaus.",12,"Next, we'll go to the line of Rick Wise from Stifel, Nicolaus."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geogra",76,"Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geographic or technology? Or I mean, is this a direction we should expect Intuitive to push looking for other technologies to bring into the ecosystem? Is that the right way to think about it?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity",136,"I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity for us? Yes. They tend to develop in time. The underlying catheter-based technologies that we're talking about now, as you know, having followed us for some time, were really first acquired by us years ago. So the answer to that is yes. We're out looking. Fosun has been a good partner. They have both a relationship with us through Chindex, but they also understand the healthcare space extremely well in multiple dimensions. And so the short answer to that is we've been doing it and expect to continue to do it."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings,",72,"A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings, rather? And maybe, particularly on colorectal, how do you accelerate colorectal adoption? Do we need more clinical data? Can you talk through some of those issues?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's",222,"Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's large value, distinct value for the procedure relative to alternatives and when the procedure is pretty well concentrated in the hands of well-trained surgeons. So take colorectal and separate it a little bit. In the case of rectal cancer, that's a complex set of procedures. Oncologic, of course, in nature, has been growing steadily. Not a super rapid rise relative to some prior adoptions, but a steady adoption for us. And data collection has been occurring, data publication has been occurring, and we're doing okay there. I think in other parts of colon, sometimes it's for benign, sometimes it's oncology. Those are typically done by different surgeons. And so they adopt at little bit different rates. You look at hernia, again, it's sub-segmented, ventral hernia versus inguinal and subsegments within inguinal. So we look at it. Ventral hernia and inguinal hernia, as we define the available markets for procedures for which we bring value, have adopting pretty nicely relative to past trends. Rectal has been on a slower adoption but a steady one, and colon is in the middle."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math wi",88,"And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math with what we're seeing internationally, should we feel reasonably optimistic that something like mid-teens procedure growth, again, with some variation? Is that the right sustainable growth rate from here, given the growing installed base, given the geographic penetration and given the continuing evolution of Intuitive technology?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January.",37,"Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We'll go to the line of Larry Biegelsen with Wells Fargo.",12,"We'll go to the line of Larry Biegelsen with Wells Fargo."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -",75,"So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -- it sounds like -- is that a good rate to use going forward? And I had a couple of follow ups."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for",87,"Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for international to support the earlier phase growth there. So you look at it overall, we're within our guidance range. We refined our full year guidance to that 13% to 14%. So again, there'll be some quarter variability, but I think we're tracking to the overall plan."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through.",28,"And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?",37,"Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time.",47,"Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?",43,"Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?"
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything abo",119,"It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything about adoption that I'd call out strongly at this time. I think both of them are moving through that first set of adopters, generating additional data. We're seeing more data now, generally supportive; it looks pretty good. I think that technique refinement and data generation is what the next round of surgeons rely upon to evaluate. And so we're seeing that kind of transition right now, really in both of those hernia domains."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our final question will come from Brandon Henry with RBC Capital Markets.",12,"Our final question will come from Brandon Henry with RBC Capital Markets."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And t",94,"So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And then separately, the company's headcount has increased meaningfully over the last couple of quarters. Can you discuss where you're making the investments in headcount? And then how much of that increase in headcount can be attributed to the Fosun JV versus some other initiatives? And then I have a follow up."
30239,402358121,1056584,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it i",341,"That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it is a routine discipline of scanning through both operating processes and manufacturing processes and parts costs and working them down as they come. You do get the first -- the greatest help on those things in the first few years of a platform release. And then after that, it starts getting increasingly hard. It's not specifically to say that it isn't possible to do it. In terms of headcount growth, it's a mixture of commercial growth, a little bit more weighted outside the U.S. than U.S., some manufacturing growth to cover volumes of things like instruments and accessories and other things that have been increasing as well as some design help. The headcount growth, as it relates to Fosun, we're not really to break out at this time. We have certainly made headcount investments over the last few years into the technologies that have underpinned that relationship. But it's not -- I wouldn't call it out as Fosun just yet. 
With that, I'll go ahead and close the call. And then we'll catch your next question on the next conference call. That was the last question. 
As we've said previously, while we focus on financial metrics, such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Se",51,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance a",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on July 20, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third quarter financial results. Patrick will discuss procedure and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. Global procedure growth was over 14% year-over-year in the",951,"Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. 
Global procedure growth was over 14% year-over-year in the quarter. Drivers of growth centered on U.S. general surgery and growth in the use of da Vinci Surgical Systems outside the United States. In the United States, year-over-year growth in ventral and inguinal hernia repair continues to be strong. U.S. colon resection and lung resection also contributed to solid growth. As we've stated in prior calls, we are expecting growth rates in mature procedures in the U.S. to moderate, and U.S. dVP is starting to follow this pattern, driven by the macroeconomic environment for prostate cancer diagnosis and treatment. 
In Europe, procedure growth tempered in the quarter, with some countries posting solid performance while growth softened in others. 
We're pleased with growth in procedures in Asia, with Korea and China, in particular, demonstrating continued strength. Patrick will review procedure trends in greater detail later in the call. 
We placed 134 da Vinci systems in the quarter, up from 117 in Q3 of 2015. While we offer a range of models and price points, our most capable model, da Vinci Xi, again represented roughly 3/4 of new capital placements. As we've said on previous calls, capital placements are lumpy, and this quarter was no exception. 
Healthy placements stood out in the U.S., while placements in our European regions softened relative to a year ago. Capital placements in Asia are particularly unpredictable, given environment constraints like reimbursements in Japan and quotas in China. Placements in Asia were in line with prior quarters. 
Turning to revenue and gross margin dynamics. We experienced some onetime tailwinds in the quarter that contributed to higher-than-expected net income. Marshall will take you through these events and our general finances in greater detail later in the call. 
Turning to highlights of our third quarter operating results. Procedures grew approximately 14% over the fourth -- third quarter of last year. We shipped 134 da Vinci Surgical Systems, up from 117 in the third quarter of 2015. Revenue for the quarter was $683 million, up 16% from the prior year. Pro forma gross profit margin was 73.1% compared to 16 -- 69.3% in the third quarter of last year. Instrument and accessory revenue increased to $348 million, up 17%. Total recurring revenue in the quarter was $478 million, representing 70% of total revenue. We generated a pro forma operating profit of $308 million in the quarter, up 28% from the third quarter of last year. And pro forma net income was $246 million, up 23% from Q3 of 2015. 
As we discussed with you on our last call, as our business has strengthened, we have increased our mid- and long-term investments in creating our next generation of products and services. We've been increasing these investments based on our belief that our -- that substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. 
We continue to enhance features and expand access to our Xi suite of instruments, accessories and imaging products. In the third quarter, we added the ability to ship Xi Single-Site, Xi 30-millimeter stapler and Firefly to several countries. In addition, interoperative table motion uptake and performance is meeting our expectations. We are continuing to invest in the expansion and refinement of our base instrument, stapling and vessel sealing products for our Xi platform. 
New system platforms continue to make good progress. Our da Vinci single port is progressing in its in-house clinical evaluations and preparations for human clinical trials expected later this quarter. As we've discussed on prior calls, we plan first markets to include head and neck surgery, urology and colorectal surgery. 
SP is a platform technology that allows high-dexterity access with great 3D vision to confined surgical spaces. Commentary by surgeons after in-house evaluations have indicated strong interest in the clinical potential of this platform. 
In the quarter, we also announced the creation of a joint venture with Fosun Pharma, owner of our current da Vinci partner in China. The JV's first objectives are to work with ISI and Fosun to produce products that address an acute need in the diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection and treatment are important. 
The technology underpinning the system is based on computer-controlled catheters, advanced image processing and sophisticated sensing. It incorporates a substantial set of proprietary intellectual property developed, owned or licensed by Intuitive over the past several years. This system is in its early stages of our human clinical experience, and final clearance and launch targets are not yet set. That said, the raw capability of the technology is compelling, and it has the potential to perform as a broader diagnostic and treatment platform over time. 
Bringing new platforms to the market represents a significant investment. We've added approximately 400 employees year-to-date and expect increased fixed investments and some lumpiness in spending in future quarters as these platforms move through design, validation, data collection and early launch. 
As we close 2016, we have focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including new clearances, additional clinical and economic validation, training centers and the expansion of our product offerings; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who'll review financial highlights."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1307,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. 
We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
Third quarter 2016 revenue was $683 million, an increase of 16% compared with $590 million for the third quarter of 2015 and an increase of 2% compared with the second quarter revenue of $670 million. Third quarter 2016 procedures increased 14% compared with the third quarter of 2015 and decreased 1% compared with last quarter. Procedure growth relative to last year has been driven by general surgery in the U.S. and urology worldwide. The decrease relative to the prior quarter primarily reflects seasonality. 
Revenue highlights are as follows: Instrument and accessory revenue of $348 million increased 17% compared with last year and increased 3% compared with the second quarter of 2016. Growth in instruments and accessory revenue generally reflects procedure growth and increased sales of stapling and vessel sealing products. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,870 per procedure compared with $1,840 last year and $1,810 last quarter. The increases relative to the third quarter of 2015 and last quarter reflect increased sales for our stapling and vessel sealing products. The increase compared to the second quarter of 2016 also reflects the impact of customer buying patterns. 
System revenue of $205 million increased 18% compared with the third quarter of 2015 and increased 1% compared with last quarter. The year-over-year and quarter-over-quarter increases reflect higher system placements and higher revenue associated with lease buyouts, partially offset by lower average system selling prices. 
We generated approximately $13 million of revenue during the quarter from lease buyouts compared with $3 million in the third quarter of 2015 and $13 million last quarter. While lease buyouts are difficult to predict, we expect the level of fourth quarter lease buyouts to be below those of the third quarter.
134 systems were placed in the third quarter of 2016 compared with 117 systems in the third quarter of 2015 and 130 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 15 last quarter and 13 systems in the third quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the third quarter, there were 74 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $2 million in the third quarter of 2015 and approximately $4 million last quarter. We exclude the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system price was $1.53 million compared with $1.61 million last year and $1.56 million last quarter. The decreases compared with prior periods primarily reflect a lower mix of dual console systems, partially offset by a lower mix of trade-in systems in the third quarter of 2016. 
Service revenue of $130 million increased 10% year-over-year and increased approximately 1% compared with the second quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: Third quarter revenue outside of the U.S. of $189 million increased 25% compared with $151 million for the third quarter of 2015 and increased 2% compared with $185 million for the second quarter. The increase compared with the previous year is comprised of a 26% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 24%. The increase compared to the second quarter reflects systems revenue growth of 2% and recurring revenue growth of 2% in a seasonally slower quarter. 
Outside the U.S., we placed 49 systems in the third quarter compared with 37 in the third quarter of 2015 and 51 systems last quarter. 
Current quarter system sales included 18 into Europe, 2 into China, 11 into Japan and 18 in the rest of world markets. System placements outside of the U.S. will continue to be lumpy as some of the OUS markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales into some markets are constrained by government regulation.
Moving on to the remainder of the P&L. Pro forma gross margin for the third quarter of 2016 was 73.1% compared with 69.3% for the third quarter of 2015 and 71.9% for the second quarter of 2016. 
The pro forma gross margin for the third quarter of 2016 included $7.1 million of Medical Device Tax refunds. Without the Medical Device Tax refunds, our pro forma gross margin would have been the same as the second quarter or 72%. 
Compared with the third quarter of 2015, the higher gross margin reflects reduced product costs, the Medical Device Tax refunds and manufacturing efficiencies. 
Future margins will fluctuate based on the mix of our newer products, the mix of system and instrument and accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs and improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 14% compared with the third quarter of 2015 and increased approximately $6 million compared with last quarter. The increases reflect increased headcount, increased product development activity and investments in our OUS commercial organization. 
We added over 400 employees, primarily in the product operations area, over the past year. The increase compared with the prior quarter primarily reflects increased headcount costs. 
Our pro forma effective tax rate for the third quarter was 22.7% compared with an effective rate of 18.4% for the third quarter of 2015 and 27.8% last quarter. The pro forma third quarter of 2016 tax rate reflected $16 million of tax benefits or $0.40 per share realized as a result of the statute of limitation expirations in various jurisdictions. The third quarter of 2015 tax rate reflected $29 million or $0.77 per share related to a favorable tax court ruling involving an independent third party. Our tax rate will fluctuate with changes in the mix of OUS and U.S. income and with the impact of onetime items. 
Our third quarter 2016 pro forma net income was $246 million or $6.19 per share compared with $199 million or $5.24 per share for the third quarter of 2015 and $220 million or $5.62 per share for the second quarter of 2016. 
Excluding onetime income tax and Medical Device Tax benefits, pro forma net income would have been $225 million or $5.65 per share.
As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results. 
GAAP net income was $211 million or $5.31 per share for the third quarter of 2016 compared with $167 million or $4.40 per share for the third quarter of 2015 and $185 million or $4.71 per share for the second quarter of 2016. 
We ended the quarter with cash and investments of $4.6 billion, up from $4.2 billion as of June 30, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. During the first 3 quarters of 2016, global procedure growth was nearly 16%. In",993,"Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. 
During the first 3 quarters of 2016, global procedure growth was nearly 16%. In the United States, taken together, growth in our mature procedures slowed in the third quarter compared to the first half of the year. General and thoracic procedure growth remained healthy. 
In U.S. urology, third quarter growth in da Vinci Prostatectomy slowed to low single-digit growth, a level that we believe to be similar to the overall rate of diagnoses of new prostate cancers. We believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market. 
In U.S. gynecology, third quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists during the third quarter. Procedures for benign gynecologic conditions grew modestly during the third quarter, continuing a trend from the first half of the year. 
Third quarter U.S. general and thoracic surgery procedure adoption remained strong, led by solid growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and existing surgeon retention and utilization remains encouraging. 
Cholecystectomy procedures declined in the quarter, with growth in multi-port procedures being offset by declines in Single-Site procedures. Early-stage adoption of lobectomies and other thoracic procedures is encouraging. 
Last month at the global symposium on robotic-assisted and minimally-invasive hernia repair, several new data sets comparing da Vinci to open and laparoscopic hernia repair were presented. Among the most notable presentations, Dr. Rosen from the Cleveland Clinic presented new data on retromuscular ventral hernia repair from the American Hernia Society's Quality Collaborative or the AHSQC. 
In a prospective cohort of more than 400 patients, case-matched between da Vinci and open surgery, da Vinci surgery was shown to reduce the length of hospitalization by 2.5 days compared to open surgery, with similar levels of wound outcomes, readmissions and reoperations. Intuitive is a founding partner of AHSQC and we are supporting its expansion to include data for inguinal hernia repair. 
Turning abroad. Procedure growth outside of the United States was approximately 25% in the third quarter, led by the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures. Total procedure growth in Europe and Asia was similar to the first half of the year, though procedure performance varied by country.  Strong growth continued in China, South Korea, Japan and Germany. 
While adoption of da Vinci in urology is the primary driver of procedure growth outside of the United States, we are seeing multi-specialty adoption in certain countries. In China, roughly half of the year-to-date procedure growth has come from categories outside of urology. In South Korea, approximately 60% of the year-to-date procedures have come from categories outside of urology. 
We are investing in the development of clinical evidence to support the adoption of da Vinci surgery in markets around the world. Globally, we support several evidence initiatives and registries, including AHSQC, gynecologic oncology societal registries in the U.S. and Europe, and the colorectal registry in Europe. 
In the U.S., we are also supporting several comparative prospective and retrospective multicenter studies on hernia repair, colorectal surgery and thoracic surgery. Outside of the United States, we are sponsoring clinical studies in Japan to support reimbursement submissions for malignant hysterectomy and gastrectomy. In Europe, we provide support for studies in colorectal, thoracic and gynecological oncology. 
We are committed to developing local evidence in key markets to support the adoption of da Vinci surgery where our technology can bring value to hospitals, surgeons, patients. 
Third quarter was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I've selected a few studies that you may find interesting. Dr. Dalesh [ph] and colleagues from Indiana University published a study in Surgical Endoscopy comparing da Vinci to laparoscopic colorectal procedures captured in the American College of Surgeons' National Surgical Quality Improvement Project or NSQIP database from 2011 through 2014. 
Including over 27,000 procedures across a range of colon and rectal resections, in exchange for an approximate 45-minute longer operative time, da Vinci low anterior resections and right colectomies showed a reduction in conversion rates. Left colectomies trended towards a reduction in conversion rates without statistical significance. Low anterior resections also showed a lower rate of sepsis with a higher rate of diverting ostomy. Across all cohorts, da Vinci surgery generated a reduction in length of hospital stay. 
The next study was published by Dr. Ozben and colleagues from the Acibadem University in Istanbul, Turkey in the Journal of Surgical Laparoscopy, Endoscopy and Percutaneous Technologies. In a small case series, the authors compared their performance in performing rectal resections on da Vinci Xi to da Vinci Si. They found that da Vinci Xi was associated with an approximate 40 minutes of reduced operative time. The reduction in operative time was attributable to an elimination of double docking and hybrid surgeries in the da Vinci Xi cohort. The surgeons also found the da Vinci Xi patient population experienced an increase in lymph nodes harvested and quicker return of bowel function with a 1 day longer length of hospital stay. 
The authors concluded ""The Xi generation appeared to allow shorter console times, and its broader capabilities promise to make it a lot easier for surgeons to perform this complex robotic procedure."" 
While this study highlights the enhanced workflow capabilities of da Vinci Xi for multi-quadrant surgery such as rectal resection, our da Vinci Si installed base has remained stable in 2016 as customers continue to find value in its utilization. 
Taken together, procedures performed on da Vinci Si and Xi platforms represented over 95% of our third quarter procedures. 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015.",526,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. 
On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015. Now as we enter the fourth quarter, we continue to forecast full year procedure growth of 14% to 15%, likely towards the higher end of the range. 
With regard to Q4 2016 system placements, we directionally expect system placements for the quarter to follow recent seasonal trends. However, we anticipate system placements outside of the U.S. will continue to be lumpy as some of our U.S. -- OUS markets are in early stages of adoption and sales into some markets are constrained by government regulations. 
Recall, we placed 13 systems into China and 7 systems into Brazil in the fourth quarter of 2015. As the quota in China expired in 2015 and a new quota has not yet been issued and as we are in the very early stages of adoption in Brazil, we do not expect comparables and placements into these markets in the fourth quarter of 2016. 
Also, we believe that the flexibility we have offered customers in the form of operating leases has been well received. As a result, as compared to prior periods, we expect a higher proportion of Q4 2016 placements to be under operating leases, with revenue recognized in future periods. 
Finally, we expect to see a lower number of lease buyouts in the fourth quarter compared to the previous 2 quarters, given the lower number of short-term leases that are outstanding at this time. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. We now expect our full year 2016 pro forma gross profit margin to be approximately 71.5% of net revenue. 
As Marshall indicated, the third quarter benefited from a $7.1 million Medical Device Tax refund. Excluding that benefit, our gross profit margin would have been 72%. We expect our fourth quarter margin to be directionally lower than the third quarter, primarily due to product mix. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will continue to accelerate. On our last call, we forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels. We are now refining this range to 13% to 14%. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015.
We expect other income to total approximately $33 million in 2016, higher than the $30 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, consistent with previous guidance, we expect our Q4 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America.",15,"[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on",83,"So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on the Medical Device Taxes and the $7 million, could you explain why that is onetime? And then on the system sales guidance that you're providing, is that essentially suggesting that systems will be globally roughly flat in Q4?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have",125,"Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have -- we've received the money, and there has been an audit, so we're all done with that. Second question had to do with the level of systems. Now, I think that what Calvin said was that the systems are seasonally stronger in Q4. What he was trying to set up, however, was that relative to the prior year, there's some hard comparables, given that we had some markets that are rather lumpy like China and Brazil."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue.",33,"You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little",109,"So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more color on what this is. Like, is this a new -- is this a new totally new system or just an add-on to Xi? Just -- should we think about it as being a couple of years away from commercialization? Or is it really a longer-term project? I'm just sort of wondering if you could provide some perspective."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along",225,"Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with some special sensing technologies and some image analysis. Currently -- the current configuration it's in, it's a stand-alone. Those types of technologies in the future could be integrated into other things, and we won't preclude ourselves from doing that. We do conceive of it as a way to access the body through natural orifices and other means, where you want to follow a prescribed pathway to get to some deep place in the body and do something. Our first clinical interest is in biopsying lung cancers or biopsying suspicious lesions in the lung. We think that, that is important globally and particularly important in China. And as a result, the partnership with Fosun, who we've known through their Chindex company for many years, made a lot of sense to us. And we're excited about it. We're not ready to give you commercial timelines yet. The technology is mature enough that we're in our initial human clinical experience. That's really the very beginnings for us, and as we get greater clarity on our launch timelines and thoughts, we'll share them with you."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Now we'll go to the line of David Lewis with Morgan Stanley.",13,"Now we'll go to the line of David Lewis with Morgan Stanley."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has u",172,"Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has usually been about one system. I know you have multiple configurations, but in this quarter alone, Xi was still 75% of new placements. But if I think about the next 2 years, right, you're still going to have Xi and all those multiple Intuitive prior systems. You have XSP, and you're also now going to have this catheter-based sensing system. So I wonder if you could help us understand are we right to think about this company as morphing these next 2 years? And how does supporting sort of multiple platforms now impact the addressable markets you can serve, your ability to accelerate growth and, obviously, just flat out R&D spending across these platforms? I know it's a big question, but I think it's an important one."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with convention",322,"Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional technologies, open surgery, conventional laparoscopy or with Xi. So we think SP can broaden clinically what surgeons can do. I think that will start in niches and then we'll move out into broader applications as we gain clinical experience. It does increase our support load a little bit in terms of complexity with regard to the SP, just because it's a new set of instruments and add-on accessories. But it's not an entirely new set of computational platform and things like that. As you start thinking about the catheter-based technologies, again, that's a new set of technologies. You had kind of framed it in a 2-year horizon. I would stretch that horizon out a little bit. I wouldn't anchor us there. I do think that takes us to different places. I think it allows access to parts of the body that you may not think of surgically. It may be more around diagnostics. And I think it will open up to practitioners' ways of approaching tissue that they just haven't thought about before. And that's why we're doing it. That -- you've seen us increase our R&D spend, and we've been both talking about it and doing it, and part of it has been investing in these technologies. And I think it matters. I think as people look -- as we look from the bottom of your feet to the top of your head and look for opportunities to get better outcomes, we think of a variety of technologies from access technologies to imaging technologies to computational technologies that can really make a difference, and that's -- we're putting our money where our mouth is."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the sp",135,"And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the spending comments you've made, I don't think it's realistic for investors to expect 200 basis points of margin expansion in '17. Based on your comments on spending and what you're going to have to do to support these platforms, I mean, how should we sort of calibrate our thinking next year between sort of an extraordinary 2016 expansion and a more moderate 2015 margin expansion? Should we be thinking about something between those 2 poles as more appropriate than what we are seeing this year, which seems very outsized?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than ex",163,"Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than existing products. And so if there were -- as we introduced stapling, for example, we saw a decline in margin initially. As we improved the manufacturability and efficiency of the manufacturing processes, we've seen improvements in margins. So I'm not going to predict what we're going to do next year. I would just say that there are a lot of moving parts. Mix, geographically, also has an impact. Mix between systems and instruments and accessories has an impact. There's just a lot of variables that go into it. I think what you've seen this last year, though, is outstanding performance by our manufacturing group to reduce the cost of newer products that were lower margin a year ago."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the Europe",68,"Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the European business, did you see any impact from Brexit? Or do you just think this is lumpiness that always occurs generally in your business?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyw",134,"Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyway, that NHS England has been looking at how to spend their money and trying to cover budget shortfall. So there's been pressure there for some time. Brexit likely doesn't help. With regard to Europe more broadly, it really is varying country-by-country. Some places, we see reasonable growth and support. Other countries have been a little bit more of a struggle. And the response to that really has been to increase local presence, increase local data generation and be in close contact with government payers and private payers."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Tycho Peterson from JPMorgan.",11,"Next, we'll go to the line of Tycho Peterson from JPMorgan."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when",55,"I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when that does roll out?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce",52,"We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce those costs."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall",66,"But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall quantities. So just based on magnitude, it's probably not going to have as big an impact on the overall margin."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?",45,"Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we p",124,"Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we performed a verification audit of our installed base records, which identified -- and identified 43 system, mostly older standard and S models, which had been retired. So we went and removed those retired systems from our installed base during the quarter. So I think the trade-out number was 33, and then most of the rest here was just kind of this adjustment we made to the base. So the trade-ins were pretty, I think, in line with previous periods."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?",39,"Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And w",165,"Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And we're also going to see additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products. And those technologies, it's nice to do tuck-ins and small licensing arrangements that we've done in the past, and we'll try to do those. But it may be that we have to buy -- to pay a greater dollar to get some of that technology in the future. So we want to have money for those things. Beyond that, to the extent that we have the right opportunity to buy back stock and return shares -- money to shareholders, we'll take that opportunity, but we'll do that opportunistically as we have in the past."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Ben Andrew with William Blair.",12,"Next, we'll go to the line of Ben Andrew with William Blair."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be",73,"Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be looking at to get something through once you've finished developments and you've done some human testing to approval? Is it quicker there? Or is it similar to the U.S.?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various p",96,"Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various products in China, typically, in our past, it's been a little bit longer process than it has in the U.S. What that looks like going forward, in particular for the new products we're talking about, I can't speak to at this time. We just don't have enough information on it."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrabl",62,"Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrably or -- that, plus the ROW placements sort of got my attention relative to some emerging opportunities overseas."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and",65,"Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and gynecologic oncology, are still fairly small. So countries like the Nordic countries, places like the U.K., where we're pretty deep, you see those growth rates slow."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are",68,"Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in hernia and kind of the trajectory of adoption relative to some of the historical fast-adopting procedures, if you would."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology h",121,"Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology has been adopted. Now hernia repair, though, is not one thing. So there's a variety of patient subsets within, a variety of different physician perspectives around the value that our technology can bring in the procedure. And so it's probably not quite like dVP in terms of the way you would think of it as being adopted. Maybe a little more benign hysterectomy, given the alternative therapies and the heterogeneous landscape out there in terms of how they address these patients."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other",66,"Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other than stapling and vessel sealing, was there anything in particular in there that caught your attention relative to mix?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actua",229,"Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actually dropped down to $1,810, and we talked about timing of orders being the main factor here. So as expected here in Q3, we saw orders rebound to offset Q2. And if you take the average of Q2 and Q3, you're right back at the $1,840, kind of in line with those trends over the past couple of years. As we said, though, we continue to see increasing utilization of the advanced instruments, including the stapler and vessel sealer. And moving forward, as we anticipate continued growth in the procedure volumes in colorectal and thoracic surgery, areas where these products are more widely used, we would anticipate a slightly higher contribution to revenue per procedure on an organic consumption model, if you will. But it's important to remember that a variety of factors impact revenue per procedure, including the type or procedure performed, the efficiency of use and optimization, use of advanced instruments, stocking orders, timing and distributors. So there's a lot of factors here. So as a result, I&A, it can be lumpy, and future trends can be difficult to forecast in the end."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Amit Hazan with Citi.",12,"Next we'll go to the line of Amit Hazan with Citi."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast",113,"Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast change in what, otherwise, would seem to me to be something that would be a slower trend line. Any more color you can add as to what's happening now and why it's happening and maybe, more importantly, just the confidence you guys have that this quarter kind of marks that bottom and that incident rate growth is kind of your right rate of growth for prostate."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thoug",121,"Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thought were consistent with the rate of diagnoses. It's hard to say in the quarter or the rate at which we've seen growth change over the course of this year. The specifics behind it, that data, typically comes to us years down the road. But we feel that the -- what we saw in the quarter is probably more consistent with the rate of diagnoses than perhaps what we've seen over the past handful of quarters."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this i",137,"Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this in a while, so I'll just throw this question out, just as one possible avenue. Just thinking about outpatient centers, ambulatory surgery centers, is there -- to what extent -- or is there kind of any increase in the success that you're having in being able to place da Vincis in outpatient centers? Is that becoming more of a focus for you at all? And is that at all a part of maybe the slightly better rates of growth we're seeing in gynecology in the U.S?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume cent",126,"Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume centers. Separately, there is a trend toward more outpatient work. We do see utilization of our systems in outpatient environments; that tends to be more in existing integrated delivery networks, possible loaned [ph] outpatient departments as part of a integrated plan. It's not something I'd call out as a major trend at this point. I'm not sure that I would quite link it to GYN. It's possible, but I think there are a lot of factors there that sorting them is not possible yet."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive s",62,"If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive surgery is adopted with the technology, it will enable hospitals to manage these patients in a more outpatient-oriented way."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10%",108,"Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10% a year. Almost every quarter, it seems like it grows about 10 -- on that 10% rate on an annual basis. Can you maybe just talk through the key drivers and maybe pressure points as we think about that number and the sustainability of that 10% growth in the installed base growth figure as you think through the next year or 2?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is",137,"A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest driver and where they see growth, I think that they move forward. The places where that can be a little bit different or disconnected is in a very early market where you're just getting started. So a new reimbursement clearance or a new quote or a new procedure clearance don't -- doesn't follow the more mature trend. So those are the 2 things that are rolling around. I think the biggest one for us is customer belief and utilization for future procedures as the best predictor of capital."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Rick Wise from Stifel, Nicolaus.",12,"Next, we'll go to the line of Rick Wise from Stifel, Nicolaus."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geogra",76,"Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geographic or technology? Or I mean, is this a direction we should expect Intuitive to push looking for other technologies to bring into the ecosystem? Is that the right way to think about it?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity",136,"I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity for us? Yes. They tend to develop in time. The underlying catheter-based technologies that we're talking about now, as you know, having followed us for some time, were really first acquired by us years ago. So the answer to that is yes. We're out looking. Fosun has been a good partner. They have both a relationship with us through Chindex, but they also understand the healthcare space extremely well in multiple dimensions. And so the short answer to that is we've been doing it and expect to continue to do it."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings,",72,"A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings, rather? And maybe, particularly on colorectal, how do you accelerate colorectal adoption? Do we need more clinical data? Can you talk through some of those issues?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's",222,"Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's large value, distinct value for the procedure relative to alternatives and when the procedure is pretty well concentrated in the hands of well-trained surgeons. So take colorectal and separate it a little bit. In the case of rectal cancer, that's a complex set of procedures. Oncologic, of course, in nature, has been growing steadily. Not a super rapid rise relative to some prior adoptions, but a steady adoption for us. And data collection has been occurring, data publication has been occurring, and we're doing okay there. I think in other parts of colon, sometimes it's for benign, sometimes it's oncology. Those are typically done by different surgeons. And so they adopt at little bit different rates. You look at hernia, again, it's sub-segmented, ventral hernia versus inguinal and subsegments within inguinal. So we look at it. Ventral hernia and inguinal hernia, as we define the available markets for procedures for which we bring value, have adopting pretty nicely relative to past trends. Rectal has been on a slower adoption but a steady one, and colon is in the middle."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math wi",88,"And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math with what we're seeing internationally, should we feel reasonably optimistic that something like mid-teens procedure growth, again, with some variation? Is that the right sustainable growth rate from here, given the growing installed base, given the geographic penetration and given the continuing evolution of Intuitive technology?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January.",37,"Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We'll go to the line of Larry Biegelsen with Wells Fargo.",12,"We'll go to the line of Larry Biegelsen with Wells Fargo."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -",75,"So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -- it sounds like -- is that a good rate to use going forward? And I had a couple of follow ups."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for",87,"Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for international to support the earlier phase growth there. So you look at it overall, we're within our guidance range. We refined our full year guidance to that 13% to 14%. So again, there'll be some quarter variability, but I think we're tracking to the overall plan."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through.",28,"And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?",37,"Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time.",47,"Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?",43,"Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?"
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything abo",119,"It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything about adoption that I'd call out strongly at this time. I think both of them are moving through that first set of adopters, generating additional data. We're seeing more data now, generally supportive; it looks pretty good. I think that technique refinement and data generation is what the next round of surgeons rely upon to evaluate. And so we're seeing that kind of transition right now, really in both of those hernia domains."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our final question will come from Brandon Henry with RBC Capital Markets.",12,"Our final question will come from Brandon Henry with RBC Capital Markets."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And t",94,"So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And then separately, the company's headcount has increased meaningfully over the last couple of quarters. Can you discuss where you're making the investments in headcount? And then how much of that increase in headcount can be attributed to the Fosun JV versus some other initiatives? And then I have a follow up."
30239,402358121,1057134,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it i",341,"That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it is a routine discipline of scanning through both operating processes and manufacturing processes and parts costs and working them down as they come. You do get the first -- the greatest help on those things in the first few years of a platform release. And then after that, it starts getting increasingly hard. It's not specifically to say that it isn't possible to do it. In terms of headcount growth, it's a mixture of commercial growth, a little bit more weighted outside the U.S. than U.S., some manufacturing growth to cover volumes of things like instruments and accessories and other things that have been increasing as well as some design help. The headcount growth, as it relates to Fosun, we're not really to break out at this time. We have certainly made headcount investments over the last few years into the technologies that have underpinned that relationship. But it's not -- I wouldn't call it out as Fosun just yet. 
With that, I'll go ahead and close the call. And then we'll catch your next question on the next conference call. That was the last question. 
As we've said previously, while we focus on financial metrics, such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Se",51,"Ladies and gentlemen, thank you for standing by, and welcome to the Intuitive Surgical Third Quarter 2016 Earnings Release Call. [Operator Instructions] As a reminder, this conference is being recorded. 
I would now like to turn the conference over to Senior Director of Finance, Investor Relations, Calvin Darling. Please go ahead."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance a",266,"Thank you. Good afternoon, and welcome to Intuitive Surgical's Third Quarter Earnings Conference Call. With me today, we have Gary Guthart, our President and CEO; Marshall Mohr, our Chief Financial Officer; and Patrick Clingan, Vice President of Finance and Sales Operations. 
Before we begin, I would like to inform you that comments mentioned on today's call may be deemed to contain forward-looking statements. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties. These risks and uncertainties are described in detail in the company's Securities and Exchange Commission filings, including our most recent Form 10-K filed on February 2, 2016, and 10-Q filed on July 20, 2016. These filings can be found through our website or at the SEC's EDGAR database. Prospective investors are cautioned not to place undue reliance on such forward-looking statements.
Please note that this conference call will be available for audio replay on our website at intuitivesurgical.com on the Audio Archives section under our Investor Relations page. In addition, today's press release and supplementary financial data tables have been posted to our website. 
Today's format will consist of providing you with highlights of our third quarter results, as described in our press release announced earlier today, followed by a question-and-answer session. Gary will present the quarter's business and operational highlights. Marshall will provide a review of our third quarter financial results. Patrick will discuss procedure and clinical highlights, then I will provide our updated financial outlook for 2016. And finally, we will host a question-and-answer session. 
With that, I'll turn it over to Gary."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. Global procedure growth was over 14% year-over-year in the",951,"Good afternoon, and thank you for joining us on the call today. Our company performance in the quarter was solid, with increasing customer adoption of procedures and growth in system placements. 
Global procedure growth was over 14% year-over-year in the quarter. Drivers of growth centered on U.S. general surgery and growth in the use of da Vinci Surgical Systems outside the United States. In the United States, year-over-year growth in ventral and inguinal hernia repair continues to be strong. U.S. colon resection and lung resection also contributed to solid growth. As we've stated in prior calls, we are expecting growth rates in mature procedures in the U.S. to moderate, and U.S. dVP is starting to follow this pattern, driven by the macroeconomic environment for prostate cancer diagnosis and treatment. 
In Europe, procedure growth tempered in the quarter, with some countries posting solid performance while growth softened in others. 
We're pleased with growth in procedures in Asia, with Korea and China, in particular, demonstrating continued strength. Patrick will review procedure trends in greater detail later in the call. 
We placed 134 da Vinci systems in the quarter, up from 117 in Q3 of 2015. While we offer a range of models and price points, our most capable model, da Vinci Xi, again represented roughly 3/4 of new capital placements. As we've said on previous calls, capital placements are lumpy, and this quarter was no exception. 
Healthy placements stood out in the U.S., while placements in our European regions softened relative to a year ago. Capital placements in Asia are particularly unpredictable, given environment constraints like reimbursements in Japan and quotas in China. Placements in Asia were in line with prior quarters. 
Turning to revenue and gross margin dynamics. We experienced some onetime tailwinds in the quarter that contributed to higher-than-expected net income. Marshall will take you through these events and our general finances in greater detail later in the call. 
Turning to highlights of our third quarter operating results. Procedures grew approximately 14% over the fourth -- third quarter of last year. We shipped 134 da Vinci Surgical Systems, up from 117 in the third quarter of 2015. Revenue for the quarter was $683 million, up 16% from the prior year. Pro forma gross profit margin was 73.1% compared to 16 -- 69.3% in the third quarter of last year. Instrument and accessory revenue increased to $348 million, up 17%. Total recurring revenue in the quarter was $478 million, representing 70% of total revenue. We generated a pro forma operating profit of $308 million in the quarter, up 28% from the third quarter of last year. And pro forma net income was $246 million, up 23% from Q3 of 2015. 
As we discussed with you on our last call, as our business has strengthened, we have increased our mid- and long-term investments in creating our next generation of products and services. We've been increasing these investments based on our belief that our -- that substantial opportunity exists to enable better outcomes and to expand access to our technologies globally. 
We continue to enhance features and expand access to our Xi suite of instruments, accessories and imaging products. In the third quarter, we added the ability to ship Xi Single-Site, Xi 30-millimeter stapler and Firefly to several countries. In addition, interoperative table motion uptake and performance is meeting our expectations. We are continuing to invest in the expansion and refinement of our base instrument, stapling and vessel sealing products for our Xi platform. 
New system platforms continue to make good progress. Our da Vinci single port is progressing in its in-house clinical evaluations and preparations for human clinical trials expected later this quarter. As we've discussed on prior calls, we plan first markets to include head and neck surgery, urology and colorectal surgery. 
SP is a platform technology that allows high-dexterity access with great 3D vision to confined surgical spaces. Commentary by surgeons after in-house evaluations have indicated strong interest in the clinical potential of this platform. 
In the quarter, we also announced the creation of a joint venture with Fosun Pharma, owner of our current da Vinci partner in China. The JV's first objectives are to work with ISI and Fosun to produce products that address an acute need in the diagnosis and cost-effective treatment of lung cancer, one of the most commonly diagnosed forms of cancer in the world and for which early detection and treatment are important. 
The technology underpinning the system is based on computer-controlled catheters, advanced image processing and sophisticated sensing. It incorporates a substantial set of proprietary intellectual property developed, owned or licensed by Intuitive over the past several years. This system is in its early stages of our human clinical experience, and final clearance and launch targets are not yet set. That said, the raw capability of the technology is compelling, and it has the potential to perform as a broader diagnostic and treatment platform over time. 
Bringing new platforms to the market represents a significant investment. We've added approximately 400 employees year-to-date and expect increased fixed investments and some lumpiness in spending in future quarters as these platforms move through design, validation, data collection and early launch. 
As we close 2016, we have focused on the following: first, expanding the use of da Vinci in general and thoracic surgery, particularly colorectal surgery and hernia repair; second, advancing our ecosystem, including new clearances, additional clinical and economic validation, training centers and the expansion of our product offerings; third, driving our organizational capabilities in markets in Europe and Asia; and finally, assisting our customers in their efforts to maximize the comprehensive value of their programs. 
I'll now turn the call over to Marshall, who'll review financial highlights."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. We provide pro forma information because we belie",1307,"Thank you, Gary. I'll be describing our results on a non-GAAP or pro forma basis, which excludes specified legal settlements and claim accruals, stock-based compensation and amortization of purchased IP. 
We provide pro forma information because we believe that business trends and operating results are easier to understand on a pro forma basis. I will also summarize our GAAP results later in my script. We have posted reconciliations of our pro forma results to our GAAP results on our website so that there's no confusion. 
Third quarter 2016 revenue was $683 million, an increase of 16% compared with $590 million for the third quarter of 2015 and an increase of 2% compared with the second quarter revenue of $670 million. Third quarter 2016 procedures increased 14% compared with the third quarter of 2015 and decreased 1% compared with last quarter. Procedure growth relative to last year has been driven by general surgery in the U.S. and urology worldwide. The decrease relative to the prior quarter primarily reflects seasonality. 
Revenue highlights are as follows: Instrument and accessory revenue of $348 million increased 17% compared with last year and increased 3% compared with the second quarter of 2016. Growth in instruments and accessory revenue generally reflects procedure growth and increased sales of stapling and vessel sealing products. 
Instrument and accessory revenue realized per procedure, including initial stocking orders, was approximately $1,870 per procedure compared with $1,840 last year and $1,810 last quarter. The increases relative to the third quarter of 2015 and last quarter reflect increased sales for our stapling and vessel sealing products. The increase compared to the second quarter of 2016 also reflects the impact of customer buying patterns. 
System revenue of $205 million increased 18% compared with the third quarter of 2015 and increased 1% compared with last quarter. The year-over-year and quarter-over-quarter increases reflect higher system placements and higher revenue associated with lease buyouts, partially offset by lower average system selling prices. 
We generated approximately $13 million of revenue during the quarter from lease buyouts compared with $3 million in the third quarter of 2015 and $13 million last quarter. While lease buyouts are difficult to predict, we expect the level of fourth quarter lease buyouts to be below those of the third quarter.
134 systems were placed in the third quarter of 2016 compared with 117 systems in the third quarter of 2015 and 130 systems last quarter. 15 systems were placed under operating lease transactions in the current quarter compared with 15 last quarter and 13 systems in the third quarter of 2015. As a reminder, revenue on operating lease transactions is recognized ratably over the life of the lease. 
As of the end of the third quarter, there were 74 systems out in the field under operating leases. We generated approximately $4 million of revenue associated with operating leases in the quarter compared with $2 million in the third quarter of 2015 and approximately $4 million last quarter. We exclude the impact of operating leases and lease buyouts from our system ASP calculations. 
Globally, our average system price was $1.53 million compared with $1.61 million last year and $1.56 million last quarter. The decreases compared with prior periods primarily reflect a lower mix of dual console systems, partially offset by a lower mix of trade-in systems in the third quarter of 2016. 
Service revenue of $130 million increased 10% year-over-year and increased approximately 1% compared with the second quarter of 2016. The year-over-year and quarter-over-quarter increases reflect growth in our installed base of da Vinci systems. 
Outside of the U.S., results were as follows: Third quarter revenue outside of the U.S. of $189 million increased 25% compared with $151 million for the third quarter of 2015 and increased 2% compared with $185 million for the second quarter. The increase compared with the previous year is comprised of a 26% growth in recurring revenue, which is driven by procedure growth of 25% and increased systems revenue of 24%. The increase compared to the second quarter reflects systems revenue growth of 2% and recurring revenue growth of 2% in a seasonally slower quarter. 
Outside the U.S., we placed 49 systems in the third quarter compared with 37 in the third quarter of 2015 and 51 systems last quarter. 
Current quarter system sales included 18 into Europe, 2 into China, 11 into Japan and 18 in the rest of world markets. System placements outside of the U.S. will continue to be lumpy as some of the OUS markets are in the early stages of adoption. Some markets are highly seasonal, reflecting budget cycles or vacation patterns and sales into some markets are constrained by government regulation.
Moving on to the remainder of the P&L. Pro forma gross margin for the third quarter of 2016 was 73.1% compared with 69.3% for the third quarter of 2015 and 71.9% for the second quarter of 2016. 
The pro forma gross margin for the third quarter of 2016 included $7.1 million of Medical Device Tax refunds. Without the Medical Device Tax refunds, our pro forma gross margin would have been the same as the second quarter or 72%. 
Compared with the third quarter of 2015, the higher gross margin reflects reduced product costs, the Medical Device Tax refunds and manufacturing efficiencies. 
Future margins will fluctuate based on the mix of our newer products, the mix of system and instrument and accessory revenue, costs associated with our scope exchange program, our ability to further reduce product costs and improve manufacturing efficiency and, in the long term, the potential reinstatement of the Medical Device Tax. 
Pro forma operating expenses increased 14% compared with the third quarter of 2015 and increased approximately $6 million compared with last quarter. The increases reflect increased headcount, increased product development activity and investments in our OUS commercial organization. 
We added over 400 employees, primarily in the product operations area, over the past year. The increase compared with the prior quarter primarily reflects increased headcount costs. 
Our pro forma effective tax rate for the third quarter was 22.7% compared with an effective rate of 18.4% for the third quarter of 2015 and 27.8% last quarter. The pro forma third quarter of 2016 tax rate reflected $16 million of tax benefits or $0.40 per share realized as a result of the statute of limitation expirations in various jurisdictions. The third quarter of 2015 tax rate reflected $29 million or $0.77 per share related to a favorable tax court ruling involving an independent third party. Our tax rate will fluctuate with changes in the mix of OUS and U.S. income and with the impact of onetime items. 
Our third quarter 2016 pro forma net income was $246 million or $6.19 per share compared with $199 million or $5.24 per share for the third quarter of 2015 and $220 million or $5.62 per share for the second quarter of 2016. 
Excluding onetime income tax and Medical Device Tax benefits, pro forma net income would have been $225 million or $5.65 per share.
As I indicated earlier, pro forma income provides an easier comparison of our financial results and business trends. I will now summarize our GAAP results. 
GAAP net income was $211 million or $5.31 per share for the third quarter of 2016 compared with $167 million or $4.40 per share for the third quarter of 2015 and $185 million or $4.71 per share for the second quarter of 2016. 
We ended the quarter with cash and investments of $4.6 billion, up from $4.2 billion as of June 30, 2016. The increase was primarily driven by cash generated from operations and proceeds from stock option exercises. As our cash builds, we will continue to evaluate our approach to capital allocation. 
And with that, I'd like to turn it over to Patrick, who will go over our procedure and clinical highlights."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. During the first 3 quarters of 2016, global procedure growth was nearly 16%. In",993,"Thanks, Marshall. Of our third quarter procedure growth of 14%; U.S. procedures grew approximately 11%; and outside of the United States, procedures grew approximately 25%. 
During the first 3 quarters of 2016, global procedure growth was nearly 16%. In the United States, taken together, growth in our mature procedures slowed in the third quarter compared to the first half of the year. General and thoracic procedure growth remained healthy. 
In U.S. urology, third quarter growth in da Vinci Prostatectomy slowed to low single-digit growth, a level that we believe to be similar to the overall rate of diagnoses of new prostate cancers. We believe that our U.S. prostatectomy volumes have been tracking to the broader prostate surgery market. 
In U.S. gynecology, third quarter procedures grew modestly year-over-year, with growth led by malignant and complex benign hysterectomy. Continuing the recent trend, we estimate a larger proportion of da Vinci hysterectomy procedures were performed by gynecologic oncologists during the third quarter. Procedures for benign gynecologic conditions grew modestly during the third quarter, continuing a trend from the first half of the year. 
Third quarter U.S. general and thoracic surgery procedure adoption remained strong, led by solid growth in hernia repair and continued adoption of colorectal procedures. Hernia repair continues to contribute the largest volume of new procedures in general surgery, and existing surgeon retention and utilization remains encouraging. 
Cholecystectomy procedures declined in the quarter, with growth in multi-port procedures being offset by declines in Single-Site procedures. Early-stage adoption of lobectomies and other thoracic procedures is encouraging. 
Last month at the global symposium on robotic-assisted and minimally-invasive hernia repair, several new data sets comparing da Vinci to open and laparoscopic hernia repair were presented. Among the most notable presentations, Dr. Rosen from the Cleveland Clinic presented new data on retromuscular ventral hernia repair from the American Hernia Society's Quality Collaborative or the AHSQC. 
In a prospective cohort of more than 400 patients, case-matched between da Vinci and open surgery, da Vinci surgery was shown to reduce the length of hospitalization by 2.5 days compared to open surgery, with similar levels of wound outcomes, readmissions and reoperations. Intuitive is a founding partner of AHSQC and we are supporting its expansion to include data for inguinal hernia repair. 
Turning abroad. Procedure growth outside of the United States was approximately 25% in the third quarter, led by the global adoption of da Vinci Prostatectomy, with solid contributions from kidney procedures. Total procedure growth in Europe and Asia was similar to the first half of the year, though procedure performance varied by country.  Strong growth continued in China, South Korea, Japan and Germany. 
While adoption of da Vinci in urology is the primary driver of procedure growth outside of the United States, we are seeing multi-specialty adoption in certain countries. In China, roughly half of the year-to-date procedure growth has come from categories outside of urology. In South Korea, approximately 60% of the year-to-date procedures have come from categories outside of urology. 
We are investing in the development of clinical evidence to support the adoption of da Vinci surgery in markets around the world. Globally, we support several evidence initiatives and registries, including AHSQC, gynecologic oncology societal registries in the U.S. and Europe, and the colorectal registry in Europe. 
In the U.S., we are also supporting several comparative prospective and retrospective multicenter studies on hernia repair, colorectal surgery and thoracic surgery. Outside of the United States, we are sponsoring clinical studies in Japan to support reimbursement submissions for malignant hysterectomy and gastrectomy. In Europe, we provide support for studies in colorectal, thoracic and gynecological oncology. 
We are committed to developing local evidence in key markets to support the adoption of da Vinci surgery where our technology can bring value to hospitals, surgeons, patients. 
Third quarter was another quarter with a large number of clinical publications evaluating da Vinci surgery. Of these, I've selected a few studies that you may find interesting. Dr. Dalesh [ph] and colleagues from Indiana University published a study in Surgical Endoscopy comparing da Vinci to laparoscopic colorectal procedures captured in the American College of Surgeons' National Surgical Quality Improvement Project or NSQIP database from 2011 through 2014. 
Including over 27,000 procedures across a range of colon and rectal resections, in exchange for an approximate 45-minute longer operative time, da Vinci low anterior resections and right colectomies showed a reduction in conversion rates. Left colectomies trended towards a reduction in conversion rates without statistical significance. Low anterior resections also showed a lower rate of sepsis with a higher rate of diverting ostomy. Across all cohorts, da Vinci surgery generated a reduction in length of hospital stay. 
The next study was published by Dr. Ozben and colleagues from the Acibadem University in Istanbul, Turkey in the Journal of Surgical Laparoscopy, Endoscopy and Percutaneous Technologies. In a small case series, the authors compared their performance in performing rectal resections on da Vinci Xi to da Vinci Si. They found that da Vinci Xi was associated with an approximate 40 minutes of reduced operative time. The reduction in operative time was attributable to an elimination of double docking and hybrid surgeries in the da Vinci Xi cohort. The surgeons also found the da Vinci Xi patient population experienced an increase in lymph nodes harvested and quicker return of bowel function with a 1 day longer length of hospital stay. 
The authors concluded ""The Xi generation appeared to allow shorter console times, and its broader capabilities promise to make it a lot easier for surgeons to perform this complex robotic procedure."" 
While this study highlights the enhanced workflow capabilities of da Vinci Xi for multi-quadrant surgery such as rectal resection, our da Vinci Si installed base has remained stable in 2016 as customers continue to find value in its utilization. 
Taken together, procedures performed on da Vinci Si and Xi platforms represented over 95% of our third quarter procedures. 
This concludes my remarks. I'll now turn the call over to Calvin."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015.",526,"Thank you, Patrick. I will be providing you with our updated financial outlook for 2016, starting with procedures. 
On our last call, we estimated full year 2016 procedure growth of 14% to 15% above the approximately 652,000 procedures performed in 2015. Now as we enter the fourth quarter, we continue to forecast full year procedure growth of 14% to 15%, likely towards the higher end of the range. 
With regard to Q4 2016 system placements, we directionally expect system placements for the quarter to follow recent seasonal trends. However, we anticipate system placements outside of the U.S. will continue to be lumpy as some of our U.S. -- OUS markets are in early stages of adoption and sales into some markets are constrained by government regulations. 
Recall, we placed 13 systems into China and 7 systems into Brazil in the fourth quarter of 2015. As the quota in China expired in 2015 and a new quota has not yet been issued and as we are in the very early stages of adoption in Brazil, we do not expect comparables and placements into these markets in the fourth quarter of 2016. 
Also, we believe that the flexibility we have offered customers in the form of operating leases has been well received. As a result, as compared to prior periods, we expect a higher proportion of Q4 2016 placements to be under operating leases, with revenue recognized in future periods. 
Finally, we expect to see a lower number of lease buyouts in the fourth quarter compared to the previous 2 quarters, given the lower number of short-term leases that are outstanding at this time. 
Turning to gross profit. On our last call, we forecast 2016 pro forma gross profit margin to be within a range of between 70% and 71% of net revenue. We now expect our full year 2016 pro forma gross profit margin to be approximately 71.5% of net revenue. 
As Marshall indicated, the third quarter benefited from a $7.1 million Medical Device Tax refund. Excluding that benefit, our gross profit margin would have been 72%. We expect our fourth quarter margin to be directionally lower than the third quarter, primarily due to product mix. 
Turning to operating expenses. Based upon investments we are making in key areas of the business, we expect expense growth will continue to accelerate. On our last call, we forecast pro forma 2016 operating expenses to grow between 12% and 15% above 2015 levels. We are now refining this range to 13% to 14%. 
Consistent with our last call, we expect our noncash stock compensation expense to range between $170 million and $180 million in 2016 compared to $168 million in 2015.
We expect other income to total approximately $33 million in 2016, higher than the $30 million forecast on our last call, due primarily to higher interest income. 
With regard to income tax, consistent with previous guidance, we expect our Q4 2016 pro forma income tax rate to be between 26.5% and 28.5% of pretax income, depending primarily on the mix of U.S. and international profits. 
That concludes our prepared comments. We will now open the call to your questions."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America.",15,"[Operator Instructions] That will come from the line of Bob Hopkins from Bank of America."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on",83,"So I had 2 questions. First, for Marshall, just to clarify a couple of things that were mentioned relating to the fourth quarter, and then a question for Gary on the Fosun agreement. But Marshall, I'll start with you. Just 2 quick clarifications. One, on the Medical Device Taxes and the $7 million, could you explain why that is onetime? And then on the system sales guidance that you're providing, is that essentially suggesting that systems will be globally roughly flat in Q4?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have",125,"Yes, sure. So the Medical Device Tax is the result -- refund is the result of a -- when you originally compute the tax, there is some subjective areas, and we modified what we had previously filed. So we get a onetime refund, and it's over. And they have -- we've received the money, and there has been an audit, so we're all done with that. Second question had to do with the level of systems. Now, I think that what Calvin said was that the systems are seasonally stronger in Q4. What he was trying to set up, however, was that relative to the prior year, there's some hard comparables, given that we had some markets that are rather lumpy like China and Brazil."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue.",33,"You got a second question on Fosun. I think Bob had a question on Fosun before he got to it, if you still have him. If not, we'll come back around in queue."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little",109,"So I just -- I was wondering if you could give us some perspective on the biopsy platform and the joint venture because it seems to me like this is an entirely new platform that you're announcing here. So I was wondering if you could just give us a little more color on what this is. Like, is this a new -- is this a new totally new system or just an add-on to Xi? Just -- should we think about it as being a couple of years away from commercialization? Or is it really a longer-term project? I'm just sort of wondering if you could provide some perspective."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along",225,"Yes, I'll give you a little bit of an overview. We'll, of course, give you additional detail in coming quarters. It is not currently designed as an add-on. The technology is based, as I said in the prepared remarks, on computer-controlled catheters, along with some special sensing technologies and some image analysis. Currently -- the current configuration it's in, it's a stand-alone. Those types of technologies in the future could be integrated into other things, and we won't preclude ourselves from doing that. We do conceive of it as a way to access the body through natural orifices and other means, where you want to follow a prescribed pathway to get to some deep place in the body and do something. Our first clinical interest is in biopsying lung cancers or biopsying suspicious lesions in the lung. We think that, that is important globally and particularly important in China. And as a result, the partnership with Fosun, who we've known through their Chindex company for many years, made a lot of sense to us. And we're excited about it. We're not ready to give you commercial timelines yet. The technology is mature enough that we're in our initial human clinical experience. That's really the very beginnings for us, and as we get greater clarity on our launch timelines and thoughts, we'll share them with you."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Now we'll go to the line of David Lewis with Morgan Stanley.",13,"Now we'll go to the line of David Lewis with Morgan Stanley."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has u",172,"Gary, I wanted to start off with a strategic question and maybe have 2 follow-up boring questions. But it occurred to me on this call that actually the Intuitive story is sort of poised for pretty significant change. I mean, I really think Intuitive has usually been about one system. I know you have multiple configurations, but in this quarter alone, Xi was still 75% of new placements. But if I think about the next 2 years, right, you're still going to have Xi and all those multiple Intuitive prior systems. You have XSP, and you're also now going to have this catheter-based sensing system. So I wonder if you could help us understand are we right to think about this company as morphing these next 2 years? And how does supporting sort of multiple platforms now impact the addressable markets you can serve, your ability to accelerate growth and, obviously, just flat out R&D spending across these platforms? I know it's a big question, but I think it's an important one."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with convention",322,"Yes. Fair enough. I think -- as you think about SP, SP shares a lot in architecture and in kind of underlying technology with the Xi platform. We do think it branches us into places that are hard to reach otherwise, literally hard to reach with conventional technologies, open surgery, conventional laparoscopy or with Xi. So we think SP can broaden clinically what surgeons can do. I think that will start in niches and then we'll move out into broader applications as we gain clinical experience. It does increase our support load a little bit in terms of complexity with regard to the SP, just because it's a new set of instruments and add-on accessories. But it's not an entirely new set of computational platform and things like that. As you start thinking about the catheter-based technologies, again, that's a new set of technologies. You had kind of framed it in a 2-year horizon. I would stretch that horizon out a little bit. I wouldn't anchor us there. I do think that takes us to different places. I think it allows access to parts of the body that you may not think of surgically. It may be more around diagnostics. And I think it will open up to practitioners' ways of approaching tissue that they just haven't thought about before. And that's why we're doing it. That -- you've seen us increase our R&D spend, and we've been both talking about it and doing it, and part of it has been investing in these technologies. And I think it matters. I think as people look -- as we look from the bottom of your feet to the top of your head and look for opportunities to get better outcomes, we think of a variety of technologies from access technologies to imaging technologies to computational technologies that can really make a difference, and that's -- we're putting our money where our mouth is."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the sp",135,"And Marshall, the company, though, has been hesitant to talk about margins on a go-forward basis. Obviously, margins this year is a huge part of the story and they have been, frankly, kind of extraordinary. So as you head into '17, just in light of the spending comments you've made, I don't think it's realistic for investors to expect 200 basis points of margin expansion in '17. Based on your comments on spending and what you're going to have to do to support these platforms, I mean, how should we sort of calibrate our thinking next year between sort of an extraordinary 2016 expansion and a more moderate 2015 margin expansion? Should we be thinking about something between those 2 poles as more appropriate than what we are seeing this year, which seems very outsized?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than ex",163,"Clearly, we'll give you guidance in January on what 2017 is going to look like. But some of the variables that could occur, obviously have to do with product mix. And as you introduce new products, new products have, by their nature, lower margins than existing products. And so if there were -- as we introduced stapling, for example, we saw a decline in margin initially. As we improved the manufacturability and efficiency of the manufacturing processes, we've seen improvements in margins. So I'm not going to predict what we're going to do next year. I would just say that there are a lot of moving parts. Mix, geographically, also has an impact. Mix between systems and instruments and accessories has an impact. There's just a lot of variables that go into it. I think what you've seen this last year, though, is outstanding performance by our manufacturing group to reduce the cost of newer products that were lower margin a year ago."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the Europe",68,"Okay. And then just -- Gary, just really quickly. Lastly, on the ex-U.S. business on systems, I think the commentary on Brazil and China, those seemed kind of very short term in nature. Eventually, those tenders will get raised. But in terms of the European business, did you see any impact from Brexit? Or do you just think this is lumpiness that always occurs generally in your business?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyw",134,"Yes, I think the dynamics in the U.K., in particular, I -- it's hard for us to segregate what's Brexit and what isn't. The capital acquisition pipelines are pretty long relative to these things. And it's been clear that in the U.K., that there -- NHS anyway, that NHS England has been looking at how to spend their money and trying to cover budget shortfall. So there's been pressure there for some time. Brexit likely doesn't help. With regard to Europe more broadly, it really is varying country-by-country. Some places, we see reasonable growth and support. Other countries have been a little bit more of a struggle. And the response to that really has been to increase local presence, increase local data generation and be in close contact with government payers and private payers."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Tycho Peterson from JPMorgan.",11,"Next, we'll go to the line of Tycho Peterson from JPMorgan."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when",55,"I actually want to follow up on Dave's question earlier on margins. If we think about the Xi experience and the impact that had on gross margins, as we think forward to SP, is that a fair proxy in terms of the magnitude of the impact on gross margins when that does roll out?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce",52,"We're not at the stage where we've introduced the product and we're manufacturing them in bulk, but I think it's fair to say that SP's margins will be lower than our existing product portfolio. And we'll work on it as we come -- over time to try to reduce those costs."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall",66,"But in terms of magnitude, Tycho, when you look at the Xi, that was our next-generation, multi-port system, and it quickly took off to a very high proportion of the sales. What we're talking about with SP is a more controlled type of launch, lower overall quantities. So just based on magnitude, it's probably not going to have as big an impact on the overall margin."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?",45,"Understood. And then can you comment on trade-ins? I know you called it out in the footnotes. You had 58 in the U.S., highest number ever. Was this kind of a onetime thing where you kind of went back and scrubbed systems in the field?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we p",124,"Yes, there was a footnote on our data tables that we referenced in the beginning. During the third quarter, we actually implemented a new system and some processes for tracking our da Vinci systems out in the field. As part of the transition process, we performed a verification audit of our installed base records, which identified -- and identified 43 system, mostly older standard and S models, which had been retired. So we went and removed those retired systems from our installed base during the quarter. So I think the trade-out number was 33, and then most of the rest here was just kind of this adjustment we made to the base. So the trade-ins were pretty, I think, in line with previous periods."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?",39,"Okay. Last one, I'll just ask the obligatory capital deployment question because you're over $4.5 billion now. Obviously, you're stepping up your own spending, but can you maybe just talk a little bit about capital deployment at this point?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And w",165,"Yes, sure. I think -- we think about capital deployment consistent with how we've talked about it before. We're in a period where there's now -- we're facing future competition, and we want to have the ability to expand and to deal with competition. And we're also going to see additional opportunities as companies get into this game for acquisition of technologies that may expand our marketplace and enhance our products. And those technologies, it's nice to do tuck-ins and small licensing arrangements that we've done in the past, and we'll try to do those. But it may be that we have to buy -- to pay a greater dollar to get some of that technology in the future. So we want to have money for those things. Beyond that, to the extent that we have the right opportunity to buy back stock and return shares -- money to shareholders, we'll take that opportunity, but we'll do that opportunistically as we have in the past."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Ben Andrew with William Blair.",12,"Next, we'll go to the line of Ben Andrew with William Blair."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be",73,"Gary, looking at the Fosun relationship, does this give you a demonstrably closer relationship over in China that may influence the tender process? And kind of as a second piece to that, from a regulatory perspective, what sort of time frames would you be looking at to get something through once you've finished developments and you've done some human testing to approval? Is it quicker there? Or is it similar to the U.S.?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various p",96,"Yes, on the first question, I think -- in the long term, I think it deepens our relationships with customers and regulators in China. I don't -- I wouldn't assume that it's a magic switch in the near term. With regard to regulatory approvals for various products in China, typically, in our past, it's been a little bit longer process than it has in the U.S. What that looks like going forward, in particular for the new products we're talking about, I can't speak to at this time. We just don't have enough information on it."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrabl",62,"Okay. And then you talked about international procedures being up about 25%, which is a strong number, but I thought I heard you say that parts of Europe were weaker than a year ago. Was there a particularly geographic pattern there? Was China demonstrably or -- that, plus the ROW placements sort of got my attention relative to some emerging opportunities overseas."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and",65,"Ben, this is Patrick. In certain international markets, we are pretty deeply penetrated in urology, and where you have seen those penetration rates increase over time, the rate of growth has decelerated. And emerging procedures, things like colorectal and gynecologic oncology, are still fairly small. So countries like the Nordic countries, places like the U.K., where we're pretty deep, you see those growth rates slow."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are",68,"Okay. And then, this may be for Patrick as well, but a competitor this morning talked about seeing some of their general surgery cases and calling out hernia being down something like 10%. Kind of give us your state of the state in terms of where you are in hernia and kind of the trajectory of adoption relative to some of the historical fast-adopting procedures, if you would."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology h",121,"Yes, hernia continues to be encouraging. The rates of both procedure adoption, surgeon retention and utilization within the existing surgeon population, as they continue to do more procedures, has been a strong point, and the way in which the technology has been adopted. Now hernia repair, though, is not one thing. So there's a variety of patient subsets within, a variety of different physician perspectives around the value that our technology can bring in the procedure. And so it's probably not quite like dVP in terms of the way you would think of it as being adopted. Maybe a little more benign hysterectomy, given the alternative therapies and the heterogeneous landscape out there in terms of how they address these patients."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other",66,"Okay. And then last question for me, I guess, is the question around the I&A. The revenue beat there with the procedures being roughly in line with our target was quite noticeable. And Marshall, you did go through some of the math there, but was -- other than stapling and vessel sealing, was there anything in particular in there that caught your attention relative to mix?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actua",229,"Yes, just kind of giving a little historical perspective. If you look at -- prior to Q2 of 2016, our I&A revenue per procedure has been running within a really tight, narrow range, $1,830 to $1,840 per procedure. You probably recall last quarter, it actually dropped down to $1,810, and we talked about timing of orders being the main factor here. So as expected here in Q3, we saw orders rebound to offset Q2. And if you take the average of Q2 and Q3, you're right back at the $1,840, kind of in line with those trends over the past couple of years. As we said, though, we continue to see increasing utilization of the advanced instruments, including the stapler and vessel sealer. And moving forward, as we anticipate continued growth in the procedure volumes in colorectal and thoracic surgery, areas where these products are more widely used, we would anticipate a slightly higher contribution to revenue per procedure on an organic consumption model, if you will. But it's important to remember that a variety of factors impact revenue per procedure, including the type or procedure performed, the efficiency of use and optimization, use of advanced instruments, stocking orders, timing and distributors. So there's a lot of factors here. So as a result, I&A, it can be lumpy, and future trends can be difficult to forecast in the end."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next we'll go to the line of Amit Hazan with Citi.",12,"Next we'll go to the line of Amit Hazan with Citi."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast",113,"Let me maybe start with prostate, just kind of thinking through the trend this year, just going from low double-digit growth in the first quarter for dVP, all the way down to low single digits, it sounds like, for this quarter. It seems like a pretty fast change in what, otherwise, would seem to me to be something that would be a slower trend line. Any more color you can add as to what's happening now and why it's happening and maybe, more importantly, just the confidence you guys have that this quarter kind of marks that bottom and that incident rate growth is kind of your right rate of growth for prostate."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thoug",121,"Yes, Amit, as you know, predicting how the patient treatment trends across prostate cancer in a mature procedure like dVP is difficult. And we've highlighted for a period of time the rates of growth that we've seen is not the rates of growth that we thought were consistent with the rate of diagnoses. It's hard to say in the quarter or the rate at which we've seen growth change over the course of this year. The specifics behind it, that data, typically comes to us years down the road. But we feel that the -- what we saw in the quarter is probably more consistent with the rate of diagnoses than perhaps what we've seen over the past handful of quarters."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this i",137,"Okay. Let me kind of -- let me move to gynecology. It sounds like there, things are still kind of like you described in the first half of the year, maybe slightly better than what we've seen in the past. And I wanted to -- I don't think we've asked this in a while, so I'll just throw this question out, just as one possible avenue. Just thinking about outpatient centers, ambulatory surgery centers, is there -- to what extent -- or is there kind of any increase in the success that you're having in being able to place da Vincis in outpatient centers? Is that becoming more of a focus for you at all? And is that at all a part of maybe the slightly better rates of growth we're seeing in gynecology in the U.S?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume cent",126,"Yes. So I think you're connecting 2 things I'm not quite sure I'd connect. So the relative health of the gynecology business seems to me to be driven by a few factors, among them concentration of patients into higher-volume surgeons and higher-volume centers. Separately, there is a trend toward more outpatient work. We do see utilization of our systems in outpatient environments; that tends to be more in existing integrated delivery networks, possible loaned [ph] outpatient departments as part of a integrated plan. It's not something I'd call out as a major trend at this point. I'm not sure that I would quite link it to GYN. It's possible, but I think there are a lot of factors there that sorting them is not possible yet."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive s",62,"If you look at GYN, overall, and you look at the history of benign hysterectomy adoption, the entrance of da Vinci surgery into benign hysterectomy has enabled the majority of patients to now be treated on an outpatient basis. So when minimally invasive surgery is adopted with the technology, it will enable hospitals to manage these patients in a more outpatient-oriented way."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10%",108,"Just one last question for me on the systems side. Just thinking through not just the fourth quarter, but just a little bit longer term, you can call it '17 if you want. But thinking about the installed base, it's been really consistently growing now 10% a year. Almost every quarter, it seems like it grows about 10 -- on that 10% rate on an annual basis. Can you maybe just talk through the key drivers and maybe pressure points as we think about that number and the sustainability of that 10% growth in the installed base growth figure as you think through the next year or 2?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is",137,"A couple of -- the way I think about it is kind of puts and takes. So the major factor is anticipated procedure growth by the customer. So customers are making capital placements based on what they think will happen in future procedure trends. So that is the biggest driver and where they see growth, I think that they move forward. The places where that can be a little bit different or disconnected is in a very early market where you're just getting started. So a new reimbursement clearance or a new quote or a new procedure clearance don't -- doesn't follow the more mature trend. So those are the 2 things that are rolling around. I think the biggest one for us is customer belief and utilization for future procedures as the best predictor of capital."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Next, we'll go to the line of Rick Wise from Stifel, Nicolaus.",12,"Next, we'll go to the line of Rick Wise from Stifel, Nicolaus."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geogra",76,"Just -- maybe just going back to Fosun, briefly. Obviously, you have alluded several times to this notion of building out the ecosystem and how important and valuable it is to Intuitive. Are there other similar opportunities to Fosun, whether it be geographic or technology? Or I mean, is this a direction we should expect Intuitive to push looking for other technologies to bring into the ecosystem? Is that the right way to think about it?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity",136,"I think the idea that if there are technologies or other assets that we can bring that we think will increase the value of robotic surgery program or minimally invasive surgery program based on a computation to one of our customers, is that an opportunity for us? Yes. They tend to develop in time. The underlying catheter-based technologies that we're talking about now, as you know, having followed us for some time, were really first acquired by us years ago. So the answer to that is yes. We're out looking. Fosun has been a good partner. They have both a relationship with us through Chindex, but they also understand the healthcare space extremely well in multiple dimensions. And so the short answer to that is we've been doing it and expect to continue to do it."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings,",72,"A couple more. Just a general question about the general surgery adoption, particularly in the U.S. Maybe just -- can you talk a little bit more about where we are just in terms of that adoption process? I mean, are these still earnings -- early innings, rather? And maybe, particularly on colorectal, how do you accelerate colorectal adoption? Do we need more clinical data? Can you talk through some of those issues?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's",222,"Sure. So as we've said in the past, adoption is really per procedure, and per procedure is really segmented. So for example, colorectal is probably really 4 or 5 underlying procedures that are a little bit different. And adoption goes quickly when there's large value, distinct value for the procedure relative to alternatives and when the procedure is pretty well concentrated in the hands of well-trained surgeons. So take colorectal and separate it a little bit. In the case of rectal cancer, that's a complex set of procedures. Oncologic, of course, in nature, has been growing steadily. Not a super rapid rise relative to some prior adoptions, but a steady adoption for us. And data collection has been occurring, data publication has been occurring, and we're doing okay there. I think in other parts of colon, sometimes it's for benign, sometimes it's oncology. Those are typically done by different surgeons. And so they adopt at little bit different rates. You look at hernia, again, it's sub-segmented, ventral hernia versus inguinal and subsegments within inguinal. So we look at it. Ventral hernia and inguinal hernia, as we define the available markets for procedures for which we bring value, have adopting pretty nicely relative to past trends. Rectal has been on a slower adoption but a steady one, and colon is in the middle."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math wi",88,"And just last for me on the procedure side. I mean, obviously, a lot of moving pieces here. Urology, maybe now a little more slower growth, now that rebounded gynecology recovering. General surgery, continuing to grow dramatically. We roll up that math with what we're seeing internationally, should we feel reasonably optimistic that something like mid-teens procedure growth, again, with some variation? Is that the right sustainable growth rate from here, given the growing installed base, given the geographic penetration and given the continuing evolution of Intuitive technology?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January.",37,"Yes. We're not ready to give our '17 forecast yet. And we'll see how we close here in the fourth quarter and roll up our estimates and answer that very question in our next call in January."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","We'll go to the line of Larry Biegelsen with Wells Fargo.",12,"We'll go to the line of Larry Biegelsen with Wells Fargo."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -",75,"So I'm new to these calls, so just maybe a couple of basic ones here. So SG&A as a percent of sales was relatively low. I apologize if I missed it. Any reason for SG&A to be relatively low this quarter? And the R&D spending of about 7% of sales, is that -- it sounds like -- is that a good rate to use going forward? And I had a couple of follow ups."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for",87,"Yes. There's going to be a variability quarter-to-quarter, lumpiness, if you will, between SG&A and R&D. We've talked a lot about our R&D investments. Gary went through them on the SG&A side. I think we're investing a little heavier disproportionally for international to support the earlier phase growth there. So you look at it overall, we're within our guidance range. We refined our full year guidance to that 13% to 14%. So again, there'll be some quarter variability, but I think we're tracking to the overall plan."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through.",28,"And Larry, given the lumpiness in some of our capital revenue from period-to-period, we typically talk about operating systems in terms of growth rates, which Calvin walked through."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?",37,"Got it, thanks. And then when we think about the pipeline and potential launches of new products and functionality, should we be expecting any meaningful product introductions later, either later this year or in 2017, excluding SP?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time.",47,"Well, we've been launching a fair amount of instruments and accessories, various things in various markets. We tend to tell you when they come out. We are -- we have not tagged a launch date either for SP or other kind of major systems at this time."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?",43,"Then lastly for me. Gary, you talked about the growth you've seen in hernia, and you talked about ventral and inguinal. Are you seeing anything different in terms of the penetration or ramp in ventral versus inguinal? Or both of them equally strong?"
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything abo",119,"It's a good question. I think the dynamics are a little bit different in them, both in terms of kind of procedure complexity and a little bit of practice patterns. But they don't track exactly the same. Having said that, I don't think there's anything about adoption that I'd call out strongly at this time. I think both of them are moving through that first set of adopters, generating additional data. We're seeing more data now, generally supportive; it looks pretty good. I think that technique refinement and data generation is what the next round of surgeons rely upon to evaluate. And so we're seeing that kind of transition right now, really in both of those hernia domains."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Operator","Our final question will come from Brandon Henry with RBC Capital Markets.",12,"Our final question will come from Brandon Henry with RBC Capital Markets."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Analysts","So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And t",94,"So Intuitive again posted strong growth in operating margins this quarter. Can you discuss some of the product and cost initiative that you -- that are driving these better margins, and then what inning you're in with some of these cost initiatives? And then separately, the company's headcount has increased meaningfully over the last couple of quarters. Can you discuss where you're making the investments in headcount? And then how much of that increase in headcount can be attributed to the Fosun JV versus some other initiatives? And then I have a follow up."
30239,402358121,1361493,"Intuitive Surgical, Inc., Q3 2016 Earnings Call, Oct 18, 2016",2016-10-18,"Earnings Calls","Intuitive Surgical, Inc.","Executives","That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it i",341,"That was 2 questions already, and I gave you one. I think I'll choose one. No, we'll go fast. On the first one, in terms of cost reductions, it's a careful and long list of activities that goes on. So you shouldn't so much think of it as one thing as it is a routine discipline of scanning through both operating processes and manufacturing processes and parts costs and working them down as they come. You do get the first -- the greatest help on those things in the first few years of a platform release. And then after that, it starts getting increasingly hard. It's not specifically to say that it isn't possible to do it. In terms of headcount growth, it's a mixture of commercial growth, a little bit more weighted outside the U.S. than U.S., some manufacturing growth to cover volumes of things like instruments and accessories and other things that have been increasing as well as some design help. The headcount growth, as it relates to Fosun, we're not really to break out at this time. We have certainly made headcount investments over the last few years into the technologies that have underpinned that relationship. But it's not -- I wouldn't call it out as Fosun just yet. 
With that, I'll go ahead and close the call. And then we'll catch your next question on the next conference call. That was the last question. 
As we've said previously, while we focus on financial metrics, such as revenues, profits and cash flow during these conference calls, our organizational focus remains on increasing value by enabling surgeons to improve surgical outcomes and reduce surgical trauma. We've built our company to take surgery beyond the limits of the human hand, and I assure you that we remain committed to driving the vital few things that truly make a difference. 
This concludes today's call. We thank you for your participation and support on this extraordinary journey to improve surgery, and we look forward to talking with you again in 3 months."
